




**World Health  
Organization**

REGIONAL OFFICE FOR **Europe**

## **SURVEILLANCE** REPORT



# Tuberculosis surveillance and monitoring in Europe

# 2015

[www.ecdc.europa.eu](http://www.ecdc.europa.eu)  
[www.euro.who.int](http://www.euro.who.int)



**Tuberculosis surveillance  
and monitoring in Europe**

**2015**

This report has been published jointly by the WHO Regional Office for Europe and ECDC. WHO Regional Office for Europe developed the overview of the European Region as a whole and validated the figures of the non-EU countries and ECDC developed the overview of the EU/EEA countries and validated the EU/EEA figures.

The report was coordinated by Vahur Hollo (ECDC) and Andrei Dadu (WHO Regional Office for Europe).

Contributing authors: Colleen Acosta<sup>2</sup>, Julien Beauté<sup>1</sup>, Pierpaolo de Colombani<sup>2</sup>, Masoud Dara<sup>2</sup>, Soudeh Ehsani<sup>2</sup>, Arax Hovhannesian<sup>2</sup>, Csaba Ködmön<sup>1</sup>, Irma Matuleviciute<sup>2</sup>, Martin van den Boom<sup>2</sup> and Marieke J. van der Werf<sup>1</sup>.

<sup>1</sup> European Centre for Disease Prevention and Control

<sup>2</sup> WHO Regional Office for Europe

This report was sent for consultation and review to the TB disease-specific experts and focal points in the Member States.

We would like to acknowledge the contribution and dedication of the experts in the Member States in reporting the data used for the production of this report.

Trend tables and country profiles are included in the online report at [www.ecdc.europa.eu/en/publications/](http://www.ecdc.europa.eu/en/publications/)

#### Erratum

Page 43. On 10 April 2015, the colour code for Cyprus was corrected from red to dark red in Map 4. Percentages of notified TB cases of foreign origin among all TB cases, European Region, 2013.

#### Suggested citation for full report:

European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2015.

Stockholm: European Centre for Disease Prevention and Control, 2015.

#### Tables and figures should be referenced:

European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2015.

This report follows the European Union Inter-institutional Style Guide with regard to country names.

The maps are reproduced with the permission of the WHO Regional Office for Europe. The designations employed and the presentation of this material do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries.

The WHO Regional Office for Europe is responsible for the accuracy of the translation of the Russian summary.

© World Health Organization, 2015

© European Centre for Disease Prevention and Control, 2015

Reproduction is authorised, provided the source is acknowledged.

Cover picture © CDC/ Dr Ray Butler; Janice Carr

ISBN 978-92-9193-624-3

ISSN 2443-5538

DOI 10.2900/666960

# Contents

<b>Abbreviations</b> .....	v
<b>Summary</b> .....	1
<b>Executive summary</b> .....	3
<b>Исполнительное резюме</b> .....	5
<b>1. Background and technical note</b> .....	7
1.1 Data reporting and analysis .....	9
1.2 Definitions .....	10
<b>2. Commentary</b> .....	13
2.1 The WHO European Region .....	15
2.2 European Union and European Economic Area countries .....	23
<b>3. Commentary – Monitoring</b> .....	27
<b>4. Annexes</b> .....	31
Annex 1: Tuberculosis surveillance system overview, 2013 .....	33
Annex 2: List of TESSy variables for 2013 TB data collection .....	34
Annex 3: Reporting completeness of main variables used for the report .....	35
Annex 4: Reporting completeness into Global TB database, 2013 .....	36
Annex 5: Laboratory practices and quality assurance for anti-TB drug susceptibility testing, WHO European Region, 2013 .....	37
<b>Maps &amp; figures</b> .....	2
Map: Tuberculosis surveillance in Europe 2013 .....	2
Figure A: Trends in the absolute number of notified MDR TB cases in 18 HPCs and combined subtotals fitted with polynomial trend line, 18 HPC, EU/EEA and non EU/EEA countries within the WHO European Region, 2008–2013 .....	18
Figure B: Absolute number of all MDR TB cases and additional rifampicin-resistant TB patients detected compared with those reported to have enrolled on second line treatment 2009–2013 in each of 18 high priority countries, and totally by 18 HPCs and WHO Region, 2009–2013 .....	19
Figure C: Absolute number of TB/HIV cases detected compared with those reported as enrolled on antiretroviral therapy and co-trimoxazole preventive therapy (2007–2013 in each of the 18 HPC, and as a total for the HPC and the EU/EEA, 2007–2013 .....	20
Figure D: TB notification rates per 100 000 population, EU/EEA, 1995–2013 .....	23
Map 1a: Estimated TB mortality per 100 000 population, European Region, 2013 .....	41
Map 1b: Estimated TB incidence per 100 000 population, European Region, 2013 .....	41
Map 2: TB notification rates per 100 000 population, European Region, 2013 .....	42
Map 3: TB notification rates, new TB cases and relapses per 100 000 population, European Region, 2013 .....	42
Map 4: Percentages of notified TB cases of foreign origin among all TB cases, European Region, 2013 .....	43
Map 5: Percentage of smear positive pulmonary TB cases among new pulmonary TB cases, European Region, 2013 .....	43
Map 6: Percentage of notified TB cases with multidrug resistance among new laboratory-confirmed pulmonary TB cases, European Region, 2013 .....	44
Map 7: Percentage of notified TB cases with multidrug resistance among previously treated pulmonary TB cases with DST results, European Region, 2013 .....	44
Map 8: Percentage of notified TB cases with multidrug resistance among all TB cases with DST results, European Region, 2013 .....	45
Map 9: Percentage of notified TB cases with extensive drug resistance among pulmonary MDR TB cases with second-line DST results, European Region, 2013 .....	45
Map 10: Percentage of HIV-positive TB cases among all TB cases with known HIV status, European Region, 2012 .....	46
Map 11: Treatment success among new and relapsed TB cases having started treatment in 2012, European Region, 2013 .....	46
Map 12: Treatment outcome after 24 months of RR TB/MDR TB cases having started second-line treatment in 2011, European Region, 2013 .....	47
Map 13: Treatment success rate among all MDR TB cases notified in 2011, EU/EEA, 2013 .....	47
Figure 1: TB estimated incidence and notification per 100 000 population, European Region, 2004–2013 .....	48
Figure 2: Estimated TB mortality per 100 000 population, European Region, 2004–2013 .....	49

Figure 3: Total TB notifications by previous treatment history and total TB case rates, Europe, 2004–2013 .....	50
Figure 4: Percentages of MDR among pulmonary laboratory-confirmed TB cases, European Region, 2004–2013 .....	51
Figure 5: Percentage of TB cases with HIV infection among TB cases with known HIV status, Europe, 2008–2013 .....	52
Figure 6: Treatment outcome, new TB cases and relapses having started treatment, European Region, 2003–2012 .....	53
Figure 7: Treatment outcome after 24 months of all RR TB/MDR TB cases starting second-line treatment in 2011, European Region, 2007–2011 .....	54

## Tables

Summary table: Tuberculosis surveillance data by region, European Region, 2013 .....	57
Table 1: Estimates of the TB disease burden 2013, European Region .....	58
Table 2: Estimates for TB/HIV co-infection and MDR TB, European Region, 2013 .....	60
Table 3: Tuberculosis cases, notification rates per 100 000 population and mean annual change in rates, European Region, 2009–2013 .....	63
Table 4: New TB cases and relapses, notification rates per 100 000 population and mean annual percentage change in rates, European Region, 2004–2013 .....	64
Table 5: Tuberculosis cases by history of previous TB treatment, European Region, 2013 .....	66
Table 6: Tuberculosis cases by site of disease, European Region, 2013 .....	67
Table 7: New pulmonary tuberculosis cases by diagnostic method, European Region, 2013 .....	68
Table 8: Laboratory-confirmed tuberculosis cases by confirmation method, EU/EEA, 2013 .....	70
Table 9: Classification of tuberculosis cases according to EU case definition, EU/EEA, 2013 .....	71
Table 10: New TB cases and relapses by age group and male-to-female ratio, European Region, 2013 .....	72
Table 11: Tuberculosis cases by origin and male-to-female ratio, European Region, 2013 .....	74
Table 12: Characteristics of anti-TB drug resistance surveillance of pulmonary laboratory-confirmed cases, European Region, 2013 .....	76
Table 13: Drug resistance in laboratory confirmed TB cases, EU/EEA, 2013 .....	77
Table 14: Multidrug-resistant TB among pulmonary laboratory confirmed TB cases by previous history of TB treatment, European Region, 2013 .....	78
Table 15: Multidrug resistant TB among all laboratory confirmed TB cases by previous history of TB treatment, EU/EEA, 2013 .....	80
Table 16: XDR TB cases among pulmonary MDR TB cases, European Region 2013 .....	82
Table 17: XDR TB cases among all MDR TB cases, EU/EEA 2013 .....	83
Table 18: Tuberculosis cases with HIV infection, European Region, 2013 .....	84
Table 19: TB in Prisons, European Region, 2012 .....	85
Table 20: Treatment outcome of new TB cases and relapses started on treatment in 2012, European Region, 2013 .....	86
Table 21: Treatment outcome of previously treated TB cases other than relapses started on treatment in 2012, European Region, 2013 .....	87
Table 22: Treatment outcome of HIV positive TB cases notified in 2012, European Region, 2013 .....	88
Table 23: Treatment outcome of all TB cases notified in 2012, EU/EEA, 2013 .....	89
Table 24: Treatment outcome after 24 months of RR TB/MDR TB cases started on second-line treatment in 2011, European Region, 2013 .....	90
Table 25: Treatment outcome after 24 months of all MDR TB cases notified in 2011, EU/EEA, 2013 .....	91
Table 26: Treatment outcome after 36 months of pulmonary XDR TB cases started on second-line treatment notified in 2010, European Region, 2013 .....	92
Table 27: Treatment outcome after 36 months of all XDR TB cases notified in 2010, European Region, 2013 .....	93

## Trend tables

Table I. All laboratory confirmed tuberculosis cases, European Region, 2004–2013 .....	96
Table II. Tuberculosis cases in children under 15 years, European Region, 2004–2013 .....	98
Table III. Tuberculosis cases of foreign origin, EU/EEA, 2004–2013 .....	100
Table IV. MDR TB notification among new pulmonary culture-positive TB cases with available DST results, European Region, 2004–2013 .....	102
Table V. MDR TB notification among pulmonary previously treated culture-positive TB cases with available DST results, European Region, 2004–2013 .....	104
Table VI. MDR TB notification among all laboratory confirmed TB cases with available DST results, EU/EEA 2004–2013 .....	106
Table VII. XDR TB notification among pulmonary MDR TB cases with second line DST results, European Region, 2006–2013 .....	108
Table VIII. XDR TB notification among all MDR TB cases with second line DST results, EU/EEA, 2006–2013 .....	110
Table IX. Tuberculosis cases with HIV infection, European Region, 2004–2013 .....	112
Table X. Treatment success after 12 months of new TB cases and relapses, European Region, 2003–2012 .....	116
Table Xa. Treatment success after 12 months of all TB cases, EU/EEA 2003–2012 .....	118
Table XI. Treatment success after 12 months of previously treated TB cases (excluding relapses), European Region, 2003–2012 .....	120
Table XII. Treatment success after 24 months of all laboratory confirmed MDR TB cases, European Region, 2005–2011 .....	122
Table XIII. Treatment success after 36 months of XDR TB cases, European Region, 2005–2010 .....	124

Country profiles .....	125
------------------------	-----

# Abbreviations

<b>ADR</b>	Adverse drug reactions
<b>AFB</b>	Acid-fast bacilli
<b>AIDS</b>	Acquired immunodeficiency syndrome
<b>ART</b>	Anti-retroviral therapy
<b>CI</b>	Confidence interval
<b>CISID</b>	Centralized Information System for Infectious Diseases
<b>CPT</b>	Co-trimoxazole preventive therapy
<b>DRS</b>	Drug resistance surveillance
<b>DST</b>	Drug susceptibility testing
<b>ECDC</b>	European Centre for Disease Prevention and Control
<b>EEA</b>	European Economic Area
<b>EPTB</b>	Extrapulmonary tuberculosis
<b>EQA</b>	External quality assessment
<b>EU</b>	European Union
<b>HIV</b>	Human immunodeficiency virus
<b>HPC</b>	18 high-priority countries in the fight against TB: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan
<b>ISO</b>	International Organization for Standardization
<b>MDR</b>	Multidrug resistance
<b>MDR TB</b>	Multidrug-resistant tuberculosis
<b>M/XDR TB</b>	Multidrug and extensively drug-resistant tuberculosis
<b>MSM</b>	Men who have sex with men
<b>PR</b>	Prevalence ratio
<b>PTB</b>	Pulmonary tuberculosis
<b>PWID</b>	People who inject drugs
<b>RR TB</b>	Rifampicin-resistant tuberculosis
<b>SLD</b>	Second line drugs
<b>TB</b>	Tuberculosis
<b>TESSy</b>	The European Surveillance System
<b>TME</b>	WHO Tuberculosis Monitoring and Evaluation platform
<b>TOM</b>	Treatment outcome monitoring
<b>UN</b>	United Nations
<b>WHO</b>	World Health Organization
<b>WRD</b>	WHO-approved rapid diagnostics
<b>XDR</b>	Extensive drug resistance
<b>XDR TB</b>	Extensively drug-resistant tuberculosis






# Summary

**Map: Tuberculosis surveillance in Europe 2013**

- TESSy reporting countries (26)
- TME reporting countries (10)
- WHO high priority countries reporting to TESSy (5)
- WHO high priority countries reporting to TME (13)



## Executive summary

This is the seventh report launched jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe following on from reports under the EuroTB project, established in 1996.

### The WHO European Region

Despite notable progress in the past decade, tuberculosis (TB) is still a public health concern in most of the countries within the WHO European Region.

In 2013, an estimated 360 000 incident TB cases (range 340 000–370 000) occurred in the WHO European Region, equivalent to an average of 39 cases (38–41) per 100 000 population. Eighty five per cent of incident TB cases in the Region occur in the 18 high-priority countries<sup>1</sup>. In 2013, the absolute number of incident TB cases fell by 20 000 compared to the previous year, corresponding to 5.6% decline. Since 2001, TB incidence has been falling at an average rate of 4.3% per year.

In 2013, there were an estimated 460 000 prevalent TB cases (range 350 000–590 000), which is equivalent to 51 (39–65) cases per 100 000 population. Considering downward trend observed during last decade, it seems feasible that the Millennium Development Goal (MDG) target of a 50% reduction by 2015 against a baseline of 1990 will not be reached.

There were an estimated 38 000 TB deaths in 2013 among HIV-negative people in the European Region, equivalent to 4.1 deaths per 100 000 population (range 4.0–4.2). Yet, despite a constant decline in estimated mortality observed over the past 12 years, the MDG target will not be achieved in the Region.

During the period 2004–2013, TB notification rates decreased by almost 20%, from 40.3 to 32.8 cases per 100 000 population. This trend reflects a true reduction in the spread of the disease, strongly influenced by the 17.7% decrease in notification rates throughout the Region's 18 high-priority countries (from 77.8 to 64.0 per 100 000 population).

In 2013, the 25–44 year age group was predominant (44%) among new TB cases registered in the European Region. The percentage of new TB patients under 15 years in the Region is around 4%.

In 2013, 17 096 (81.4%) TB cases with HIV co-infection were detected from approximately 21 000 cases in the European Region, based on an estimated prevalence of HIV infection among incident TB patients of 5.8%. Due to low HIV testing coverage (68%) the status was only known for

219 095 TB cases, 17 096 of which were detected as having HIV-co-infection. Moreover, there was a notable decrease in anti-retroviral therapy (ART) coverage among HIV-positive TB patients (from 62.3% in 2012 to 53.8% in 2013).

Overall, 6.4% of the burden of new TB cases in the Region originated from prisons. In EU and EEA countries the proportion of TB cases detected in prisons was only 1.6% of all new TB cases detected in the country, while the corresponding proportion in non-EU countries was 7.4%. Overall, the notification rate of new TB cases in prisons within the WHO European Region was 893 per 100 000 population, indicating that the risk of developing TB in prisons was, on average, around 23 times higher than in the general population.

Of an estimated 75 000 multidrug-resistant (MDR) TB cases in the European Region in 2013, 34 941 (46.6%) were detected. The prevalence of MDR among new pulmonary TB cases in the Region amounted to 16.9% and was 48.0% among previously treated cases. Information relating to second line drug susceptibility testing (SLD DST) remains limited as only a few countries provided data, altogether accounting for 12% of all notified MDR TB cases. Coverage of SLD DST among the reporting countries was 56.4%. In total, 532 extensively drug-resistant (XDR) TB cases were detected, equivalent to 12.7% XDR prevalence among MDR TB patients.

Coverage of second-line TB treatment continued to improve in 2013. In total, 46 710 TB patients were enrolled into MDR treatment, 45 147 of whom had confirmed MDR TB. In 2013, the proportion of patients starting MDR treatment out of the total notified cases of MDR TB was 116.7%, or 110.7% including rifampicin-resistant TB (RR TB). In some countries the number of patients enrolled exceeded the total notified because prevalent MDR cases detected in previous years were still enrolled in treatment.

Treatment success among new and relapse TB cases was 75.6%. Among previously treated cases (excluding relapses) it was 57.1%. The treatment success rate in the MDR TB cohort was 46.0%, which is lower than in 2012.

Given all of the above, and the fact that the vast majority of the TB burden occurs in the 18 high-priority countries of the European Region (85% of TB incidence, 86% of prevalence, 90% of the mortality caused by TB, 90% of TB/HIV co-infections and 99.5% of the MDR TB), the main efforts to combat and prevent TB in the Region still need to be focused there.

In collaboration with national and international partners and civil society organisations, WHO Regional Office for Europe has been implementing the Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis, 2011–2015 at regional level

<sup>1</sup> The 18 high-priority countries (HPC) are: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan.

and helping Member States to adopt evidence-based interventions in order to improve TB and M/XDR TB prevention and control. The WHO Regional Office for Europe has also established the European Green Light Committee and the European Laboratory Initiative to help countries develop and/or adjust their national plans in response to the M/XDR-TB threat. Now that implementation of the Consolidated Action Plan is in its final year, and with the endorsement of the post-2015 global End TB Strategy by the sixty-seventh session of the World Health Assembly, Member States, WHO and partners are currently developing a new TB Action Plan for the WHO European Region, 2016–2020.

## European Union and European Economic Area countries

In 2013, 64 844 cases of TB were reported in 30 EU/EEA countries, which was 6.0% less than in 2012, reflecting a decrease in 19 countries. The EU/EEA notification rate was 12.7 per 100 000 population, continuing a long-term decreasing trend.

Of all notified TB cases 77.9% were newly diagnosed and 74.3% of new pulmonary TB cases were confirmed by culture, smear or nucleic acid amplification test. Twenty-eight per cent of all TB cases were of foreign origin, mostly residing in low-incidence countries.

Overall, adult age groups were equally affected by TB. Children under 15 years of age accounted for 4.1% of all 64 844 TB cases with a notification rate of 3.3 per 100 000 population. Countries with the highest age-specific notification rates in children were all high-priority countries. Males were over-represented in almost all EU/EEA Member States, with the greatest gender imbalance among those aged 45 to 64 years.

Multidrug resistant (MDR) TB was reported for 4.1% of cases with drug susceptibility testing (DST) results (2.6% of new pulmonary TB cases and 17.0% of previously treated pulmonary cases) and continues to be most prevalent in the three Baltic countries. Extensively drug-resistant (XDR) TB was reported for 17.5% of 963 MDR TB cases tested for second-line drug susceptibility.

In total, 73.5% of TB cases notified in 2012, 37.8% of MDR TB cases notified in 2011 and 25.9% of XDR TB cases notified in 2010 had successfully completed their treatment.

Of all TB cases with a known HIV status 4.9% were co-infected with the virus.

# Исполнительное резюме

Это седьмой доклад, опубликованный совместно Европейским центром по контролю и профилактике заболеваний (ЕЦКЗ) и Европейским региональным бюро ВОЗ (ЕРБ ВОЗ) в продолжение работы в рамках проекта EuroTB, учрежденного в 1996 году.

## Европейский регион ВОЗ

Несмотря на заметный прогресс, достигнутый за последнее десятилетие, в большинстве стран Европейского региона ВОЗ, туберкулез (ТБ) по-прежнему остается значимой проблемой общественного здравоохранения.

По оценкам, в 2013 году в Европейском регионе ВОЗ расчетное число новых случаев заболевания ТБ и рецидивов составило 360 000 (в диапазоне 340 000–370 000), что эквивалентно в среднем 39 случаям (38–41) на 100 000 населения. Восемьдесят пять процентов случаев заболевания ТБ в Регионе приходятся на 18 стран высокого приоритета по борьбе с ТБ в Регионе<sup>2</sup>. В 2013 году абсолютное число случаев заболевания ТБ сократилось на 20 000 по сравнению с предыдущим годом, что соответствует снижению на 5,6%. С 2001 года показатель заболеваемости ТБ снижается в среднем на 4,3% в год.

В 2013 году, по оценкам, насчитывалось всего 460 000 случаев активного ТБ (в диапазоне 350 000–590 000), что эквивалентно 51 (39–65) случаев на 100 000 населения. При сохранении тенденции к снижению распространённости достижение целевого показателя Цели тысячелетия в области развития (ЦРТ), а именно 50%-го сокращения распространённости ТБ к 2015 году от исходного показателя 1990 года, представляется невозможным.

В 2013 году расчетное число случаев смерти от ТБ среди ВИЧ-отрицательных лиц в Европейском регионе составило 38 000, что эквивалентно показателю смертности 4,1 на 100 000 населения (в диапазоне 4,0–4,2). Тем не менее, несмотря на последовательное снижение расчетного показателя смертности, наблюдаемое в течение последних 12 лет, целевой показатель ЦРТ по смертности ТБ в Регионе не будет достигнут.

За период 2004–2013 годов показатель регистрации новых случаев ТБ и рецидивов сократился почти на 20% с 40,3 до 32,8 случаев на 100 000 населения. Данная тенденция отражает истинное сокращение темпов распространения заболевания, большое влияние на которое оказало уменьшение показателя регистрации новых случаев ТБ и рецидивов на 17,7% в 18 странах

высокого приоритета по ТБ в Регионе (с 77,8 до 64,0 случаев на 100 000 населения).

В 2013 году в структуре впервые выявленных случаев ТБ, зарегистрированных в Европейском регионе, преобладала возрастная группа 25–44 лет (44%). Доля впервые выявленных больных ТБ в возрасте младше 15 лет в Регионе составила около 4%.

В 2013 году в Европейском регионе было выявлено 17 096 (81,4%) из расчетного 21 000 случаев ТБ с сочетанной ВИЧ-инфекцией, исходя из расчетного показателя распространенности ВИЧ-инфекции среди впервые выявленных больных ТБ и рецидивов на уровне 5,8%. В связи с низким охватом тестированием на ВИЧ (68%), соответствующий статус был известен только у 219 095 больных ТБ, у 17 096 из которых была выявлена сочетанная ВИЧ-инфекция. Более того, имело место заметное уменьшение охвата антиретровирусной терапией (АРТ) ВИЧ-инфицированных больных ТБ (с 62,3% в 2012 году до 53,8% в 2013 году).

В целом, 6,4% бремени ТБ в Регионе приходится на долю лишения свободы. В странах Евросоюза и Европейской экономической зоны доля случаев ТБ в местах лишения свободы составила лишь 1,6% от числа всех новых случаев ТБ, выявленных в стране, в то время как соответствующий показатель в странах, не являющихся членами Европейского союза, составил 7,4%. В целом, показатель регистрации впервые выявленных случаев ТБ в тюрьмах в Европейском регионе ВОЗ составил 893 на 100 000 населения, что свидетельствует о том, что риск развития ТБ в местах лишения свободы в среднем в 23 раза выше, чем среди гражданского населения в целом.

Из 75 000 расчетных случаев ТБ с множественной лекарственной устойчивостью (МЛУ), имевших место в Европейском регионе в 2013 году, 34 941 (46,6%) случаев был выявлен в 2013 г. Распространенность МЛУ среди впервые выявленных больных ТБ легких в Регионе составила 16,9% и 48,0% среди ранее леченных больных. Информация о результатах тестов на лекарственную чувствительность к препаратам второго ряда (ТЛЧ ПВР) остается неполной, т.к. соответствующие данные предоставляют не все страны, и в целом охватывает 12% от всех зарегистрированных случаев МЛУ-ТБ. Охват ТЛЧ ПВР в странах, предоставляющих данные, составил 56,4%. Всего было выявлено 532 случая ТБ с широкой лекарственной устойчивостью (ШЛУ), что эквивалентно распространенности ШЛУ-ТБ среди больных МЛУ-ТБ на уровне 12,7%.

В 2013 году отмечалось дальнейшее расширение охвата лечением противотуберкулезными препаратами второго ряда. Всего на лечение МЛУ-ТБ было взято 46 710 больных, из которых диагноз МЛУ-ТБ был

<sup>2</sup> Восемнадцать стран высокого приоритета (СВП): Азербайджан, Армения, Беларусь, Болгария, Грузия, Казахстан, Кыргызстан, Латвия, Литва, Республика Молдова, Россия, Румыния, Таджикистан, Туркменистан, Турция, Узбекистан, Украина, Эстония.

подтвержден у 45 147. В 2013 году отношение числа больных, начавших лечение МЛУ-ТБ, к числу зарегистрированных больных составило 116,7% или 110,7%, включая случаи ТБ с устойчивостью к рифампицину (РУ-ТБ). В некоторых странах число больных, взятых на лечение, превышало общее число зарегистрированных случаев, т.к. на лечение брались также больные МЛУ-ТБ, выявленные в прошлом.

Показатель успешного лечения впервые выявленных случаев и рецидивов ТБ составил 75,6%. Среди ранее леченных больных (за исключением случаев рецидивов) он составил 57,1%. Показатель успешного лечения в когорте больных МЛУ-ТБ составил 46,0%, что ниже соответствующего показателя за 2012 год.

Учитывая все вышесказанное и тот факт, что основное бремя ТБ приходится на долю 18 стран высокого приоритета Европейского региона (85% - заболеваемость ТБ, 86% - распространенность, 90% - смертность от ТБ, 90% случаев сочетанной инфекции ТБ/ВИЧ и 99,5% случаев МЛУ-ТБ), основные усилия по борьбе и профилактике ТБ в Регионе должны предприниматься именно в этих странах.

В сотрудничестве с национальными и международными партнерами, а также организациями гражданского общества Европейское региональное бюро ВОЗ реализует Комплексный план действий по профилактике и борьбе с туберкулезом с множественной и широкой лекарственной устойчивостью 2011–2015 на региональном уровне, а также оказывает помощь государствам-членам в разработке научно-обоснованных мероприятий с целью совершенствования профилактики и контроля ТБ и М/ШЛУ-ТБ. Все страны с высоким бременем МЛУ-ТБ, за исключением Российской Федерации, в соответствии с региональным планом подготовили и завершили оформление национальных планов действий по борьбе с МЛУ-ТБ. В некоторых странах министерствам здравоохранения еще предстоит официально утвердить национальные планы действий.

Европейское региональное бюро ВОЗ учредило Европейский комитет зеленого света и Европейскую лабораторную инициативу с целью оказания помощи странам в разработке и/или адаптации национальных планов ответных действий в ответ на угрозу М/ШЛУ-ТБ. Это позволит странам уменьшить долю случаев МЛУ-ТБ среди ранее леченных больных на 20%, выявить 85% от расчетного числа больных МЛУ-ТБ и успешно пролечить минимум 75% из них.

## Страны Европейского союза и Европейской экономической зоны

В 2013 году в 30 странах ЕС/ЕЭЗ сообщалось о 64 844 случаях ТБ что на 6,0% меньше, чем в 2012 году, и является отражением снижения показателей в 19 странах. Показатель регистрации случаев ТБ в странах ЕС/ЕЭЗ составил 12,7 на 100 000 населения и продолжает долгосрочную тенденцию к снижению.

Из числа всех зарегистрированных случаев ТБ 77,9% были впервые выявленные, и 74,3% впервые выявленных случаев ТБ легких были подтверждены результатами посева, мазка или теста амплификации нуклеиновых кислот. Двадцать восемь процентов всех больных ТБ имели иностранное происхождение, большинство проживали в странах с низкой заболеваемостью ТБ.

В целом, все взрослые возрастные группы были равномерно затронуты ТБ. На долю детей в возрасте младше 15 лет пришлось 4,1% от всех 64 844 случаев ТБ; показатель регистрации случаев ТБ в этой возрастной группе составил 3,3 на 100 000 населения. Странами с самыми высокими по возрасту показателями регистрации случаев ТБ у детей были все страны высокого приоритета. В структуре больных ТБ мужчины преобладали практически во всех государствах-членах ЕС/ЕЭЗ, при этом гендерный дисбаланс был наиболее выраженным среди лиц в возрасте от 45 до 64 лет.

ТБ с множественной лекарственной устойчивостью (МЛУ) был зарегистрирован у 4,1% больных, имевших результаты тестов лекарственной чувствительности (ТЛЧ) (2,6% впервые выявленных больных ТБ и 17,0% ранее леченных больных ТБ легких), по-прежнему МЛУ-ТБ наиболее распространен в трех странах Балтии. Туберкулез с широкой лекарственной устойчивостью (ШЛУ) был зарегистрирован у 17,5% из 963 больных МЛУ-ТБ, которым были проведены тесты лекарственной чувствительности к противотуберкулезным препаратам второго ряда.

Всего 73,5% больных, зарегистрированных в 2012 году, 37,8% больных МЛУ-ТБ, зарегистрированных в 2011 году, и 25,9% больных ШЛУ-ТБ, зарегистрированных в 2010 году, успешно завершили лечение.

Из всех больных ТБ с известным статусом ВИЧ 4,9% больных имели сочетанную ВИЧ-инфекцию.

# 1. Background and technical note





# 1. Background and technical note

Between 1996 and 2007, TB surveillance data from the European Region were collected and analysed annually under the 'EuroTB' project.

Since 1 January 2008, ECDC and the WHO Regional Office for Europe have jointly coordinated the collection and analysis of TB surveillance data in Europe, aiming to ensure data standardisation and high quality across the countries of the WHO European Region. The underlying standards and definitions have been agreed by leading European experts [1]. The definitions used in this report follow the latest WHO revised definitions [2].

This report covers the 53 countries of the WHO European Region plus Liechtenstein. These countries are collectively referred to as the 'European Region'.

The data published in this report may differ from figures in national reports due to variation in reporting periods. The deadline for updating the data used in this report was 1 October 2014.

## 1.1 Data reporting and analysis

Designated experts within the national surveillance institutes submitted their TB surveillance and control programme management data for 2013 electronically to the ECDC–WHO/Europe Joint TB Information System via a common portal<sup>3</sup>. The TB surveillance data from the European Union and European Economic Area (EU/EEA) countries were redirected to The European Surveillance System (TESSy) platform hosted by ECDC (Annex 1). The surveillance data from the non-EU/EEA countries and the programme management data from the entire European Region were processed through WHO's Tuberculosis Monitoring and Evaluation (TME) platform in aggregated format. A total of 30 EU/EEA Member States reported case-based data<sup>4</sup>. All countries in the European Region were also asked to provide updates for 2010, 2011 and 2012 to allow for the exclusion of duplicate cases or those later found not to have TB, as well as for updates of treatment outcome variables.

The TESSy variable list for collection of the 2013 data (Annex 2) has not undergone any changes compared to the previous year. Reporting completeness (Annex 3) varied among countries due to differences in legislation, national surveillance systems and TB case ascertainment. Although the quality and comparability of reported data have improved in recent years, the reader should still be cautious when making comparisons across countries. Data from Italy and France have been noted as provisional. For the calculation of notification rates, country total population denominators by age group and gender were obtained

from Eurostat<sup>5</sup> (13 August 2014 update) for the EU and EEA countries and from United Nations Population Division statistics<sup>6</sup> for all others.

Reported data were analysed according to the main epidemiological (time, place, gender, age, patient origin) and case management determinants (history of previous anti-TB treatment, localisation of disease, laboratory results, HIV serostatus and treatment outcome). Associations between variables were quantified as prevalence ratios and their 95% confidence intervals, assuming an association if the confidence interval did not include 1.

### TB/HIV co-infection

Case-based HIV serostatus was reported by Belgium, Bulgaria, Czech Republic, Estonia, Greece, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, Portugal, Romania, Slovakia, Slovenia and Spain. The Netherlands and all non-EU/EEA countries submitted this information in aggregate format via WHO's TME platform. Cyprus and Denmark reported the number of HIV-infected TB cases, but not the denominator of known HIV test results, and were therefore excluded from the analysis. The number of cases with known HIV status was expressed as a percentage of all reported TB cases. HIV status had to be available for >50% of all TB cases to be considered complete in the country profiles.

### Drug resistance

Since the reporting year 1998, the results of drug susceptibility testing (DST) from initial isolates of *Mycobacterium tuberculosis* have been collected for isoniazid, rifampicin, ethambutol and streptomycin. Data on second-line drug resistance to amikacin, kanamycin, capreomycin, ciprofloxacin and ofloxacin have been reported via TESSy since 2008 and via CISID/TME since 2009. Data on resistance to gatifloxacin, levofloxacin and moxifloxacin were added in 2013. In countries where DST results are linked to TB case notifications, case-based information on DST is collected (27 countries in 2013). When individual DST data are not available, data are collected in aggregate format in CISID/TME on the basis of previous anti-TB treatment history. Information on the organisation and laboratory practices of anti-TB DST in the country is also collected using the TME module of the joint TB surveillance system. Drug resistance surveillance (DRS) methods vary across countries. Initial DST results may be collected routinely for all culture-positive TB cases notified, or only for cases included in specific surveys or diagnosed in/referred to selected laboratories. Geographic coverage of DRS is incomplete in France, Greece, Italy, Kazakhstan, Kyrgyzstan, Romania,

<sup>3</sup> ECDC/WHO/Europe Joint Surveillance  
<http://www.ecdcwhosurveillance.org/>

<sup>4</sup> As Liechtenstein has not provided any TB data, except for five cases in 2007, it is not included in the commentary.

<sup>5</sup> Available from: <http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home/>

<sup>6</sup> Population by UN Population Division, World Population Prospects: The 2013 Revision, medium variant (2014).

Portugal, Spain, Tajikistan, Turkey, Turkmenistan and Uzbekistan.

DRS data were considered complete if:

- they were collected nationwide and linked to TB case notifications in countries routinely using culture (> 50% culture confirmation);
- DST results for isoniazid and rifampicin were available for ≥75% of culture-positive cases;
- at least 95% of external quality assessment (EQA) results were confirmed by a supranational reference laboratory.

Percentages of laboratory-confirmed drug-resistant cases were calculated using as the denominator cases for which DST results were available (at least isoniazid and rifampicin). If the cases had DST results for ethambutol and streptomycin, these were shown under resistance to any TB drugs. The results of DST for second-line drugs were analysed for MDR TB cases only.

### Treatment outcome monitoring (TOM)

Since the reporting year 2002, treatment outcome data have been provided by EU/EEA countries through the submission of an updated dataset for cases notified one year prior to the year of reporting. The same applies to MDR TB treatment outcome for cases reported two years earlier and XDR TB treatment outcome for cases reported three years earlier. Thus, as part of the 2014 data call, outcome data were collected for TB cases reported in 2012, MDR TB cases reported in 2011 and XDR TB cases reported in 2010. Non-EU/EEA countries have reported aggregated treatment outcome data for the past three years. This report includes a data analysis for outcome at 12 months, outcome at 24 months and outcome at 36 months after starting treatment.

For the purpose of TOM analysis, two types of cases were considered: (i) cases with a known treatment start; (ii) cases with no indication of treatment. For countries reporting case-based data, the most recently updated information was used. This could result in denominators differing from the number of notified cases reported in the previous year's report. For countries reporting aggregate outcome data, completeness of cohorts is assessed by comparing the total number of cases included in TOM cohorts with those initially notified as pulmonary and culture or smear-positive, depending on the type of cohort.

### Geographical areas

The following 28 EU Member States and three EEA countries are presented separately in tables and in Chapter 2.2: Austria, Belgium, Bulgaria, Cyprus, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom.

The 23 remaining countries in the WHO European Region (non-EU/EEA) are: Albania, Andorra, Armenia, Azerbaijan,

Belarus, Bosnia and Herzegovina, Georgia, Israel, Kazakhstan, Kyrgyzstan, the former Yugoslav Republic of Macedonia, Moldova, Monaco, Montenegro, Russia, San Marino, Serbia, Switzerland, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan.

Data from Serbia include TB cases reported from Kosovo, and these are also stratified separately in tables to reflect UN Security Council Resolution No. 1244 (1999).

In order to highlight the 18 high-priority countries (HPC) [3] identified by WHO, their data are presented in italics and as subtotals alongside the subtotals for the EU/EEA and non-EU/EEA Member States. The 18 high-priority countries in the WHO European Region are: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan.

TB notifications from France include overseas territories. TB notifications from Greenland (totalling 96 TB cases – 84 new and twelve relapse cases) are not included in the totals for the European Region.

## 1.2 Definitions

### TB case definition for surveillance

Information from EU/EEA countries was collected to enable the classification of cases according to the case definition approved by the EU Member States and published by the European Commission<sup>7</sup>. It classifies cases as 'possible', 'probable' or 'confirmed'. Possible cases meet clinical criteria only. Probable cases are defined by the additional detection of acid-fast bacilli (AFB) or *M. tuberculosis* nucleic acid or granulomata. Confirmed cases require a positive culture or detection of both AFB with microscopy and *M. tuberculosis* in nucleic acid amplification testing.

Data from the remaining countries in the European Region follow the WHO-recommended definitions – 2013 revision<sup>8</sup>. They define a 'case of tuberculosis' as a patient in whom TB has been confirmed by bacteriology or diagnosed by a clinician. A 'bacteriologically confirmed TB case' is one from whom a biological specimen is positive by smear microscopy, culture or WHO-approved rapid diagnostics (WRD) such as Xpert MTB/RIF.

A 'clinically diagnosed TB case' does not fulfil the criteria for bacteriological confirmation, but has been diagnosed with active TB by a clinician or other medical practitioner who has decided to give the patient a full course of TB treatment.

Cases discovered post-mortem, with gross pathological findings consistent with active TB that would have indicated

7 European Union Commission. 2008/426/EC: Commission Decision of 28 April 2008 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council (notified under document number C(2008) 1589). OJ L 159, 18.06.2008, p. 46

8 World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision, Geneva: WHO, 2013. WHO/HTM/TB/2013.2

anti-TB treatment, had the patient been diagnosed before dying, also fit the clinical criteria and are included.

### Previous anti-TB treatment status

**New patients** have never been treated for TB or have taken anti-TB drugs for less than one month.

**Previously treated patients** have received one month or more of anti-TB drugs in the past. They are further classified by the outcome of their most recent course of treatment as follows:

- **Relapse:** patients have previously been treated for TB, were declared cured or to have completed their treatment at the end of their most recent course of treatment, and are now diagnosed with a recurrent episode of TB (either a true relapse or a new episode of TB caused by reinfection).
- **Treatment after failure:** patients who have previously been treated for TB and whose treatment failed at the end of their most recent course of treatment.
- **Treatments after loss to follow-up:** patients have previously been treated for TB and were declared lost to follow-up at the end of their most recent course of treatment. (These were previously classified as ‘treatment after default’).
- **Other previous treatment:** patients who have previously been treated for TB but whose outcome after their most recent course of treatment is unknown or undocumented.

**Patients with unknown previous TB treatment history** do not fit any of the categories listed above.

New cases and relapses of TB are **incident TB cases**.

### Site of disease

**Pulmonary tuberculosis (PTB)** refers to any bacteriologically confirmed or clinically diagnosed case of TB involving the lung parenchyma or the tracheobronchial tree (laryngeal TB is included for EU/EEA countries). A patient with both pulmonary and extrapulmonary TB should be classified as a case of PTB.

**Extrapulmonary tuberculosis (EPTB)** refers to any bacteriologically confirmed or clinically diagnosed case of TB involving organs other than the lungs, e.g. pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones or meninges.

### Notes on the definition

- The above definitions are in accordance with the European Commission’s approved definitions for TB surveillance.
- All possible, probable and confirmed cases are reported to the joint European surveillance database. For countries with laboratory-based reporting where no clinical information is available, laboratory-confirmed cases should be reported.
- Cases should be notified only once in a given 12-month period. However, a case should be reported again if the

diagnosis of confirmed tuberculosis is made following completion of anti-TB treatment (relapse), even if this occurs within 12 months of reporting the initial episode of disease.

- Cases which have never been treated are commonly referred to as new cases, although this term should not be considered to indicate incidence in the strict epidemiological sense.
- Among re-treated cases, relapses are included in notifications from all countries, whereas cases re-treated after failure or default and chronic cases are not included or further defined by Belgium, Czech Republic, Denmark, France, Ireland, Italy, Norway, Spain and United Kingdom.
- DST data were analysed for laboratory-confirmed cases.

### Origin

The geographic origin of a TB case is classified according to place of birth (born in the country/foreign origin) for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Iceland, Ireland, Israel, Italy, Kyrgyzstan, Latvia, Lithuania, Luxembourg, the former Yugoslav Republic of Macedonia, Malta, Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Tajikistan, Turkey, United Kingdom and Uzbekistan. Albania, Andorra, Austria, Armenia, Belarus, Belgium, Bosnia and Herzegovina, Georgia, Greece, Hungary, Kazakhstan, Moldova, Montenegro, Poland, Russia, Serbia, Turkmenistan and Ukraine used citizenship (citizen/non-citizen) for classification. Azerbaijan, Liechtenstein, Monaco, and San Marino did not report any cases or information on origin. In Denmark, the birthplace of the parents is also used to classify origin (similarly, in the Netherlands, the birthplace of parents is notified for case management purposes). The country of origin is included in case-based data. The term ‘native’ as used in this report refers to cases born in, or having the citizenship (nationality) of the reporting country. ‘Foreign origin’ refers to cases born in (or citizens of) a country different from the reporting country. Notification rates in Table III are calculated on the basis of the total population of the respective country.

### Drug resistance

**Resistance among cases never treated:** indicates primary drug resistance due to infection with resistant bacilli.

**Resistance among cases previously treated:** usually indicates acquired drug resistance emerging during treatment as a consequence of selection of drug-resistant mutant bacilli. It can also result from exogenous re-infection with resistant bacilli.

**Multidrug resistance (MDR):** resistance to at least isoniazid and rifampicin.

**Extensive drug resistance (XDR):** resistance to (i) isoniazid and rifampicin (i.e. MDR), and (ii) resistance to a

fluoroquinolone, and (iii) resistance to one or more of the following injectable drugs: amikacin, capreomycin, or kanamycin [4].

**Rifampicin resistance:** resistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-TB drugs. This includes any resistance to rifampicin, whether monoresistance, multi-drug resistance, polydrug resistance or extensive drug resistance.

## Treatment outcome

### Cohort

All TB cases notified in the calendar year of interest, after exclusion of cases with a final diagnosis other than TB or cases found to have been reported more than once.

In accordance with the new WHO treatment outcome definitions, two types of case were considered:

- patients treated for drug-susceptible TB
- patients treated for drug-resistant TB using second-line treatment (defined as combination chemotherapy for drug-resistant tuberculosis).

The two groups are mutually exclusive. Any patient found to have drug-resistant TB and placed on second-line treatment is removed from the drug-susceptible TB outcome cohort.

Note: 24-month outcome was collected for MDR TB cases notified in 2011 and 36-month outcome was included for XDR TB cases notified in 2010.

### Period of observation

Cases are observed until the first outcome up to a maximum of 12 months after the start of treatment. For MDR TB cases in EU/EEA countries, treatment outcome after 24 months should be reported if treatment lasts longer than 12 months and the reported 12-month outcome is coded as 'still on treatment'<sup>9</sup>. For XDR TB cases in EU/EEA countries, treatment outcome after 36 months should be reported if treatment lasts longer than 24 months and the reported 12-month and 24-month outcomes are coded as 'still on treatment'<sup>10</sup>. Non-EU/EEA countries evaluate treatment outcomes according to the WHO definition.

### Treatment outcome categories

All outcome categories but one apply to the entire region and follow the recommendations in 'Definitions and reporting framework for tuberculosis – 2013 revision'. The additional category: 'still on treatment' only applies to the EU/EEA Member States [5]. The categories are as follows:

**Cured:** A pulmonary TB patient with bacteriologically confirmed TB at the beginning of treatment who was smear- or culture-negative in the last month of treatment and on at least one previous occasion.

**Cured for MDR TB:** Treatment completed as recommended under national policy without evidence of failure AND three or more consecutive cultures taken at least 30 days apart are negative after the intensive phase.

**Treatment completed:** Treatment completed, but does not meet the criteria to be classified as cure or treatment failure.

**Treatment failed:** A TB patient whose sputum smear or culture is positive at month 5 or later during treatment.

**Treatment failed for MDR TB case:** Treatment terminated or need for permanent regimen change of at least two anti-TB drugs because of:

- lack of conversion by the end of the intensive phase, or
- bacteriological reversion in the continuation phase after conversion to negative, or
- evidence of additional acquired resistance to fluoroquinolones or second-line injectable drugs, or
- adverse drug reactions (ADRs).

**Died:** A TB patient who dies for any reason before starting or during the course of treatment.

**Lost to follow-up:** A TB patient who did not start treatment or whose treatment was interrupted for 2 consecutive months or more.

### Still on treatment<sup>11</sup>:

- patient still on treatment at 12 months without any other outcome during treatment;

or

- patient reported as still on treatment at 12 months and still on treatment at 24 months without any other outcome.

**Not evaluated:** A TB patient for whom no treatment outcome is assigned. This includes cases 'transferred out' to another treatment unit as well as cases for whom the treatment outcome is unknown to the reporting unit.

In this report:

**Success:** The sum of 'cured' and 'treatment completed'.

<sup>9</sup> The degree of adherence to the 12-month limit is unknown, and a number of countries are known to exceed it.

<sup>10</sup> The degree of adherence to the 24-month limit is unknown.

<sup>11</sup> Definition applicable to the EU/EEA countries only.

## 2. Commentary



## 2. Commentary

### 2.1 The WHO European Region

#### Tuberculosis burden estimates (incidence, prevalence and mortality)

In 2013, an estimated 360 000 new and relapse TB cases (range 340 000–370 000) occurred in the WHO European Region, equivalent to an average incidence of 39 cases (38–41) per 100 000 population. This represents about 4% of the total burden of tuberculosis in the world. During 2013, the absolute number of incident TB cases in the WHO European Region fell by 20 000 compared to the previous year, reflecting the decrease in TB observed throughout the Region over the last 12 years. The vast majority of estimated TB cases occur in the 18 high-priority countries<sup>12</sup>. These countries account for 85% of the total incident TB cases in the region. Countries with the largest absolute number of incident TB cases were Russia (130 000), Ukraine (44 000), Kazakhstan and Uzbekistan (23 000 each). The number of TB cases relative to population (incidence rate) was highest in Moldova (159 per 100 000 population), followed by Kyrgyzstan (141 per 100 000 population), Kazakhstan (139 per 100 000 population), Georgia (116 per 100 000 population) and Tajikistan (100 per 100 000 population).

Tuberculosis incidence in the WHO European Region increased rapidly from 1990 onwards, reaching a peak around 1999–2000, but since 2001 it has been falling at an average rate of 4.5% per year, which is the fastest decline in the world<sup>13</sup>. Consequently, the Millennium Development Goal (MDG) target for the Region – to reverse the incidence of TB – has been met. All the high-priority countries in the Region have experienced a decline in TB incidence rate.

In 2013, there were an estimated 460 000 prevalent TB cases (range 350 000–590 000), which is equivalent to 51 (39–65) cases per 100 000 population. The 18 high-priority countries collectively account for 86% of prevalent TB cases in the Region. In 1990, TB prevalence in the WHO European Region was estimated at around 67 cases per 100 000 population. It then increased until 1998, reaching a rate of 110 cases per 100 000. Since then the trend has been steadily declining. However, achieving the MDG target of a 50% reduction by 2015 does not seem feasible.

There were an estimated 38 000 TB deaths among HIV-negative people in the European Region in 2013, equivalent to 4.1 deaths per 100 000 population (range 4.0–4.2). It is estimated that an additional 3 800 TB deaths occurred in 2013 among HIV-positive TB cases in the Region. The TB mortality rate is highest in Turkmenistan (25 cases per 100 000), followed by Moldova and Ukraine (14 cases per

100 000 in each). In the EU/EEA region the TB mortality rate is below one case per 100 000 population. Russia alone accounts for 45% of the TB deaths in the European Region and the 18 high-priority countries together comprise 90% of TB deaths in the Region.

Yet, despite a constant decline in estimated mortality observed over the past 12 years, the MDG target of 50% reduction in TB mortality by 2015 against the 1990 baseline will not be achieved in the Region.

In 2013, HIV infection contributed to 5.8% of the total incident (new and relapse) TB cases occurring in the Region, 4.0% (3.8–4.3) in the EU/EEA group of countries and 6.3% (6.0–6.7) in the non-EU/EEA group of countries (Table 2). The countries with comparatively high estimates of HIV proportions are Latvia (20%), Portugal (18%), Ukraine (16%), Estonia (12%) and France (11%).

#### Overall TB notification by previous treatment history

In 2013, a total of 360 420 TB cases were reported from 51 countries<sup>14</sup> in the WHO European Region (40 per 100 000 population) (Table 3). This represents a 10.8% drop against the 2009 rate (44.6 per 100 000), 1.8% against 2012 (40.5) and a 2.8% mean annual decrease for the period 2009–2013.

During the period 2004–2013, an overall downward trend of 18.6% was observed in the notification of incident TB cases, from 40.3 to 32.8 cases per 100 000 population (Table 4). This trend reflects a true reduction in the spread of the disease, strongly influenced by the 17.7% decrease in notification rates in the Region's 18 high-priority countries (from 77.8 to 64.0 per 100 000 population). Before 2004 there was a sustained plateau in the notification rate for new TB and relapses. Despite encouraging trends, the notification rate of new and relapse cases in the high-priority countries remained twice as high as for the Region overall (64 cases per 100 000 compared to 33 for the Region) and over five times higher than the rate in the EU/EEA (12 cases per 100 000 population).

The notification rate of new and relapse cases varies widely among countries, from 3.4 (Iceland) to 129 (Moldova) per 100 000 population (Table 4). In addition to Moldova, there were two countries with notification rates above 100 per 100 000 population for new and relapse cases: Kyrgyzstan (128), and Kazakhstan (115).

In 2013, the number of countries with low notification of new and relapse cases (less than 20 cases per 100 000) [1] was 37. Most of these 37 countries are in the western and central part of the Region and the majority of them

<sup>12</sup> The 18 high-priority countries are: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan.

<sup>13</sup> World Health Organization Global Tuberculosis Report 2014, page 17

<sup>14</sup> There are 53 countries in WHO European Region. Monaco and San Marino did not report data in 2013.

represent high-income countries<sup>15</sup>. Six countries reported new or relapse case rates between 20 and 50 per 100 000 population. Nine reported between 50 and 100 cases per 100 000 population: Ukraine (81), Georgia (79), Romania (78), Russia (74), Uzbekistan (72), Tajikistan (68), Azerbaijan (62), Turkmenistan (58) and Lithuania (53). The 18 high-priority countries with new and relapse case notifications account for about 85% of the regional burden, with the largest contribution coming from Russia: 36% of the new and relapse cases (106 053) are from Russia.

The percentage of reported cases that had previously been treated was 24.7 (Table 5). In 2013, previously treated cases represented 11.7% and 27.5% in the EU/EEA and non-EU/EEA respectively. There were 13 countries in which previously treated cases accounted for 15% or more of all TB cases: Kazakhstan (37.0%), Russia (36.4%), Uzbekistan (34.2%), Moldova (28.1%), Georgia (27.5%), Belarus (26.4%), Armenia (25.7%), Romania (23.0%), Estonia (21.3%), Kyrgyzstan (18.7%), Lithuania (18.3%), and Tajikistan (18.3%) and Slovakia (15.0%). Reasons for the high percentage of previous treatment among all cases include clinical failures and lack of programme management, possible re-infection and/or misclassification. TB cases with unknown treatment history were more often notified by countries in the western part of the Region. These included four countries where more than 25% of the TB cases identified had no previous treatment history: Luxemburg (100%), Germany (67.1%), France (41.7%) and Ireland (30.2%). Azerbaijan was the only country from the HPCs which did not provide data on TB notification by previous treatment.

### Disease localisation

In 2013, pulmonary localisation was notified in about 80% of the overall TB cases in the Region. In EU/EEA countries the proportion of pulmonary localisation was somewhat lower (77%) than in non-EU/EEA countries (81%). Data completeness on disease localisation in the Region is comparable to that for 2012, with only 7% of notifications having an unknown site of disease. However, four non-EU/EEA countries still need to improve their notification by disease localisation: Azerbaijan (no sites reported), Uzbekistan (15.7%), Georgia (12.9% unknown) and Switzerland (11.4% unknown). Extra-pulmonary TB was notified on average for 13% of all TB cases in the Region. However, seven countries (with at least 100 TB cases) reported more than 30% of their tuberculosis cases having extra-pulmonary localisation and three of these countries had percentages exceeding 40%: United Kingdom (47.6%), the Netherlands (46.3%) and Sweden (43.2%).

### Bacteriological confirmation

Laboratory confirmation of TB diagnosis was reported for 115 484 (57.1%) of all 202 093 new pulmonary cases in the Region; 105 288 (52.1%) cases were confirmed by culture and 10 196 (5.0%) by microscopy (Table 7). New rapid methods to support TB diagnosis have been scaled up in most of the countries in the Region. This explains

the notable increase in the proportion of culture-confirmed cases among new pulmonary TB cases from 45.9% in 2012 to 52.1% in 2013. Despite this increase, the proportion of culture confirmed cases among newly-detected pulmonary TB cases was lower in non-EU/EEA countries than in EU/EEA countries (48.1 versus 69.0%) (Table 7). In 10 countries over 30% of new pulmonary cases were sputum-smear-negative and culture-positive, underlining the need to culture smear-negative isolates: Latvia (45.7%), Denmark (45.3%), Slovenia (40.8%), Belgium (39.1%), Kazakhstan (37.7%), Estonia (35.0%), Czech Republic (33.8%), Belarus (33.3%), Finland (32.4%) and Austria (31.4%).

### Age and gender

There were twice as many males as females reported among all TB cases (Table 10), however a large variation was observed for male predominance in the gender distribution of TB cases, ranging from almost even distribution in Slovenia (1.0:1) to three times greater in Armenia (3.2:1). There were 16 other countries where the male to female ratio among TB cases was greater than two to one: Albania, Andorra, Armenia, Azerbaijan, Belarus, Czech Republic, Estonia, the former Yugoslav Republic of Macedonia, Georgia, Greece, Israel, Lithuania, Malta, Moldova, Russia and Ukraine. This gender difference in TB case notification most likely reflects the overrepresentation of males in the various TB risk groups, notably the homeless, prisoners, seasonal migrant workers and HIV-infected individuals among men who have sex with men (MSM) and people who inject drugs (PWID).

In 2013, most (44%) of the newly detected TB cases in the European Region were in the 25–44 year age group (Table 10). This was also the most affected age group in both EU/EEA and non-EU/EEA countries compared to other age groups, with age-specific notification rates of 15.1 and 86.5 new TB cases per 100 000 respectively. In 11 countries the oldest age group (65+ years) contained more than 25% of the new TB cases: Finland (47.4%), Slovenia (41.7%), Bosnia and Herzegovina (39.8%), Croatia (36.0%), Serbia (32.5%), Czech Republic (31.4%), Iceland (27.3%), Greece (26.5%), Slovakia (26.6%), Poland (26.1%), and Germany (27%).

In countries with at least 100 new TB cases the proportion of notified childhood TB cases varied at the country level from 0.3% (Belarus) to 10.1% (Kyrgyzstan) of all new cases. The difference in proportions of childhood TB cases across the countries may reflect differences in case-finding practice (e.g. contact tracing), population age-structure and under-/over-diagnosis or -reporting of childhood TB. The average percentage of new TB patients under 15 years in the Region is 4.1%. In 10 countries with middle income economies the proportion of child TB cases was below 5%, indicating external inconsistency of surveillance systems. These countries were Armenia (3.0%), Albania (4%), Azerbaijan (4.7%), Belarus (0.3%), Bosnia Herzegovina (1.0%), Kazakhstan (2.7%), Moldova (3.0%), Romania (4.5%), Serbia (1.2%), and Ukraine (1.7%).

<sup>15</sup> High-income countries are those with a per capita gross national income of USD 12 476 or more in 2011, as defined by the World Bank (<http://data.worldbank.org/about/country-classifications>).



### Origin of cases

TB cases of foreign origin represent 28.0% of the total TB cases reported from EU/EEA countries and only 1.6% from non-EU/EEA countries (Table 11). In many countries, TB cases of foreign-origin represent a large majority: Luxemburg (94.7%), Sweden (88.7%), Malta (88.0%), Norway (86.0%), Cyprus (85.4%), Israel (82.5%), Netherlands (73.9%), Switzerland (75.3%), and United Kingdom (70.1%). This is also an indication that access to TB diagnosis in these countries is good and that they are committed to the global effort to control TB.

### Drug resistance

In 2013, 47 countries in the Region reported on first-line anti-TB drug susceptibility test (DST) results. The prevalence of MDR TB among 92 384 new pulmonary TB cases tested for first-line DST in the Region was 16.9%, which is notably higher than data for 2012 (15.0%). While 17 countries reported 0 or less than 1% MDR among new TB cases, for seven countries this rate was over 20% (Table 14). With the exception of the Baltic States, where MDR TB among new cases varied from 8.8% in Latvia to 17.3% in Estonia, the prevalence was 4% or lower in all EU/EEA countries. In the non-EU/EEA area, four countries had an MDR TB prevalence ranging from 10–19% among new cases tested for first-line DST. Four countries had 20–29% of MDR TB among new cases: Kyrgyzstan (28.4%), Kazakhstan (26.3%), Moldova (24.5%) and Russia (21.2%). Three countries reported above 30% MDR prevalence among pulmonary TB cases: Tajikistan (34.5%), Belarus (35.2%) and Uzbekistan (36.3%).

The proportion of MDR TB among 40 056 previously treated TB cases whose isolates were tested for first-line DST was 48.0%, comparable to the rate measured in 2012 (47.1%). Fourteen countries had between 15% and 50% MDR TB among previously treated cases tested for first line DST. In six countries this rate was even higher: Moldova (62.1%), Kazakhstan (57.8%), Russia (56.3%), Uzbekistan (56.1%), Kyrgyzstan (55.1%) and Belarus (54.5%) (Table 14).

Trends in the MDR TB notification rate among culture-positive cases with available DST results have differed significantly by country over the past five years (Table IV). Over the last five years the rate of MDR among those new pulmonary TB cases tested for drug resistance remained stable in the EU/EEA, amounting to 2.6% in 2013, while in the non-EU/EEA countries the rate increased from 13.9% in 2008 to 20.8% in 2013.

An analysis of trends in the absolute number of notified MDR TB cases among new cases from countries with universal coverage of DST for bacteriologically-confirmed cases suggests that in some settings the number of MDR TB cases is decreasing (Bulgaria, Estonia, Latvia, Armenia) or has levelled off (Lithuania, Moldova and Turkey). This indicates that with appropriate control measures it is possible to reduce the burden of MDR TB within a short period of time. In many other high-priority countries the increase observed in the absolute number of MDR TB cases might reflect an increased country laboratory capacity to perform DST (for example in Tajikistan, Ukraine and

Uzbekistan). However, for those countries with high DST coverage the increased trends in notified MDR TB cases might be a sign of a true increase in MDR burden among new TB cases (e.g. Belarus, Russia and Ukraine).

In 2013, a total of 39 countries reported second-line DST data (25 EU/EEA and 14 non-EU/EEA countries – see Table 16). Of the 4 176 MDR TB cases subjected to second-line DST, 532 (12.7%) were extensively drug-resistant (XDR TB) which is significantly higher than the 9.1% of XDR prevalence among MDR recorded in 2012. In EU/EEA countries, where 62.9% of MDR TB cases were tested for second-line drugs (SLD), the prevalence of XDR among MDR cases was 17.8%. In non-EU/EEA countries, where 55.1% of notified MDR cases from reporting countries had an SLD DST result, the prevalence of XDR TB cases among MDR cases with second-line drugs DST results was 11.6%. Among the countries reporting at least 30 MDR cases with second line DST results and at least 70% of SLD testing coverage, the highest XDR prevalence was reported in Lithuania (24.7%) followed by Latvia (21.7%) and Georgia (19.2%).


### MDR detection rate

If all notified TB patients with pulmonary TB in the Region had been tested in 2013 for drug resistance to rifampicin and isoniazid, an estimated 75 000 cases of MDR TB would have been found among notified TB patients. In 2013, a total of 34 941 MDR TB cases were detected among notified TB patients in the WHO European Region. This is 46.6% of all estimated cases, indicating notable progress in MDR case detection compared to the baseline (34.5%) documented in 2009. In EU/EEA countries, MDR case detection rate was 89.4% versus 45.2% and 45.7% in non-EU and the 18 high-priority countries respectively. Those countries that are not achieving the 50% MDR case detection rate in the Region are Russia, Bulgaria (33.3% each), Armenia (34.7%) and Uzbekistan (38.4%).

### Enrolment into second-line treatment

A total of 46 710 TB patients were enrolled into MDR treatment in 2013, 42 210 of them having confirmed RR/MDR TB. In 2013, the ratio of the number of patients starting MDR treatment to those notified as having rifampicin-resistant or multidrug-resistant TB (RR/MDR TB) was 116.8% (110.7% when rifampicin-resistant TB cases are included). In a few countries, such as Armenia, Belarus, Georgia and Ukraine, the number of patients enrolled exceeded the total notified. This was due to prevalent MDR cases detected during previous years remaining on the waiting lists for enrolment into MDR treatment. A discrepancy of over 5% between the number of patients enrolled and the number diagnosed was noted in five high-priority countries: Azerbaijan, Bulgaria, Estonia, Tajikistan, and Uzbekistan. The common shortfalls of MDR treatment expansion include shortage of second-line TB drugs and the insufficient capacity of national tuberculosis programmes to manage drug-resistant tuberculosis.

**Figure A:** Trends in the absolute number of notified MDR TB cases in 18 HPCs and combined subtotals fitted with polynomial trend line, 18 HPC, EU/EEA and non EU/EEA countries within the WHO European Region, 2008–2013



HPC: High Priority Countries

**Figure B:** Absolute number of all MDR TB cases and additional rifampicin-resistant TB patients detected compared with those reported to have enrolled on second line treatment 2009–2013 in each of 18 high priority counties, and totally by 18 HPCs and WHO Region, 2009–2013



HPC: High Priority Countries

**Figure C:** Absolute number of TB/HIV cases detected compared with those reported as enrolled on antiretroviral therapy and co-trimoxazole preventive therapy (2007–2013 in each of the 18 HPC, and as a total for the HPC and the EU/EEA, 2007–2013)



HPC: High Priority Countries

## TB/HIV co-infection

Overall, 36 countries provided surveillance data on TB/HIV co-infection. In the reporting countries, of 324 084 notified TB patients 219 095 had documented HIV test results. The total proportion of TB patients with known HIV results was 67.6%. However, it should be noted that testing coverage in the Region is under-estimated due to the fact that Russia only provides HIV testing coverage data for new TB cases. HIV testing coverage was 75% and above in 17 countries of the Region. Seven high-priority countries achieved a testing level above 90%: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Kazakhstan and Uzbekistan.

A total of 17 096 TB cases were detected with HIV-positive status, 7.8 % of those with a recorded test result. This is higher than the 6.1% with HIV-positive status recorded in 2012, indicating that HIV/TB co-infection continues to increase in the Region by an average of 18% annually, as it has done since 2004. Among those countries reporting representative HIV testing (above 50% HIV testing coverage), three documented a significant overlap of the HIV and TB epidemics by exceeding 10% HIV prevalence among new and re-treatment TB cases (Table 18): Ukraine (19.6%), Portugal (14.5%) and Estonia (13.0%). A number of other countries had more than 5% HIV prevalence: Greece (9.6%), Belgium (7.3%), Russia (7.2%), Moldova (6.1%), Spain (6.7%), Belarus and Israel (5.1% each). In 2013, 26 countries in the Region provided information on anti-retroviral therapy (ART) enrolment among TB cases with HIV-positive status. Of 11 492 HIV-positive tuberculosis cases, 6 177 had received ART, which is equivalent to 53.8%. This is significantly lower than in 2012 (62.3%). Among the HPCs there were only four countries that achieved coverage of over 75%: Bulgaria, Belarus, Georgia and Tajikistan.

Reporting on co-trimoxazole preventive therapy (CPT) enrolment was less complete. In total, 20 countries, accounting cumulatively for 41% of notified TB cases, contributed information. Of all the HIV-positive TB cases notified in reporting countries, 55.9% received CPT. This is much lower than the results for 2012 (67.0%) and far below the WHO-recommended coverage of 100%.

## TB in prisons

During 2012, 32 countries in the Region provided information on TB case detection and treatment in prisons. Overall, 6.4% of the new and relapse TB cases reported in the Region were from prisons. In EU/EEA countries the proportion of TB cases in prisons represented only 1.6% of the country total; in non-EU countries the proportion was 7.4%. Among the reporting countries, two had TB cases in prisons exceeding 10% of the country total: Georgia (12.5%) and Russia (10%). In the non-EU/EEA countries, the notification rate in prisons was 1 123 new TB cases per 100 000 population, which is about seven times higher than in the EU/EEA sub-region (165 per 100 000). The overall notification rate for new TB cases in prisons in the WHO European Region was 893 per 100 000 population. The highest TB notification rates in prisons were in Georgia (2 031 per 100 000 detainees), Kyrgyzstan (1 860 per 100 000 detainees), Kazakhstan (1 679 per 100 000 detainees), Tajikistan (1 470 per 100 000

detainees) and Russia (1 329 per 100 000 detainees). The highest TB relative risks in prison are calculated to be in Georgia (28), Tajikistan (23) and Kazakhstan (22). High relative risk in prisons is due to higher TB transmission as a result of poor control measures and/or a concentration of inmates from higher TB risk groups in the civilian population, such as immigrants from high-TB-incidence countries, injecting drug users, etc.

## Treatment outcome

The treatment success rate among 250 299 new TB cases and relapses having started treatment in 2012 was 75.6% (Table 20). The treatment success rate was slightly higher in the EU/EEA countries than in non-EU/EEA countries (77.1% vs. 75.1%). Only 14 countries achieved an 85% treatment success rate in this treatment cohort. Another twelve countries were close to the target, with success rates of 80–85%. Five countries had treatment success rates below 60%.

In the 2012 yearly cohort of new and relapse cases, a total of 17 777 (7.1%) cases were reported to have died, 6.2% to have been lost to follow-up and 5.1% to have had treatment that failed. These unfavourable outcomes were lower in the EU/EEA countries than the rest of the Region, exemplified by the proportion of patients with failed treatment – 0.9% in EU/EEA versus 6.3% in non-EU/EEA countries (Table 20). Countries reporting fatal outcomes in excess of 10% were Czech Republic, Slovenia and Ukraine. Countries reporting the highest failure rate were Russia (8.9%), Turkmenistan (8.5%), Tajikistan (7.3%) and Ukraine (6.6%).

Commonly reported reasons for poor treatment outcomes are HIV co-infection and a significant level of drug use and alcoholism in some countries.

In ten EU/EEA and six non EU/EEA countries the proportion of patients lost to follow-up was above five per cent among new and relapse TB patients.

As expected, the treatment outcome among previously-treated TB cases other than relapses was lower than among new and relapse cases. For 2012, the treatment success rate among the 29 696 previously treated cases other than relapse was 57.1% (Table 21). Unlike the situation for new and relapse TB cases, the success rate was higher in the non EU/EEA countries than in EU/EEA countries (57.4% vs. 54.5%). Nine countries had a treatment success rate of 50% or lower among previously-treated TB cases. Sixteen had a success rate of 70% and above. Among previously treated cases in the Region with unsuccessful outcomes 11.7% died, 11.0% failed and another 13.3% were lost to follow-up.

The treatment outcome for 32 033 RR TB/MDR TB cases, all representing laboratory-confirmed RR TB/MDR TB cases notified in 2011, was reported by 38 countries (Table 24). For the whole Region the treatment success among MDR TB cases was 46.0%, which is lower than the 49% treatment success rate reported for 2010 MDR treatment cohort. The proportion of successfully treated RR TB/MDR TB cases was higher in the non-EU/EEA countries than in the EU/EEA

countries (46.3% vs. 38.1%). The countries that performed best were Norway, Sweden (75% treatment success rate each), Kazakhstan (74.3%) and Belgium (73.3%). In the Region 14.7% of MDR TB cases died, 17.1% failed and 14.5% was lost to follow-up.

## Conclusion

In the WHO European Region the overall TB trend is similar to that in previous years, illustrated by a further drop in TB incidence of about 5.6%. However, to reach the projected milestones currently under development in the new TB Regional Action Plan [2016–2020], in line with the global End-TB Strategy, the Region needs to ensure the acceleration of this reduction.

Country capacities for MDR TB detection have improved by about 40% since the inception of the Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis, in the WHO European Region, 2011–2015 (shown by an increase from 28 000 MDR TB patients detected in 2009 to almost 40 000 MDR TB patients detected in 2013).

One of the achievements in TB control in the regions is the improvement in coverage of second line drug susceptibility testing and enrolling MDR TB patients into efficient treatment programmes (62% in 2009 compared to universal coverage in 2013). As regards the percentage of MDR TB patients tested for second line drug susceptibility, 31% were tested in 2009, compared to 51% in 2013).

Along with positive developments there are also a number of challenges associated with TB control in the Region. WHO European Region is the most highly affected Region in the world in terms of the proportion of MDR TB cases among TB patients. The rate of MDR TB in previously treated cases is more than double the global estimate (44% versus 21%) and almost four times the rate for new TB cases (14% versus 3.5%). There is ongoing transmission of MDR TB, as shown by the increase among new MDR TB cases. MDR TB among previously treated patients has levelled off since the implementation of the Consolidated Action Plan.

TB in the Region is becoming more and more difficult to treat. Treatment success remains low (less than 50% of MDR TB cases are treated successfully which means that current tools and interventions have to be used more efficiently, and could benefit from being complemented by new and more effective ones).

TB is one of the diseases that kills most people living with HIV, and this deadly combination is increasing in the Region. The prevalence of HIV among TB cases increased from 3.4% in 2008 to 7.8% in 2013. Timely detection and appropriate treatment are therefore extremely important. In 2013 only 68% of TB patients had documented HIV test results and only 54% of them were offered antiretroviral treatment.

To tackle these challenges in the WHO European Region is to adapt the global End-TB Strategy on a regional basis. (Development of a Regional TB Action Plan (TB-AP) is already underway and is also based on the current regional M/XDR TB plan). The Strategy will focus on improving

surveillance systems to help tailor and target the appropriate interventions to different populations in different settings. Another focus will be on scaling up the safe, rational and efficient introduction of new TB drugs and innovations for rapid diagnosis and patient-centred care. These activities will be informed and accelerated through a scaling up of both scientific and operational research for TB. The Strategy will also attempt to foster TB relevant healthcare reforms, such as more patient-friendly treatment and care, and a shift towards more outpatient-based TB care. This should improve treatment adherence and outcomes and introduce sustainable healthcare financing models. The Strategy will continue to focus on both the 18 high-priority countries and on low-burden countries. In the high-priority countries special attention will be given to targeting risk groups and vulnerable populations, by applying the right mix of new and existing interventions and tools to boost advocacy and inter-sectoral collaboration. The significance of the latter is also underscored by the preparatory contributions of both, WHO and ECDC, to a multi-partner high level TB event in Riga, Latvia, March 2015.

## 2.2 European Union and European Economic Area countries

### Data completeness

Data on TB notification for 2013 were reported by 30 countries (no data was received from Liechtenstein). As with TB cases notified in 2010–2012, the reporting of non-mandatory variables in 2013 was complete or near-complete for age, gender, TB site and variables defining the origin of a case (Annex 3). Previous treatment history was available for 89.6% of cases overall, with differences across countries due to data on previous TB history being missing from Luxembourg, and Germany having reported it for only 32.9% of cases.

Reporting completeness for the results of culture (79.7%) was very similar to 2012, with three countries below 60% coverage (France, Italy and United Kingdom). Reporting completeness for microscopy also remained similar to 2012 (71.1%). Drug susceptibility reporting completeness for first-line TB drugs increased from around 70% in 2011 and 2012 to 86.9% in 2013, but was reported very differently during the period by France, Italy and Spain (Table 13). For second-line drugs DST reporting completeness remained similar to 2012 at 64.9% of MDR TB cases. The Netherlands did not report data, Germany reported it for only 29.0% of MDR TB cases and Poland for 10.0% of MDR TB cases. Reporting of HIV status has continued to increase since 2010 (from 23.9% in 2010 to 33.6% in 2013). It is worth noting that Greece started reporting HIV status in 2013. HIV status for TB cases is, however, still missing from Austria, Croatia, Cyprus, Denmark, Finland, France, Germany, Hungary, Italy, Norway, Poland, Sweden and United Kingdom.

Treatment outcome reporting in 2013 was similar to 2012, with 12-month, 24-month and 36-month data available for 81.6% of all reported cases, 85.8% of MDR TB and 95.0% of XDR TB cases, respectively. Treatment outcome was not reported by France, Greece, Italy and Luxembourg, and treatment outcome for MDR TB cases was also missing from Croatia, Cyprus, Finland, Iceland and Spain.

### Time and place

In 2013, 64 844 cases of TB were reported in 30 EU/EEA countries (Table 3). Three countries (Poland, Romania and the United Kingdom) accounted for nearly 50% of all reported cases with Romania alone accounting for 25.8% of all cases.


The EU/EEA notification rate in 2013 was 12.7 per 100 000 population, which was 5.9% less than in 2012, continuing the downward trend observed since the launch of European enhanced TB surveillance in 1996 (Figure D).

Similar to 2012, country-specific notification rates in 2013 differed 25-fold, ranging from 3.4 in Iceland to 83.5 per 100 000 in Romania. Rates were below 10 per 100 000 in 18 countries and below 20 per 100 000 in 24 countries. Rates were above 40 per 100 000 in three countries (Latvia, Lithuania and Romania). In a majority of countries the notification rates dropped steadily during the period 2009–2013 (Table 3). The downward trend is especially pronounced in three of the five high priority countries (Bulgaria, Estonia, and Romania) where it decreased on average by 8–9% per year. However in Latvia, another high priority country, the previously observed decline has halted since 2011 and during the period 2009–2013 there was no net change in notification rate. The decline is more moderate in several low-incidence countries, and in the Nordic countries (Denmark, Norway and Sweden) notification rates are actually increasing on average by 1% per year. In Iceland notification rates increased on average by 26.9% per year between 2009 and 2013, however this only involves a small absolute number of cases.

### Previous treatment, laboratory confirmation and TB site

The distribution of cases by previous treatment history in 2013 was very similar to the distributions observed in previous years: 50 493 (77.9%) of 64 844 TB cases reported in 2013 were newly-diagnosed, 7 606 (11.7%) had been previously treated for TB and 6 745 (10.4%) had an unknown previous treatment status (Table 5). The Member States with the lowest proportions of new cases had the highest proportions of cases with unknown previous treatment

Figure D: TB notification rates per 100 000 population, EU/EEA, 1995–2013<sup>a</sup>



<sup>a</sup> Data missing from Liechtenstein (except 2007).

Data source: ECDC Surveillance Atlas of Infectious Diseases. <http://www.ecdc.europa.eu/en/data-tools/atlas/Pages/atlas.aspx>

status. France and Germany accounted for only 14.3% of all TB cases reported in the EU/EEA in 2013, yet 73.5% of cases had unknown previous treatment status. Proportions of previously treated cases were above 10% in seven countries (Bulgaria, Estonia, Latvia, Lithuania, Poland, Romania and Slovakia).

Laboratory confirmation was reported for 40 249 (62.1%) of 64 844 cases overall (Table 8). Country-specific proportions of laboratory-confirmed cases ranged from 21.4% in Italy to 94.3% in Slovenia. Overall, the proportion of laboratory-confirmed cases has almost doubled since 1995 but seems to have levelled off over the past five years<sup>16</sup>. This overall trend also masks important disparities between countries. For example, the proportion of laboratory-confirmed cases has continuously declined in Italy over the past decade from 46.3% in 2004 to 21.4% in 2013.

Of all 64 844 TB cases reported in 2013, 45 725 (70.5%) were diagnosed with pulmonary TB, 14 460 (22.3%) with extrapulmonary TB, 4 393 (6.8%) with a combination of both, and 266 (0.4%) had no TB site reported (Table 6). The proportion of extrapulmonary TB was highest in Iceland (63.6%, but only a small absolute number of cases), the United Kingdom (47.6%), the Netherlands (46.3%) and Sweden (43.2%) and lowest in Hungary (4.7%) and Poland (5.7%).

Of 38 322 new pulmonary TB cases reported in 2013, 28 478 (74.3%) were confirmed by culture, smear and/or nucleic acid amplification test (Table 7). Italy and Hungary had the lowest proportion of confirmed new pulmonary cases, with 38.9% and 46.3% respectively.

According to the EU case definition, 40 249 (62.1%) of 64 844 TB cases reported in 2013 would be classified as confirmed, 5 156 (8.0%) as probable and 19 439 (30.0%) as possible (Table 9). The percentages of clinically diagnosed cases were highest in Bulgaria (41.8%), Hungary (55.3%) and Italy (66.4%).

It is unclear if the low proportion of laboratory-confirmed cases and the reliance on clinical diagnosis reflects a potential risk for over-diagnosis of TB in these countries, or if it is related to under-reporting of laboratory results to the national surveillance systems.

### Age and gender

Of 61 569 new TB cases and relapses, 39 922 (64.8%) were aged between 25 and 64 years (Table 10). The highest notification rate was observed in the 25–44 year age group with 15.1 per 100 000. Adults over 64 years of age accounted for less than 20% of all cases on average but more than 40% of the cases reported by Slovenia and Finland were in this age group.

Children under 15 years of age accounted for 2 655 (4.1%) of all 64 844 TB cases reported in 2013, with a notification rate of 3.3 per 100 000 (Table II). France, Romania, Spain and the United Kingdom contributed 62.6% of this

subset. The four countries (Bulgaria, Latvia, Lithuania, and Romania) with the highest age-specific notification rates in children were all high-priority countries. The high notification rates among children indicate that there is still significant ongoing transmission in these countries.

In 2013, the male-to-female ratio in new TB cases and relapses was 1.7 (Table 10). Similar to 2012, males were over-represented in all EU/EEA Member States but Iceland. Males were at least twice as frequently reported as females by Bulgaria, Czech Republic, Estonia, Greece, Latvia, Lithuania, Malta, Poland, and Romania. Gender imbalance was less pronounced in children under 15 (1.0) years and adults over 64 (1.4) years.

### Origin of cases

Of the 64 844 TB cases notified in 2013, 45 279 (69.8%) were born in or citizens of the reporting country (referred to as 'native'), 18 180 (28.0%) were of foreign origin and 1 385 (2.1%) were of unknown origin (Table 11). Country-specific proportions of foreign-origin TB cases ranged from below 1% in Bulgaria, Poland and Romania to above 85% in Cyprus, Luxembourg, Malta, Norway and Sweden. Croatia, France, Germany, Italy, Spain and UK have the highest percentage of cases for which country of origin was unknown or not reported, a phenomenon which has been consistent in these countries since they began data reporting to TESSy. Overall, the notification rate of foreign-origin TB cases has remained stable since 2004 (fluctuating between 3.4 and 3.8 per 100 000) however the percentage has increased from 18.2% in 2004 to 28.0% in 2013 (Table III). Of the 18 180 cases of foreign origin in 2013, 5 529 (30.4%) were reported by the United Kingdom. Five countries (France, Germany, Italy, Spain and the United Kingdom) accounted for 77.7% of the cases of foreign origin.

### Drug resistance

Annex 5 displays participation in an external quality assessment (EQA) scheme for drug susceptibility testing (DST) and gives results by Member State.

Of 41 808 laboratory-confirmed TB cases notified in 2013, 36 349 (86.9%) underwent isoniazid and rifampicin susceptibility testing (Table 13, which varies from Table 8 for some of the figures relating to laboratory-confirmed cases due to different data sources). Resistance to at least one anti-TB drug was reported for 3 891 (10.7%) of the cases tested overall and for 28–37% of cases tested in Estonia, Latvia and Lithuania. MDR TB was reported for 1 484 (4.1%) of 36 349 cases with DST results overall and for 12–23% of the cases tested in Estonia, Latvia and Lithuania. The rate of notified MDR TB cases has remained unchanged over the past five years at 0.3 per 100 000 population (Table VI). Overall, XDR TB was reported for 169 (17.5%) of 963 MDR TB cases that had undergone second-line drug susceptibility testing (Table 17). Since 2006, the proportion of XDR TB cases among MDR TB cases having undergone second-line drug susceptibility testing has been fluctuating (8–21%) with no obvious trend (Table VIII).

Among 25 188 pulmonary TB cases with DST results, 1 241 (4.9%) were resistant to isoniazid and rifampicin (Table 16).

<sup>16</sup> European Centre for Disease Prevention and Control. ECDC Surveillance Atlas of Infectious Diseases. <http://www.ecdc.europa.eu/en/data-tools/atlas/Pages/atlas.aspx>



Of these 1241 MDR TB pulmonary cases, 780 (62.9%) were tested for susceptibility to second-line drugs and 139 (17.8%) of them showed XDR TB. Of 19 738 new confirmed pulmonary TB cases with DST results, 510 (2.6%) were resistant to isoniazid and rifampicin. Of 4 045 previously treated confirmed pulmonary TB cases with DST results, 687 (17.0%) were resistant to isoniazid and rifampicin (Table 14). Compared to new cases, previously treated confirmed pulmonary TB cases were almost eight times more likely to be resistant to isoniazid and rifampicin (odds ratio [OR] 7.7, 95% confidence interval [CI] 6.8-8.7). The same association was observed for all laboratory confirmed TB cases (OR=8.0, 95% CI 7.1-9.1, Table 15).

### HIV co-infection

HIV status was reported for 21 765 (65.2%) of 33 364 TB cases from 17 countries (Table 18). Of 21 765 cases with known HIV status, 1 060 (4.9%) were reported as HIV-positive. Among countries with at least 50% reporting completeness for HIV status, the proportion of co-infected cases was highest in Portugal and Estonia, at 14.5% and 13.0% respectively. Since 2007, the proportion of HIV-co-infected TB cases has continuously decreased (Table IX).

### TB in prisons

For 2012, thirteen EU/EEA countries reported 577 new TB cases in prisons, resulting in a notification rate of 165.2 per 100 000 inmates and a relative risk of 8.8 compared to the general population (Table 19). TB cases in prisons accounted for 1.6% of all new cases notified, with country-specific proportions ranging from <1% in Ireland, Romania and the UK to 6.3% in Latvia.

### Treatment outcome

Of the 60 296 TB cases notified in 2012 with a treatment outcome reported, 44 318 (73.5%) were treated successfully, 4 571 (7.6%) died, 852 (1.4%) experienced treatment failure, 3 343 (5.5%) were lost to follow-up, 2 312 (3.8%) were still on treatment in 2013 and 4 900 (8.1%) were not evaluated (Table 23). France, Greece, Italy, and Luxembourg did not report treatment outcome. In Croatia as much as 81.4% of the cases had no treatment outcome reported. In countries for which at least 75% of the TB cases had a known outcome, treatment success ranged from 58.0% in Estonia to 87.8% in Slovakia. For Estonia the low treatment success is partly linked to a high percentage of cases still on treatment (17%). The overall proportion of successfully treated cases has been stable over the past 10 years, oscillating between 72 and 76% (Table Xa).

Of 13 866 MDR TB cases notified in 2011 with a treatment outcome reported, 524 (37.8%) were treated successfully, 235 (17.0%) died, 227 (16.4%) experienced treatment failure, 257 (18.5%) were lost to follow-up, 98 (7.1%) were still on treatment in 2013 and 45 (3.2%) were not evaluated (Table 25). In addition to the countries that did not report any treatment outcome data, Croatia, Cyprus, Finland Iceland, and Spain did not report treatment outcome after 24 months. Overall, the 24-month MDR TB treatment success rate remains low but seems to have been improving slightly over the past five years (Table XII).

Of 116 XDR TB cases notified by 12 countries in 2010 with a treatment outcome reported, 30 (25.9%) were treated successfully, 32 (27.6%) died, 36 (31.0%) experienced treatment failure, 15 (12.9%) were lost to follow-up, and three (2.6%) were not evaluated (Table 27). Due to the small number of XDR TB cases with treatment outcome reported, no consistent trend can be observed, but treatment success has fluctuated between 22% and 26% since 2007 (Table XIII).

### Conclusions for the EU/EEA

In 2013, the overall TB notification rate continued to decline in the EU/EEA. This decline was not merely driven by decreases in those countries reporting large numbers of cases, it was observed in the vast majority of countries. The decrease was particularly pronounced in three of the five high priority countries, including Romania, which accounts for 25.8% of all reported cases. Five years after the start of the financial crisis in 2008, these numbers suggest that the TB programmes in place are still effective or that preventive efforts made in previous years have produced long-standing benefits. Nevertheless, the surveillance data presented in this report cannot provide insight into potential under-diagnosis or under-reporting of cases as a consequence of the financial crisis.

The success in promoting proper laboratory diagnosis of TB, as illustrated by the proportion of culture-confirmed cases, seems to be wearing off. Following more than a decade of improvement, the proportion of culture-confirmed cases has been stable over the past three years. Further progress will have to come from countries with a very low proportion of confirmed-cases, such as Italy and Hungary.

Overall, the notification rate of foreign-origin TB cases has remained stable over the past five years with important disparities across countries. Although the absolute number of cases and the notification rates of foreign-origin cases have remained stable, the percentage of foreign-born cases has continuously increased since 2004, while the number of TB cases in the native population has been steadily decreasing. A better understanding of such cases (countries of origin, treatment outcome, drug susceptibility, etc.) could help better target this population. TB in migrants from outside the EU/EEA increasingly contributes to the TB burden in the EU/EEA. While the majority of non-EU originating TB cases are from the Eastern Mediterranean Region and the South-East Asian Region, the majority of MDR TB and XDR TB cases of non-EU/EEA origin are from the European Region, and higher proportions of TB-HIV co-infection were shown in cases coming from Africa [6].

Reporting completeness for 2013 was very similar to 2012. Notification rates of both MDR TB and XDR TB cases showed no sign of decline, confirming the findings of a recent analysis of the 2007–2012 period [7].

In 2013, there was good news related to surveillance of HIV co-infection. Data completeness continued to improve and the proportion of HIV-co-infected TB cases continued to decrease. There may be several explanations for this. Firstly, it may reflect a change in the epidemiology of HIV

in the EU/EEA. The number of HIV cases in migrants, a population with higher TB co-infection, is decreasing [8] and HIV cases are now more efficiently treated, meaning that patients are less susceptible to opportunistic infections. Secondly, testing for HIV may have become less selective, with increasing percentages of TB cases being tested for HIV. Finally, the decrease could be the result of successful TB and HIV control programmes.

Data on TB in prisons throughout the EU/EEA are scarce. Only a third of reporting countries provided data for 2012. Previous studies have suggested that TB incidence in prisons could be much higher than in the general population [9]. Surveillance data from the EU/EEA would confirm these findings with an estimated relative risk of TB in prison inmates amounting to nine, compared to the general population. Targeted screening in the hard-to-reach inmate population could be highly cost-effective, as suggested by the National Institute for Health and Clinical Excellence (NICE) [10].

Finally, treatment success rates have remained unchanged over the past 10 years, with a persistently poor outcome for MDR TB cases. The underlying reasons for this situation should be further investigated to reduce both the burden of disease and the cost associated with relapses and second line treatments.

## 3. Commentary – Monitoring



### 3. Commentary – Monitoring

Last year marked the production of the second TB monitoring report, providing an overview of progress on TB control in the WHO European Region and the EU/EEA. For the WHO European Region, WHO's Regional Office for Europe followed up on two frameworks; monitoring of the Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region 2011–2015 [11], and implementation of the 2007 Berlin Declaration on Tuberculosis [12], dealing with the overall TB health threat to the Region. In 2010, ECDC launched the epidemiological and strategic monitoring framework 'Progressing towards TB elimination' [13]. The 2012 report 'Tuberculosis surveillance and monitoring in Europe' [14] presented the first measurement of the indicators described in the monitoring framework 'Progressing towards TB elimination'. The 2014 report [15] presented results from the second round of monitoring progress towards TB elimination in the EU/EEA. Both reports also presented the monitoring framework for follow-up of the Consolidated Action Plan to Prevent and Combat Multidrug and Extensively Drug-Resistant Tuberculosis in the WHO European Region 2011–2015 and the Berlin Declaration Monitoring and Evaluation Framework.

It was agreed to report on progress every other year, so the next monitoring results will be presented in 2016. More in-depth analysis and lists of indicators can be found in the 2014 report [15]. According to the Resolution of the WHO Regional Committee for Europe EUR/R61/R7 [16], the WHO Regional Director reports on progress in implementing the Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region 2011–2015. The progress report was presented at the 63rd session of the WHO Regional Committee for Europe in September 2013 using quantitative data collected and presented in this report. The latest qualitative data on progress in implementing the Action Plan will be analysed at WHO's Regional Office for Europe and will be presented in the 65th WHO Regional Committee for Europe.

#### References

1. Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, Loddenkemper R et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. *Eur Respir J* 2002;19:765–752.
2. World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision, Geneva: WHO, 2013. WHO/HTM/TB/2013.2
3. WHO Regional Office for Europe. Plan to Stop TB in 18 High-priority Countries in the WHO European Region, 2007–2015. Copenhagen: WHO, 2007
4. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis (4th ed.). Geneva: WHO, 2009. WHO/CDS/TB/2009.422
5. Falzon D, Scholten J, Infuso A. Tuberculosis outcome monitoring - Is it time to update European recommendations? *Euro Surveillance* 2006;11(3):20–5
6. Ködmön C, van der Werf M. Migration-related tuberculosis from outside the European Union and European Economic Area, 2007–2013, [unpublished, to be submitted 2015].
7. Van der Werf MJ, Ködmön C, Hollo V, Sandgren A, Zucs P. Drug resistance among tuberculosis cases in the European Union and European Economic Area, 2007 to 2012. *EuroSurveill.* 2014;19(10).
8. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2012. Stockholm: European Centre for Disease Prevention and Control; 2013. Available at: <http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-report-2012-20131127.pdf>
9. Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F. Tuberculosis Incidence in Prisons: A Systematic Review. *PLoS Med* [Internet]. 2010 Dec [cited 2014 Nov 14];7(12). Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006353/>
10. Kmietowicz Z. NICE advises screening for TB in hostels and prisons to reduce UK cases. *BMJ.* 2012;344:e2309.
11. The World Health Organization Regional Office for Europe. Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis (M/XDR TB) in the WHO European Region 2011–2015. Copenhagen: WHO/Europe, 12–15 September 2011.
12. The WHO European Ministerial Forum. The Berlin Declaration on Tuberculosis. Copenhagen: WHO/Europe, 22 October 2007.
13. European Centre for Disease Prevention and Control. Progressing towards TB elimination. A follow-up to the Framework Action Plan to Fight Tuberculosis in the European Union, 2010.
14. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. Stockholm: ECDC, 2012.
15. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2014. Stockholm: ECDC, 2014.
16. The World Health Organization Regional Committee for Europe. Resolution EUR/R61/R7. Multidrug- and extensively drug-resistant tuberculosis in the WHO European Region. Baku, Azerbaijan, 12–15 September 2011



## 4. Annexes





## Annex 1: Tuberculosis surveillance system overview, 2013

Country	Data source	Legal character <sup>a</sup>	Comprehensiveness <sup>b</sup>	Type <sup>c</sup>	Coverage <sup>d</sup>	Data used:		
						EuroTB aggregated data	EuroTB case-based data <sup>e</sup>	TESSy case-based data <sup>f</sup>
Austria	AT-TUBERKULOSEGESETZ	Cp	Co	C	Y	-	-	1995–2013
Belgium	BE-TUBERCULOSIS	Cp	Co	C	Y	-	1995–2004	2005–2013
Bulgaria	BG-MOH	Cp	Co	C	-	1995–2006	-	2007–2013
Croatia <sup>g</sup>	HR-CNIPH	Cp	Co	C	Y	1995–2007	-	2012, 2013
Cyprus	CY-NOTIFIED_DISEASES	Cp	Co	C	Y	1995–2001	2002–2004	2005–2013
Czech Republic	CZ-TUBERCULOSIS	Cp	Co	C	Y	-	1995–2004	2005–2013
Denmark	DK-MIS	Cp	Co	C	Y	-	1995–2004	2005–2013
Estonia	EE-TBC	Cp	Co	C	Y	-	1995–2004	2005–2013
Finland	FI-NIDR	Cp	Co	C	Y	-	-	1995–2013
France	FR-MANDATORY_INFECTIOUS_DISEASES	Cp	Co	C	Y	-	1995–1999	2000–2013
Germany	DE-SURVNET@RKI-7.1/6	Cp	Co	C	Y	1995–2000	2001–2004	2005–2013
Greece	GR-NOTIFIABLE_DISEASES	Cp	Co	C	Y	1995–2001	2002–2004	2006–2013
Hungary	HU-TUBERCULOSIS	Cp	Co	C	Y	1995–1998	1999–2004	2005–2013
Iceland	IS-TUBERCULOSIS	Cp	Co	C	Y	-	1995–2004	2005–2013
Ireland	IE-TB	Cp	Co	C	Y	1995–1997	1998–2004	2005–2013
Italy	IT-NRS	Cp	Co	C	Y	-	1995–2004	2005–2013
Latvia	LV-TB	Cp	Co	C	Y	1995–2000	2001–2004	2005–2013
Liechtenstein	-	-	-	-	-	-	-	2007
Lithuania	LT-TB_REGISTER	Cp	Co	C	Y	1995–2002	2003, 2004	2005–2013
Luxembourg	LU-SYSTEM1	Cp	Co	C	Y	-	1995–2006	2007–2013
Malta	MT-DISEASE_SURVEILLANCE	Cp	Co	C	Y	-	1995–2004	2005–2013
Netherlands	NL-NTR	Cp	Co	C	Y	-	1995–2004	2005–2013
Norway	NO-MSIS_A	Cp	Co	C	Y	-	1995–2005	2006–2013
Poland	PL_CR	Cp	Co	C	Y	1995–1999	2000–2004	2006–2013
Portugal	PT-TUBERCULOSIS	Cp	Co	C	Y	1995–1999	2000–2005	2006–2013
Romania	RO-NTBSy	Cp	Co	C	Y	-	1995–2004	2005–2013
Slovakia	SK-NRT	Cp	Co	C	Y	1995	1996–2004	2005–2013
Slovenia	SI-TUBERCULOSIS	Cp	Co	C	Y	-	1995–2004	2005–2013
Spain	ES-STATUTORY_DISEASES	Cp	Co	C	Y	1995–2006	-	2007–2013
Sweden	SE-SweTBReg	Cp	Co	C	Y	-	1995–2006	2007–2013
United Kingdom	UK-TUBERCULOSIS	Cp	Co	C	Y	1995–1997	-	1998–2013

<sup>a</sup> Legal: compulsory reporting - Cp<sup>b</sup> Comprehensiveness: comprehensive - Co, Sentinel - Se, Other - O<sup>c</sup> Type: case based - C, unknown - U<sup>d</sup> Coverage: national - Y. Not specified in TESSy “-”<sup>e</sup> Data uploaded to TESSy in 2010, not updated later.<sup>f</sup> TME data for DST analysis of France, Spain and Italy, aggregated HIV data for Latvia and Netherlands<sup>g</sup> 2012 and 2013 data reported to TESSy, historical data extracted from WHO TB monitoring and evaluation database (TME).

Annex 2: List of TESSy variables for 2013 TB data collection<sup>a</sup>

List	Description
<b>Common set of variables</b>	
1 RecordId	Unique identifier for each record generated by the national surveillance system
2 RecordType	Structure and format of the data
3 RecordTypeVersion	Indicates which version the sender uses when generating the data for upload
4 Subject	Disease to report
5 Status	Status of reporting NEW/UPDATE or DELETE (inactivate)
6 DataSource	The data source (surveillance system) that the record originates from.
7 ReportingCountry	The country reporting the record.
8 PlaceOfNotification <sup>b</sup>	Place of the first notification of the case to a regional authority.
9 PlaceOfResidence <sup>b</sup>	Place of residence of patient at the time of disease onset.
10 Age	Age of patient in years as reported in the national system.
11 Gender	Gender of the reported case.
12 Outcome <sup>c</sup>	Information on whether the case is alive or deceased. (Not applicable for TB. Use DiagnosedAnteMortem instead).
13 DateOfOnset <sup>b</sup>	Date of onset of disease. (Optional for TB. Not reflected on reports.)
14 DateOfDiagnosis	First date of clinical or lab diagnosis.
15 DateOfNotification	Date when the case is first reported to public health authorities.
16 DateUsedForStatistics	The reference date used for standard reports. Usually one of upper's.
17 Classification	Case classification according to EU case definition.
18 LaboratoryResult	Laboratory criteria used to classify a case as confirmed or probable.
19 EpiLinked <sup>b</sup>	The criteria for an epidemiological link in the case definition is met. Not analysed for TB.
<b>Disease-specific variables</b>	
20 BornReportingCountry	The patient was born in the country of report.
21 CountryOfBirth	Country of birth of patient.
22 CountryOfNationality	Country of nationality of patient.
23 NationalityReportingCountry	Origin of the patient (based on citizenship).
24 MajorSiteOfTB	Major site of the disease.
25 MinorSiteOfTB	Minor site of the disease.
26 PrevDiagnosis	Previous diagnosis of tuberculosis in the past.
27 PrevDiagnosisYear	Year of previous diagnosis.
28 PrevTreatment	Previous anti-TB drug treatment (at least one month of drug combination).
29 PrevTreatmentCompletion	Completion of the previous anti-tuberculosis drug treatment.
30 DiagnosedAnteMortem	Vital status of the patient at the time of diagnosis. Was TB diagnosed ante-mortem?
31 EnrolledToTreatment	Patient started appropriate TB treatment according to international recommendations.
32 Outcome12Months	Patient first outcome at 12 months from the start of the treatment.
33 Outcome24Months	The first outcome observed 13 to 24 months from the start of treatment.
34 Outcome36Months	The first outcome observed 25 to 36 months from the start of treatment.
35 ResultCulture	The result of the culture test for M. Tuberculosis complex.
36 ResultMicroscopy	The result of the microscopy test performed.
37 ResultOtherTest	Additional lab test results.
37 Pathogen	Species and gene (M. tuberculosis complex) of the pathogen which is the cause of the reported disease.
38 HIVStatus	Result of the last HIV test.
39 SIR_AMK	Susceptibility to Amikacin (without Intermediate)
40 SIR_CAP	Susceptibility to Capreomycin (without Intermediate)
41 SIR_CIP	Susceptibility to Ciprofloxacin (without Intermediate)
42 SIR_ETH	Susceptibility to Ethambutol.
43 SIR_GAT	Susceptibility to Gatifloxacin.
44 SIR_INH	Susceptibility to Isoniazid.
45 SIR_KAN	Susceptibility to Kanamycin.
46 SIR_LVX	Susceptibility to Levofloxacin.
47 SIR_MFX	Susceptibility to Moxifloxacin.
48 SIR_OFX	Susceptibility to Ofloxacin.
49 SIR_RIF	Susceptibility to Rifampicin.
50 SIR_STR	Susceptibility to Streptomycin.
51 IsolateID	Unique identifier for each isolate within the data source / lab system related to the case.
52 ECDCIsolateID	Identifier for each isolate record that is guaranteed to be unique across countries/labs/pathogens and not contain additional encoded information..
53 SpoligoCode	Spoligo pattern code.
54 RflpCode	National cluster code based on IS6110 RFLP.
55 MiruCode	MIRU pattern code.
56 BeijingGenotype	Beijing genotype identification.

Note: Variables 53–56 are optional, complementary for TB molecular surveillance.

<sup>a</sup> Notification of TB cases for 2012, treatment outcome data updated for cohort 2011 and MDR TB treatment outcome data updated for cohort 2010 and XDR TB treatment outcome data for cohort 2009

<sup>b</sup> Optional for TB reporting

<sup>c</sup> Not applicable for TB, variable DiagnosedAnteMortem to be used instead

Annex 3: Reporting completeness of main variables used for the report<sup>a</sup>

	DateUsedForStatistics	Age	Gender	Origin <sup>b</sup>	CountryOfOrigin	Site	Previous treatment history	Diagnosed AnteMortem	Result Culture	Result Microscopy	DST FLD <sup>c</sup>	DST SLD <sup>d</sup>	HIV Status <sup>e</sup>	Enrolled to treatment	Outcome12Months <sup>f</sup>	Outcome24Months <sup>g</sup>	Outcome36Months <sup>h</sup>
Austria	(100.0)	(100.0)	(100.0)	(99.7)	(99.8)	(99.7)	(80.6)	(100.0)	(90.9)	(68.7)	(68.7)	(100.0)	(0.0)	(100.0)	(100.0)	(100.0)	(100.0)
Belgium	(100.0)	(100.0)	(100.0)	(99.8)	(99.8)	(100.0)	(78.7)	(100.0)	(94.7)	(75.5)	(74.3)	(100.0)	(50.2)	(97.3)	(96.2)	(93.3)	(100.0)
Bulgaria	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(85.1)	(85.6)	(38.0)	(100.0)	(97.0)	(100.0)	(99.6)	(100.0)	(100.0)
Croatia	(100.0)	(100.0)	(100.0)	(67.7)	(100.0)	(87.8)	(88.0)	(86.5)	(78.3)	(84.1)	(60.9)	-	(0.0)	(79.9)	(18.8)	(0.0)	-
Cyprus	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(95.1)	(100.0)	(75.6)	(65.9)	(73.2)	(100.0)	(0.0)	(100.0)	(71.0)	(0.0)	-
Czech Republic	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(96.2)	(94.2)	(64.1)	-	(25.0)	(100.0)	(100.0)	(85.7)	(100.0)
Denmark	(100.0)	(100.0)	(100.0)	(99.4)	(81.5)	(100.0)	(100.0)	(100.0)	(93.0)	(94.9)	(77.2)	(100.0)	(2.2)	(100.0)	(78.1)	(33.3)	-
Estonia	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(96.2)	(96.2)	(76.9)	(98.0)	(96.5)	(100.0)	(100.0)	(100.0)	(100.0)
Finland	(100.0)	(100.0)	(100.0)	(98.5)	(98.5)	(100.0)	(98.2)	(100.0)	(75.3)	(83.0)	(74.9)	(100.0)	(0.0)	(0.0)	(59.4)	(0.0)	-
France	(100.0)	(100.0)	(99.4)	(92.6)	(91.5)	(99.3)	(58.3)	(0.0)	(50.8)	(86.4)	(86.2)	(97.6)	(0.0)	(0.0)	(0.0)	(0.0)	-
Germany	(100.0)	(99.9)	(95.6)	(94.6)	(94.8)	(99.3)	(32.9)	(98.3)	(86.5)	(27.4)	(67.2)	(29.0)	(0.0)	(99.0)	(91.8)	(69.6)	-
Greece	(100.0)	(98.9)	(99.4)	(99.1)	(95.0)	(97.2)	(88.1)	(0.0)	(62.6)	(75.4)	(43.1)	(100.0)	(67.2)	(89.3)	(0.0)	(0.0)	-
Hungary	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(88.0)	(84.5)	(34.4)	(90.0)	(0.0)	(100.0)	(99.7)	(100.0)	(50.0)
Iceland	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(81.8)	(36.4)	(63.6)	-	(72.7)	(45.5)	(100.0)	-	-
Ireland	(100.0)	(100.0)	(99.5)	(98.2)	(98.2)	(99.5)	(69.8)	(100.0)	(82.8)	(52.3)	(70.3)	(75.0)	(26.8)	(100.0)	(71.6)	(33.3)	-
Italy	(100.0)	(81.4)	(83.7)	(92.5)	(75.9)	(100.0)	(89.3)	(0.0)	(32.3)	(45.2)	(74.5)	(70.5)	(0.0)	(0.0)	(0.0)	(0.0)	-
Latvia	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(95.1)	(99.1)	(75.3)	(92.4)	(46.5)	(100.0)	(100.0)	(98.9)	(100.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(99.4)	(100.0)	(100.0)	(100.0)	(79.4)	(73.4)	(67.1)	(100.0)	(99.3)	(99.3)	(98.0)
Luxembourg	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(0.0)	(100.0)	(100.0)	(100.0)	(84.2)	-	(94.7)	(100.0)	(0.0)	(0.0)	-
Malta	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(80.0)	(100.0)	(80.0)	(70.0)	(54.0)	(100.0)	(88.0)	(100.0)	(23.8)	-	-
Netherlands	(100.0)	(100.0)	(99.9)	(100.0)	(99.5)	(99.9)	(99.5)	(100.0)	(83.5)	(41.0)	(71.6)	(0.0)	(50.9)	(100.0)	(95.7)	(94.1)	-
Norway	(100.0)	(100.0)	(100.0)	(99.3)	(99.0)	(99.5)	(93.5)	(100.0)	(81.0)	(36.2)	(79.3)	(100.0)	(2.0)	(96.5)	(92.2)	(100.0)	-
Poland	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(94.8)	(90.0)	(61.7)	(10.0)	(0.5)	(0.0)	(81.5)	(78.0)	(100.0)
Portugal	(100.0)	(99.9)	(100.0)	(99.2)	(87.6)	(99.4)	(100.0)	(100.0)	(67.8)	(77.5)	(43.2)	(73.3)	(71.5)	(100.0)	(100.0)	(86.1)	(100.0)
Romania	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(91.1)	(84.5)	(42.7)	(48.3)	(61.0)	(100.0)	(100.0)	(100.0)	(100.0)
Slovakia	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(96.0)	(100.0)	(98.3)	(96.0)	(52.9)	(66.7)	(91.8)	(100.0)	(97.7)	(100.0)	-
Slovenia	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(99.3)	(79.3)	(94.3)	-	(75.0)	(100.0)	(100.0)	-	-
Spain	(100.0)	(99.8)	(99.8)	(98.6)	(82.8)	(100.0)	(94.6)	(0.0)	(84.4)	(66.4)	(28.2)	(100.0)	(73.5)	(0.0)	(81.8)	(0.0)	(0.0)
Sweden	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(87.2)	(100.0)	(99.8)	(30.6)	(80.7)	(100.0)	(0.0)	(100.0)	(94.2)	(82.4)	-
United Kingdom	(100.0)	(100.0)	(100.0)	(96.7)	(95.2)	(99.5)	(95.1)	(95.1)	(59.3)	(38.2)	(58.4)	(95.9)	(0.0)	(91.2)	(97.9)	(98.8)	(66.7)
<b>Total EU/EEA countries</b>	<b>(100.0)</b>	<b>(99.1)</b>	<b>(99.1)</b>	<b>(97.9)</b>	<b>(95.2)</b>	<b>(99.6)</b>	<b>(89.6)</b>	<b>(77.3)</b>	<b>(79.7)</b>	<b>(71.1)</b>	<b>(56.1)</b>	<b>(64.9)</b>	<b>(33.6)</b>	<b>(65.9)</b>	<b>(81.6)</b>	<b>(85.8)</b>	<b>(95.0)</b>

<sup>a</sup> Data in green obtained from WHO Tuberculosis Monitoring and Evaluation database (TME)  
<sup>b</sup> To determine the origin two variables were merged: BornReportingCountry and NationalityReportingCountry depending on Member States' preference.  
<sup>c</sup> FLD DST - drug susceptibility testing for first line TB drugs calculated for all TB cases.  
<sup>d</sup> SLD DST - drug susceptibility testing for second line TB drugs calculated only for MDR TB cases (Croatia, Czech Republic, Luxembourg and Slovenia reported zero MDR TB cases for 2013).  
<sup>e</sup> Denmark, Norway, Poland reported only positive HIV cases, and not published in the report.  
<sup>f</sup> Data for 2012 cohort  
<sup>g</sup> Data for MDR 2011 cohort, Iceland, Malta, Slovenia reported zero MDR TB cases in 2011  
<sup>h</sup> Data for XDR 2010 cohort, Cyprus, Denmark, Iceland, Malta, Norway, Slovakia, Slovenia and Sweden did report zero XDR TB cases in 2010

## Annex 4: Reporting completeness into Global TB database, 2013

Country	Section 1 Identification (%)	Section 2 (TB notification and treatment outcome) (%)								Section 3 Implementing Stop TB strategy (%)	Section 4 Finance (%)
		Notification of new cases by age, site and smear, HIV and MDR status	TB cases by history, site and smear result	TB cases by geographic origin, age and sex	Anti- tuberculosis drug resistance surveillance	Treatment outcome of TB cases	Treatment outcome HIV positive TB cases	Treatment outcome M/XDR TB cases	Treatment outcome TB cases in prison		
<b>EU/EEA</b>											
Austria	(0.0)	(83.7)	(100.0)	(100.0)	(76.5)	(68.4)	(0.0)	(100.0)	(0.0)	(0.0)	(0.0)
Belgium	(86.7)	(81.6)	(42.3)	(100.0)	(86.3)	(68.4)	(100.0)	(100.0)	(91.3)	(39.1)	(0.0)
<i>Bulgaria</i>	(73.3)	(89.8)	(100.0)	(100.0)	(86.3)	(68.4)	(100.0)	(100.0)	(73.9)	(68.7)	(61.8)
Croatia	(0.0)	(63.3)	(100.0)	(100.0)	(66.7)	(68.4)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Cyprus	(0.0)	(63.3)	(100.0)	(100.0)	(76.5)	(68.4)	(100.0)	(0.0)	(0.0)	(0.0)	(0.0)
Czech Republic	(100.0)	(81.6)	(100.0)	(100.0)	(76.5)	(68.4)	(100.0)	(0.0)	(100.0)	(42.6)	(0.0)
Denmark	(0.0)	(57.1)	(42.3)	(100.0)	(86.3)	(68.4)	(100.0)	(100.0)	(0.0)	(0.0)	(0.0)
<i>Estonia</i>	(100.0)	(91.8)	(100.0)	(100.0)	(86.3)	(68.4)	(100.0)	(100.0)	(43.5)	(83.5)	(49.4)
Finland	(66.7)	(73.5)	(100.0)	(100.0)	(76.5)	(68.4)	(0.0)	(0.0)	(0.0)	(40.0)	(0.0)
France	(93.3)	(81.6)	(100.0)	(100.0)	(23.5)	(0.0)	(0.0)	(0.0)	(13.0)	(39.1)	(0.0)
Germany	(93.3)	(69.4)	(100.0)	(100.0)	(76.5)	(68.4)	(0.0)	(100.0)	(4.3)	(39.1)	(0.0)
Greece	(60.0)	(79.6)	(100.0)	(100.0)	(86.3)	(0.0)	(0.0)	(0.0)	(4.3)	(41.7)	(0.0)
Hungary	(73.3)	(81.6)	(100.0)	(100.0)	(76.5)	(68.4)	(0.0)	(100.0)	(73.9)	(44.3)	(0.0)
Iceland	(0.0)	(63.3)	(100.0)	(100.0)	(76.5)	(68.4)	(100.0)	-	(0.0)	(0.0)	(0.0)
Ireland	(73.3)	(83.7)	(42.3)	(100.0)	(86.3)	(68.4)	(100.0)	(100.0)	(73.9)	(46.1)	(0.0)
Italy	(26.7)	(63.3)	(100.0)	(100.0)	(84.3)	(0.0)	(0.0)	(0.0)	(0.0)	(13.9)	(0.0)
<i>Latvia</i>	(100.0)	(93.9)	(100.0)	(100.0)	(86.3)	(68.4)	(100.0)	(100.0)	(100.0)	(83.5)	(70.8)
Liechtenstein	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
<i>Lithuania</i>	(60.0)	(89.8)	(100.0)	(100.0)	(86.3)	(68.4)	(100.0)	(100.0)	(73.9)	(93.9)	(0.0)
Luxembourg	(100.0)	(81.6)	(100.0)	(100.0)	(76.5)	(0.0)	(0.0)	(0.0)	(100.0)	(42.6)	(0.0)
Malta	(66.7)	(87.8)	(100.0)	(100.0)	(86.3)	(68.4)	(100.0)	-	(69.6)	(25.2)	(0.0)
Netherlands	(100.0)	(87.8)	(100.0)	(100.0)	(66.7)	(68.4)	(0.0)	(100.0)	(73.9)	(36.5)	(2.2)
Norway	(100.0)	(75.5)	(42.3)	(100.0)	(86.3)	(68.4)	(100.0)	(100.0)	(4.3)	(43.5)	(0.0)
Poland	(100.0)	(67.3)	(100.0)	(100.0)	(76.5)	(68.4)	(0.0)	(100.0)	(73.9)	(35.7)	(0.0)
Portugal	(100.0)	(83.7)	(100.0)	(100.0)	(86.3)	(68.4)	(100.0)	(100.0)	(65.2)	(42.6)	(2.2)
<i>Romania</i>	(100.0)	(100.0)	(100.0)	(100.0)	(86.3)	(68.4)	(100.0)	(100.0)	(73.9)	(87.0)	(98.9)
Slovakia	(66.7)	(98.0)	(100.0)	(100.0)	(86.3)	(68.4)	(100.0)	(100.0)	(73.9)	(31.3)	(2.2)
Slovenia	(100.0)	(91.8)	(100.0)	(100.0)	(76.5)	(68.4)	(100.0)	-	(73.9)	(46.1)	(0.0)
Spain	(100.0)	(67.3)	(100.0)	(100.0)	(78.4)	(68.4)	(100.0)	(0.0)	(4.3)	(20.0)	(0.0)
Sweden	(73.3)	(83.7)	(100.0)	(100.0)	(76.5)	(68.4)	(0.0)	(100.0)	(4.3)	(42.6)	(0.0)
United Kingdom	(100.0)	(75.5)	(42.3)	(100.0)	(76.5)	(68.4)	(0.0)	(100.0)	(73.9)	(33.0)	(0.0)
<b>Subtotal EU/EEA</b>	<b>(68.2)</b>	<b>(77.2)</b>	<b>(87.5)</b>	<b>(96.8)</b>	<b>(78.6)</b>	<b>(55.2)</b>	<b>(54.8)</b>	<b>(58.1)</b>	<b>(43.3)</b>	<b>(37.5)</b>	
<b>Non-EU/EEA</b>											
Albania	(100.0)	(91.8)	(100.0)	(100.0)	(100.0)	(68.4)	(100.0)	(0.0)	(73.9)	(45.2)	(0.0)
Andorra	(53.3)	(91.8)	(100.0)	(100.0)	(100.0)	(68.4)	(100.0)	-	(69.6)	(28.7)	(2.2)
<i>Armenia</i>	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(68.4)	(0.0)	(100.0)	(69.6)	(82.6)	(97.8)
<i>Azerbaijan</i>	(93.3)	(95.9)	(0.0)	(0.0)	(54.9)	(68.4)	(100.0)	(50.0)	(65.2)	(80.9)	(0.0)
<i>Belarus</i>	(100.0)	(91.8)	(46.2)	(100.0)	(56.9)	(68.4)	(100.0)	(50.0)	(69.6)	(79.1)	(45.5)
Bosnia and Herzegovina	(100.0)	(85.7)	(100.0)	(100.0)	(92.2)	(68.4)	(100.0)	(100.0)	(4.3)	(82.6)	(92.7)
former Yugoslav Republic of Macedonia, the	(100.0)	(91.8)	(100.0)	(100.0)	(100.0)	(68.4)	(100.0)	(100.0)	(100.0)	(94.8)	(98.9)
<i>Georgia</i>	(93.3)	(95.9)	(80.8)	(34.1)	(72.5)	(68.4)	(100.0)	(100.0)	(73.9)	(80.0)	(100.0)
Israel	(86.7)	(85.7)	(100.0)	(100.0)	(88.2)	(36.8)	(100.0)	(100.0)	(73.9)	(39.1)	(0.0)
<i>Kazakhstan</i>	(100.0)	(95.9)	(96.2)	(100.0)	(64.7)	(68.4)	(100.0)	(100.0)	(73.9)	(67.8)	(48.3)
<i>Kyrgyzstan</i>	(100.0)	(83.7)	(100.0)	(19.5)	(58.8)	(5.3)	(0.0)	(100.0)	(73.9)	(74.8)	(0.0)
<i>Moldova</i>	(93.3)	(87.8)	(100.0)	(100.0)	(88.2)	(68.4)	(100.0)	(50.0)	(73.9)	(83.5)	(96.6)
Monaco	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Montenegro	(100.0)	(91.8)	(100.0)	(100.0)	(98.0)	(68.4)	(100.0)	(100.0)	(73.9)	(93.9)	(97.8)
<i>Russia</i>	(60.0)	(79.6)	(40.4)	(100.0)	(17.6)	(68.4)	(0.0)	(50.0)	(73.9)	(58.3)	(54.5)
San Marino	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Serbia	(100.0)	(87.8)	(100.0)	(100.0)	(100.0)	(68.4)	(100.0)	(100.0)	(73.9)	(87.0)	(73.6)
Switzerland	(100.0)	(71.4)	(100.0)	(100.0)	(80.4)	(0.0)	(0.0)	(0.0)	(4.3)	(41.7)	(2.2)
<i>Tajikistan</i>	(100.0)	(89.8)	(17.3)	(34.1)	(100.0)	(68.4)	(100.0)	(50.0)	(73.9)	(82.6)	(98.9)
<i>Turkey</i>	(100.0)	(85.7)	(100.0)	(100.0)	(88.2)	(68.4)	(100.0)	(100.0)	(73.9)	(74.8)	(2.8)
<i>Turkmenistan</i>	(100.0)	(24.5)	(44.2)	(0.0)	(2.0)	(68.4)	(0.0)	(0.0)	(0.0)	(62.6)	(5.1)
<i>Ukraine</i>	(100.0)	(89.8)	(17.3)	(22.0)	(29.4)	(68.4)	(0.0)	(50.0)	(73.9)	(70.4)	(53.4)
<i>Uzbekistan</i>	(100.0)	(98.0)	(100.0)	(100.0)	(100.0)	(68.4)	(100.0)	(100.0)	(73.9)	(94.8)	(100.0)
<b>Subtotal non-EU/EEA</b>	<b>(86.1)</b>	<b>(79.0)</b>	<b>(71.4)</b>	<b>(70.0)</b>	<b>(69.2)</b>	<b>(55.4)</b>	<b>(65.2)</b>	<b>(60.9)</b>	<b>(58.4)</b>	<b>(65.4)</b>	<b>(46.5)</b>
<b>Total European Region</b>	<b>(75.8)</b>	<b>(77.9)</b>	<b>(80.6)</b>	<b>(85.4)</b>	<b>(73.2)</b>	<b>(56.5)</b>	<b>(59.3)</b>	<b>(59.3)</b>	<b>(49.8)</b>	<b>(49.4)</b>	<b>(25.1)</b>
<b>Subtotal 18 HPC</b>	<b>(93.0)</b>	<b>(88.0)</b>	<b>(74.6)</b>	<b>(72.8)</b>	<b>(70.3)</b>	<b>(64.9)</b>	<b>(72.2)</b>	<b>(77.8)</b>	<b>(68.6)</b>	<b>(78.3)</b>	<b>(54.7)</b>

\*European Region\* comprises the 53 countries of the WHO European Region and Liechtenstein.  
WHO European Region 18 TB High Priority Countries presented in italics.

Annex 5: Laboratory practices and quality assurance for anti-TB drug susceptibility testing, WHO European Region, 2013<sup>a</sup>

Country	No. of labs performing					External quality assessment for the reference laboratory						
	Microscopy	Culture	DST	Line Probe Assay	Xpert MTB/Rif	Smear microscopy		First-line DST				
						Year	Acceptable performance <sup>b</sup>	Year	Percentage agreement of results for:		Acceptable performance <sup>b</sup>	
									Isoniazid	Rifampicin		
<b>EU/EEA</b>												
Austria	-	-	-	-	-	-	-	-	-	-	-	-
Belgium	112	114	14	-	-	2013	Y	2013	100	100	Y	
<i>Bulgaria</i>	34	30	12	4	0	2013	Y	2013	95	100	Y	
Croatia	-	-	-	-	-	-	-	-	-	-	-	
Cyprus	-	-	-	-	-	-	-	-	-	-	-	
Czech Republic	40	40	17	18	-	2013	Y	2013	100	100	Y	
Denmark	-	-	-	-	-	2012	Y	2012	100	100	Y	
<i>Estonia</i>	6	2	2	2	2	2013	Y	2013	100	100	Y	
Finland	10	10	1	4	3	2013	Y	2013	100	100	Y	
France	235	230	70	21	20	2011	Y	2012	100	100	Y	
Germany	242	176	74	-	-	2013	Y	2013	100	100	Y	
Greece	71	54	7	2	2	2013	Y	2013	95	84	Y	
Hungary	11	11	7	2	2	2013	Y	2013	100	100	Y	
Iceland	-	-	-	-	-	2012	Y	-	-	-	-	
Ireland	11	9	2	3	4	2013	Y	2013	100	100	Y	
Italy	-	-	39	-	-	-	-	-	-	-	-	
<i>Latvia</i>	16	4	1	1	2	2013	Y	2013	100	100	Y	
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	
<i>Lithuania</i>	13	6	6	2	8	2013	Y	2013	100	100	Y	
Luxembourg	1	1	1	1	0	2013	Y	2013	100	100	Y	
Malta	1	1	0	0	0	2013	Y	-	-	-	-	
Netherlands	37	33	6	-	-	2013	Y	2012	100	100	Y	
Norway	16	9	3	4	3	2013	Y	2013	100	100	Y	
Poland	76	76	46	2	9	2012	Y	2013	100	100	Y	
Portugal	54	52	29	17	1	2013	Y	2013	100	100	Y	
<i>Romania</i>	103	89	43	5	0	2013	Y	2013	100	100	Y	
Slovakia	-	-	-	-	-	2012	Y	2012	100	100	Y	
Slovenia	3	3	1	1	1	2013	Y	2013	100	100	Y	
Spain	-	-	-	-	-	2012	Y	2012	100	100	Y	
Sweden	5	5	5	5	0	2013	-	2013	100	100	Y	
United Kingdom	-	-	7	-	-	2012	Y	2013	100	100	Y	
<b>Subtotal EU/EEA</b>	<b>1097</b>	<b>955</b>	<b>393</b>	<b>94</b>	<b>57</b>	<b>2012-2013</b>	<b>25</b>	<b>2012-2013</b>	<b>99.6</b>	<b>99.3</b>	<b>24</b>	
<b>Non-EU/EEA</b>												
Albania	16	1	1	0	0	-	-	2013	90	100	Y	
Andorra	8	8	8	0	0	-	-	-	-	-	-	
Armenia	29	1	1	1	2	-	-	2013	100	100	Y	
<i>Azerbaijan</i>	64	7	2	0	11	-	-	2013	100	100	Y	
<i>Belarus</i>	154	29	8	8	8	-	-	2013	100	100	Y	
Bosnia and Herzegovina	15	13	4	3	0	-	-	2013	100	100	Y	
former Yugoslav Republic of Macedonia, the	7	3	1	0	0	-	-	2010	100	100	Y	
<i>Georgia</i>	11	2	1	1	1	-	-	2013	-	-	-	
Israel	19	19	2	0	0	-	-	2013	100	100	Y	
<i>Kazakhstan</i>	466	126	22	0	19	-	-	2013	95	95	Y	
<i>Kyrgyzstan</i>	122	8	2	0	8	-	-	2013	98	96	Y	
<i>Moldova</i>	57	4	4	4	28	-	-	2013	100	100	Y	
Monaco	-	-	-	-	-	-	-	-	-	-	-	
Montenegro	1	1	1	0	0	-	-	2011	100	100	Y	
<i>Russia</i>	5296	330	218	0	72	-	-	-	-	-	-	
San Marino	-	-	-	-	-	-	-	-	-	-	-	
Serbia	31	29	4	0	0	-	-	2013	100	100	Y	
Serbia excluding UN administered province of Kosovo	31	29	4	0	0	-	-	2013	100	100	Y	
UN administered province of Kosovo	-	-	-	-	-	-	-	-	-	-	-	
Switzerland	40	23	10	0	14	-	-	2013	100	100	Y	
<i>Tajikistan</i>	87	4	1	2	11	-	-	2013	97	91	Y	
<i>Turkey</i>	383	153	79	0	19	-	-	2013	100	100	Y	
<i>Turkmenistan</i>	61	3	3	0	4	-	-	2013	-	-	-	
<i>Ukraine</i>	808	81	32	0	15	-	-	2012	100	100	Y	
<i>Uzbekistan</i>	305	7	2	2	11	-	-	2013	100	100	Y	
<b>Subtotal non-EU/EEA</b>	<b>7980</b>	<b>852</b>	<b>406</b>	<b>21</b>	<b>223</b>			<b>2010-2013</b>	<b>98.8</b>	<b>98.9</b>	<b>18</b>	
<b>Total European Region</b>	<b>9077</b>	<b>1807</b>	<b>799</b>	<b>115</b>	<b>280</b>			<b>2010-2013</b>	<b>96.8</b>	<b>96.7</b>	<b>42</b>	
<b>Subtotal 18 HPC</b>	<b>8015</b>	<b>792</b>	<b>391</b>	<b>26</b>	<b>213</b>			<b>2013</b>	<b>99.0</b>	<b>98.8</b>	<b>15</b>	

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> Data obtained from WHO Tuberculosis Monitoring and Evaluation database (TME).

<sup>c</sup> Acceptable performance defined as reference laboratory achieving 80% performance (smear and DST)




## 5. Maps & figures







**Map 1a:** Estimated TB mortality per 100 000 population, European Region, 2013




**Map 1b:** Estimated TB incidence per 100 000 population, European Region, 2013




**Map 2: TB notification rates per 100 000 population, European Region, 2013**




**Map 3: TB notification rates, new TB cases and relapses per 100 000 population, European Region, 2013**




**Map 4:** Percentages of notified TB cases of foreign origin among all TB cases, European Region, 2013




**Map 5:** Percentage of smear positive pulmonary TB cases among new pulmonary TB cases, European Region, 2013




**Map 6:** Percentage of notified TB cases with multidrug resistance among new laboratory-confirmed pulmonary TB cases, European Region, 2013




**Map 7:** Percentage of notified TB cases with multidrug resistance among previously treated pulmonary TB cases with DST results, European Region, 2013




**Map 8:** Percentage of notified TB cases with multidrug resistance among all TB cases with DST results, European Region, 2013




**Map 9:** Percentage of notified TB cases with extensive drug resistance among pulmonary MDR TB cases with second-line DST results, European Region, 2013



**Map 10:** Percentage of HIV-positive TB cases among all TB cases with known HIV status, European Region, 2012



**Map 11:** Treatment success among new and relapsed TB cases having started treatment in 2012, European Region, 2013



**Map 12:** Treatment outcome after 24 months of RR TB/MDR TB cases having started second-line treatment in 2011, European Region, 2013



**Map 13:** Treatment success rate among all MDR TB cases notified in 2011, EU/EEA, 2013






Figure 1: TB estimated incidence and notification per 100 000 population, European Region, 2004–2013







**Figure 2: Estimated TB mortality per 100 000 population, European Region, 2004–2013**




**Figure 3: Total TB notifications by previous treatment history and total TB case rates, Europe, 2004–2013**



\* Excluded: 2004–2006, 2008–2013: Liechtenstein



\* Excluded: 2004: Kyrgyzstan, Liechtenstein, Monaco, Montenegro, Turkey, Ukraine; 2005: Liechtenstein, Monaco, San Marino, Ukraine; 2006: Liechtenstein, Monaco, San Marino; 2007: Monaco, San Marino; 2008: Liechtenstein, Monaco, San Marino; 2009: Liechtenstein, Monaco, San Marino; 2010: Liechtenstein, Monaco, San Marino; 2011: Liechtenstein, Monaco, San Marino; 2012: Liechtenstein, Monaco, San Marino; 2013: Liechtenstein, Monaco, San Marino




\* Excluded: 2002: Belarus, Russian Federation, Tajikistan, Turkey, Ukraine; 2003: Belarus, Tajikistan, Ukraine; 2004: Kyrgyzstan, Turkey, Ukraine; 2005: Ukraine


Data sources: TESSy, CISID, EuroTB historical database: Sitebac.

**Figure 4:** Percentages of MDR among pulmonary laboratory-confirmed TB cases, European Region, 2004–2013




**Figure 5: Percentage of TB cases with HIV infection among TB cases with known HIV status, Europe, 2008–2013**

\* Excluded: 2008: Austria, Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Liechtenstein, Lithuania, Luxembourg, Norway, Poland, Romania, Sweden, United Kingdom; 2009: Austria, Cyprus, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Liechtenstein, Lithuania, Luxembourg, Norway, Poland, Sweden, United Kingdom; 2010: Austria, Croatia, Finland, Germany, Greece, Hungary, Italy, Liechtenstein, Lithuania, Norway, Poland, Sweden, United Kingdom; 2011: Austria, Cyprus, Finland, Germany, Greece, Hungary, Italy, Liechtenstein, Norway, Poland, Sweden, United Kingdom; 2012: Austria, Croatia, Cyprus, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Liechtenstein, Norway, Poland, Sweden, United Kingdom; 2013: Austria, Croatia, Cyprus, Denmark, Finland, France, Germany, Hungary, Italy, Liechtenstein, Norway, Poland, Sweden, United Kingdom




\* Excluded: 2008: Andorra, Austria, Bosnia and Herzegovina, Croatia, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Monaco, Norway, Poland, San Marino, Serbia, Sweden, Switzerland, Turkey, Turkmenistan, United Kingdom; 2009: Andorra, Austria, Azerbaijan, Bosnia and Herzegovina, Croatia, Cyprus, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Monaco, Norway, Poland, San Marino, Serbia, Sweden, Switzerland, Turkey, Turkmenistan, United Kingdom; 2010: Andorra, Austria, Azerbaijan, Bosnia and Herzegovina, Croatia, Cyprus, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Monaco, Norway, Poland, San Marino, Serbia, Sweden, Switzerland, United Kingdom; 2011: Andorra, Austria, Bosnia and Herzegovina, Croatia, Cyprus, Denmark, Finland, Germany, Greece, Hungary, Italy, Liechtenstein, Monaco, Norway, Poland, San Marino, Sweden, Turkmenistan, United Kingdom; 2012: Austria, Croatia, Cyprus, Denmark, Finland, Germany, Greece, Hungary, Italy, Liechtenstein, Monaco, Norway, Poland, San Marino, Sweden, Switzerland, Turkmenistan, United Kingdom; 2013: Austria, Croatia, Cyprus, Denmark, Finland, France, Germany, Hungary, Italy, Liechtenstein, Monaco, Norway, Poland, San Marino, Sweden, Turkmenistan, United Kingdom




\* Excluded: 2008: Lithuania, Turkey, Turkmenistan; 2009: Azerbaijan, Lithuania, Turkey, Turkmenistan; 2010: Azerbaijan, Lithuania; 2011: Turkmenistan; 2012: Turkmenistan; 2013: Turkmenistan


**Figure 6: Treatment outcome, new TB cases and relapses having started treatment, European Region, 2003–2012**



\* Excluded: Finland (until 2007), France, Greece, Italy, Liechtenstein and Luxembourg




\* Excluded: Andorra, Finland (until 2007), France, Greece, Italy, Monaco, Luxembourg, San Marino and Switzerland  
2012 treatment cohort includes new and relapsed cases except Azerbaijan, Kosovo, Turkey, Turkmenistan and Uzbekistan




\* 2012 treatment cohort includes new and relapsed cases except Azerbaijan, Turkey, Turkmenistan and Uzbekistan


**Figure 7: Treatment outcome after 24 months of all RR TB/MDR TB cases starting second-line treatment in 2011, European Region, 2007–2011<sup>a</sup>**



\* Excluded: Austria (2007), Croatia, Cyprus, Finland, France, Greece, Italy, Iceland, Liechtenstein, Lithuania (2007), Luxembourg, Portugal until 2010, Spain



\* Excluded: 2007: Azerbaijan, Belarus, Bosnia and Herzegovina, Croatia, Finland, France, Greece, Italy, Liechtenstein, Lithuania, Luxembourg, Monaco, Portugal, Russia, San Marino, Serbia, Spain, Switzerland, Tajikistan, Turkmenistan and Ukraine; 2008: Albania, Belarus, Bosnia and Herzegovina, Croatia, Cyprus, Finland, France, Greece, Italy, Iceland, Liechtenstein, Luxembourg, Monaco, Portugal, San Marino, Serbia, Spain, Switzerland, Tajikistan, Turkmenistan and Ukraine; 2009: Finland, France, Greece, Hungary, Italy, Iceland, Liechtenstein, Luxembourg, Moldova, Monaco, Portugal, Russia, San Marino, Spain, Switzerland, Turkmenistan; 2010: Croatia, Cyprus, Finland, France, Greece, Iceland, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, San Marino, Spain, Switzerland, Turkmenistan; 2011: Albania, Croatia, Cyprus, Czech Republic, Finland, France, Greece, Iceland, Italy, Liechtenstein, Luxembourg, Monaco, San Marino, Spain, Switzerland, Turkmenistan



\* Excluded: 2007: Azerbaijan, Belarus, Russia, Tajikistan, Turkmenistan and Ukraine; 2008: Belarus, Tajikistan, Turkmenistan and Ukraine; 2009: Moldova, Russia, Turkmenistan; 2010: Turkmenistan; 2011: Turkmenistan

<sup>a</sup> Includes all MDR TB cases for 2007–2010 and cases starting second line TB treatment for 2011.

## 6. Tables





**Summary table: Tuberculosis surveillance data by region, European Region, 2013**

	Table showing data by country	Region							
		EU/EEA		Non-EU/EEA		Total		18 High-Priority Countries (HPC)	
		Number of reporting countries <sup>a</sup>		Number of reporting countries <sup>a</sup>		Number of reporting countries <sup>a</sup>		Number of reporting countries <sup>a</sup>	
<b>Total population (millions)</b>	-	<b>30</b>	<b>512.2</b>	<b>23</b>	<b>392.2</b>	<b>53</b>	<b>904.4</b>	<b>18</b>	<b>390.6</b>
<b>Estimates of TB disease burden 2013<sup>b</sup></b>									
Estimated TB prevalence rate per 100 000 population	1	30	18.4	23	93.2	51	51.0	18	100.3
Estimated TB mortality rate (excluding HIV-related deaths) per 100 000 population	1	30	0.9	23	8.4	53	4.1	18	8.7
Estimated TB incidence rate per 100 000 population	1	30	14.2	23	73.1	53	39.0	18	77.9
Estimated MDR TB among all notified TB cases	2	17	1587	17	29 148	34	30 000	17	29 396
Estimated proportion of HIV-infection among incident TB cases (new and relapses)	2	29	4.0	16	6.3	45	6	17	6.2
<b>Notifications of TB cases, 2013</b>									
Total number of TB cases	3	30	64 844	21	295 576	51	360 420	18	326 656
All TB cases per 100 000 population	3	30	12.7	21	74.8	53	39.8	18	79.8
Mean annual % change of notification rate (2009–2013)	3	30	-5.6%	21	-2.1%	51	-2.8%	18	-2.5%
Total number of new TB cases and relapses	4	30	61 569	21	235 950	51	297 519	18	251 007
New TB cases and relapses per 100 000 population	4	30	12.0	21	60.2	51	32.8	18	64.0
Mean annual % change of notification rate of new TB cases and relapses (2009–2013)	4	30	-4.7%	20	-1.8%	50	-2.5%	18	-2.3%
Percentage of new cases among all TB cases	5	29	77.9%	19	65.4%	48	67.6%	17	65.9%
Percentage of retreatment cases among all TB cases	5	29	11.7%	19	27.5%	48	24.7%	17	27.4%
Percentage of pulmonary TB among all TB cases	6	30	77.3%	20	80.7%	49	80.0%	17	81.0%
Male-to-female ratio of all TB cases	11	30	1.8	19	2.0	49	1.9	16	2.0
<b>TB case confirmation, multidrug resistance (MDR) and extensive drug resistance (XDR), 2013</b>									
Percentage of laboratory-confirmed cases among pulmonary TB cases <sup>c</sup>	12	28	61.8%	21	49.6%	49	51.7%	16	51.1%
Percentage of MDR TB among pulmonary TB cases	12	28	4.8%	21	31.0%	49	26.0%	11	29.7%
Percentage of laboratory-confirmed cases among all TB cases	9	30	62.1%	-	-	-	-	-	-
Percentage of MDR TB among all TB cases	13	30	4.1%	-	-	-	-	-	-
Mean annual % change in MDR TB notification rate (2004–2013)	VI	23	-2.8%	-	-	-	-	-	-
Percentage of XDR TB among pulmonary MDR TB cases with DST for SLD <sup>d</sup>	16	22	17.8%	14	11.6%	36	12.7%	12	12.8%
Percentage of XDR TB among all MDR TB cases with DST for SLD	17	27	17.5%	-	-	-	-	-	-
<b>TB-HIV coinfection, 2013</b>									
Percentage of all TB cases with known HIV status	18	17	65.2%	20	67.9%	37	67.6%	17	37.2%
Percentage of HIV-positive cases among all TB cases with known HIV status	18	17	4.9%	20	8.1%	37	7.8%	17	7.8%
<b>Treatment outcome</b>									
Treatment outcome of new TB cases and relapses started on treatment in 2012									
Success (cure or treatment completion)	20	26	77.1%	19	75.1%	45	75.6%	17	76.1%
Died	20	26	6.5%	19	7.3%	45	7.1%	17	7.3%
Failed	20	26	0.9%	19	6.3%	45	5.1%	17	6.0%
Lost to follow up	20	26	4.8%	19	6.6%	45	6.2%	17	6.5%
Still on treatment	20	26	2.7%	-	-	26	0.6%	-	0.0%
Not evaluated (transferred, unknown)	20	26	8.1%	19	4.7%	45	5.5%	17	4.1%
Treatment outcome of all TB cases reported in 2012									
Success (cure or treatment completion)	23	23	73.5%	-	-	-	-	-	-
Died	23	26	7.6%	-	-	-	-	-	-
Failed	23	26	1.4%	-	-	-	-	-	-
Lost to follow up	23	26	5.5%	-	-	-	-	-	-
Still on treatment	23	26	3.8%	-	-	-	-	-	-
Not evaluated (transferred, unknown)	23	26	8.1%	-	-	-	-	-	-
24-month treatment outcome of RR-/MDR TB cases who started on second-line treatment in 2011									
Success (cure or treatment completion)	24	21	38.1%	18	46.3%	39	46.0%	17	45.9%
Died	24	21	16.7%	18	14.6%	39	14.7%	17	14.8%
Failed	24	21	16.4%	18	17.1%	39	17.1%	17	17.3%
Lost to follow up	24	21	18.4%	18	14.4%	39	14.5%	17	14.6%
Still on treatment	24	21	7.1%	-	-	21	0.3%	-	0.2%
Not evaluated (transferred, unknown)	24	21	3.3%	18	7.6%	39	7.4%	17	7.3%
24-month treatment success of all MDR TB cases reported in 2011									
Success (cure or treatment completion)	25	21	37.8%	-	-	-	-	-	-
Died	25	21	17.0%	-	-	-	-	-	-
Failed	25	21	16.4%	-	-	-	-	-	-
Lost to follow up	25	21	18.5%	-	-	-	-	-	-
Still on treatment	25	21	7.1%	-	-	-	-	-	-
Not evaluated (transferred, unknown)	25	21	3.2%	-	-	-	-	-	-

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein

HPC: 18 'high priority' countries in the WHO European Region: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine, Uzbekistan.

<sup>b</sup> Number of countries with available data included in the statistics.

<sup>c</sup> WHO estimates, as published in report: Global tuberculosis control 2014.

<sup>d</sup> Laboratory-confirmed means confirmation according to EU case definition for EU/EEA countries and smear and/or culture confirmation for non-EU/EEA countries.

<sup>e</sup> SLD: anti-TB treatment with second-line drugs.

Table 1: Estimates of the TB disease burden 2013, European Region

Country	Population <sup>a</sup>	Estimated number of deaths from TB (all forms, excluding HIV)						Estimated prevalence of TB (all forms)					
		Number			per 100 000			Number			per 100 000		
		Best	Low	High	Best	Low	High	Best	Low	High	Best	Low	High
<b>EU/EEA</b>													
Austria	8 495 145	29	29	30	0.3	0.3	0.4	930	400	1700	11.0	4.7	20.0
Belgium	11 104 476	18	18	19	0.2	0.2	0.2	1300	540	2300	11.0	4.9	21.0
Bulgaria	7 222 943	150	150	150	2.1	2.0	2.1	2700	1100	5000	37.0	15.0	69.0
Croatia	4 289 714	52	51	52	1.2	1.2	1.2	790	360	1400	18.0	8.4	32.0
Cyprus	1 141 166	2	2	3	0.2	0.2	0.3	70	21	150	6.1	1.8	13.0
Czech Republic	10 702 197	28	28	28	0.3	0.3	0.3	760	320	1400	7.1	3.0	13.0
Denmark	5 619 096	24	22	25	0.4	0.4	0.4	480	190	900	8.5	3.4	16.0
Estonia	1 287 251	32	31	32	2.5	2.4	2.5	340	150	610	27.0	12.0	47.0
Finland	5 426 323	17	17	18	0.3	0.3	0.3	370	130	720	6.8	2.5	13.0
France	64 291 280	340	320	350	0.5	0.5	0.6	7000	3200	12000	11.0	5.0	19.0
Germany	82 726 626	300	290	300	0.4	0.4	0.4	6200	2600	11000	7.5	3.2	14.0
Greece	11 127 990	77	72	81	0.7	0.7	0.7	730	320	1300	6.5	2.9	12.0
Hungary	9 954 941	81	81	81	0.8	0.8	0.8	2900	1500	4700	29.0	15.0	48.0
Iceland	329 535	1	1	1	0.3	0.3	0.3	12	4	25	3.8	1.3	7.6
Ireland	4 627 173	18	18	19	0.4	0.4	0.4	490	200	910	11.0	4.4	20.0
Italy	60 990 277	310	310	310	0.5	0.5	0.5	4100	1500	7900	6.7	2.5	13.0
Latvia	2 050 317	43	43	43	2.1	2.1	2.1	1200	570	2000	58.0	28.0	100.0
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	3 016 933	250	250	260	8.4	8.4	8.5	2600	1200	4500	85.0	39.0	148.0
Luxembourg	530 380	2	2	2	0.4	0.4	0.4	62	30	110	12.0	5.6	20.0
Malta	429 004	2	2	2	0.4	0.4	0.4	60	24	110	14.0	5.6	26.0
Netherlands	16 759 229	20	19	20	0.1	0.1	0.1	1300	540	2300	7.6	3.2	14.0
Norway	5 042 671	4	4	5	0.1	0.1	0.1	540	240	970	11.0	4.7	19.0
Poland	38 216 635	650	630	670	1.7	1.6	1.7	10000	4300	19000	27.0	11.0	50.0
Portugal	10 608 156	140	140	150	1.3	1.3	1.4	3100	1400	5500	30.0	13.0	52.0
Romania	21 698 585	1200	1200	1200	5.4	5.4	5.5	27000	13000	45000	123.0	60.0	209.0
Slovakia	5 450 223	35	35	35	0.6	0.6	0.7	580	270	1000	11.0	5.0	18.0
Slovenia	2 071 997	21	21	21	1.0	1.0	1.0	190	74	360	9.2	3.6	17.0
Spain	46 926 963	240	230	240	0.5	0.5	0.5	7300	3100	13000	16.0	6.5	28.0
Sweden	9 571 105	13	13	13	0.1	0.1	0.1	860	350	1600	9.0	3.7	17.0
United Kingdom	63 136 265	340	340	340	0.5	0.5	0.5	11000	4300	20000	17.0	6.8	32.0
<b>Subtotal EU/EEA</b>	<b>514 844 596</b>	<b>4439</b>	<b>4369</b>	<b>4499</b>	<b>0.9</b>	<b>0.8</b>	<b>0.9</b>	<b>94 964</b>	<b>41 933</b>	<b>167 465</b>	<b>18.4</b>	<b>8.1</b>	<b>32.5</b>
<b>Non-EU/EEA</b>													
Albania	3 173 271	20	14	27	0.6	0.5	0.9	490	150	1000	15.0	4.6	33.0
Andorra	79 218	0	0	1	0.3	0.1	0.7	7	2	14	8.2	2.5	17.0
Armenia	2 976 566	170	140	200	5.7	4.8	6.7	2000	930	3400	66.0	31.0	115.0
Azerbaijan	9 413 420	360	330	390	3.9	3.5	4.2	9900	4000	19000	105.0	42.0	197.0
Belarus	9 356 678	850	790	910	9.1	8.5	9.8	9500	4900	16000	102.0	52.0	168.0
Bosnia and Herzegovina	3 829 307	190	170	210	4.9	4.4	5.4	1300	400	2800	35.0	10.0	74.0
former Yugoslav Republic of Macedonia, the	2 107 158	33	31	34	1.5	1.5	1.6	310	94	660	15.0	4.5	31.0
Georgia	4 340 895	310	200	430	7.0	4.7	9.8	7100	3400	12000	163.0	79.0	277.0
Israel	7 733 144	16	16	16	0.2	0.2	0.2	550	220	1000	7.1	2.9	13.0
Kazakhstan	16 440 586	1600	1200	2000	9.5	7.1	12.0	31000	15000	54000	190.0	89.0	328.0
Kyrgyzstan	5 547 548	620	620	630	11.0	11.0	11.0	11000	4900	18000	190.0	88.0	329.0
Moldova	3 487 204	480	450	500	14.0	13.0	14.0	7900	4000	13000	226.0	113.0	375.0
Monaco	37 831	0	0	0	0.1	0.0	0.2	1	0	2	2.4	0.7	5.2
Montenegro	621 383	1	1	2	0.2	0.1	0.2	160	61	290	25.0	9.8	47.0
Russia	142 833 689	17000	17000	18000	12.0	12.0	13.0	160000	74000	290000	114.0	51.0	201.0
San Marino	31 448	0	0	0	-	-	-	0	0	1	1.5	0.4	3.1
Serbia	9 510 506	150	140	160	1.6	1.4	1.7	2600	1300	4300	28.0	14.0	46.0
Switzerland	8 077 833	17	17	17	0.2	0.2	0.2	650	250	1200	8.0	3.2	15.0
Tajikistan	8 207 834	570	430	730	6.9	5.2	8.9	12000	5700	20000	142.0	70.0	239.0
Turkey	74 932 641	310	180	480	0.4	0.2	0.7	17000	7900	30000	23.0	11.0	39.0
Turkmenistan	5 240 072	1300	1100	1500	25.0	22.0	28.0	3200	970	6800	61.0	18.0	130.0
Ukraine	45 238 805	6600	6400	6700	14.0	14.0	15.0	54000	27000	91000	120.0	59.0	202.0
Uzbekistan	28 934 102	2200	1900	2500	7.6	6.6	8.7	35000	18000	58000	120.0	61.0	199.0
<b>Subtotal non-EU/EEA</b>	<b>392 151 139</b>	<b>32 797</b>	<b>32 079</b>	<b>33 516</b>	<b>8.4</b>	<b>8.2</b>	<b>8.5</b>	<b>365 668</b>	<b>252 122</b>	<b>479 214</b>	<b>93.2</b>	<b>64.3</b>	<b>122.2</b>
<b>Total European Region</b>	<b>906 995 735</b>	<b>38 000</b>	<b>37 000</b>	<b>39 000</b>	<b>4.1</b>	<b>4.0</b>	<b>4.2</b>	<b>460 000</b>	<b>350 000</b>	<b>590 000</b>	<b>51</b>	<b>39</b>	<b>65</b>
<b>Subtotal 18 HPC</b>	<b>392 226 069</b>	<b>34 045</b>	<b>33 575</b>	<b>34 515</b>	<b>8.7</b>	<b>8.6</b>	<b>8.8</b>	<b>393 440</b>	<b>350 697</b>	<b>436 183</b>	<b>100.3</b>	<b>89.4</b>	<b>111.2</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> Population estimate 2013 by UN Statistical Database for all countries

	Estimated number of incident cases (all forms)					
	Number			per 100 000		
	Best	Low	High	Best	Low	High
	710	660	780	8.4	7.7	9.1
	1000	940	1100	9.1	8.5	10.0
	2100	2000	2400	29.0	27.0	33.0
	580	540	610	13.0	13.0	14.0
	66	58	74	5.8	5.1	6.5
	590	550	650	5.5	5.1	6.1
	400	370	430	7.0	6.5	7.7
	290	270	320	22.0	21.0	25.0
	310	290	340	5.7	5.3	6.2
	5600	5400	5900	8.8	8.4	9.1
	4800	4400	5200	5.8	5.3	6.3
	550	500	600	5.0	4.5	5.4
	1800	1700	2000	18.0	17.0	20.0
	12	11	13	3.6	3.3	3.9
	390	370	440	8.5	8.0	9.5
	3500	3300	3900	5.7	5.5	6.4
	1000	960	1100	50.0	47.0	54.0
	-	-	-	-	-	-
	2000	1800	2200	65.0	61.0	72.0
	46	41	48	8.7	7.7	9.1
	49	46	54	11.0	11.0	13.0
	1000	950	1100	6.1	5.7	6.7
	410	380	440	8.2	7.5	8.8
	8300	7600	9000	22.0	20.0	24.0
	2700	2500	3000	26.0	24.0	28.0
	19000	17000	22000	87.0	79.0	101.0
	420	380	450	7.7	6.9	8.2
	160	150	180	7.5	7.2	8.5
	6100	5800	6800	13.0	12.0	15.0
	690	640	750	7.2	6.7	7.9
	8700	8400	9100	14.0	13.0	14.0
	<b>73273</b>	<b>68006</b>	<b>80979</b>	<b>14.2</b>	<b>13.2</b>	<b>15.7</b>
	590	500	680	18.0	16.0	22.0
	6	5	7	7.3	6.4	8.2
	1500	1300	1700	49.0	45.0	57.0
	8000	7200	9300	85.0	77.0	99.0
	6500	5800	7500	70.0	62.0	80.0
	1700	1300	2300	46.0	33.0	60.0
	370	320	410	17.0	15.0	20.0
	5000	4700	5500	116.0	109.0	126.0
	450	420	490	5.8	5.5	6.4
	23000	22000	27000	139.0	132.0	164.0
	7800	6900	8700	141.0	124.0	157.0
	5500	5000	6300	159.0	142.0	180.0
	1	1	1	2.1	1.8	2.4
	130	110	130	21.0	18.0	22.0
	130000	120000	140000	89.0	82.0	100.0
	0	0	1	1.5	1.3	1.7
	1700	1600	1900	18.0	17.0	20.0
	530	500	580	6.5	6.1	7.2
	8200	7300	9400	100.0	89.0	114.0
	15000	14000	17000	20.0	19.0	22.0
	3800	3100	4600	72.0	59.0	87.0
	44000	39000	50000	96.0	87.0	110.0
	23000	20000	28000	80.0	68.0	97.0
	<b>286777</b>	<b>275019</b>	<b>298535</b>	<b>73.1</b>	<b>70.1</b>	<b>76.1</b>
	<b>360000</b>	<b>340000</b>	<b>370000</b>	<b>39</b>	<b>38</b>	<b>41</b>
	<b>305690</b>	<b>298928</b>	<b>312452</b>	<b>77.9</b>	<b>76.2</b>	<b>79.7</b>

Table 2: Estimates for TB/HIV co-infection and MDR TB, European Region, 2013

Country	Estimated HIV-infection among TB incidence (new and relapses)						Estimated MDR TB among notified new TB cases					
	Number			%			Number			%		
	Best	Low	High	Best	Low	High	Best	Low	High	Best	Low	High
<b>EU/EEA</b>												
Austria	6	6	14	0.9	0.4	1.5	12	5	25	2.5	1.0	5.1
Belgium	40	38	40	4.0	3.6	4.3	-	-	-	1.6	0.7	3.1
Bulgaria	6	6	7	0.3	0.3	0.3	28	16	45	2.3	1.3	3.8
Croatia	2	2	2	0.4	0.3	0.4	-	-	-	0.4	0.0	2.0
Cyprus	0	0	0	-	-	-	-	-	-	0.0	0.0	8.8
Czech Republic	2	1	2	0.3	0.2	0.3	-	-	-	0.5	0.1	1.9
Denmark	13	13	13	3.2	2.9	3.5	-	-	-	0.4	0.0	2.1
Estonia	34	30	40	12.0	9.9	14.0	37	25	51	17.0	12.0	24.0
Finland	1	1	3	0.4	0.2	0.6	1	-	7	0.6	0.0	3.4
France	620	520	730	11.0	9.3	13.0	-	-	-	0.5	0.2	0.8
Germany	34	31	83	0.7	0.3	1.3	73	54	97	2.3	1.7	3.1
Greece	5	5	13	1.0	0.4	1.8	6	-	34	1.5	0.0	8.0
Hungary	4	3	8	0.2	0.1	0.3	-	-	0	2.5	1.3	4.3
Iceland	1	1	1	11.0	7.9	15.0	-	-	3	0.0	0.0	71.0
Ireland	6	4	7	1.5	1.1	2.0	4	-	13	1.5	0.2	5.4
Italy	89	85	100	2.6	2.3	2.9	62	32	110	2.6	1.4	4.6
Latvia	200	190	220	20.0	18.0	22.0	61	45	80	8.8	6.6	12.0
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	97	21	170	5.0	1.9	9.5	137	119	175	11.0	9.5	14.0
Luxembourg	2	1	2	4.5	3.2	5.9	-	-	-	0.0	0.0	0.0
Malta	2	2	2	3.7	3.4	4.0	-	-	9	0.0	0.0	25.0
Netherlands	40	37	44	3.9	3.5	4.4	9	4	17	2.0	0.8	4.1
Norway	3	2	5	0.6	0.3	1.0	5	1	13	2.2	0.6	5.6
Poland	96	44	100	1.2	0.8	1.6	30	18	47	0.5	0.3	0.8
Portugal	500	490	500	18.0	17.0	20.0	15	8	26	1.0	0.5	1.7
Romania	520	470	600	2.7	2.3	3.3	300	190	440	2.8	1.8	4.2
Slovakia	1	0	2	0.2	0.1	0.4	-	-	7	0.0	0.0	2.6
Slovenia	1	0	4	0.8	0.2	2.1	-	-	4	0.0	0.0	3.6
Spain	530	390	670	8.7	6.5	11.0	8	1	30	0.2	0.0	0.8
Sweden	10	5	11	1.5	1.1	2.0	6	2	14	1.8	0.6	4.2
United Kingdom	100	90	180	1.2	0.7	1.7	52	40	66	1.4	1.0	1.7
<b>Subtotal EU/EEA</b>	<b>2964</b>	<b>2758</b>	<b>3171</b>	<b>4.0</b>	<b>3.8</b>	<b>4.3</b>	<b>1587</b>	<b>36</b>	<b>3211</b>	<b>4.4</b>	<b>0.1</b>	<b>8.9</b>
<b>Non-EU/EEA</b>												
Albania	0	0	0	-	-	-	2	0	10	0.6	0.0	3.2
Andorra	0	0	0	-	-	-	0	0	3	0.0	0.0	60.0
Armenia	66	60	72	4.5	3.9	5.2	75	56	100	9.4	7.0	12.0
Azerbaijan	130	110	150	1.6	1.3	1.9	480	380	590	13.0	10.0	16.0
Belarus	320	290	380	5.0	4.1	6.0	1100	1100	1200	35.0	33.0	37.0
Bosnia and Herzegovina	0	0	0	-	-	-	0	0	6	0.0	0.0	0.6
former Yugoslav Republic of Macedonia, the	0	0	0	-	-	-	0	0	5	0.0	0.0	2.2
Georgia	97	69	130	1.9	1.4	2.6	270	230	310	11.0	9.7	13.0
Israel	13	13	15	2.9	2.6	3.3	9	3	18	3.8	1.4	8.2
Kazakhstan	590	560	690	2.6	2.2	3.0	2700	2600	2900	25.0	24.0	26.0
Kyrgyzstan	240	190	260	3.0	2.5	3.7	1100	950	1300	26.0	23.0	31.0
Moldova	340	300	400	6.2	5.1	7.4	770	700	850	24.0	21.0	26.0
Monaco	0	0	0	-	-	-	0	0	0	1.7	0.9	2.6
Montenegro	3	2	3	2.1	1.8	2.3	0	0	6	0.0	0.0	5.4
Russia	7900	6900	9100	6.2	5.2	7.3	16000	11000	20000	19.0	14.0	25.0
San Marino	0	0	0	-	-	-	0	0	0	1.7	0.9	2.6
Serbia	12	4	20	0.7	0.3	1.2	8	3	17	0.9	0.3	1.8
Switzerland	11	10	26	2.0	0.8	3.8	5	1	14	1.5	0.3	4.4
Tajikistan	260	200	360	3.2	2.3	4.4	480	380	600	13.0	9.8	16.0
Turkey	76	73	76	0.5	0.5	0.6	190	160	230	2.5	2.1	3.0
Turkmenistan	0	0	0	-	-	-	85	25	210	3.8	1.1	9.5
Ukraine	7200	7100	7200	16.0	15.0	19.0	4100	3900	4300	14.0	14.0	15.0
Uzbekistan	930	900	940	4.0	3.3	4.8	2800	2200	3600	23.0	18.0	29.0
<b>Subtotal non-EU/EEA</b>	<b>18188</b>	<b>17103</b>	<b>19272</b>	<b>6.3</b>	<b>6.0</b>	<b>6.7</b>	<b>29148</b>	<b>23620</b>	<b>34676</b>	<b>17.4</b>	<b>14.1</b>	<b>20.7</b>
<b>Total European Region</b>	<b>21000</b>	<b>20000</b>	<b>22000</b>	<b>5.8</b>	<b>5.6</b>	<b>6.1</b>	<b>30000</b>	<b>21000</b>	<b>40000</b>	<b>14.0</b>	<b>9.7</b>	<b>19.0</b>
<b>Subtotal 18 HPC</b>	<b>19006</b>	<b>17917</b>	<b>20095</b>	<b>6.2</b>	<b>5.9</b>	<b>6.6</b>	<b>29396</b>	<b>22489</b>	<b>36302</b>	<b>16.6</b>	<b>12.7</b>	<b>20.5</b>

'European Region' comprises the 53 countries of the WHO European Region. WHO European Region 18 TB High Priority Countries presented in italics.

	Estimated MDR TB among notified previously treated TB cases						Estimated MDR TB among all notified TB cases		
	Number			%			Number		
	Best	Low	High	Best	Low	High	Best	Low	High
	14	7	21	38.0	19.0	59.0	26	14	37
	-	-	-	13.0	5.5	25.0	0	0	0
	50	36	67	23.0	17.0	31.0	78	58	99
	-	-	-	0.0	0.0	12.0	0	0	0
	-	-	-	0.0	0.0	84.0	0	0	0
	-	-	-	7.7	1.0	25.0	0	0	0
	-	-	-	0.0	0.0	9.3	0	0	0
	27	18	35	48.0	32.0	63.0	64	49	78
	0	0	6	0.0	0.0	52.0	1	0	4
	0	0	0	13.0	7.4	21.0	0	0	0
	49	33	69	21.0	14.0	30.0	120	95	150
	4	-	18	9.1	0.2	41.0	10	0	25
	-	-	-	8.1	3.3	16.0	0	0	0
	-	-	-	0.0	0.0	0.0	0	0	3
	0	-	7	0.0	0.0	26.0	4	0	8
	12	6	20	8.8	4.6	15.0	73	38	110
	31	21	42	26.0	18.0	35.0	91	72	110
	-	-	-	-	-	-	-	-	-
	139	123	155	44.0	39.0	49.0	276	245	308
	-	-	-	0.0	0.0	98.0	0	0	0
	-	-	-	0.0	0.0	98.0	0	0	9
	11	5	19	33.0	15.0	57.0	20	11	29
	2	-	11	5.9	0.2	29.0	7	1	14
	36	22	54	4.3	2.7	6.5	66	45	86
	8	3	17	4.9	1.6	11.0	23	12	34
	410	300	540	11.0	8.0	15.0	710	540	870
	2	-	11	3.7	0.1	19.0	2	0	6
	-	-	3	0.0	0.0	46.0	0	0	0
	21	10	39	7.1	3.3	13.0	29	12	47
	5	1	15	13.0	1.6	38.0	11	3	20
	17	10	29	5.7	3.2	9.4	69	54	85
	<b>1151</b>	<b>348</b>	<b>1955</b>	<b>19.2</b>	<b>5.8</b>	<b>32.6</b>	<b>2738</b>	<b>384</b>	<b>5166</b>
	0	0	4	0.0	0.0	22.0	2	0	5
	0	0	0	0.0	0.0	0.0	0	0	3
	120	100	130	43.0	38.0	49.0	190	170	220
	1100	890	1400	28.0	22.0	34.0	1600	1300	1800
	690	660	730	55.0	52.0	57.0	1800	1800	1900
	2	0	8	1.6	0.0	8.5	2	0	5
	2	0	9	6.3	0.2	30.0	2	0	5
	440	400	490	38.0	34.0	42.0	720	650	780
	3	0	3	100.0	2.5	100.0	12	5	18
	3800	3800	3900	55.0	54.0	56.0	6600	6400	6700
	660	620	700	55.0	52.0	58.0	1800	1600	1900
	880	840	930	62.0	59.0	65.0	1700	1600	1700
	0	0	0	13.0	11.0	15.0	0	0	0
	0	0	5	0.0	0.0	52.0	0	0	0
	25000	20000	30000	49.0	40.0	59.0	41000	35000	48000
	0	0	0	13.0	11.0	15.0	0	0	0
	5	1	12	4.7	1.3	11.0	13	5	21
	14	6	25	24.0	11.0	41.0	19	9	29
	670	610	720	56.0	52.0	60.0	1100	1000	1300
	160	130	190	18.0	15.0	21.0	350	310	400
	170	100	250	18.0	11.0	28.0	250	140	360
	5300	5100	5500	32.0	31.0	33.0	9400	9200	9700
	5100	4300	5800	62.0	52.0	71.0	7900	7400	8500
	<b>43469</b>	<b>37085</b>	<b>49947</b>	<b>46.3</b>	<b>39.5</b>	<b>53.2</b>	<b>72617</b>	<b>68051</b>	<b>84623</b>
	<b>45000</b>	<b>37000</b>	<b>53000</b>	<b>44.0</b>	<b>36.0</b>	<b>52.0</b>	<b>75000</b>	<b>68000</b>	<b>82000</b>
	<b>43983</b>	<b>36555</b>	<b>51412</b>	<b>45.0</b>	<b>37.4</b>	<b>52.6</b>	<b>73379</b>	<b>59045</b>	<b>87714</b>



**Table 3: Tuberculosis cases, notification rates per 100 000 population and mean annual change in rates, European Region, 2009–2013**

Country	2009		2010		2011		2012		2013		Mean annual % change in rate, 2009–2013
	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	
<b>EU/EEA</b>											
Austria	696	8.4	691	8.3	684	8.2	647	7.7	649	7.7	-2.0%
Belgium	994	9.2	1086	10.0	1019	9.3	975	8.8	981	8.8	-1.1%
Bulgaria	2910	39.0	2649	35.7	2406	32.6	2280	31.1	1932	26.5	-9.1%
Croatia	855	20.1	695	16.4	619	14.6	575	13.7	517	12.3	-11.4%
Cyprus	55	6.9	61	7.4	54	6.4	69	8.0	41	4.7	-5.5%
Czech Republic	694	6.7	668	6.4	600	5.7	598	5.7	501	4.8	-7.8%
Denmark	334	6.1	366	6.6	381	6.9	389	7.0	356	6.4	1.4%
Estonia	411	30.8	333	25.0	339	25.5	288	21.7	286	21.7	-8.0%
Finland	413	7.8	317	5.9	324	6.0	276	5.1	271	5.0	-9.8%
France <sup>a</sup>	5276	8.2	5116	7.9	4991	7.7	4978	7.6	4939	7.5	-2.1%
Germany	4444	5.4	4390	5.4	4307	5.3	4217	5.2	4318	5.3	-0.7%
Greece	589	5.3	487	4.4	489	4.4	558	5.0	540	4.9	-1.2%
Hungary	1407	14.2	1741	17.7	1445	14.7	1223	12.4	1045	10.6	-5.7%
Iceland	9	2.8	22	6.9	9	2.8	11	3.4	11	3.4	26.9%
Ireland	479	10.6	420	9.2	413	9.0	359	7.8	384	8.4	-5.4%
Italy <sup>b</sup>	4244	7.2	4692	7.9	3521	5.9	3142	5.3	3153	5.3	-6.5%
Latvia	977	45.2	935	44.1	885	42.7	993	48.6	904	44.7	0.0%
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-
Lithuania	2081	65.4	1938	61.7	1904	62.4	1781	59.3	1705	57.4	-3.2%
Luxembourg	27	5.5	29	5.8	26	5.1	45	8.6	38	7.1	11.2%
Malta	44	10.7	32	7.7	33	8.0	42	10.1	50	11.9	4.9%
Netherlands	1158	7.0	1068	6.4	1004	6.0	957	5.7	848	5.1	-7.9%
Norway	358	7.5	336	6.9	354	7.2	374	7.5	401	7.9	1.7%
Poland	8236	21.6	7509	19.7	8478	22.0	7542	19.6	7250	18.8	-3.0%
Portugal	2871	27.7	2715	26.2	2611	25.2	2605	24.7	2393	22.8	-4.7%
Romania	23164	114.6	21059	105.1	19202	96.4	18190	90.5	16711	83.5	-7.6%
Slovakia	506	9.4	439	8.1	399	7.4	345	6.4	401	7.4	-5.0%
Slovenia	188	9.3	172	8.4	192	9.4	138	6.7	140	6.8	-6.2%
Spain	7592	16.4	7239	15.6	6798	14.6	6070	13.0	5539	11.9	-7.8%
Sweden	617	6.7	667	7.1	580	6.2	623	6.6	648	6.8	0.8%
United Kingdom	8878	14.4	8398	13.5	8923	14.3	8729	13.7	7892	12.4	-3.6%
<b>Subtotal EU/EEA</b>	<b>80507</b>	<b>15.9</b>	<b>76270</b>	<b>15.0</b>	<b>72990</b>	<b>14.3</b>	<b>69019</b>	<b>13.5</b>	<b>64844</b>	<b>12.7</b>	<b>-5.6%</b>
<b>Non-EU/EEA</b>											
Albania	447	14.2	445	14.1	431	13.7	420	13.3	474	14.9	1.5%
Andorra	9	11.4	7	9.0	4	5.1	9	11.5	5	6.3	3.6%
Armenia	2006	67.6	1780	60.1	1582	53.4	1518	51.1	1417	47.6	-8.3%
Azerbaijan	10417	115.9	8394	92.3	10100	109.8	8140	87.4	8597	91.3	-4.3%
Belarus	5511	57.9	5554	58.5	5118	54.2	5246	55.8	4863	51.9	-2.6%
Bosnia and Herzegovina	1772	46.0	1390	36.1	1385	36.1	1420	37.0	1261	32.9	-7.5%
former Yugoslav Republic of Macedonia, the	473	22.5	420	20.0	362	17.2	355	16.9	323	15.3	-9.1%
Georgia	5978	135.8	5796	132.1	5533	126.5	4974	114.1	4319	99.5	-7.4%
Israel	347	4.8	343	4.6	418	5.5	509	6.7	308	4.0	-0.8%
Kazakhstan	30578	194.2	28550	179.3	26304	163.4	21523	132.3	19857	120.8	-11.1%
Kyrgyzstan	6358	120.8	6295	118.0	6666	123.4	6916	126.3	7209	129.9	1.9%
Moldova	5591	155.1	5447	152.4	5341	150.8	5341	152.0	5052	144.8	-1.7%
Monaco	0	0.0	1	2.7	-	-	-	-	-	-	-
Montenegro	120	19.4	114	18.4	112	18.0	107	17.2	120	19.3	0.2%
Russia	156222	108.7	162553	113.2	159479	111.2	149921	104.7	142261	99.8	-2.0%
San Marino	-	-	-	-	-	-	-	-	-	-	-
Serbia	2595	26.7	2385	24.7	2216	23.1	1917	20.1	2103	22.1	-4.8%
Serbia excluding UN Administered Province of Kosovo <sup>c</sup>	1625	22.2	1501	20.6	1341	18.5	1215	16.9	1181	16.6	-
UN Administered Province of Kosovo <sup>c</sup>	970	40.7	884	37.5	875	37.4	702	29.8	922	38.8	-
Switzerland	554	7.2	548	7.0	578	7.3	463	5.8	526	6.5	-1.5%
Tajikistan	7482	100.5	7641	100.2	7609	97.4	6929	86.5	6495	79.1	-5.7%
Turkey	17402	24.4	16551	22.9	15679	21.5	14691	19.9	13409	17.9	-7.5%
Turkmenistan	3157	63.4	3230	64.1	3022	59.2	3422	66.2	3675	70.1	2.8%
Ukraine	38901	84.1	36409	79.1	42676	93.2	45569	100.1	48134	106.4	6.4%
Uzbekistan	21453	78.3	20330	73.2	15913	56.5	16810	58.9	25168	87.0	5.6%
<b>Subtotal non-EU/EEA</b>	<b>317373</b>	<b>81.7</b>	<b>314183</b>	<b>80.5</b>	<b>310528</b>	<b>79.2</b>	<b>296200</b>	<b>75.3</b>	<b>295576</b>	<b>74.8</b>	<b>-2.1%</b>
<b>Total European Region</b>	<b>397880</b>	<b>44.6</b>	<b>390453</b>	<b>43.6</b>	<b>383518</b>	<b>42.8</b>	<b>365219</b>	<b>40.5</b>	<b>360420</b>	<b>39.8</b>	<b>-2.8%</b>
<b>Subtotal 18 HPC</b>	<b>340599</b>	<b>88.2</b>	<b>335444</b>	<b>86.6</b>	<b>329758</b>	<b>84.8</b>	<b>314532</b>	<b>80.7</b>	<b>311994</b>	<b>79.8</b>	<b>-2.5%</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

Note 1: For TB cases and notification rates by country and year for the period 1995–2013, see <http://ecdc.europa.eu/en/data-tools/atlas/Pages/atlas.aspx>

Note 2: The data published in this report might differ from figures in national reports due to different times of reporting. The deadline for correcting and updating the data used in this report in the joint database was 1 October 2014.

<sup>b</sup> Provisional data for 2013 from France including overseas territories.

<sup>c</sup> Provisional data for 2013.

<sup>d</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 4: New TB cases and relapses, notification rates per 100 000 population and mean annual percentage change in rates, European Region, 2004–2013<sup>a</sup>**

Country	2004		2005		2006		2007		2008		2009	
	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate
<b>EU/EEA</b>												
Austria	1053	12.9	966	11.8	882	10.7	850	10.3	813	9.8	671	8.1
Belgium	1108	10.7	1042	10.0	1034	9.8	943	8.9	912	8.5	918	8.5
Bulgaria	2923	37.5	3101	40.0	3011	39.0	2967	39.2	3068	40.8	2816	37.7
Croatia	1170	27.4	1050	24.6	1029	24.1	951	22.3	980	23.0	832	19.5
Cyprus	30	4.2	36	4.9	36	4.8	41	5.4	48	6.2	52	6.5
Czech Republic	1027	10.1	886	8.7	872	8.5	770	7.5	806	7.8	632	6.1
Denmark	355	6.6	397	7.3	351	6.5	355	6.5	340	6.2	292	5.3
Estonia	561	41.1	501	36.9	439	32.5	468	34.8	414	30.9	377	28.2
Finland	319	6.1	345	6.6	281	5.3	342	6.5	335	6.3	404	7.6
France <sup>b</sup>	5181	8.3	4990	8.0	4931	7.8	5220	8.2	5380	8.4	4925	7.7
Germany	6331	7.7	5811	7.2	5231	6.4	4875	5.9	4408	5.4	4318	5.3
Greece	731	6.6	694	6.3	616	5.5	571	5.1	586	5.2	542	4.8
Hungary	2301	22.8	1923	19.1	1825	18.2	1639	16.5	1583	16.0	1381	14.0
Iceland	12	4.1	10	3.4	13	4.3	12	3.9	6	1.9	9	2.8
Ireland	396	9.8	406	9.9	420	10.0	424	9.8	429	9.6	427	9.4
Italy <sup>c</sup>	3968	6.9	3926	6.8	4264	7.3	4280	7.4	4240	7.2	4087	6.9
Latvia	1579	69.4	1409	62.6	1290	57.9	1231	55.7	1051	48.0	953	44.1
Liechtenstein	-	-	-	-	-	-	5	14.2	-	-	-	-
Lithuania	2036	59.9	2377	70.9	2367	72.0	2237	68.8	2098	65.3	1898	59.6
Luxembourg	31	6.8	37	8.0	33	7.0	39	8.2	28	5.8	27	5.5
Malta	19	4.8	24	6.0	30	7.4	38	9.4	51	12.5	43	10.5
Netherlands	1330	8.2	1081	6.6	998	6.1	958	5.9	977	6.0	1142	6.9
Norway	264	5.8	254	5.5	258	5.6	258	5.5	274	5.8	328	6.8
Poland	8951	23.4	8850	23.2	8193	21.5	8254	21.7	7679	20.1	7858	20.6
Portugal	3661	35.5	3206	31.0	3307	32.0	3033	29.3	2905	28.0	2768	26.7
Romania	28612	133.9	26722	125.9	24608	116.7	22916	109.4	22678	111.0	21342	105.6
Slovakia	699	13.0	746	13.9	718	13.4	676	12.6	619	11.5	493	9.2
Slovenia	256	12.8	272	13.6	213	10.6	217	10.8	209	10.4	187	9.2
Spain	5516	13.0	6185	14.3	6101	13.9	7347	16.4	7754	17.0	7191	15.6
Sweden	430	4.8	531	5.9	493	5.4	446	4.9	510	5.6	572	6.2
United Kingdom	7088	11.9	7779	13.0	7832	13.0	7809	12.9	8033	13.1	8136	13.2
<b>Subtotal EU/EEA</b>	<b>87938</b>	<b>17.7</b>	<b>85557</b>	<b>17.2</b>	<b>81676</b>	<b>(16.3)</b>	<b>80172</b>	<b>16.0</b>	<b>79214</b>	<b>15.7</b>	<b>75621</b>	<b>14.9</b>
<b>Non-EU/EEA</b>												
Albania	547	17.0	506	15.8	469	14.8	438	13.8	427	13.5	445	14.1
Andorra	7	8.9	10	12.3	12	14.7	5	6.2	4	5.0	8	10.2
Armenia	1660	54.9	2206	73.2	1767	58.8	1682	56.3	1655	55.6	1560	52.6
Azerbaijan	5404	63.8	6034	70.5	5705	65.8	5521	63.0	7632	86.0	9462	105.3
Belarus	5443	56.0	5308	54.9	5142	53.4	5351	55.8	5126	53.6	5250	55.1
Bosnia and Herzegovina	2353	60.5	2111	54.4	1778	45.9	2373	61.3	1719	44.5	1725	44.8
former Yugoslav Republic of Macedonia, the	644	30.9	598	28.6	561	26.8	526	25.1	450	21.4	450	21.4
Georgia	4011	88.8	4503	100.6	4555	102.5	4312	97.4	4423	100.2	5687	129.2
Israel	456	7.0	371	5.6	340	5.0	396	5.7	322	4.5	347	4.8
Kazakhstan	28432	190.8	28629	190.0	26619	174.8	26710	173.5	23140	148.6	24905	158.2
Kyrgyzstan	6104	121.6	6329	125.5	6174	121.5	6098	118.8	6769	130.2	5931	112.6
Moldova	4806	125.5	5141	136.5	4990	134.3	4857	132.2	4464	122.8	4471	124.1
Monaco	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	0	0.0	156	25.3	167	27.1	147	23.8	131	21.2	114	18.4
Russia	121426	84.1	127930	88.9	124689	86.8	127338	88.6	128263	89.3	132653	92.3
San Marino	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	-	-	3208	32.2	3146	31.8	2891	29.4	2714	27.9	2526	26.1
Serbia excluding UN Administered Province of Kosovo <sup>d</sup>	-	-	-	-	-	-	-	-	1722	23.4	1625	22.2
UN Administered Province of Kosovo <sup>d</sup>	-	-	-	-	-	-	-	-	992	41.1	901	37.8
Switzerland	551	7.5	514	6.9	473	6.3	420	5.6	463	6.0	503	6.5
Tajikistan	4529	68.0	5460	80.2	5365	77.1	6297	88.6	6396	87.9	7210	96.8
Turkey	17543	26.2	19744	29.1	19629	28.6	18878	27.2	17603	25.0	16771	23.5
Turkmenistan	3382	72.0	3191	67.2	3223	67.1	3428	70.6	3757	76.4	3157	63.4
Ukraine	38403	80.9	39608	84.0	41265	88.0	37517	80.4	37832	81.4	36075	78.0
Uzbekistan	20289	78.7	21513	82.6	23900	90.7	19779	74.2	17176	63.6	19973	72.9
<b>Subtotal non-EU/EEA</b>	<b>265990</b>	<b>70.2</b>	<b>283070</b>	<b>74.5</b>	<b>279969</b>	<b>73.5</b>	<b>274964</b>	<b>71.9</b>	<b>270466</b>	<b>70.4</b>	<b>279223</b>	<b>72.3</b>
<b>Total European Region</b>	<b>353928</b>	<b>40.3</b>	<b>368627</b>	<b>41.8</b>	<b>361645</b>	<b>40.9</b>	<b>355136</b>	<b>40.0</b>	<b>349680</b>	<b>39.2</b>	<b>354844</b>	<b>39.6</b>
<b>Subtotal 18 HPC</b>	<b>297143</b>	<b>77.8</b>	<b>309706</b>	<b>80.9</b>	<b>304738</b>	<b>79.5</b>	<b>297587</b>	<b>77.4</b>	<b>293545</b>	<b>76.0</b>	<b>300491</b>	<b>77.6</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

Note 1: For TB cases and case rates by country and year for the period 1995–2013, see <http://www.who.int/tb/country/data/download/en/>

<sup>b</sup> Cases with missing information on previous history of TB treatment are included among new cases. For countries with no information on relapse, only new and cases with unknown previous TB history are counted.

<sup>c</sup> Provisional data for 2013 including overseas territories.

<sup>d</sup> Provisional data for 2013.

<sup>e</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).



	2010		2011		2012		2013		Mean annual % change in rate, 2004–2013
	N	Rate	N	Rate	N	Rate	N	Rate	
	662	7.9	675	8.1	629	7.5	624	7.4	-5.9%
	1001	9.2	963	8.8	898	8.1	906	8.1	-2.9%
	2551	34.4	2313	31.4	2212	30.2	1930	26.5	-3.6%
	688	16.2	619	14.6	539	12.8	511	12.2	-8.4%
	61	7.4	52	6.2	65	7.5	41	4.7	3.4%
	619	5.9	568	5.4	558	5.3	471	4.5	-8.3%
	331	6.0	359	6.5	342	6.1	330	5.9	-0.8%
	304	22.8	316	23.8	268	20.2	263	19.9	-7.4%
	305	5.7	318	5.9	265	4.9	266	4.9	-1.2%
	4801	7.4	4726	7.3	4705	7.2	4708	7.2	-1.5%
	4215	5.2	4186	5.1	4096	5.0	4193	5.1	-4.3%
	443	4.0	454	4.1	520	4.7	494	4.5	-3.9%
	1639	16.6	1377	14.0	1182	12.0	1040	10.5	-7.7%
	22	6.9	9	2.8	11	3.4	11	3.4	11.6%
	387	8.5	388	8.5	334	7.3	356	7.8	-2.4%
	4539	7.7	3421	5.8	3096	5.2	3019	5.1	-2.9%
	917	43.2	871	42.0	971	47.5	872	43.1	-4.9%
	-	-	-	-	-	-	-	-	-
	1755	55.9	1751	57.4	1640	54.6	1573	52.9	-1.1%
	29	5.8	25	4.9	45	8.6	38	7.1	3.9%
	29	7.0	32	7.7	41	9.8	50	11.9	13.1%
	1040	6.3	985	5.9	935	5.6	832	5.0	-5.0%
	295	6.1	320	6.5	340	6.8	362	7.2	2.7%
	7229	18.9	8175	21.2	7285	18.9	7043	18.3	-2.5%
	2647	25.5	2553	24.7	2557	24.3	2338	22.3	-4.9%
	19303	96.3	17672	88.7	16764	83.4	15523	77.5	-5.8%
	432	8.0	397	7.4	344	6.4	398	7.4	-5.6%
	171	8.4	190	9.3	138	6.7	139	6.8	-6.1%
	6888	14.8	6410	13.7	5738	12.3	5244	11.2	-1.2%
	615	6.6	542	5.8	591	6.2	610	6.4	3.9%
	7857	12.7	8392	13.4	8207	12.9	7384	11.6	-0.2%
	<b>71775</b>	<b>14.2</b>	<b>69059</b>	<b>13.6</b>	<b>65316</b>	<b>12.8</b>	<b>61569</b>	<b>12.0</b>	<b>-4.7%</b>
	431	13.7	422	13.4	408	12.9	474	14.9	-1.2%
	7	9.0	3	3.9	9	11.5	5	6.3	18.8%
	1410	47.6	1261	42.5	1213	40.9	1397	46.9	-0.7%
	7550	83.0	9146	99.4	6363	68.4	5860	62.3	1.9%
	5098	53.7	4697	49.7	4783	50.9	4470	47.8	-1.7%
	1321	34.3	1360	35.4	1409	36.8	1261	32.9	-5.1%
	384	18.3	335	15.9	346	16.4	318	15.1	-7.5%
	4678	106.6	4547	103.9	3940	90.4	3434	79.1	-0.4%
	340	4.6	412	5.5	506	6.6	308	4.0	-4.0%
	23399	147.0	25074	155.8	18006	110.7	18958	115.3	-4.8%
	5652	106.0	5980	110.7	6195	113.2	7075	127.5	0.8%
	4135	115.7	4233	119.5	4409	125.5	4485	128.6	0.4%
	1	2.7	-	-	-	-	-	-	-
	110	17.7	110	17.7	98	15.8	119	19.2	-2.8%
	125310	87.3	112910	78.7	105753	73.8	106053	74.3	-1.3%
	-	-	-	-	-	-	-	-	-
	2326	24.2	2171	22.7	1870	19.6	2153	22.6	-4.0%
	1442	19.8	1296	17.9	1168	16.2	1161	12.2	-
	884	37.5	875	37.4	702	29.8	992	38.8	-
	508	6.5	524	6.6	416	5.2	466	5.8	-2.3%
	6994	91.7	7035	90.0	6508	81.3	5576	67.9	0.6%
	15879	22.0	15054	20.6	14139	19.1	13170	17.6	-4.2%
	3230	64.1	2731	53.5	2937	56.8	3046	58.1	-1.9%
	33857	73.5	34237	74.7	40990	90.0	36510	80.7	-0.1%
	16883	60.8	15345	54.5	14832	52.0	20812	71.9	0.5%
	<b>259503</b>	<b>66.9</b>	<b>247587</b>	<b>63.6</b>	<b>235130</b>	<b>60.2</b>	<b>235950</b>	<b>60.2</b>	<b>-1.8%</b>
	<b>331278</b>	<b>36.9</b>	<b>316646</b>	<b>35.1</b>	<b>300446</b>	<b>33.2</b>	<b>297519</b>	<b>32.8</b>	<b>-2.5%</b>
	<b>278905</b>	<b>71.8</b>	<b>265173</b>	<b>68.0</b>	<b>251923</b>	<b>64.4</b>	<b>251007</b>	<b>64.0</b>	<b>-2.3%</b>

Table 5: Tuberculosis cases by history of previous TB treatment, European Region, 2013

Country	New		Unknown previous TB history		Previously treated										All TB cases	
					Previously treated total		Previous treatment completed		Previous treatment failed		Previous treatment defaulted		Other retreatment <sup>a</sup>			
	N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>		N
<b>EU/EEA</b>																
Austria	485	(74.7)	126	(19.4)	38	(5.9)	13	(34.2)	1	(2.6)	0	(0.0)	24	(63.2)	649	
Belgium <sup>d</sup>	697	(71.0)	209	(21.3)	75	(7.6)	0	(0.0)	0	(0.0)	0	(0.0)	75	(100.0)	981	
Bulgaria	1680	(87.0)	0	(0.0)	252	(13.0)	250	(99.2)	0	(0.0)	2	(0.8)	0	(0.0)	1932	
Croatia	429	(83.0)	62	(12.0)	26	(5.0)	20	(76.9)	2	(7.7)	0	(0.0)	4	(15.4)	517	
Cyprus	38	(92.7)	2	(4.9)	1	(2.4)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	41	
Czech Republic	471	(94.0)	0	(0.0)	30	(6.0)	0	(0.0)	0	(0.0)	0	(0.0)	30	(100.0)	501	
Denmark <sup>d</sup>	330	(92.7)	0	(0.0)	26	(7.3)	0	(0.0)	0	(0.0)	0	(0.0)	26	(100.0)	356	
Estonia	225	(78.7)	0	(0.0)	61	(21.3)	38	(62.3)	7	(11.5)	16	(26.2)	0	(0.0)	286	
Finland	253	(93.4)	5	(1.8)	13	(4.8)	8	(61.5)	0	(0.0)	0	(0.0)	5	(38.5)	271	
France <sup>e</sup>	2650	(53.7)	2058	(41.7)	231	(4.7)	0	(0.0)	0	(0.0)	0	(0.0)	231	(100.0)	4939	
Germany	1159	(26.8)	2899	(67.1)	260	(6.0)	135	(51.9)	9	(3.5)	39	(15.0)	77	(29.6)	4318	
Greece	430	(79.6)	64	(11.9)	46	(8.5)	0	(0.0)	0	(0.0)	1	(2.2)	45	(97.8)	540	
Hungary	975	(93.3)	0	(0.0)	70	(6.7)	65	(92.9)	0	(0.0)	2	(2.9)	3	(4.3)	1045	
Iceland	11	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	11	
Ireland <sup>d</sup>	240	(62.5)	116	(30.2)	28	(7.3)	0	(0.0)	0	(0.0)	0	(0.0)	28	(100.0)	384	
Italy <sup>f</sup>	2683	(85.1)	336	(10.7)	134	(4.2)	0	(0.0)	0	(0.0)	0	(0.0)	134	(100.0)	3153	
Latvia	776	(85.8)	0	(0.0)	128	(14.2)	96	(75.0)	4	(3.1)	28	(21.9)	0	(0.0)	904	
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Lithuania	1383	(81.1)	10	(0.6)	312	(18.3)	180	(57.7)	32	(10.3)	100	(32.1)	0	(0.0)	1705	
Luxembourg	-	-	38	(100.0)	-	-	-	-	-	-	-	-	-	-	38	
Malta	40	(80.0)	10	(20.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	50	
Netherlands	803	(94.7)	4	(0.5)	41	(4.8)	25	(61.0)	0	(0.0)	8	(19.5)	8	(19.5)	848	
Norway <sup>d</sup>	336	(83.8)	26	(6.5)	39	(9.7)	0	(0.0)	0	(0.0)	0	(0.0)	39	(100.0)	401	
Poland	6403	(88.3)	0	(0.0)	847	(11.7)	640	(75.6)	0	(0.0)	0	(0.0)	207	(24.4)	7250	
Portugal	2209	(92.3)	0	(0.0)	184	(7.7)	129	(70.1)	2	(1.1)	27	(14.7)	26	(14.1)	2393	
Romania	12860	(77.0)	0	(0.0)	3851	(23.0)	2663	(69.2)	583	(15.1)	605	(15.7)	0	(0.0)	16711	
Slovakia	325	(81.0)	16	(4.0)	60	(15.0)	57	(95.0)	0	(0.0)	0	(0.0)	3	(5.0)	401	
Slovenia	133	(95.0)	0	(0.0)	7	(5.0)	6	(85.7)	0	(0.0)	1	(14.3)	0	(0.0)	140	
Spain	4946	(89.3)	298	(5.4)	295	(5.3)	0	(0.0)	0	(0.0)	0	(0.0)	295	(100.0)	5539	
Sweden	522	(80.6)	83	(12.8)	43	(6.6)	5	(11.6)	0	(0.0)	2	(4.7)	36	(83.7)	648	
United Kingdom <sup>d</sup>	7001	(88.7)	383	(4.9)	508	(6.4)	0	(0.0)	0	(0.0)	0	(0.0)	508	(100.0)	7892	
<b>Subtotal EU/EEA</b>	<b>50493</b>	<b>(77.9)</b>	<b>6745</b>	<b>(10.4)</b>	<b>7606</b>	<b>(11.7)</b>	<b>4331</b>	<b>(56.9)</b>	<b>640</b>	<b>(8.4)</b>	<b>831</b>	<b>(10.9)</b>	<b>1804</b>	<b>(23.7)</b>	<b>64844</b>	
<b>Non-EU/EEA</b>																
Albania	455	(96.0)	0	(0.0)	19	(4.0)	18	(94.7)	0	(0.0)	1	(5.3)	0	(0.0)	474	
Andorra	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Armenia	1053	(74.3)	0	(0.0)	364	(25.7)	344	(94.5)	12	(3.3)	8	(2.2)	0	(0.0)	1417	
Azerbaijan	-	-	8597	(100.0)	-	-	-	-	-	-	-	-	-	-	8597	
Belarus	3577	(73.6)	0	(0.0)	1286	(26.4)	893	(69.4)	141	(11.0)	43	(3.3)	209	(16.3)	4863	
Bosnia and Herzegovina	1158	(91.8)	0	(0.0)	103	(8.2)	103	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	1261	
former Yugoslav Republic of Macedonia, the	290	(89.8)	0	(0.0)	33	(10.2)	28	(84.8)	0	(0.0)	0	(0.0)	5	(15.2)	323	
Georgia	3133	(72.5)	0	(0.0)	1186	(27.5)	301	(25.4)	104	(8.8)	226	(19.1)	555	(46.8)	4319	
Israel	304	(98.7)	0	(0.0)	4	(1.3)	4	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	308	
Kazakhstan	12510	(63.0)	0	(0.0)	7347	(37.0)	6448	(87.8)	434	(5.9)	465	(6.3)	0	(0.0)	19857	
Kyrgyzstan	5859	(81.3)	0	(0.0)	1350	(18.7)	1216	(90.1)	65	(4.8)	69	(5.1)	0	(0.0)	7209	
Moldova	3604	(71.3)	27	(0.5)	1421	(28.1)	881	(62.0)	217	(15.3)	323	(22.7)	0	(0.0)	5052	
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Montenegro	111	(92.5)	0	(0.0)	9	(7.5)	8	(88.9)	0	(0.0)	1	(11.1)	0	(0.0)	120	
Russia	90488	(63.6)	0	(0.0)	51773	(36.4)	15293	(29.5)	18287	(35.3)	6342	(12.2)	11851	(22.9)	142261	
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Serbia	1967	(93.5)	1	(0.0)	135	(6.4)	115	(85.2)	6	(4.4)	13	(9.6)	1	(0.7)	2103	
Serbia excluding UN Administered Province of Kosovo <sup>g</sup>	1064	(90.1)	1	(0.1)	116	(9.8)	96	(82.8)	6	(5.2)	13	(11.2)	1	(0.9)	1181	
UN Administered Province of Kosovo <sup>g</sup>	903	(97.9)	0	(0.0)	19	(2.1)	19	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	922	
Switzerland	339	(64.4)	127	(24.1)	60	(11.4)	0	(0.0)	0	(0.0)	0	(0.0)	60	(100.0)	526	
Tajikistan	5306	(81.7)	0	(0.0)	1189	(18.3)	270	(22.7)	133	(11.2)	58	(4.9)	728	(61.2)	6495	
Turkey	12352	(92.1)	0	(0.0)	1057	(7.9)	818	(77.4)	70	(6.6)	169	(16.0)	0	(0.0)	13409	
Turkmenistan	2774	(75.5)	629	(17.1)	272	(7.4)	272	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	3675	
Ukraine	31399	(65.2)	11624	(24.1)	5111	(10.6)	5111	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	48134	
Uzbekistan	16555	(65.8)	0	(0.0)	8613	(34.2)	4257	(49.4)	311	(3.6)	103	(1.2)	3942	(45.8)	25168	
<b>Subtotal non-EU/EEA</b>	<b>193234</b>	<b>(65.4)</b>	<b>21005</b>	<b>(7.1)</b>	<b>81332</b>	<b>(27.5)</b>	<b>36380</b>	<b>(44.7)</b>	<b>19780</b>	<b>(24.3)</b>	<b>7821</b>	<b>(9.6)</b>	<b>17351</b>	<b>(21.3)</b>	<b>295571</b>	
<b>Total European Region</b>	<b>243727</b>	<b>(67.6)</b>	<b>27750</b>	<b>(7.7)</b>	<b>88938</b>	<b>(24.7)</b>	<b>40711</b>	<b>(45.8)</b>	<b>20420</b>	<b>(23.0)</b>	<b>8652</b>	<b>(9.7)</b>	<b>19155</b>	<b>(21.5)</b>	<b>360415</b>	
<b>Subtotal 18 HPC</b>	<b>205534</b>	<b>(65.9)</b>	<b>20887</b>	<b>(6.7)</b>	<b>85573</b>	<b>(27.4)</b>	<b>39331</b>	<b>(46.0)</b>	<b>20400</b>	<b>(23.8)</b>	<b>8557</b>	<b>(10.0)</b>	<b>17285</b>	<b>(20.2)</b>	<b>311994</b>	

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in *italics*.

<sup>b</sup> Includes retreatment cases with previous treatment completion not specified and cases with previous treatment transferred out.

<sup>c</sup> Percentage among all TB cases.

<sup>d</sup> Percentage among previously treated TB cases.

<sup>e</sup> Distribution by previous diagnosis.

<sup>f</sup> Provisional data for 2013 including overseas territories.

<sup>g</sup> Provisional data for 2013.

<sup>h</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 6: Tuberculosis cases by site of disease, European Region, 2013

Country	Pulmonary						Extrapulmonary		No site reported		Total
	Pulmonary only		Pulmonary + extrapulmonary		Total pulmonary		N	(%)	N	(%)	
	N	(%)	N	(%)	N	(%)					
<b>EU/EEA</b>											
Austria	471	(72.6)	52	(8.0)	523	(80.6)	124	(19.1)	2	(0.3)	649
Belgium	599	(61.1)	83	(8.5)	682	(69.5)	299	(30.5)	0	(0.0)	981
<i>Bulgaria</i>	1338	(69.3)	87	(4.5)	1425	(73.8)	507	(26.2)	0	(0.0)	1932
Croatia	403	(77.9)	17	(3.3)	420	(81.2)	34	(6.6)	63	(12.2)	517
Cyprus	28	(68.3)	1	(2.4)	29	(70.7)	12	(29.3)	0	(0.0)	41
Czech Republic	414	(82.6)	27	(5.4)	441	(88.0)	60	(12.0)	0	(0.0)	501
Denmark	218	(61.2)	8	(2.2)	226	(63.5)	64	(18.0)	66	(18.5)	356
<i>Estonia</i>	235	(82.2)	33	(11.5)	268	(93.7)	18	(6.3)	0	(0.0)	286
Finland	217	(80.1)	0	(0.0)	217	(80.1)	54	(19.9)	0	(0.0)	271
France <sup>a</sup>	2845	(57.6)	728	(14.7)	3573	(72.3)	1333	(27.0)	33	(0.7)	4939
Germany	2838	(65.7)	460	(10.7)	3298	(76.4)	989	(22.9)	31	(0.7)	4318
Greece	429	(79.4)	27	(5.0)	456	(84.4)	69	(12.8)	15	(2.8)	540
Hungary	973	(93.1)	23	(2.2)	996	(95.3)	49	(4.7)	0	(0.0)	1045
Iceland	3	(27.3)	1	(9.1)	4	(36.4)	7	(63.6)	0	(0.0)	11
Ireland	230	(59.9)	23	(6.0)	253	(65.9)	129	(33.6)	2	(0.5)	384
Italy <sup>b</sup>	2158	(68.4)	290	(9.2)	2448	(77.6)	705	(22.4)	0	(0.0)	3153
<i>Latvia</i>	762	(84.3)	46	(5.1)	808	(89.4)	96	(10.6)	0	(0.0)	904
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	1562	(91.6)	3	(0.2)	1565	(91.8)	140	(8.2)	0	(0.0)	1705
Luxembourg	32	(84.2)	0	(0.0)	32	(84.2)	6	(15.8)	0	(0.0)	38
Malta	33	(66.0)	5	(10.0)	38	(76.0)	12	(24.0)	0	(0.0)	50
Netherlands	363	(42.8)	91	(10.7)	454	(53.5)	393	(46.3)	1	(0.1)	848
Norway	198	(49.4)	52	(13.0)	250	(62.3)	149	(37.2)	2	(0.5)	401
Poland	6801	(93.8)	34	(0.5)	6835	(94.3)	415	(5.7)	0	(0.0)	7250
Portugal	1531	(64.0)	155	(6.5)	1686	(70.5)	693	(29.0)	14	(0.6)	2393
<i>Romania</i>	13224	(79.1)	1052	(6.3)	14276	(85.4)	2435	(14.6)	0	(0.0)	16711
Slovakia	307	(76.6)	37	(9.2)	344	(85.8)	57	(14.2)	0	(0.0)	401
Slovenia	80	(57.1)	29	(20.7)	109	(77.9)	31	(22.1)	0	(0.0)	140
Spain	3998	(72.2)	0	(0.0)	3998	(72.2)	1541	(27.8)	0	(0.0)	5539
Sweden	298	(46.0)	70	(10.8)	368	(56.8)	280	(43.2)	0	(0.0)	648
United Kingdom	3137	(39.7)	959	(12.2)	4096	(51.9)	3759	(47.6)	37	(0.5)	7892
<b>Subtotal EU/EEA</b>	<b>45725</b>	<b>(70.5)</b>	<b>4393</b>	<b>(6.8)</b>	<b>50118</b>	<b>(77.3)</b>	<b>14460</b>	<b>(22.3)</b>	<b>266</b>	<b>(0.4)</b>	<b>64844</b>
<b>Non-EU/EEA</b>											
Albania	-	-	-	-	333	(70.3)	141	(29.7)	0	(0.0)	474
Andorra	-	-	-	-	-	-	-	-	5	-	5
Armenia	-	-	-	-	1069	(75.4)	348	(24.6)	0	(0.0)	1417
<i>Azerbaijan</i>	-	-	-	-	-	-	-	-	8597	(100.0)	8597
<i>Belarus</i>	-	-	-	-	4311	(88.6)	343	(7.1)	209	(4.3)	4863
Bosnia and Herzegovina	-	-	-	-	1094	(86.8)	167	(13.2)	0	(0.0)	1261
former Yugoslav Republic of Macedonia, the	-	-	-	-	249	(77.1)	69	(21.4)	5	(1.5)	323
<i>Georgia</i>	-	-	-	-	3014	(69.8)	750	(17.4)	555	(12.9)	4319
Israel	-	-	-	-	226	(73.4)	82	(26.6)	0	(0.0)	308
<i>Kazakhstan</i>	-	-	-	-	17843	(89.9)	2014	(10.1)	0	(0.0)	19857
<i>Kyrgyzstan</i>	-	-	-	-	5383	(74.7)	1826	(25.3)	0	(0.0)	7209
<i>Moldova</i>	-	-	-	-	4673	(92.5)	379	(7.5)	0	(0.0)	5052
Monaco	-	-	-	-	-	-	-	-	-	-	-
Montenegro	-	-	-	-	112	(93.3)	8	(6.7)	0	(0.0)	120
<i>Russia</i>	-	-	-	-	121327	(85.3)	9083	(6.4)	11851	(8.3)	142261
San Marino	-	-	-	-	-	-	-	-	-	-	-
Serbia	-	-	-	-	1712	(81.4)	390	(18.5)	1	(0.1)	2103
Serbia excluding UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	1030	(87.2)	150	(12.7)	1	(0.1)	1181
UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	682	(74.0)	240	(26.0)	-	-	922
Switzerland	-	-	-	-	320	(60.8)	146	(27.8)	60	(11.4)	526
<i>Tajikistan</i>	-	-	-	-	4313	(66.4)	1454	(22.4)	728	(11.2)	6495
<i>Turkey</i>	-	-	-	-	8655	(64.5)	4754	(35.5)	0	(0.0)	13409
<i>Turkmenistan</i>	-	-	-	-	3094	(84.2)	581	(15.8)	0	(0.0)	3675
<i>Ukraine</i>	-	-	-	-	44257	(91.9)	3877	(8.1)	0	(0.0)	48134
<i>Uzbekistan</i>	-	-	-	-	16403	(65.2)	4823	(19.2)	3942	(15.7)	25168
<b>Subtotal non-EU/EEA</b>	-	-	-	-	<b>238388</b>	<b>(80.7)</b>	<b>31235</b>	<b>(10.6)</b>	<b>25953</b>	<b>(8.8)</b>	<b>295576</b>
<b>Total European Region</b>	-	-	-	-	<b>288506</b>	<b>(80.0)</b>	<b>45695</b>	<b>(12.7)</b>	<b>26219</b>	<b>(7.3)</b>	<b>360420</b>
<b>Subtotal 18 HPC</b>	-	-	-	-	<b>252684</b>	<b>(81.0)</b>	<b>33428</b>	<b>(10.7)</b>	<b>25882</b>	<b>(8.3)</b>	<b>311994</b>

<sup>a</sup>European Region<sup>a</sup> comprises the 53 countries of the WHO European Region and Liechtenstein.  
WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup>Provisional data for 2013 including overseas territories.

<sup>c</sup>Provisional data for 2013.

<sup>d</sup>In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 7: New pulmonary tuberculosis cases by diagnostic method, European Region, 2013

Country	New pulmonary TB cases <sup>a</sup>											
	N	(%) <sup>b</sup>	Confirmed by culture, smear and/or nucleic acid amplification test		Culture-positive or positive using WHO-recommended rapid diagnostics such as Xpert MTB/RIF							
			N	(%)	Smear positive		Smear negative		Smear unknown		Total	
					N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>d</sup>
<b>EU/EEA</b>												
Austria	389	(74.4)	324	(83.3)	158	(40.6)	122	(31.4)	31	(8.0)	311	(79.9)
Belgium	489	(71.7)	428	(87.5)	223	(45.6)	191	(39.1)	11	(2.2)	425	(86.9)
Bulgaria	1209	(84.8)	843	(69.7)	645	(53.3)	147	(12.2)	5	(0.4)	797	(65.9)
Croatia	394	(93.8)	339	(86.0)	211	(53.6)	97	(24.6)	4	(1.0)	312	(79.2)
Cyprus	27	(93.1)	25	(92.6)	13	(48.1)	6	(22.2)	4	(14.8)	23	(85.2)
Czech Republic	414	(93.9)	315	(76.1)	164	(39.6)	140	(33.8)	8	(1.9)	312	(75.4)
Denmark	203	(89.8)	203	(100.0)	111	(54.7)	92	(45.3)	0	(0.0)	203	(100.0)
Estonia	214	(79.9)	174	(81.3)	99	(46.3)	75	(35.0)	0	(0.0)	174	(81.3)
Finland	204	(94.0)	170	(83.3)	87	(42.6)	66	(32.4)	15	(7.4)	168	(82.4)
France <sup>e</sup>	1871	(52.4)	1404	(75.0)	476	(25.4)	452	(24.2)	34	(1.8)	962	(51.4)
Germany	874	(26.5)	757	(86.6)	310	(35.5)	0	(0.0)	434	(49.7)	744	(85.1)
Greece	368	(80.7)	303	(82.3)	175	(47.6)	64	(17.4)	6	(1.6)	245	(66.6)
Hungary	929	(93.3)	430	(46.3)	176	(18.9)	215	(23.1)	23	(2.5)	414	(44.6)
Iceland	4	(100.0)	3	(75.0)	2	(50.0)	1	(25.0)	0	(0.0)	3	(75.0)
Ireland	152	(60.1)	135	(88.8)	81	(53.3)	24	(15.8)	29	(19.1)	134	(88.2)
Italy <sup>f</sup>	2057	(84.0)	801	(38.9)	326	(15.8)	96	(4.7)	46	(2.2)	468	(22.8)
Latvia	691	(85.5)	573	(82.9)	246	(35.6)	316	(45.7)	0	(0.0)	562	(81.3)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	1249	(79.8)	1006	(80.5)	716	(57.3)	290	(23.2)	0	(0.0)	1006	(80.5)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-
Malta	33	(86.8)	18	(54.5)	10	(30.3)	7	(21.2)	0	(0.0)	17	(51.5)
Netherlands	425	(93.6)	366	(86.1)	130	(30.6)	115	(27.1)	120	(28.2)	365	(85.9)
Norway	213	(85.2)	188	(88.3)	62	(29.1)	53	(24.9)	73	(34.3)	188	(88.3)
Poland	6007	(87.9)	4132	(68.8)	2503	(41.7)	1333	(22.2)	279	(4.6)	4115	(68.5)
Portugal	1553	(92.1)	1377	(88.7)	787	(50.7)	358	(23.1)	40	(2.6)	1185	(76.3)
Romania	10557	(73.9)	8085	(76.6)	5715	(54.1)	1838	(17.4)	0	(0.0)	7553	(71.5)
Slovakia	271	(78.8)	170	(62.7)	96	(35.4)	66	(24.4)	0	(0.0)	162	(59.8)
Slovenia	103	(94.5)	101	(98.1)	39	(37.9)	42	(40.8)	20	(19.4)	101	(98.1)
Spain	3553	(88.9)	2881	(81.1)	1581	(44.5)	987	(27.8)	75	(2.1)	2643	(74.4)
Sweden	309	(84.0)	279	(90.3)	81	(26.2)	85	(27.5)	113	(36.6)	279	(90.3)
United Kingdom	3560	(86.9)	2648	(74.4)	1076	(30.2)	671	(18.8)	830	(23.3)	2577	(72.4)
<b>Subtotal EU/EEA</b>	<b>38322</b>	<b>(76.5)</b>	<b>28478</b>	<b>(74.3)</b>	<b>16299</b>	<b>(42.5)</b>	<b>7949</b>	<b>(20.7)</b>	<b>2200</b>	<b>(5.7)</b>	<b>26448</b>	<b>(69.0)</b>
<b>Non-EU/EEA</b>												
Albania	314	(94.3)	213	(67.8)	119	(37.9)	17	(5.4)	0	(0.0)	136	(43.3)
Andorra	-	-	-	-	-	-	-	-	-	-	-	-
Armenia	803	(75.1)	395	(49.2)	265	(33.0)	107	(13.3)	0	(0.0)	372	(46.3)
Azerbaijan	-	-	-	-	-	-	-	-	-	-	-	-
Belarus	3247	(75.3)	2259	(69.6)	1035	(31.9)	1080	(33.3)	0	(0.0)	2115	(65.1)
Bosnia and Herzegovina	995	(91.0)	643	(64.6)	487	(48.9)	156	(15.7)	0	(0.0)	643	(64.6)
former Yugoslav Republic of Macedonia, the	225	(90.4)	183	(81.3)	135	(60.0)	32	(14.2)	0	(0.0)	167	(74.2)
Georgia	2412	(80.0)	1828	(75.8)	1242	(51.5)	480	(19.9)	14	(0.6)	1736	(72.0)
Israel	223	(98.7)	163	(73.1)	86	(38.6)	65	(29.1)	5	(2.2)	156	(70.0)
Kazakhstan	10873	(60.9)	7942	(73.0)	2831	(26.0)	4097	(37.7)	4	(0.0)	6932	(63.8)
Kyrgyzstan	4185	(77.7)	1731	(41.4)	1667	(39.8)	64	(1.5)	0	(0.0)	1731	(41.4)
Moldova	3268	(69.9)	1857	(56.8)	977	(29.9)	690	(21.1)	4	(0.1)	1671	(51.1)
Monaco	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	103	(92.0)	67	(65.0)	40	(38.8)	27	(26.2)	0	(0.0)	67	(65.0)
Russia	81638	(67.3)	37720	(46.2)	20645	(25.3)	12808	(15.7)	0	(0.0)	33453	(41.0)
San Marino	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	923	(89.6)	773	(83.7)	494	(53.5)	240	(26.0)	2	(0.2)	736	(79.7)
Serbia excluding UN Administered Province of Kosovo <sup>g</sup>	923	(89.6)	773	(83.7)	494	(53.5)	240	(26.0)	2	(0.2)	736	(79.7)
UN Administered Province of Kosovo <sup>g</sup>	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	232	(72.5)	202	(87.1)	65	(28.0)	41	(17.7)	94	(40.5)	200	(86.2)
Tajikistan	3852	(89.3)	2205	(57.2)	2205	(57.2)	0	(0.0)	0	(0.0)	2205	(57.2)
Turkey	7791	(90.0)	5975	(76.7)	3600	(46.2)	1165	(15.0)	446	(5.7)	5211	(66.9)
Turkmenistan	2248	(72.7)	1220	(54.3)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Ukraine	28343	(64.0)	16125	(56.9)	16125	(56.9)	0	(0.0)	0	(0.0)	16125	(56.9)
Uzbekistan	12096	(73.7)	5505	(45.5)	3970	(32.8)	1214	(10.0)	0	(0.0)	5184	(42.9)
<b>Subtotal non-EU/EEA</b>	<b>163771</b>	<b>(68.9)</b>	<b>87006</b>	<b>(53.1)</b>	<b>55988</b>	<b>(34.2)</b>	<b>22283</b>	<b>(13.6)</b>	<b>569</b>	<b>(0.3)</b>	<b>78840</b>	<b>(48.1)</b>
<b>Total European Region</b>	<b>202093</b>	<b>(70.2)</b>	<b>115484</b>	<b>(57.1)</b>	<b>72287</b>	<b>(35.8)</b>	<b>30232</b>	<b>(15.0)</b>	<b>2769</b>	<b>(1.4)</b>	<b>105288</b>	<b>(52.1)</b>
<b>Subtotal 18 HPC</b>	<b>174676</b>	<b>(69.1)</b>	<b>95443</b>	<b>(54.6)</b>	<b>61983</b>	<b>(35.5)</b>	<b>24371</b>	<b>(14.0)</b>	<b>473</b>	<b>(0.3)</b>	<b>86827</b>	<b>(49.7)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in *italics*.

<sup>b</sup> Cases with unknown previous TB history are included among new TB cases for non-EU/EEA countries.

<sup>c</sup> Percentage among pulmonary TB cases.

<sup>d</sup> Percentage among new pulmonary TB cases.

<sup>e</sup> Percentage among all TB cases.

<sup>f</sup> Provisional data for 2013 including overseas territories.

<sup>g</sup> Provisional data for 2013.

<sup>h</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	New pulmonary TB cases <sup>a</sup>								All pulmonary TB cases	All culture and/or nucleic-acid-test confirmed TB cases		All TB cases
	Culture-negative or negative using WHO-recommended rapid diagnostics such as Xpert MTB/RIF or not tested											
	Smear positive		Smear negative		Smear unknown		Total					
	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>				
13	(3.3)	52	(13.4)	13	(3.3)	78	(20.1)	523	(80.6)	506	(78.0)	649
3	(0.6)	50	(10.2)	11	(2.2)	64	(13.1)	682	(69.5)	799	(81.4)	981
46	(3.8)	338	(28.0)	28	(2.3)	412	(34.1)	1425	(73.8)	957	(49.5)	1932
27	(6.9)	44	(11.2)	11	(2.8)	82	(20.8)	420	(81.2)	346	(66.9)	517
2	(7.4)	1	(3.7)	1	(3.7)	4	(14.8)	29	(70.7)	30	(73.2)	41
3	(0.7)	83	(20.0)	16	(3.9)	102	(24.6)	441	(88.0)	361	(72.1)	501
0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	226	(63.5)	294	(82.6)	356
0	(0.0)	32	(15.0)	8	(3.7)	40	(18.7)	268	(93.7)	228	(79.7)	286
2	(1.0)	30	(14.7)	4	(2.0)	36	(17.6)	217	(80.1)	215	(79.3)	271
442	(23.6)	411	(22.0)	56	(3.0)	909	(48.6)	3573	(72.3)	2335	(47.3)	4939
13	(1.5)	0	(0.0)	117	(13.4)	130	(14.9)	3298	(76.4)	3444	(79.8)	4318
58	(15.8)	29	(7.9)	36	(9.8)	123	(33.4)	456	(84.4)	345	(63.9)	540
16	(1.7)	395	(42.5)	104	(11.2)	515	(55.4)	996	(95.3)	448	(42.9)	1045
0	(0.0)	0	(0.0)	1	(25.0)	1	(25.0)	4	(36.4)	7	(63.6)	11
1	(0.7)	7	(4.6)	10	(6.6)	18	(11.8)	253	(65.9)	292	(76.0)	384
333	(16.2)	262	(12.7)	994	(48.3)	1589	(77.2)	2448	(77.6)	675	(21.4)	3153
11	(1.6)	110	(15.9)	8	(1.2)	129	(18.7)	808	(89.4)	702	(77.7)	904
-	-	-	-	-	-	-	-	-	-	-	-	-
0	(0.0)	243	(19.5)	0	(0.0)	243	(19.5)	1565	(91.8)	1354	(79.4)	1705
-	-	-	-	-	-	-	-	32	(84.2)	33	(86.8)	38
1	(3.0)	10	(30.3)	5	(15.2)	16	(48.5)	38	(76.0)	27	(54.0)	50
1	(0.2)	18	(4.2)	41	(9.6)	60	(14.1)	454	(53.5)	659	(77.7)	848
0	(0.0)	0	(0.0)	25	(11.7)	25	(11.7)	250	(62.3)	335	(83.5)	401
17	(0.3)	1618	(26.9)	257	(4.3)	1892	(31.5)	6835	(94.3)	4825	(66.6)	7250
192	(12.4)	93	(6.0)	83	(5.3)	368	(23.7)	1686	(70.5)	1493	(62.4)	2393
532	(5.0)	2349	(22.3)	123	(1.2)	3004	(28.5)	14276	(85.4)	10890	(65.2)	16711
8	(3.0)	99	(36.5)	2	(0.7)	109	(40.2)	344	(85.8)	231	(57.6)	401
0	(0.0)	2	(1.9)	0	(0.0)	2	(1.9)	109	(77.9)	135	(96.4)	140
238	(6.7)	490	(13.8)	182	(5.1)	910	(25.6)	3998	(72.2)	3631	(65.6)	5539
0	(0.0)	0	(0.0)	30	(9.7)	30	(9.7)	368	(56.8)	544	(84.0)	648
71	(2.0)	336	(9.4)	576	(16.2)	983	(27.6)	4096	(51.9)	4731	(59.9)	7892
<b>2030</b>	<b>(5.3)</b>	<b>7102</b>	<b>(18.5)</b>	<b>2742</b>	<b>(7.2)</b>	<b>11874</b>	<b>(31.0)</b>	<b>50118</b>	<b>(77.3)</b>	<b>40872</b>	<b>(63.0)</b>	<b>64844</b>
77	(24.5)	93	(29.6)	8	(2.5)	178	(56.7)	333	(70.3)	154	(32.5)	474
-	-	-	-	-	-	-	-	-	-	-	-	-
23	(2.9)	408	(50.8)	0	(0.0)	431	(53.7)	1069	(75.4)	456	(32.2)	1417
-	-	-	-	-	-	-	-	-	-	-	-	-
144	(4.4)	988	(30.4)	0	(0.0)	1132	(34.9)	4311	(88.6)	3276	(67.4)	4863
0	(0.0)	352	(35.4)	0	(0.0)	352	(35.4)	1094	(86.8)	708	(56.1)	1261
16	(7.1)	38	(16.9)	4	(1.8)	58	(25.8)	249	(77.1)	188	(58.2)	323
92	(3.8)	560	(23.2)	24	(1.0)	676	(28.0)	3014	(69.8)	2461	(57.0)	4319
7	(3.1)	42	(18.8)	18	(8.1)	67	(30.0)	226	(73.4)	210	(68.2)	308
1010	(9.3)	2895	(26.6)	36	(0.3)	3941	(36.2)	17843	(89.9)	14707	(74.1)	19857
0	(0.0)	2441	(58.3)	13	(0.3)	2454	(58.6)	5383	(74.7)	2298	(31.9)	7209
186	(5.7)	1307	(40.0)	104	(3.2)	1597	(48.9)	4673	(92.5)	2580	(51.1)	5052
-	-	-	-	-	-	-	-	-	-	-	-	-
0	(0.0)	36	(35.0)	0	(0.0)	36	(35.0)	112	(93.3)	73	(60.8)	120
4267	(5.2)	43100	(52.8)	818	(1.0)	48185	(59.0)	121327	(85.3)	40409	(28.4)	142261
-	-	-	-	-	-	-	-	-	-	-	-	-
37	(4.0)	137	(14.8)	13	(1.4)	187	(20.3)	1030	(87.2)	850	(72.0)	1181
37	(4.0)	137	(14.8)	13	(1.4)	187	(20.3)	1030	(87.2)	850	(72.0)	1181
-	-	-	-	-	-	-	-	-	-	-	-	-
2	(0.9)	0	(0.0)	30	(12.9)	32	(13.8)	320	(60.8)	429	(81.6)	526
0	(0.0)	1647	(42.8)	0	(0.0)	1647	(42.8)	4313	(66.4)	2842	(43.8)	6495
764	(9.8)	939	(12.1)	877	(11.3)	2580	(33.1)	8655	(64.5)	6169	(46.0)	13409
1220	(54.3)	1028	(45.7)	0	(0.0)	2248	(100.0)	3094	(84.2)	0	(0.0)	3675
0	(0.0)	12218	(43.1)	0	(0.0)	12218	(43.1)	44257	(91.9)	26786	(55.6)	48134
321	(2.7)	6591	(54.5)	0	(0.0)	6912	(57.1)	16403	(65.2)	9323	(37.0)	25168
<b>8166</b>	<b>(5.0)</b>	<b>74820</b>	<b>(45.7)</b>	<b>1945</b>	<b>(1.2)</b>	<b>84931</b>	<b>(51.9)</b>	<b>237706</b>	<b>(83.1)</b>	<b>113919</b>	<b>(39.8)</b>	<b>286052</b>
<b>10196</b>	<b>(5.0)</b>	<b>81922</b>	<b>(40.5)</b>	<b>4687</b>	<b>(2.3)</b>	<b>96805</b>	<b>(47.9)</b>	<b>287824</b>	<b>(82.0)</b>	<b>154791</b>	<b>(44.1)</b>	<b>350896</b>
<b>8616</b>	<b>(4.9)</b>	<b>77194</b>	<b>(44.2)</b>	<b>2039</b>	<b>(1.2)</b>	<b>87849</b>	<b>(50.3)</b>	<b>252684</b>	<b>(83.3)</b>	<b>125438</b>	<b>(41.3)</b>	<b>303397</b>

**Table 8: Laboratory-confirmed tuberculosis cases by confirmation method, EU/EEA, 2013**

Country	Smear-positive and nucleic-acid-test-positive only		Culture-positive only		Meeting both criteria <sup>a</sup>		All laboratory-confirmed cases <sup>b</sup>		All tuberculosis cases (N)
	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>c</sup>	N	(%) <sup>d</sup>	
Austria	12	(2.6)	294	(63.0)	161	(34.5)	467	(72.0)	649
Belgium	3	(0.4)	607	(78.8)	160	(20.8)	770	(78.5)	981
<i>Bulgaria</i>	0	(0.0)	951	(100.0)	0	(0.0)	951	(49.2)	1932
Croatia	0	(0.0)	346	(100.0)	0	(0.0)	346	(66.9)	517
Cyprus	0	(0.0)	30	(100.0)	0	(0.0)	30	(73.2)	41
Czech Republic	0	(0.0)	338	(96.8)	11	(3.2)	349	(69.7)	501
Denmark	2	(0.7)	181	(65.1)	95	(34.2)	278	(78.1)	356
<i>Estonia</i>	1	(0.4)	99	(44.4)	123	(55.2)	223	(78.0)	286
Finland	1	(0.5)	180	(87.8)	24	(11.7)	205	(75.6)	271
France <sup>e</sup>	0	(0.0)	2335	(100.0)	0	(0.0)	2335	(47.3)	4939
Germany	59	(1.9)	2260	(71.7)	831	(26.4)	3150	(73.0)	4318
Greece	15	(4.4)	167	(49.3)	157	(46.3)	339	(62.8)	540
Hungary	0	(0.0)	448	(100.0)	0	(0.0)	448	(42.9)	1045
Iceland	0	(0.0)	7	(100.0)	0	(0.0)	7	(63.6)	11
Ireland	3	(1.1)	228	(80.9)	51	(18.1)	282	(73.4)	384
Italy <sup>e</sup>	0	(0.0)	675	(100.0)	0	(0.0)	675	(21.4)	3153
<i>Latvia</i>	0	(0.0)	702	(100.0)	0	(0.0)	702	(77.7)	904
Liechtenstein	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	0	(0.0)	1354	(100.0)	0	(0.0)	1354	(79.4)	1705
Luxembourg	0	(0.0)	33	(100.0)	0	(0.0)	33	(86.8)	38
Malta	0	(0.0)	27	(100.0)	0	(0.0)	27	(54.0)	50
Netherlands	2	(0.3)	488	(80.1)	119	(19.5)	609	(71.8)	848
Norway	1	(0.3)	256	(80.3)	62	(19.4)	319	(79.6)	401
Poland	0	(0.0)	4825	(100.0)	0	(0.0)	4825	(66.6)	7250
Portugal	6	(0.4)	1365	(93.9)	82	(5.6)	1453	(60.7)	2393
<i>Romania</i>	0	(0.0)	10890	(100.0)	0	(0.0)	10890	(65.2)	16711
Slovakia	0	(0.0)	201	(94.8)	11	(5.2)	212	(52.9)	401
Slovenia	0	(0.0)	99	(75.0)	33	(25.0)	132	(94.3)	140
Spain <sup>e</sup>	0	(0.0)	3631	(100.0)	0	(0.0)	3631	(65.6)	5539
Sweden	0	(0.0)	425	(81.3)	98	(18.7)	523	(80.7)	648
United Kingdom	4	(0.1)	4614	(98.5)	66	(1.4)	4684	(59.4)	7892
<b>Total EU/EEA</b>	<b>109</b>	<b>(0.3)</b>	<b>38 056</b>	<b>(94.6)</b>	<b>2 084</b>	<b>(5.2)</b>	<b>40 249</b>	<b>(62.1)</b>	<b>64 844</b>

EU/EEA countries designated as High Priority Countries by WHO are presented in italics.

<sup>a</sup> Confirmed by sputum-smear positive and nucleic acid amplification test positive and culture positive.

<sup>b</sup> Laboratory-confirmed TB cases according to EU case definition.

<sup>c</sup> Percentage among all laboratory-confirmed TB cases.

<sup>d</sup> Percentage among all TB cases.

<sup>e</sup> Data reported to TESSy may differ from numbers reported to TME by French, Italian and Spanish National Reference Laboratories.

**Table 9: Classification of tuberculosis cases according to EU case definition, EU/EEA, 2013**

Country	Confirmed		Probable		Possible		All tuberculosis cases (N)
	N	(%)	N	(%)	N	(%)	
Austria	467	(72.0)	83	(12.8)	99	(15.3)	649
Belgium	770	(78.5)	77	(7.8)	134	(13.7)	981
<i>Bulgaria</i>	951	(49.2)	174	(9.0)	807	(41.8)	1932
Croatia	346	(66.9)	31	(6.0)	140	(27.1)	517
Cyprus	30	(73.2)	2	(4.9)	9	(22.0)	41
Czech Republic	349	(69.7)	65	(13.0)	87	(17.4)	501
Denmark	278	(78.1)	16	(4.5)	62	(17.4)	356
<i>Estonia</i>	223	(78.0)	12	(4.2)	51	(17.8)	286
Finland	205	(75.6)	28	(10.3)	38	(14.0)	271
France <sup>a</sup>	2335	(47.3)	878	(17.8)	1726	(34.9)	4939
Germany	3150	(73.0)	345	(8.0)	823	(19.1)	4318
Greece	339	(62.8)	86	(15.9)	115	(21.3)	540
Hungary	448	(42.9)	19	(1.8)	578	(55.3)	1045
Iceland	7	(63.6)	0	(0.0)	4	(36.4)	11
Ireland	282	(73.4)	37	(9.6)	65	(16.9)	384
Italy <sup>b</sup>	675	(21.4)	384	(12.2)	2094	(66.4)	3153
<i>Latvia</i>	702	(77.7)	77	(8.5)	125	(13.8)	904
Liechtenstein	-	-	-	-	-	-	-
<i>Lithuania</i>	1354	(79.4)	0	(0.0)	351	(20.6)	1705
Luxembourg	33	(86.8)	1	(2.6)	4	(10.5)	38
Malta	27	(54.0)	3	(6.0)	20	(40.0)	50
Netherlands	609	(71.8)	79	(9.3)	160	(18.9)	848
Norway	319	(79.6)	16	(4.0)	66	(16.5)	401
Poland	4825	(66.6)	20	(0.3)	2405	(33.2)	7250
Portugal	1453	(60.7)	506	(21.1)	434	(18.1)	2393
<i>Romania</i>	10890	(65.2)	1313	(7.9)	4508	(27.0)	16711
Slovakia	212	(52.9)	59	(14.7)	130	(32.4)	401
Slovenia	132	(94.3)	7	(5.0)	1	(0.7)	140
Spain	3631	(65.6)	273	(4.9)	1635	(29.5)	5539
Sweden	523	(80.7)	43	(6.6)	82	(12.7)	648
United Kingdom	4684	(59.4)	522	(6.6)	2686	(34.0)	7892
<b>Total EU/EEA</b>	<b>40 249</b>	<b>(62.1)</b>	<b>5156</b>	<b>(8.0)</b>	<b>19 439</b>	<b>(30.0)</b>	<b>64 844</b>

EU/EEA countries designated as High Priority Countries by WHO are presented in italics.

<sup>a</sup> Provisional data for 2013 including overseas territories.

<sup>b</sup> Provisional data for 2013.

Table 10: New TB cases and relapses by age group and male-to-female ratio, European Region, 2013<sup>a</sup>

Country	0-4				5-14				15-24				25-44			
	N	(%)	Rate	M:F ratio	N	(%)	Rate	M:F ratio	N	(%)	Rate	M:F ratio	N	(%)	Rate	M:F ratio
<b>EU/EEA</b>																
Austria	10	(1.6)	2.5	4.0	13	(2.1)	1.6	1.2	89	(14.3)	8.7	1.0	185	(29.6)	8.0	1.5
Belgium	35	(3.9)	5.3	2.9	24	(2.6)	1.9	1.4	121	(13.4)	9.0	1.1	386	(42.6)	13.0	1.6
Bulgaria	46	(2.4)	13.3	1.1	100	(5.2)	15.5	0.7	162	(8.4)	20.4	1.2	627	(32.5)	30.1	1.9
Croatia	0	(0.0)	0.0	-	4	(0.8)	0.9	0.3	30	(5.9)	6.0	1.7	96	(18.8)	8.4	1.7
Cyprus	0	(0.0)	0.0	-	0	(0.0)	0.0	-	4	(9.8)	3.1	3.0	25	(61.0)	9.3	0.7
Czech Republic	3	(0.6)	0.5	2.0	2	(0.4)	0.2	1.0	30	(6.4)	2.6	0.8	122	(25.9)	3.8	2.2
Denmark	7	(2.1)	2.2	2.5	15	(4.5)	2.3	1.5	39	(11.8)	5.4	3.3	123	(37.3)	8.7	1.8
Estonia	1	(0.4)	1.3	N/F	0	(0.0)	0.0	-	8	(3.0)	5.1	1.7	101	(38.4)	27.3	2.0
Finland	0	(0.0)	0.0	-	2	(0.8)	0.3	1.0	32	(12.0)	4.8	2.2	54	(20.3)	4.0	1.3
France <sup>b</sup>	133	(2.8)	3.3	1.3	125	(2.7)	1.5	1.1	598	(12.7)	7.5	1.3	1756	(37.3)	10.5	1.7
Germany	76	(1.8)	2.2	1.4	92	(2.2)	1.3	0.9	460	(11.0)	5.1	1.4	1325	(31.6)	6.3	1.4
Greece	12	(2.4)	2.2	11.0	18	(3.6)	1.7	1.3	57	(11.5)	4.9	3.4	158	(32.0)	5.0	3.6
Hungary	6	(0.6)	1.3	5.0	1	(0.1)	0.1	N/F	48	(4.6)	4.0	0.8	229	(22.0)	7.9	1.4
Iceland	0	(0.0)	0.0	-	0	(0.0)	0.0	-	1	(9.1)	2.1	N/F	6	(54.5)	6.9	1.0
Ireland	7	(2.0)	1.9	0.8	2	(0.6)	0.3	1.0	47	(13.2)	8.7	0.7	164	(46.1)	11.5	1.5
Italy <sup>c</sup>	43	(1.4)	1.6	1.0	81	(2.7)	1.4	1.1	308	(10.2)	5.2	0.9	988	(32.7)	6.1	1.5
Latvia	13	(1.5)	12.8	0.4	32	(3.7)	16.7	0.6	72	(8.3)	29.6	1.1	348	(39.9)	62.4	2.1
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	10	(0.6)	6.6	1.5	27	(1.7)	9.5	0.9	91	(5.8)	22.6	1.2	564	(35.9)	73.0	2.5
Luxembourg	1	(2.6)	3.3	N/F	0	(0.0)	0.0	-	5	(13.2)	7.7	1.5	21	(55.3)	12.9	2.0
Malta	0	(0.0)	0.0	-	0	(0.0)	0.0	-	24	(48.0)	43.1	11.0	19	(38.0)	16.3	1.1
Netherlands	8	(1.0)	0.9	1.7	24	(2.9)	1.2	1.2	118	(14.2)	5.8	1.5	348	(41.8)	8.0	1.6
Norway	5	(1.4)	1.6	1.5	12	(3.3)	2.0	0.5	100	(27.6)	15.0	1.2	173	(47.8)	12.5	1.0
Poland	28	(0.4)	1.4	1.2	88	(1.2)	2.4	0.7	327	(4.6)	6.7	1.3	1640	(23.3)	14.0	2.1
Portugal	22	(0.9)	4.6	0.7	26	(1.1)	2.4	1.0	212	(9.1)	18.9	1.5	805	(34.4)	27.4	1.6
Romania	247	(1.6)	24.7	1.1	448	(2.9)	20.9	1.0	2153	(13.9)	91.0	1.1	5174	(33.3)	85.9	1.9
Slovakia	22	(5.5)	7.5	0.6	16	(4.0)	3.0	1.7	29	(7.3)	4.1	1.4	69	(17.3)	4.1	2.3
Slovenia	1	(0.7)	0.9	N/M	1	(0.7)	0.5	N/F	5	(3.6)	2.3	1.5	27	(19.4)	4.5	1.7
Spain	204	(3.9)	8.4	1.0	173	(3.3)	3.7	1.2	488	(9.3)	10.6	1.1	2040	(38.9)	14.1	1.3
Sweden	7	(1.1)	1.2	0.8	41	(6.7)	3.9	0.6	142	(23.3)	11.5	2.0	256	(42.0)	10.4	1.1
United Kingdom	112	(1.5)	2.8	1.4	199	(2.7)	2.7	0.8	992	(13.4)	12.0	1.5	3407	(46.1)	19.9	1.4
<b>Subtotal EU/EEA</b>	<b>1059</b>	<b>(1.7)</b>	<b>3.9</b>	<b>1.2</b>	<b>1566</b>	<b>(2.5)</b>	<b>2.9</b>	<b>1.0</b>	<b>6792</b>	<b>(11.0)</b>	<b>11.5</b>	<b>1.3</b>	<b>21236</b>	<b>(34.5)</b>	<b>15.1</b>	<b>1.7</b>
<b>Non-EU/EEA</b>																
Albania	7	(1.5)	3.6	6.0	12	(2.5)	2.6	2.0	88	(18.6)	15.0	2.1	140	(29.5)	16.8	2.0
Andorra	0	(0.0)	0.0	-	0	(0.0)	0.0	-	0	(0.0)	0.0	-	2	(40.0)	8.1	1.0
Armenia	17	(1.2)	8.2	1.4	25	(1.8)	6.3	1.5	166	(11.9)	34.3	2.3	463	(33.1)	53.3	2.6
Azerbaijan	51	(1.1)	6.5	2.4	164	(3.6)	12.5	1.2	1334	(29.5)	75.8	2.5	1648	(36.4)	55.7	2.7
Belarus	2	(0.0)	0.4	0.0	12	(0.3)	1.3	0.5	293	(6.6)	24.8	1.2	1896	(42.4)	67.6	2.6
Bosnia and Herzegovina	2	(0.2)	1.2	1.0	10	(0.8)	2.3	1.5	110	(8.7)	19.7	1.1	255	(20.2)	24.7	1.7
former Yugoslav Republic of Macedonia, the	6	(1.9)	5.3	1.0	17	(5.3)	7.1	1.1	26	(8.2)	8.5	1.2	91	(28.6)	14.3	2.1
Georgia	51	(1.5)	17.4	1.7	132	(3.8)	27.3	1.2	585	(17.0)	95.4	1.4	1454	(42.3)	123.1	2.3
Israel	12	(3.9)	1.5	1.0	3	(1.0)	0.2	2.0	49	(15.9)	4.3	2.3	162	(52.6)	7.7	2.4
Kazakhstan	130	(0.7)	7.9	1.2	381	(2.0)	14.7	0.8	3703	(19.5)	137.7	1.2	8720	(46.0)	172.8	1.8
Kyrgyzstan	107	(1.8)	15.9	1.0	487	(8.3)	48.2	1.0	1541	(26.3)	134.6	1.2	2161	(36.9)	136.5	1.3
Moldova	39	(0.9)	18.5	1.1	95	(2.1)	25.8	1.2	444	(9.9)	82.7	1.3	1996	(44.5)	194.9	2.7
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	0	(0.0)	0.0	-	1	(0.8)	1.3	N/F	14	(11.8)	16.1	1.3	38	(31.9)	22.0	1.9
Russia	1059	(1.2)	12.7	1.0	2239	(2.5)	15.8	1.0	9567	(10.6)	54.0	1.6	47937	(53.0)	108.8	2.4
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	1	(0.1)	0.3	N/F	13	(1.1)	1.6	0.6	89	(7.7)	9.0	0.9	288	(24.8)	13.7	1.3
Serbia excluding UN Administered Province of Kosovo <sup>d</sup>	1	(0.1)	0.3	N/F	13	(1.1)	1.6	0.6	89	(7.7)	9.0	0.9	288	(24.8)	13.7	1.3
UN Administered Province of Kosovo <sup>d</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	11	(2.4)	2.7	2.7	11	(2.4)	1.4	1.8	65	(13.9)	6.9	1.5	214	(45.9)	9.5	0.8
Tajikistan	104	(2.0)	8.8	1.3	285	(5.4)	16.2	1.1	1570	(29.6)	91.1	1.5	2037	(38.4)	91.8	1.4
Turkey	138	(1.0)	2.2	1.1	443	(3.4)	3.4	0.9	2274	(17.3)	17.9	1.3	4367	(33.2)	18.7	1.3
Turkmenistan																
Ukraine	249	(0.7)	10.1	1.0	389	(1.1)	9.6	1.1	2774	(7.6)	49.8	1.2	17348	(47.5)	126.2	2.3
Uzbekistan	384	(1.8)	13.1	1.8	1576	(7.6)	29.6	1.5	2656	(12.8)	43.7	1.4	7913	(38.0)	91.2	1.7
<b>Subtotal non-EU/EEA</b>	<b>2370</b>	<b>(1.1)</b>	<b>8.7</b>	<b>1.2</b>	<b>6295</b>	<b>(2.9)</b>	<b>12.9</b>	<b>1.1</b>	<b>27348</b>	<b>(12.8)</b>	<b>49.0</b>	<b>1.4</b>	<b>99130</b>	<b>(46.4)</b>	<b>86.5</b>	<b>2.1</b>
<b>Total European Region</b>	<b>3429</b>	<b>(1.2)</b>	<b>6.3</b>	<b>1.2</b>	<b>7861</b>	<b>(2.9)</b>	<b>7.7</b>	<b>1.1</b>	<b>34140</b>	<b>(12.4)</b>	<b>29.8</b>	<b>1.4</b>	<b>120366</b>	<b>(43.8)</b>	<b>46.9</b>	<b>2.0</b>
<b>Subtotal 18 HPC</b>	<b>2648</b>	<b>(1.2)</b>	<b>9.7</b>	<b>1.2</b>	<b>6835</b>	<b>(3.0)</b>	<b>14.0</b>	<b>1.1</b>	<b>29393</b>	<b>(12.8)</b>	<b>52.2</b>	<b>1.4</b>	<b>104754</b>	<b>(45.6)</b>	<b>88.5</b>	<b>2.1</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

N/F: no female in subgroup

N/M: no male in subgroup

<sup>b</sup> Cases with missing information on previous history of TB treatment are included among new cases. For countries with no information on relapse, only new and cases with unknown previous TB history are counted.

<sup>c</sup> Provisional data for 2013 including overseas territories.

<sup>d</sup> Provisional data for 2013.

<sup>e</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).



	45-64				> 64				Unknown				Total	
	N	(%)	Rate	M:F ratio	N	(%)	Rate	M:F ratio	N	(%)	Rate	M:F ratio	N	M:F ratio
183	(29.3)	7.7	1.5	144	(23.1)	9.4	1.5	0	(0.0)	-	-	624	1.5	
197	(21.7)	6.6	1.8	143	(15.8)	7.3	1.9	0	(0.0)	-	-	906	1.8	
630	(32.6)	31.1	2.0	365	(18.9)	26.2	1.7	0	(0.0)	-	-	1930	2.0	
197	(38.6)	16.3	1.6	184	(36.0)	26.0	1.0	0	(0.0)	-	-	511	1.6	
7	(17.1)	3.3	1.2	5	(12.2)	4.4	1.5	0	(0.0)	-	-	41	1.2	
166	(35.2)	5.9	2.1	148	(31.4)	8.4	1.3	0	(0.0)	-	-	471	2.1	
123	(37.3)	8.2	1.9	23	(7.0)	2.3	2.8	0	(0.0)	-	-	330	1.9	
105	(39.9)	30.1	2.1	48	(18.3)	20.2	0.5	0	(0.0)	-	-	263	2.1	
52	(19.5)	3.4	1.6	126	(47.4)	12.4	1.7	0	(0.0)	-	-	266	1.6	
1097	(23.3)	6.4	1.6	997	(21.2)	8.7	1.4	2	(0.0)	-	1.0	4708	1.6	
1106	(26.4)	4.5	1.6	1131	(27.0)	6.7	1.5	3	(0.1)	-	1.0	4193	1.6	
112	(22.7)	3.9	2.7	131	(26.5)	5.9	1.5	6	(1.2)	-	-	494	2.7	
513	(49.3)	19.1	1.8	243	(23.4)	14.7	1.3	0	(0.0)	-	-	1040	1.8	
1	(9.1)	1.3	0.8	3	(27.3)	7.2	0.0	0	(0.0)	-	-	11	0.8	
88	(24.7)	8.3	1.7	48	(13.5)	8.5	2.7	0	(0.0)	-	-	356	1.7	
521	(17.3)	3.1	1.3	493	(16.3)	3.9	1.0	585	(19.4)	-	1.9	3019	1.3	
316	(36.2)	57.3	2.0	91	(10.4)	24.0	1.5	0	(0.0)	-	-	872	2.0	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	
647	(41.1)	79.1	2.6	234	(14.9)	43.2	2.2	0	(0.0)	-	-	1573	2.6	
9	(23.7)	6.3	1.9	2	(5.3)	2.7	0.0	0	-	-	-	38	1.9	
0	(0.0)	0.0	2.3	7	(14.0)	9.7	0.8	0	(0.0)	-	-	50	2.3	
204	(24.5)	4.3	1.5	130	(15.6)	4.6	1.4	0	(0.0)	-	-	832	1.5	
45	(12.4)	3.5	1.1	27	(7.5)	3.4	0.7	0	(0.0)	-	-	362	1.1	
3121	(44.3)	29.5	2.2	1839	(26.1)	33.5	1.4	0	(0.0)	-	-	7043	2.2	
777	(33.2)	27.3	1.8	493	(21.1)	24.3	1.4	3	(0.1)	-	2.0	2338	1.8	
5230	(33.7)	99.9	2.0	2271	(14.6)	69.7	1.3	0	(0.0)	-	-	15523	2.0	
156	(39.2)	10.7	1.7	106	(26.6)	14.9	0.9	0	(0.0)	-	-	398	1.7	
47	(33.8)	7.9	1.0	58	(41.7)	16.5	0.5	0	(0.0)	-	-	139	1.0	
1282	(24.4)	10.5	1.5	1048	(20.0)	12.7	1.5	9	(0.2)	-	1.3	5244	1.5	
100	(16.4)	4.1	1.1	64	(10.5)	3.5	1.1	0	(0.0)	-	-	610	1.1	
1654	(22.4)	10.2	1.4	1020	(13.8)	9.3	1.2	0	(0.0)	-	-	7384	1.4	
<b>18686</b>	<b>(30.3)</b>	<b>13.4</b>	<b>1.7</b>	<b>11622</b>	<b>(18.9)</b>	<b>12.5</b>	<b>1.4</b>	<b>608</b>	<b>(1.0)</b>	<b>-</b>	<b>1.9</b>	<b>61569</b>	<b>1.7</b>	
126	(26.6)	16.6	2.9	101	(21.3)	29.5	2.0	0	(0.0)	-	-	474	2.2	
3	(60.0)	14.4	N/F	0	(0.0)	0.0	-	0	(0.0)	-	-	5	4.0	
571	(40.9)	80.1	4.7	155	(11.1)	50.6	3.7	0	(0.0)	-	-	1397	3.2	
1132	(25.0)	54.5	3.2	199	(4.4)	37.7	1.7	0	(0.0)	-	-	4528	2.6	
1785	(39.9)	67.3	4.8	482	(10.8)	37.5	0.9	0	(0.0)	-	-	4470	2.6	
382	(30.3)	36.8	2.2	502	(39.8)	84.1	0.7	0	(0.0)	-	-	1261	1.2	
117	(36.8)	21.1	2.7	61	(19.2)	23.5	2.1	0	(0.0)	-	-	318	2.1	
909	(26.5)	79.3	4.3	303	(8.8)	48.5	1.6	0	(0.0)	-	-	3434	2.2	
40	(13.0)	2.6	2.3	42	(13.6)	5.1	1.3	0	(0.0)	-	-	308	2.1	
4819	(25.4)	142.3	2.5	1205	(6.4)	111.1	1.0	0	(0.0)	-	-	18958	1.7	
1218	(20.8)	134.5	1.8	345	(5.9)	151.0	1.0	0	(0.0)	-	-	5859	1.3	
1663	(37.1)	174.7	3.8	248	(5.5)	62.7	1.7	0	(0.0)	-	-	4485	2.6	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	
41	(34.5)	25.0	1.9	25	(21.0)	30.8	1.3	0	(0.0)	-	-	119	1.6	
24692	(27.3)	61.8	3.0	4933	(5.5)	26.6	1.2	0	(0.0)	-	-	90427	2.2	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	
393	(33.9)	20.2	3.0	377	(32.5)	37.2	1.2	0	(0.0)	-	-	1161	1.6	
393	(33.9)	20.2	3.0	377	(32.5)	37.2	1.2	0	(0.0)	-	-	1161	1.6	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	
89	(19.1)	4.0	1.3	76	(16.3)	5.3	1.1	0	(0.0)	-	-	466	1.0	
969	(18.3)	90.9	1.0	341	(6.4)	130.9	1.1	0	(0.0)	-	-	5306	1.3	
3837	(29.1)	27.1	1.9	2111	(16.0)	38.2	1.2	0	(0.0)	-	-	13170	1.4	
10708	(29.3)	85.0	3.4	2676	(7.3)	39.3	1.2	2366	(6.5)	-	-	36510	2.5	
6019	(28.9)	128.9	1.7	2264	(10.9)	183.4	1.0	0	(0.0)	-	-	20812	1.6	
<b>59513</b>	<b>(27.9)</b>	<b>65.7</b>	<b>2.7</b>	<b>16446</b>	<b>(7.7)</b>	<b>40.7</b>	<b>1.1</b>	<b>2366</b>	<b>(1.1)</b>	<b>-</b>	<b>-</b>	<b>213468</b>	<b>2.0</b>	
<b>78199</b>	<b>(28.4)</b>	<b>33.9</b>	<b>2.7</b>	<b>28068</b>	<b>(10.2)</b>	<b>20.9</b>	<b>1.2</b>	<b>2974</b>	<b>(1.1)</b>	<b>-</b>	<b>1.9</b>	<b>275037</b>	<b>1.9</b>	
<b>65250</b>	<b>(28.4)</b>	<b>69.7</b>	<b>2.8</b>	<b>18271</b>	<b>(8.0)</b>	<b>42.9</b>	<b>1.2</b>	<b>2366</b>	<b>(1.0)</b>	<b>-</b>	<b>-</b>	<b>229517</b>	<b>2.0</b>	

Table 11: Tuberculosis cases by origin and male-to-female ratio, European Region, 2013

Country	Criterion	Native						Foreign					
		Male	Female	Gender unknown	Total	(%)	M:F ratio	Male	Female	Gender unknown	Total	(%)	M:F ratio
<b>EU/EEA</b>													
Austria	citizenship	196	119	0	315	(48.5)	1.6	195	137	0	332	(51.2)	1.4
Belgium	citizenship	299	168	0	467	(47.6)	1.8	335	177	0	512	(52.2)	1.9
Bulgaria	birthplace	1278	644	0	1922	(99.5)	2.0	6	4	0	10	(0.5)	1.5
Croatia	birthplace	179	108	0	287	(55.5)	1.7	39	24	0	63	(12.2)	1.6
Cyprus	birthplace	4	2	0	6	(14.6)	2.0	18	17	0	35	(85.4)	1.1
Czech Republic	birthplace	285	137	0	422	(84.2)	2.1	53	26	0	79	(15.8)	2.0
Denmark <sup>a</sup>	birthplace	97	44	0	141	(39.6)	2.2	141	74	0	215	(60.4)	1.9
Estonia	birthplace	168	75	0	243	(85.0)	2.2	26	17	0	43	(15.0)	1.5
Finland	birthplace	112	70	0	182	(67.2)	1.6	54	31	0	85	(31.4)	1.7
France	birthplace	1193	818	11	2022	(40.9)	1.5	1639	899	15	2553	(51.7)	1.8
Germany	birthplace	1158	612	4	1774	(41.1)	1.9	1378	920	11	2309	(53.5)	1.5
Greece	citizenship	206	98	2	306	(56.7)	2.1	187	41	1	229	(42.4)	4.6
Hungary	citizenship	641	370	0	1011	(96.7)	1.7	27	7	0	34	(3.3)	3.9
Iceland	birthplace	2	4	0	6	(54.5)	0.5	3	2	0	5	(45.5)	1.5
Ireland	birthplace	137	69	0	206	(53.6)	2.0	101	68	2	171	(44.5)	1.5
Italy	birthplace	440	478	26	944	(29.9)	0.9	913	572	488	1973	(62.6)	1.6
Latvia	birthplace	580	284	0	864	(95.6)	2.0	25	15	0	40	(4.4)	1.7
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	birthplace	1221	444	0	1665	(97.7)	2.8	32	8	0	40	(2.3)	4.0
Luxembourg	birthplace	0	2	0	2	(5.3)	N/M	25	11	0	36	(94.7)	2.3
Malta	birthplace	3	3	0	6	(12.0)	1.0	32	12	0	44	(88.0)	2.7
Netherlands	birthplace	134	87	0	221	(26.1)	1.5	373	253	1	627	(73.9)	1.5
Norway	birthplace	28	25	0	53	(13.2)	1.1	183	162	0	345	(86.0)	1.1
Poland	citizenship	4950	2248	0	7198	(99.3)	2.2	41	11	0	52	(0.7)	3.7
Portugal	birthplace	1274	710	0	1984	(82.9)	1.8	246	143	0	389	(16.3)	1.7
Romania	birthplace	11341	5322	0	16663	(99.7)	2.1	29	19	0	48	(0.3)	1.5
Slovakia	birthplace	251	144	0	395	(98.5)	1.7	5	1	0	6	(1.5)	5.0
Slovenia	birthplace	42	52	0	94	(67.1)	0.8	30	16	0	46	(32.9)	1.9
Spain	birthplace	2266	1429	9	3704	(66.9)	1.6	1003	749	3	1755	(31.7)	1.3
Sweden	birthplace	44	29	0	73	(11.3)	1.5	301	274	0	575	(88.7)	1.1
United Kingdom	birthplace	1199	904	0	2103	(26.6)	1.3	3208	2321	0	5529	(70.1)	1.4
<b>Subtotal EU/EEA</b>		<b>29728</b>	<b>15499</b>	<b>52</b>	<b>45279</b>	<b>(69.8)</b>	<b>1.9</b>	<b>10648</b>	<b>7011</b>	<b>521</b>	<b>18180</b>	<b>(28.0)</b>	<b>1.5</b>
<b>Non-EU/EEA</b>													
Albania	citizenship	327	146	0	473	(99.8)	2.2	1	0	0	1	(0.2)	N/F
Andorra	citizenship	4	1	0	5	(100.0)	4.0	0	0	0	0	(0.0)	N/R
Armenia	citizenship	1082	329	0	1411	(99.6)	3.3	4	2	0	6	(0.4)	2.0
Azerbaijan	citizenship	-	-	-	-	-	-	-	-	-	-	-	-
Belarus	citizenship	3535	1324	0	4859	(100.0)	2.7	0	0	0	0	(0.0)	N/R
Bosnia and Herzegovina	citizenship	695	566	0	1261	(100.0)	1.2	0	0	0	0	(0.0)	N/R
former Yugoslav Republic of Macedonia, the	birthplace	211	97	0	308	(95.4)	2.2	8	7	0	15	(4.6)	1.1
Georgia	citizenship	3091	1228	0	4319	(100.0)	2.5	0	0	0	0	(0.0)	N/R
Israel	birthplace	34	20	0	54	(17.5)	1.7	175	79	0	254	(82.5)	2.2
Kazakhstan	citizenship	12493	7321	0	19814	(99.8)	1.7	21	22	0	43	(0.2)	1.0
Kyrgyzstan	birthplace	3319	2540	0	5859	(100.0)	1.3	0	0	0	0	(0.0)	N/R
Moldova	citizenship	3689	1323	0	5012	(99.2)	2.8	28	11	0	39	(0.8)	2.5
Monaco	birthplace	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	citizenship	73	45	0	118	(98.3)	1.6	2	0	0	2	(1.7)	N/F
Russia	citizenship	60407	27588	0	87995	(97.3)	2.2	1927	505	0	2432	(2.7)	3.8
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia		724	449	0	1173	(99.3)	1.6	3	4	0	7	(0.6)	0.8
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>	citizenship	724	449	0	1173	(99.3)	1.6	3	4	0	7	(0.6)	0.8
UN Administered Province of Kosovo <sup>b</sup>	birthplace	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	birthplace	66	47	0	113	(21.5)	1.4	203	193	0	396	(75.3)	1.1
Tajikistan	birthplace	2995	2311	0	5306	(100.0)	1.3	0	0	0	0	(0.0)	N/R
Turkey	birthplace	7601	5317	0	12918	(96.3)	1.4	280	211	0	491	(3.7)	1.3
Turkmenistan	citizenship	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	citizenship	0	0	0	0	(0.0)	N/R	0	0	0	0	(0.0)	N/R
Uzbekistan	birthplace	15303	9798	0	25101	(99.7)	1.6	15	14	0	29	(0.1)	1.1
<b>Subtotal non-EU/EEA</b>		<b>115649</b>	<b>60450</b>	<b>0</b>	<b>176099</b>	<b>(77.2)</b>	<b>1.9</b>	<b>2667</b>	<b>1048</b>	<b>0</b>	<b>3715</b>	<b>(1.6)</b>	<b>2.5</b>
<b>Total European Region</b>		<b>145377</b>	<b>75949</b>	<b>52</b>	<b>221378</b>	<b>(75.6)</b>	<b>1.9</b>	<b>13315</b>	<b>8059</b>	<b>521</b>	<b>21895</b>	<b>(7.5)</b>	<b>1.7</b>
<b>Subtotal 18 HPC</b>		<b>128103</b>	<b>65848</b>	<b>0</b>	<b>193951</b>	<b>(79.1)</b>	<b>1.9</b>	<b>2393</b>	<b>828</b>	<b>0</b>	<b>3221</b>	<b>(1.3)</b>	<b>2.9</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

N/M - no male in subgroup

N/F - no female in subgroup

N/R - no cases in subgroup

<sup>b</sup> By birthplace of parents for Danish-born cases under 26 years of age.

<sup>c</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	Unknown						Total				
	Male	Female	Gender unknown	Total	(%)	M:F ratio	Male	Female	Gender unknown	Total	M:F ratio
	1	1	0	2	(0.3)	1.0	392	257	0	649	1.5
	0	2	0	2	(0.2)	N/M	634	347	0	981	1.8
	0	0	0	0	(0.0)	N/R	1284	648	0	1932	2.0
	100	67	0	167	(32.3)	1.5	318	199	0	517	1.6
	0	0	0	0	(0.0)	N/R	22	19	0	41	1.2
	0	0	0	0	(0.0)	N/R	338	163	0	501	2.1
	0	0	0	0	(0.0)	N/R	238	118	0	356	2.0
	0	0	0	0	(0.0)	N/R	194	92	0	286	2.1
	2	2	0	4	(1.5)	1.0	168	103	0	271	1.6
	214	148	2	364	(7.4)	1.4	3046	1865	28	4939	1.6
	129	105	1	235	(5.4)	1.2	2665	1637	16	4318	1.6
	4	1	0	5	(0.9)	4.0	397	140	3	540	2.8
	0	0	0	0	(0.0)	N/R	668	377	0	1045	1.8
	0	0	0	0	(0.0)	N/R	5	6	0	11	0.8
	4	3	0	7	(1.8)	1.3	242	140	2	384	1.7
	134	102	0	236	(7.5)	1.3	1487	1152	514	3153	1.3
	0	0	0	0	(0.0)	N/R	605	299	0	904	2.0
	-	-	-	-	-	-	-	-	-	-	-
	0	0	0	0	(0.0)	N/R	1253	452	0	1705	2.8
	0	0	0	0	(0.0)	N/R	25	13	0	38	1.9
	0	0	0	0	(0.0)	N/R	35	15	0	50	2.3
	0	0	0	0	(0.0)	N/R	507	340	1	848	1.5
	1	2	0	3	(0.7)	0.5	212	189	0	401	1.1
	0	0	0	0	(0.0)	N/R	4991	2259	0	7250	2.2
	11	9	0	20	(0.8)	1.2	1531	862	0	2393	1.8
	0	0	0	0	(0.0)	N/R	11370	5341	0	16711	2.1
	0	0	0	0	(0.0)	N/R	256	145	0	401	1.8
	0	0	0	0	(0.0)	N/R	72	68	0	140	1.1
	51	29	0	80	(1.4)	1.8	3320	2207	12	5539	1.5
	0	0	0	0	(0.0)	N/R	345	303	0	648	1.1
	153	107	0	260	(3.3)	1.4	4560	3332	0	7892	1.4
	<b>804</b>	<b>578</b>	<b>3</b>	<b>1385</b>	<b>(2.1)</b>	<b>1.4</b>	<b>41180</b>	<b>23088</b>	<b>576</b>	<b>64844</b>	<b>1.8</b>
	0	0	0	0	(0.0)	N/R	328	146	0	474	2.2
	0	0	0	0	(0.0)	N/R	4	1	0	5	4.0
	0	0	0	0	(0.0)	N/R	1086	331	0	1417	3.3
	-	-	-	-	-	-	-	-	-	-	-
	0	0	0	0	(0.0)	N/R	3535	1324	0	4859	2.7
	0	0	0	0	(0.0)	N/R	695	566	0	1261	1.2
	0	0	0	0	(0.0)	N/R	219	104	0	323	2.1
	0	0	0	0	(0.0)	N/R	3091	1228	0	4319	2.5
	0	0	0	0	(0.0)	N/R	209	99	0	308	2.1
	0	0	0	0	(0.0)	N/R	12514	7343	0	19857	1.7
	0	0	0	0	(0.0)	N/R	3319	2540	0	5859	1.3
	0	0	0	0	(0.0)	N/R	3717	1334	0	5051	2.8
	-	-	-	-	-	-	-	-	-	-	-
	0	0	0	0	(0.0)	N/R	75	45	0	120	1.7
	0	0	0	0	(0.0)	N/R	62334	28093	0	90427	2.2
	-	-	-	-	-	-	-	-	-	-	-
	1	0	0	1	(0.1)	N/R	728	453	0	1181	1.6
	1	0	0	1	(0.1)	N/R	728	453	0	1181	1.6
	-	-	-	-	-	-	-	-	-	-	-
	7	10	0	17	(3.2)	N/R	276	250	0	526	1.1
	0	0	0	0	(0.0)	N/R	2995	2311	0	5306	1.3
	0	0	0	0	(0.0)	N/R	7881	5528	0	13409	1.4
	-	-	-	-	-	-	-	-	-	-	-
	27800	11777	8557	48134	(100.0)	2.4	27800	11777	8557	48134	2.4
	28	10	0	38	(0.2)	2.8	15346	9822	0	25168	1.6
	<b>27836</b>	<b>11797</b>	<b>8557</b>	<b>48190</b>	<b>(21.1)</b>	<b>2.4</b>	<b>146152</b>	<b>73295</b>	<b>8557</b>	<b>228004</b>	<b>2.0</b>
	<b>28640</b>	<b>12375</b>	<b>8560</b>	<b>49575</b>	<b>(16.9)</b>	<b>2.3</b>	<b>187332</b>	<b>96383</b>	<b>9133</b>	<b>292848</b>	<b>1.9</b>
	<b>27828</b>	<b>11787</b>	<b>8557</b>	<b>48172</b>	<b>(19.6)</b>	<b>2.4</b>	<b>158324</b>	<b>78463</b>	<b>8557</b>	<b>245344</b>	<b>2.0</b>

**Table 12: Characteristics of anti-TB drug resistance surveillance of pulmonary laboratory-confirmed cases, European Region, 2013**

Country	Source of data	Coverage	Laboratory-confirmed TB cases <sup>a</sup>		DST results (Isoniazid and Rifampicin)		MDR cases		Cases resistant to any anti-TB drug <sup>b</sup>		Reporting completeness <sup>c</sup>
			N	(%)	N	(%)	N	(%)	N	(%)	
<b>EU/EEA</b>											
Austria	TESSy	national	385	(73.6)	369	(95.8)	16	(4.3)	54	(14.0)	Y
Belgium	TESSy	national	582	(85.3)	554	(95.2)	10	(1.8)	44	(7.6)	Y
Bulgaria	TESSy	national	924	(64.8)	728	(78.8)	26	(3.6)	89	(9.6)	Y
Croatia	TESSy	national	328	(78.1)	297	(90.5)	0	(0.0)	12	(3.7)	Y
Cyprus	TESSy	national	25	(86.2)	25	(100.0)	1	(4.0)	4	(16.0)	Y
Czech Republic	TESSy	national	320	(72.6)	294	(91.9)	0	(0.0)	13	(4.1)	Y
Denmark	TESSy	national	219	(96.9)	217	(99.1)	2	(0.9)	15	(6.8)	Y
Estonia	TESSy	national	215	(80.2)	212	(98.6)	50	(23.6)	82	(38.1)	Y
Finland	TESSy	national	173	(79.7)	171	(98.8)	2	(1.2)	8	(4.6)	Y
France	NRL-TME <sup>d</sup>	sub-national	-	-	-	-	-	-	-	-	N
Germany	TESSy	national	2573	(78.0)	2370	(92.1)	85	(3.6)	295	(11.5)	Y
Greece	TESSy	national	298	(65.4)	210	(70.5)	10	(4.8)	22	(7.4)	N
Hungary	TESSy	national	439	(44.1)	353	(80.4)	10	(2.8)	43	(9.8)	Y
Iceland	TESSy	national	3	(75.0)	3	(100.0)	0	(0.0)	0	(0.0)	Y
Ireland	TESSy	national	206	(81.4)	199	(96.6)	4	(2.0)	27	(13.1)	Y
Italy	NRL-TME <sup>d</sup>	sub-national	-	-	-	-	-	-	-	-	-
Latvia	TESSy	national	671	(83.0)	650	(96.9)	75	(11.5)	191	(28.5)	Y
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-
Lithuania	TESSy	national	1315	(84.0)	1315	(100.0)	253	(19.2)	457	(34.8)	Y
Luxembourg	TESSy	national	28	(87.5)	27	(96.4)	0	(0.0)	1	(3.6)	Y
Malta	TESSy	national	20	(52.6)	20	(100.0)	1	(5.0)	3	(15.0)	Y
Netherlands	TESSy	national	372	(81.9)	370	(99.5)	14	(3.8)	43	(11.6)	Y
Norway	TESSy	national	209	(83.6)	208	(99.5)	5	(2.4)	44	(21.1)	Y
Poland	TESSy	national	4663	(68.2)	4324	(92.7)	40	(0.9)	269	(5.8)	Y
Portugal	TESSy	national	1261	(74.8)	914	(72.5)	14	(1.5)	114	(9.0)	N
Romania	TESSy	national	10 630	(74.5)	7000	(65.9)	547	(7.8)	984	(9.3)	N
Slovakia	TESSy	national	194	(56.4)	194	(100.0)	3	(1.5)	14	(7.2)	Y
Slovenia	TESSy	national	106	(97.2)	106	(100.0)	0	(0.0)	4	(3.8)	Y
Spain <sup>e</sup>	NRL-TME <sup>d</sup>	sub-national	1561	(39.0)	1561	(100.0)	34	(2.2)	128	(8.2)	N
Sweden	TESSy	national	321	(87.2)	321	(100.0)	7	(2.2)	34	(10.6)	Y
United Kingdom	TESSy	national	2924	(71.4)	2870	(98.2)	46	(1.6)	252	(8.6)	Y
<b>Subtotal EU/EEA</b>			<b>30 965</b>	<b>(61.8)</b>	<b>25 882</b>	<b>(83.6)</b>	<b>1 255</b>	<b>(4.8)</b>	<b>3 246</b>	<b>(12.5)</b>	<b>24</b>
<b>Non-EU/EEA</b>											
Albania	NRL-TME	national	154	(46.2)	31	(20.1)	1	(0.6)	-	-	N
Andorra	NRL-TME	national	4	-	4	(100.0)	0	(0.0)	-	-	N
Armenia	NRL-TME	national	438	(41.0)	438	(100.0)	66	(15.1)	-	-	Y
Azerbaijan	NRL-TME	sub-national	3 325	-	2 824	(84.9)	965	(29.0)	-	-	Y
Belarus	NRL-TME	national	3 408	(79.1)	3 242	(95.1)	1 353	(39.7)	-	-	Y
Bosnia and Herzegovina	NRL-TME	national	706	(64.5)	706	(100.0)	1	(0.1)	-	-	Y
former Yugoslav Republic of Macedonia, the	NRL-TME	sub-national	188	(75.5)	179	(95.2)	1	(0.5)	-	-	Y
Georgia	NRL-TME	-	2 319	(76.9)	2 156	(93.0)	384	(16.6)	-	-	Y
Israel	NRL-TME	national	157	(69.5)	157	(100.0)	7	(4.5)	-	-	Y
Kazakhstan	NRL-TME	national	14 707	(82.4)	14 573	(99.1)	6 032	(41.0)	-	-	N
Kyrgyzstan	NRL-TME	-	3 150	(58.5)	3 150	(100.0)	1 160	(36.8)	-	-	-
Moldova	NRL-TME	national	2 695	(58.0)	2 317	(86.0)	912	(33.8)	-	-	Y
Monaco	-	national	-	-	-	-	-	-	-	-	-
Montenegro	NRL-TME	national	72	(64.3)	72	(100.0)	0	(0.0)	-	-	Y
Russia	NRL-TME	sub-national	47 428	(39.1)	43 743	(92.2)	13 521	(28.5)	-	-	Y
San Marino	-	sub-national	-	-	-	-	-	-	-	-	-
Serbia	-	sub-national	792	(77.0)	792	(100.0)	10	(1.3)	-	-	-
Serbia excluding UN Administered Province of Kosovo <sup>f</sup>	NRL-TME	national	792	(77.0)	792	(100.0)	10	(1.3)	-	-	Y
UN Administered Province of Kosovo <sup>g</sup>	-	sub-national	-	-	-	-	-	-	-	-	N
Switzerland	NRL-TME	national	311	(134.1)	304	(97.7)	12	(3.9)	-	-	Y
Tajikistan	NRL-TME	sub-national	2 838	(65.8)	460	(16.2)	159	(34.6)	-	-	N
Turkey	NRL-TME	sub-national	5 539	(64.0)	5 530	(99.8)	228	(4.1)	-	-	Y
Turkmenistan	NRL-TME	sub-national	-	-	-	-	-	-	-	-	-
Ukraine	NRL-TME	national	22 491	(67.6)	21 170	(94.1)	5 844	(26.0)	-	-	Y
Uzbekistan	NRL-TME	sub-national	7 080	(43.2)	6 898	(97.4)	3 030	(42.8)	-	-	N
<b>Subtotal non-EU/EEA</b>			<b>117 802</b>	<b>(49.6)</b>	<b>108 746</b>	<b>(92.3)</b>	<b>33 686</b>	<b>(31.0)</b>	<b>-</b>	<b>-</b>	<b>13</b>
<b>Total European Region</b>			<b>148 767</b>	<b>(51.7)</b>	<b>134 628</b>	<b>(90.5)</b>	<b>34 941</b>	<b>(26.0)</b>	<b>3 246</b>	<b>(2.4)</b>	<b>37</b>
<b>Subtotal 18 HPC</b>			<b>129 173</b>	<b>(51.1)</b>	<b>116 406</b>	<b>(90.1)</b>	<b>34 605</b>	<b>(29.7)</b>	<b>1 803</b>	<b>(1.5)</b>	<b>13</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> Includes only countries reporting first-line anti-TB drug susceptibility testing. Laboratory confirmed cases consist of culture-positive and smear-positive/nucleic acid amplification test-positive cases.

<sup>c</sup> Any resistance to isoniazid, rifampicin, ethambutol or streptomycin expressed as a percentage of cases with DST results available at least for isoniazid and rifampicin. Not all countries have routine testing for ethambutol and streptomycin.

<sup>d</sup> Data considered complete when national coverage 100% or culture results available for 90% of all cases, and 50% of all cases culture-positive, and 75% of them with DST results, and EQA results accurate in 95% of samples for reported year.

<sup>e</sup> NRL: National reference laboratory; TME: WHO Tuberculosis Monitoring and Evaluation Database.

<sup>f</sup> Data from Spain reported by NRL may differ from data shown elsewhere in this report.

<sup>g</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 13: Drug resistance in laboratory confirmed TB cases, EU/EEA, 2013

Country	Source of data	Coverage	Laboratory-confirmed TB cases <sup>a</sup>		DST results (Isoniazid and Rifampicin)		MDR cases		Cases resistant to any anti-TB drug <sup>b</sup>		Reporting completeness <sup>c</sup>
			N	(%)	N	(%)	N	(%)	N	(%)	
<b>EU/EEA</b>											
Austria	TESSy	national	467	(72.0)	446	(95.5)	16	(3.6)	59	(12.6)	Y
Belgium	TESSy	national	770	(78.5)	729	(94.7)	13	(1.8)	57	(7.4)	Y
Bulgaria	TESSy	national	951	(49.2)	734	(77.2)	27	(3.7)	91	(9.6)	Y
Croatia	TESSy	national	346	(66.9)	315	(91.0)	0	(0.0)	12	(3.5)	Y
Cyprus	TESSy	national	30	(73.2)	30	(100.0)	1	(3.3)	5	(16.7)	Y
Czech Republic	TESSy	national	349	(69.7)	321	(92.0)	0	(0.0)	14	(4.0)	Y
Denmark	TESSy	national	278	(78.1)	275	(98.9)	2	(0.7)	19	(6.8)	Y
Estonia	TESSy	national	223	(78.0)	220	(98.7)	50	(22.7)	83	(37.2)	Y
Finland	TESSy	national	205	(75.6)	203	(99.0)	2	(1.0)	10	(4.9)	Y
France <sup>d</sup>	NRL-TME <sup>e</sup>	sub-national	4258	(86.2)	4258	(100.0)	83	(1.9)	-	-	N
Germany	TESSy	national	3150	(73.0)	2901	(92.1)	100	(3.4)	363	(11.5)	Y
Greece	TESSy	national	339	(62.8)	233	(68.7)	10	(4.3)	24	(7.1)	N
Hungary	TESSy	national	448	(42.9)	360	(80.4)	10	(2.8)	44	(9.8)	Y
Iceland	TESSy	national	7	(63.6)	7	(100.0)	0	(0.0)	0	(0.0)	Y
Ireland	TESSy	national	282	(73.4)	270	(95.7)	4	(1.5)	36	(12.8)	Y
Italy <sup>d</sup>	NRL-TME <sup>e</sup>	sub-national	2381	(75.5)	2350	(98.7)	78	(3.3)	263	(11.2)	Y
Latvia	TESSy	national	702	(77.7)	681	(97.0)	79	(11.6)	198	(28.2)	Y
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-
Lithuania	TESSy	national	1354	(79.4)	1354	(100.0)	256	(18.9)	466	(34.4)	Y
Luxembourg	TESSy	national	33	(86.8)	32	(97.0)	0	(0.0)	2	(6.1)	Y
Malta	TESSy	national	27	(54.0)	27	(100.0)	1	(3.7)	4	(14.8)	Y
Netherlands	TESSy	national	609	(71.8)	607	(99.7)	17	(2.8)	69	(11.3)	Y
Norway	TESSy	national	319	(79.6)	318	(99.7)	6	(1.9)	62	(19.4)	Y
Poland	TESSy	national	4825	(66.6)	4470	(92.6)	40	(0.9)	276	(5.7)	Y
Portugal	TESSy	national	1453	(60.7)	1033	(71.1)	15	(1.5)	132	(9.1)	N
Romania	TESSy	national	10890	(65.2)	7141	(65.6)	555	(7.8)	1000	(9.2)	N
Slovakia	TESSy	national	212	(52.9)	212	(100.0)	3	(1.4)	14	(6.6)	Y
Slovenia	TESSy	national	132	(94.3)	132	(100.0)	0	(0.0)	4	(3.0)	Y
Spain <sup>d</sup>	NRL-TME <sup>e</sup>	sub-national	1561	(39.0)	1561	(100.0)	34	(2.2)	128	(8.2)	N
Sweden	TESSy	national	523	(80.7)	523	(100.0)	8	(1.5)	50	(9.6)	Y
United Kingdom	TESSy	national	4684	(59.4)	4606	(98.3)	74	(1.6)	406	(8.7)	Y
<b>Total EU/EEA</b>			<b>41808</b>	<b>(64.5)</b>	<b>36349</b>	<b>(86.9)</b>	<b>1484</b>	<b>(4.1)</b>	<b>3891</b>	<b>(10.7)</b>	<b>25</b>

<sup>a</sup> Includes only countries reporting first-line anti-TB drug susceptibility testing. Laboratory-confirmed cases consist of culture-positive and smear-positive/nucleic acid amplification test-positive cases.

<sup>b</sup> Any resistance to isoniazid, rifampicin, ethambutol or streptomycin expressed as a percentage of cases with available DST results at least for isoniazid and rifampicin. No routine testing for ethambutol and streptomycin in all countries.

<sup>c</sup> Data considered complete when national coverage 100% or culture results available for 90% of all cases, and 50% of all cases culture-positive, and 75% of them with DST results, and EQA results accurate in 95% of samples for reported year.

<sup>d</sup> Data from France, Italy and Spain reported by NRL may differ from data shown elsewhere in this report.

<sup>e</sup> NRL: National reference laboratory; TME: WHO Tuberculosis Monitoring and Evaluation Database.

**Table 14: Multidrug-resistant TB among pulmonary laboratory confirmed TB cases by previous history of TB treatment, European Region, 2013<sup>a</sup>**

Country	New pulmonary...							Previously treated pulmonary...							
	...laboratory-confirmed TB cases with DST results		...laboratory-confirmed MDR TB cases		...laboratory-confirmed TB cases		...TB cases	...laboratory-confirmed TB cases with DST results		...laboratory-confirmed MDR -TB cases		...laboratory-confirmed TB cases		...TB cases	
	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>d</sup>		N	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N		(%) <sup>e</sup>
<b>EU/EEA</b>															
Austria	279	(96.5)	7	(2.5)	289	(74.3)	389	24	(100.0)	9	(37.5)	24	(68.6)	35	
Belgium	399	(95.2)	7	(1.8)	419	(85.7)	489	41	(93.2)	1	(2.4)	44	(77.2)	57	
Bulgaria	619	(78.2)	12	(1.9)	792	(65.5)	1209	109	(82.6)	14	(12.8)	132	(61.1)	216	
Croatia	282	(90.4)	0	(0.0)	312	(79.2)	394	14	(93.3)	0	(0.0)	15	(60.0)	25	
Cyprus	23	(100.0)	0	(0.0)	23	(85.2)	27	1	(100.0)	1	(100.0)	1	(100.0)	1	
Czech Republic	284	(91.9)	0	(0.0)	309	(74.6)	414	10	(90.9)	0	(0.0)	11	(40.7)	27	
Denmark	197	(99.0)	1	(0.5)	199	(98.0)	203	20	(100.0)	1	(5.0)	20	(87.0)	23	
Estonia	168	(98.2)	29	(17.3)	171	(79.9)	214	44	(100.0)	21	(47.7)	44	(81.5)	54	
Finland	163	(98.8)	2	(1.2)	165	(80.9)	204	5	(100.0)	0	(0.0)	5	(50.0)	10	
France	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Germany	651	(91.2)	14	(2.2)	714	(81.7)	874	118	(92.2)	25	(21.2)	128	(59.3)	216	
Greece	173	(71.8)	7	(4.0)	241	(65.5)	368	17	(65.4)	2	(11.8)	26	(61.9)	42	
Hungary	332	(80.2)	6	(1.8)	414	(44.6)	929	21	(84.0)	4	(19.0)	25	(37.3)	67	
Iceland	3	(100.0)	0	(0.0)	3	(75.0)	4	0	-	0	-	0	-	0	
Ireland	131	(98.5)	2	(1.5)	133	(87.5)	152	12	(85.7)	0	(0.0)	14	(63.6)	22	
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Latvia	545	(97.0)	48	(8.8)	562	(81.3)	691	105	(96.3)	27	(25.7)	109	(93.2)	117	
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Lithuania	1006	(100.0)	116	(11.5)	1006	(80.5)	1249	306	(100.0)	135	(44.1)	306	(100.0)	306	
Luxembourg	0	-	0	-	0	-	0	0	-	0	-	0	-	0	
Malta	17	(100.0)	0	(0.0)	17	(51.5)	33	0	-	0	-	0	-	0	
Netherlands	348	(99.4)	7	(2.0)	350	(82.4)	425	21	(100.0)	7	(33.3)	21	(77.8)	27	
Norway	180	(99.4)	4	(2.2)	181	(85.0)	213	16	(100.0)	1	(6.3)	16	(69.6)	23	
Poland	3835	(93.2)	19	(0.5)	4115	(68.5)	6007	489	(89.2)	21	(4.3)	548	(66.2)	828	
Portugal	858	(73.2)	9	(1.0)	1172	(75.5)	1553	56	(62.9)	5	(8.9)	89	(66.9)	133	
Romania	4737	(62.7)	151	(3.2)	7553	(71.5)	10557	2263	(73.5)	396	(17.5)	3077	(82.7)	3719	
Slovakia	148	(100.0)	1	(0.7)	148	(54.6)	271	35	(100.0)	1	(2.9)	35	(59.3)	59	
Slovenia	100	(100.0)	0	(0.0)	100	(97.1)	103	6	(100.0)	0	(0.0)	6	(100.0)	6	
Spain <sup>f</sup>	1458	(55.2)	27	(1.9)	2643	(74.4)	3553	103	(54.8)	7	(6.8)	188	(79.3)	237	
Sweden	276	(100.0)	5	(1.8)	276	(89.3)	309	16	(100.0)	2	(12.5)	16	(76.2)	21	
United Kingdom	2526	(98.3)	36	(1.4)	2570	(72.2)	3560	193	(95.5)	7	(3.6)	202	(66.4)	304	
<b>Subtotal EU/EEA</b>	<b>19738</b>	<b>(79.3)</b>	<b>510</b>	<b>(2.6)</b>	<b>24877</b>	<b>(72.3)</b>	<b>34394</b>	<b>4045</b>	<b>(79.3)</b>	<b>687</b>	<b>(17.0)</b>	<b>5102</b>	<b>(77.6)</b>	<b>6575</b>	
<b>Non-EU/EEA</b>															
Albania	27	(18.6)	1	(3.7)	145	(46.2)	314	4	(44.4)	0	(0.0)	9	(47.4)	19	
Andorra	4	(100.0)	0	(0.0)	4	-	-	0	(0.0)	0	(0.0)	0	-	0	
Armenia	371	(100.0)	43	(11.6)	371	(46.2)	803	67	(100.0)	23	(34.3)	67	(25.2)	266	
Azerbaijan	1230	(93.5)	187	(15.2)	1315	-	-	1594	(79.3)	778	(48.8)	2010	-	-	
Belarus	2145	(95.0)	755	(35.2)	2259	(69.6)	3247	1097	(95.5)	598	(54.5)	1149	(108.0)	1064	
Bosnia and Herzegovina	643	(100.0)	0	(0.0)	643	(64.6)	995	63	(100.0)	1	(1.6)	63	(63.6)	99	
former Yugoslav Republic of Macedonia, the	163	(94.8)	0	(0.0)	172	(76.4)	225	16	(100.0)	1	(6.3)	16	(66.7)	24	
Georgia	1629	(93.8)	183	(11.2)	1736	(72.0)	2412	527	(90.4)	201	(38.1)	583	(96.8)	602	
Israel	156	(100.0)	6	(3.8)	156	(70.0)	223	1	(100.0)	1	(100.0)	1	(33.3)	3	
Kazakhstan	7589	(98.5)	1997	(26.3)	7701	(70.8)	10873	6984	(99.7)	4035	(57.8)	7006	(100.5)	6970	
Kyrgyzstan	2157	(100.0)	613	(28.4)	2157	(51.5)	4185	993	(100.0)	547	(55.1)	993	(82.9)	1198	
Moldova	1400	(84.2)	343	(24.5)	1662	(50.9)	3268	903	(88.6)	561	(62.1)	1019	(73.9)	1379	
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Montenegro	67	(100.0)	0	(0.0)	67	(65.0)	103	5	(100.0)	0	(0.0)	5	(55.6)	9	
Russia	31677	(94.6)	6726	(21.2)	33499	(41.0)	81638	12066	(86.6)	6795	(56.3)	13929	(35.1)	39689	
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Serbia	705	(100.0)	6	(0.9)	705	(76.4)	923	86	(100.0)	4	(4.7)	86	(81.1)	106	
Serbia excluding UN Administered Province of Kosovo <sup>g</sup>	705	(100.0)	6	(0.9)	705	(76.4)	923	86	(100.0)	4	(4.7)	86	(81.1)	106	
UN Administered Province of Kosovo <sup>g</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Switzerland	196	(98.0)	3	(1.5)	200	(86.2)	232	34	(100.0)	8	(23.5)	34	-	0	
Tajikistan	414	(18.8)	143	(34.5)	2201	(22.4)	3852	46	(7.2)	16	(34.8)	637	(138.2)	461	
Turkey	4939	(99.8)	123	(2.5)	4947	(63.5)	7791	591	(99.8)	105	(17.8)	592	(68.5)	864	
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Ukraine	12900	(95.3)	2479	(19.2)	13538	(47.8)	28343	8270	(92.4)	3365	(40.7)	8953	(180.9)	4950	
Uzbekistan	4234	(99.2)	1535	(36.3)	4267	(35.3)	12096	2664	(99.2)	1495	(56.1)	2813	(65.3)	4307	
<b>Subtotal non-EU/EEA</b>	<b>72646</b>	<b>(93.4)</b>	<b>15143</b>	<b>(20.8)</b>	<b>77745</b>	<b>(48.1)</b>	<b>161523</b>	<b>36011</b>	<b>(90.1)</b>	<b>18534</b>	<b>(51.5)</b>	<b>39965</b>	<b>(64.4)</b>	<b>62010</b>	
<b>Total European Region</b>	<b>92384</b>	<b>(90.0)</b>	<b>15653</b>	<b>(16.9)</b>	<b>102622</b>	<b>(52.4)</b>	<b>195917</b>	<b>40056</b>	<b>(88.9)</b>	<b>19221</b>	<b>(48.0)</b>	<b>45067</b>	<b>(65.7)</b>	<b>68585</b>	
<b>Subtotal 18 HPC</b>	<b>77760</b>	<b>(90.7)</b>	<b>15483</b>	<b>(19.9)</b>	<b>85737</b>	<b>(49.7)</b>	<b>172428</b>	<b>38629</b>	<b>(89.0)</b>	<b>19112</b>	<b>(49.5)</b>	<b>43419</b>	<b>(65.6)</b>	<b>66162</b>	

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

<sup>b</sup> WHO European Region 18 TB High Priority Countries presented in *italics*.

<sup>c</sup> Cases classified according to previous TB treatment history. In Belgium, Denmark, Ireland, Norway and United Kingdom previous diagnosis was used as a proxy for previous treatment.

<sup>d</sup> Percentage among laboratory-confirmed pulmonary TB cases.

<sup>e</sup> Percentage among laboratory-confirmed pulmonary TB cases with DST results.

<sup>f</sup> Percentage among pulmonary TB cases.

<sup>g</sup> Data from Spain reported by NRL may differ from data shown elsewhere in this report.

<sup>h</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	Previous treatment unknown pulmonary...							All pulmonary...						
	...laboratory-confirmed TB cases with DST results		...laboratory-confirmed MDR-TB cases		...laboratory-confirmed pulmonary TB cases		...TB cases	...laboratory-confirmed TB cases with DST results		...laboratory-confirmed MDR TB cases		...laboratory-confirmed TB cases		...TB cases
	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>d</sup>	N	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>d</sup>	N
	66	(91.7)	0	(0.0)	72	(72.7)	99	369	(95.8)	16	(4.3)	385	(73.6)	523
	114	(95.8)	2	(1.8)	119	(87.5)	136	554	(95.2)	10	(1.8)	582	(85.3)	682
	0	-	0	-	0	-	0	728	(78.8)	26	(3.6)	924	(64.8)	1425
	1	(100.0)	0	(0.0)	1	(100.0)	1	297	(90.5)	0	(0.0)	328	(78.1)	420
	1	(100.0)	0	(0.0)	1	(100.0)	1	25	(100.0)	1	(4.0)	25	(86.2)	29
	0	-	0	-	0	-	0	294	(91.9)	0	(0.0)	320	(72.6)	441
	0	-	0	-	0	-	0	217	(99.1)	2	(0.9)	219	(96.9)	226
	0	-	0	-	0	-	0	212	(98.6)	50	(23.6)	215	(80.2)	268
	3	(100.0)	0	(0.0)	3	(100.0)	3	171	(98.8)	2	(1.2)	173	(79.7)	217
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	1601	(92.5)	46	(2.9)	1731	(78.4)	2208	2370	(92.1)	85	(3.6)	2573	(78.0)	3298
	20	(64.5)	1	(5.0)	31	(67.4)	46	210	(70.5)	10	(4.8)	298	(65.4)	456
	0	-	0	-	0	-	0	353	(80.4)	10	(2.8)	439	(44.1)	996
	0	-	0	-	0	-	0	3	(100.0)	0	(0.0)	3	(75.0)	4
	56	(94.9)	2	(3.6)	59	(74.7)	79	199	(96.6)	4	(2.0)	206	(81.4)	253
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	0	-	0	-	0	-	0	650	(96.9)	75	(11.5)	671	(83.0)	808
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	3	(100.0)	2	(66.7)	3	(30.0)	10	1315	(100.0)	253	(19.2)	1315	(84.0)	1565
	27	(96.4)	0	(0.0)	28	(87.5)	32	27	(96.4)	0	(0.0)	28	(87.5)	32
	3	(100.0)	1	(33.3)	3	(60.0)	5	20	(100.0)	1	(5.0)	20	(52.6)	38
	1	(100.0)	0	(0.0)	1	(50.0)	2	370	(99.5)	14	(3.8)	372	(81.9)	454
	12	(100.0)	0	(0.0)	12	(85.7)	14	208	(99.5)	5	(2.4)	209	(83.6)	250
	0	-	0	-	0	-	0	4324	(92.7)	40	(0.9)	4663	(68.2)	6835
	0	-	0	-	0	-	0	914	(72.5)	14	(1.5)	1261	(74.8)	1686
	0	-	0	-	0	-	0	7000	(65.9)	547	(7.8)	10630	(74.5)	14276
	11	(100.0)	1	(9.1)	11	(78.6)	14	194	(100.0)	3	(1.5)	194	(56.4)	344
	0	-	0	-	0	-	0	106	(100.0)	0	(0.0)	106	(97.2)	109
	0	(0.0)	0	-	145	(69.7)	208	1561	(52.5)	34	(2.2)	2976	(74.4)	3998
	29	(100.0)	0	(0.0)	29	(76.3)	38	321	(100.0)	7	(2.2)	321	(87.2)	368
	151	(99.3)	3	(2.0)	152	(65.5)	232	2870	(98.2)	46	(1.6)	2924	(71.4)	4096
	<b>2099</b>	<b>(87.4)</b>	<b>58</b>	<b>(2.8)</b>	<b>2401</b>	<b>(76.8)</b>	<b>3128</b>	<b>25882</b>	<b>(79.9)</b>	<b>1255</b>	<b>(4.8)</b>	<b>32380</b>	<b>(73.4)</b>	<b>44097</b>
	0	(0.0)	0	(0.0)	0	-	0	31	(86.1)	1	(3.2)	36	(10.8)	333
	0	(0.0)	0	(0.0)	0	-	-	4	(100.0)	0	(0.0)	4	-	-
	0	(0.0)	0	(0.0)	0	-	0	438	(100.0)	66	(15.1)	438	(41.0)	1069
	0	(0.0)	0	(0.0)	0	-	-	2824	(87.2)	965	(34.2)	3240	-	-
	0	(0.0)	0	(0.0)	0	-	0	3242	(98.4)	1353	(41.7)	3294	(76.4)	4311
	0	(0.0)	0	(0.0)	0	-	0	706	(100.0)	1	(0.1)	706	(64.5)	1094
	0	(0.0)	0	(0.0)	0	-	0	179	(100.0)	1	(0.6)	179	(71.9)	249
	0	(0.0)	0	(0.0)	0	-	0	2156	(97.5)	384	(17.8)	2212	(73.4)	3014
	0	(0.0)	0	(0.0)	0	-	0	157	(100.0)	7	(4.5)	157	(69.5)	226
	0	(0.0)	0	(0.0)	0	-	0	14573	(99.8)	6032	(41.4)	14595	(81.8)	17843
	0	(0.0)	0	(0.0)	0	-	0	3150	(100.0)	1160	(36.8)	3150	(58.5)	5383
	14	(100.0)	8	(57.1)	14	(53.8)	26	2317	(95.2)	912	(39.4)	2433	(52.1)	4673
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	0	(0.0)	0	(0.0)	0	-	0	72	(100.0)	0	(0.0)	72	(64.3)	112
	0	(0.0)	0	(0.0)	0	-	0	43743	(95.9)	13521	(30.9)	45606	(37.6)	121327
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	1	(100.0)	0	(0.0)	1	(100.0)	1	792	(100.0)	10	(1.3)	792	(76.9)	1030
	1	(100.0)	0	(0.0)	1	(100.0)	1	792	(100.0)	10	(1.3)	792	(76.9)	1030
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	74	(96.1)	1	(1.4)	77	(87.5)	88	304	(99.0)	12	(3.9)	307	(95.9)	320
	0	(0.0)	0	(0.0)	0	-	0	460	(43.8)	159	(34.6)	1051	(24.4)	4313
	0	(0.0)	0	(0.0)	0	-	0	5530	(100.0)	228	(4.1)	5531	(63.9)	8655
	0	-	-	-	-	-	-	-	-	-	-	-	-	-
	0	(0.0)	0	(0.0)	0	(0.0)	10964	21170	(96.9)	5844	(27.6)	21853	(49.4)	44257
	0	(0.0)	0	(0.0)	0	-	0	6898	(97.9)	3030	(43.9)	7047	(43.0)	16403
	<b>89</b>	<b>(96.7)</b>	<b>9</b>	<b>(10.1)</b>	<b>92</b>	<b>(0.8)</b>	<b>11079</b>	<b>108746</b>	<b>(96.5)</b>	<b>33686</b>	<b>(31.0)</b>	<b>112703</b>	<b>(48.0)</b>	<b>234612</b>
	<b>2188</b>	<b>(87.8)</b>	<b>67</b>	<b>(3.1)</b>	<b>2493</b>	<b>(17.5)</b>	<b>14207</b>	<b>134628</b>	<b>(92.8)</b>	<b>34941</b>	<b>(26.0)</b>	<b>145083</b>	<b>(52.1)</b>	<b>278709</b>
	<b>17</b>	<b>(100.0)</b>	<b>10</b>	<b>(58.8)</b>	<b>17</b>	<b>(0.2)</b>	<b>11000</b>	<b>116406</b>	<b>(93.7)</b>	<b>34605</b>	<b>(29.7)</b>	<b>124205</b>	<b>(49.8)</b>	<b>249590</b>

**Table 15: Multidrug resistant TB among all laboratory confirmed TB cases by previous history of TB treatment, EU/EEA, 2013<sup>a</sup>**

Country	New...							Previously treated...							
	...laboratory-confirmed TB cases with DST results		...MDR TB cases		...laboratory-confirmed TB cases		...TB cases	...TB cases with DST results			... MDR TB cases		...laboratory-confirmed TB cases		...TB cases
	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>d</sup>	N	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>d</sup>	N	
<b>EU/EEA</b>															
Austria	340	(96.3)	7	(2.1)	353	(72.8)	485	25	(100.0)	9	(36.0)	25	(65.8)	38	
Belgium	520	(95.2)	10	(1.9)	546	(78.3)	697	48	(90.6)	1	(2.1)	53	(70.7)	75	
Bulgaria	625	(76.3)	13	(2.1)	819	(48.8)	1680	109	(82.6)	14	(12.8)	132	(52.4)	252	
Croatia	300	(90.9)	0	(0.0)	330	(76.9)	429	14	(93.3)	0	(0.0)	15	(57.7)	26	
Cyprus	28	(100.0)	0	(0.0)	28	(73.7)	38	1	(100.0)	1	(100.0)	1	(100.0)	1	
Czech Republic	310	(92.0)	0	(0.0)	337	(71.5)	471	11	(91.7)	0	(0.0)	12	(40.0)	30	
Denmark	255	(98.8)	1	(0.4)	258	(78.2)	330	20	(100.0)	1	(5.0)	20	(76.9)	26	
Estonia	175	(98.3)	29	(16.6)	178	(79.1)	225	45	(100.0)	21	(46.7)	45	(73.8)	61	
Finland	192	(99.0)	2	(1.0)	194	(76.7)	253	6	(100.0)	0	(0.0)	6	(46.2)	13	
France	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Germany	809	(91.4)	17	(2.1)	885	(76.4)	1159	134	(92.4)	27	(20.1)	145	(55.8)	260	
Greece	194	(71.1)	7	(3.6)	273	(63.5)	430	17	(60.7)	2	(11.8)	28	(60.9)	46	
Hungary	338	(80.1)	6	(1.8)	422	(43.3)	975	22	(84.6)	4	(18.2)	26	(37.1)	70	
Iceland	7	(100.0)	0	(0.0)	7	(63.6)	11	0	(9.0)	0	-	0	-	0	
Ireland	183	(97.9)	2	(1.1)	187	(77.9)	240	14	(87.5)	0	(0.0)	16	(57.1)	28	
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Latvia	572	(97.1)	50	(8.7)	589	(75.9)	776	109	(96.5)	29	(26.6)	113	(88.3)	128	
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Lithuania	1039	(100.0)	119	(11.5)	1039	(75.1)	1383	312	(100.0)	135	(43.3)	312	(100.0)	312	
Luxembourg	0	-	0	-	0	-	0	0	-	0	-	0	-	0	
Malta	20	(100.0)	0	(0.0)	20	(50.0)	40	0	(0.0)	0	-	0	-	0	
Netherlands	577	(99.7)	9	(1.6)	579	(72.1)	803	29	(100.0)	8	(27.6)	29	(70.7)	41	
Norway	270	(99.6)	5	(1.9)	271	(80.7)	336	25	(100.0)	1	(4.0)	25	(64.1)	39	
Poland	3973	(93.1)	19	(0.5)	4268	(66.7)	6403	497	(89.2)	21	(4.2)	557	(65.8)	847	
Portugal	971	(71.8)	10	(1.0)	1353	(61.2)	2209	62	(62.0)	5	(8.1)	100	(54.3)	184	
Romania	4869	(62.5)	156	(3.2)	7796	(60.6)	12860	2272	(73.4)	399	(17.6)	3094	(80.3)	3851	
Slovakia	166	(100.0)	1	(0.6)	166	(51.1)	325	35	(100.0)	1	(2.9)	35	(58.3)	60	
Slovenia	125	(100.0)	0	(0.0)	125	(94.0)	133	7	(100.0)	0	(0.0)	7	(100.0)	7	
Spain <sup>e</sup>	1458	(45.1)	27	(1.9)	3230	(65.3)	4946	103	(47.9)	7	(6.8)	215	(72.9)	295	
Sweden	437	(100.0)	6	(1.4)	437	(83.7)	522	26	(100.0)	2	(7.7)	26	(60.5)	43	
United Kingdom	4128	(98.4)	59	(1.4)	4193	(59.9)	7001	250	(96.2)	10	(4.0)	260	(51.2)	508	
<b>Total EU/EEA</b>	<b>22881</b>	<b>(79.2)</b>	<b>555</b>	<b>(2.4)</b>	<b>28883</b>	<b>(64.0)</b>	<b>45160</b>	<b>4193</b>	<b>(79.2)</b>	<b>698</b>	<b>(16.6)</b>	<b>5297</b>	<b>(73.2)</b>	<b>7241</b>	

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> In Belgium, Denmark, Ireland, Norway and United Kingdom previous diagnosis was used as a proxy for previous treatment.

<sup>c</sup> Percentage among laboratory-confirmed TB cases.

<sup>d</sup> Percentage among laboratory-confirmed TB cases with DST results.

<sup>e</sup> Percentage among all TB cases according to previous treatment.

<sup>f</sup> Data from Spain reported by NRL may differ from data shown elsewhere in this report.



	Previous treatment unknown...						All...			
	...cases with DST results		...MDR TB cases		...laboratory-confirmed TB cases		...TB cases	...laboratory-confirmed TB cases		...TB cases
	N	(%) <sup>b</sup>	N	(%) <sup>c</sup>	N	(%) <sup>d</sup>	N	N	(%) <sup>f</sup>	N
	81	(91.0)	0	(0.0)	89	(70.6)	126	467	(72.0)	649
	161	(94.2)	2	(1.2)	171	(81.8)	209	770	(78.5)	981
	0	-	0	-	0	-	0	951	(49.2)	1932
	1	(100.0)	0	(0.0)	1	(1.6)	62	346	(66.9)	517
	1	(100.0)	0	(0.0)	1	(50.0)	2	30	(73.2)	41
	0	-	0	-	0	-	0	349	(69.7)	501
	0	-	0	-	0	-	0	278	(78.1)	356
	0	-	0	-	0	-	0	223	(78.0)	286
	5	(100.0)	0	(0.0)	5	(100.0)	5	205	(75.6)	271
	-	-	-	-	-	-	-	-	-	-
	1958	(92.4)	56	(2.9)	2120	(73.1)	2899	3150	(73.0)	4318
	22	(57.9)	1	(4.5)	38	(59.4)	64	339	(62.8)	540
	0	-	0	-	0	-	0	448	(42.9)	1045
	0	-	0	-	0	-	0	7	(63.6)	11
	73	(92.4)	2	(2.7)	79	(68.1)	116	282	(73.4)	384
	-	-	-	-	-	-	-	-	-	-
	0	-	0	-	0	-	0	702	(77.7)	904
	-	-	-	-	-	-	-	-	-	-
	3	(100.0)	2	(66.7)	3	(30.0)	10	1354	(79.4)	1705
	32	(97.0)	0	(0.0)	33	(86.8)	38	33	(86.8)	38
	7	(100.0)	1	(14.3)	7	(70.0)	10	27	(54.0)	50
	1	(100.0)	0	(0.0)	1	(25.0)	4	609	(71.8)	848
	23	(100.0)	0	(0.0)	23	(88.5)	26	319	(79.6)	401
	0	-	0	-	0	-	0	4825	(66.6)	7250
	0	-	0	-	0	-	0	1453	(60.7)	2393
	0	-	0	-	0	-	0	10890	(65.2)	16711
	11	(100.0)	1	(9.1)	11	(68.8)	16	212	(52.9)	401
	0	-	0	-	0	-	0	132	(94.3)	140
	0	(0.0)	0	-	186	(62.4)	298	3631	(0.0)	5539
	60	(100.0)	0	(0.0)	60	(72.3)	83	523	(80.7)	648
	228	(98.7)	5	(2.2)	231	(60.3)	383	4684	(59.4)	7892
	<b>2667</b>	<b>(61.3)</b>	<b>70</b>	<b>(1.6)</b>	<b>3059</b>	<b>(70.3)</b>	<b>4351</b>	<b>37239</b>	<b>(65.6)</b>	<b>56752</b>

Table 16: XDR TB cases among pulmonary MDR TB cases, European Region 2013<sup>a</sup>

Country	Pulmonary TB cases with FLD DST (N)	MDR TB among pulmonary TB cases		MDR TB with SLD		XDR TB	
		N	%	N	%	N	%
<b>EU/EEA</b>							
Austria	369	16	(4.3)	16	(100.0)	3	(18.8)
Belgium	554	10	(1.8)	10	(100.0)	0	(0.0)
<i>Bulgaria</i>	728	26	(3.6)	26	(100.0)	4	(15.4)
Croatia	-	-	-	-	-	-	-
Cyprus	25	1	(4.0)	1	(100.0)	1	(100.0)
Czech Republic	294	0	(0.0)	0	-	0	-
Denmark	217	2	(0.9)	2	(100.0)	1	(50.0)
<i>Estonia</i>	212	50	(23.6)	49	(98.0)	8	(16.3)
Finland	171	2	(1.2)	2	(100.0)	0	(0.0)
France	-	-	-	-	-	-	-
Germany	2370	85	(3.6)	26	(30.6)	2	(7.7)
Greece	210	10	(4.8)	10	(100.0)	0	(0.0)
Hungary	353	10	(2.8)	9	(90.0)	1	(11.1)
Iceland	3	0	(0.0)	0	-	0	-
Ireland	199	4	(2.0)	3	(75.0)	1	(33.3)
Italy	-	-	-	-	-	-	-
<i>Latvia</i>	650	75	(11.5)	69	(92.0)	15	(21.7)
Liechtenstein	-	-	-	-	-	-	-
<i>Lithuania</i>	1315	253	(19.2)	186	(73.5)	46	(24.7)
Luxembourg	-	-	-	-	-	-	-
Malta	20	1	(5.0)	1	(100.0)	1	(100.0)
Netherlands	-	-	-	-	-	-	-
Norway	208	5	(2.4)	5	(100.0)	1	(20.0)
Poland	4324	40	(0.9)	4	(10.0)	1	(25.0)
Portugal	914	14	(1.5)	11	(78.6)	4	(36.4)
<i>Romania</i>	7000	547	(7.8)	264	(48.3)	44	(16.7)
Slovakia	194	3	(1.5)	2	(66.7)	0	(0.0)
Slovenia	106	0	(0.0)	0	-	0	-
Spain	1561	34	(2.2)	34	(100.0)	2	(5.9)
Sweden	321	7	(2.2)	7	(100.0)	2	(28.6)
United Kingdom	2870	46	(1.6)	43	(93.5)	2	(4.7)
<b>Subtotal EU/EEA</b>	<b>25188</b>	<b>1241</b>	<b>(4.9)</b>	<b>780</b>	<b>(62.9)</b>	<b>139</b>	<b>(17.8)</b>
<b>Non-EU/EEA</b>							
Albania	31	1	(3.2)	0	(0.0)	0	-
Andorra	4	0	(0.0)	0	-	0	-
<i>Armenia</i>	438	66	(15.1)	66	(100.0)	7	(10.6)
<i>Azerbaijan</i>	-	-	-	-	-	-	-
<i>Belarus</i>	3242	1353	(41.7)	1353	(100.0)	80	(5.9)
Bosnia and Herzegovina	-	-	-	-	-	-	-
former Yugoslav Republic of Macedonia, the	179	1	(0.6)	0	(0.0)	0	-
<i>Georgia</i>	2156	384	(17.8)	369	(96.1)	71	(19.2)
Israel	157	7	(4.5)	7	(100.0)	1	(14.3)
<i>Kazakhstan</i>	-	-	-	-	-	-	-
<i>Kyrgyzstan</i>	-	-	-	-	-	-	-
<i>Moldova</i>	2317	912	(39.4)	782	(85.7)	35	(4.5)
Monaco	-	-	-	-	-	-	-
Montenegro	72	0	-	0	-	0	-
<i>Russia</i>	-	-	-	-	-	-	-
San Marino	-	-	-	-	-	-	-
Serbia	792	10	(1.3)	6	(60.0)	0	(0.0)
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>	792	10	(1.3)	6	(60.0)	0	(0.0)
UN Administered Province of Kosovo <sup>b</sup>	-	-	-	-	-	-	-
Switzerland	304	12	(3.9)	12	(100.0)	1	(8.3)
<i>Tajikistan</i>	460	159	(34.6)	159	(100.0)	28	(17.6)
<i>Turkey</i>	5530	228	(4.1)	114	(50.0)	3	(2.6)
<i>Turkmenistan</i>	-	-	-	-	-	-	-
<i>Ukraine</i>	-	-	-	-	-	-	-
<i>Uzbekistan</i>	6898	3030	(43.9)	528	(17.4)	167	(31.6)
<b>Subtotal non-EU/EEA</b>	<b>22580</b>	<b>6163</b>	<b>(27.3)</b>	<b>3396</b>	<b>(55.1)</b>	<b>393</b>	<b>(11.6)</b>
<b>Total European Region</b>	<b>47768</b>	<b>7404</b>	<b>(15.5)</b>	<b>4176</b>	<b>(56.4)</b>	<b>532</b>	<b>(12.7)</b>
<b>Subtotal 18 HPC</b>	<b>30946</b>	<b>7083</b>	<b>(22.9)</b>	<b>3965</b>	<b>(56.0)</b>	<b>508</b>	<b>(12.8)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region TB High Priority Countries presented in italics. FLD DST – drug susceptibility tested for at least two main first-line TB drugs: isoniazid and rifampicin. SLD DST – drug susceptibility testing for second-line TB drugs.

<sup>b</sup> Includes only countries reporting second-line anti-TB drug susceptibility testing – at least one fluoroquinolone (ofloxacin, moxifloxacin and ciprofloxacin) and one injectable drug (amikacin, kanamycin and capreomycin).

<sup>c</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 17: XDR TB cases among all MDR TB cases, EU/EEA 2013<sup>a</sup>

Country	Pulmonary TB cases with FLD DST (N)	MDR TB among all TB cases		MDR TB with SLD		XDR TB	
		N	%	N	%	N	%
<b>EU/EEA</b>							
Austria	446	16	(3.6)	16	(100.0)	3	(18.8)
Belgium	729	13	(1.8)	13	(100.0)	0	(0.0)
<i>Bulgaria</i>	734	27	(3.7)	27	(100.0)	4	(14.8)
Croatia	-	-	-	-	-	-	-
Cyprus	30	1	(3.3)	1	(100.0)	1	(100.0)
Czech Republic	321	0	(0.0)	0	-	0	-
Denmark	275	2	(0.7)	2	(100.0)	1	(50.0)
<i>Estonia</i>	220	50	(22.7)	49	(98.0)	8	(16.3)
Finland	203	2	(1.0)	2	(100.0)	0	(0.0)
France <sup>b</sup>	4 258	83	(1.9)	81	(97.6)	21	(25.9)
Germany	2 901	100	(3.4)	29	(29.0)	2	(6.9)
Greece	233	10	(4.3)	10	(100.0)	0	(0.0)
Hungary	360	10	(2.8)	9	(90.0)	1	(11.1)
Iceland	7	0	-	0	-	0	-
Ireland	270	4	(1.5)	3	(75.0)	1	(33.3)
Italy	2 350	78	(3.3)	55	(70.5)	7	(12.7)
<i>Latvia</i>	681	79	(11.6)	73	(92.4)	15	(20.5)
Liechtenstein	-	-	-	-	-	-	-
<i>Lithuania</i>	1 354	256	(18.9)	188	(73.4)	47	(25.0)
Luxembourg	-	-	-	-	-	-	-
Malta	27	1	(3.7)	1	(100.0)	1	(100.0)
Netherlands	-	-	-	-	-	-	-
Norway	318	6	(1.9)	6	(100.0)	1	(16.7)
Poland	4 470	40	(0.9)	4	(10.0)	1	(25.0)
Portugal	1 033	15	(1.5)	11	(73.3)	4	(36.4)
<i>Romania</i>	7 141	555	(7.8)	268	(48.3)	44	(16.4)
Slovakia	212	3	(1.4)	2	(66.7)	0	(0.0)
Slovenia	132	0	(0.0)	0	-	0	-
Spain <sup>b</sup>	1 561	34	(2.2)	34	(100.0)	2	(5.9)
Sweden	523	8	(1.5)	8	(100.0)	2	(25.0)
United Kingdom	4 606	74	(1.6)	71	(95.9)	3	(4.2)
<b>Total EU/EEA</b>	<b>35 395</b>	<b>1 467</b>	<b>(4.1)</b>	<b>963</b>	<b>(65.6)</b>	<b>169</b>	<b>(17.5)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region TB High Priority Countries presented in italics.

FLD DST – drug susceptibility tested for at least two main first-line TB drugs: isoniazid and rifampicin.

SLD DST – drug susceptibility testing for second-line TB drugs.

<sup>a</sup> Includes only countries reporting second-line anti-TB drug susceptibility testing – at least one fluoroquinolone (ofloxacin, moxifloxacin and ciprofloxacin) and one injectable drug (amikacin, kanamycin and capreomycin).

<sup>b</sup> France and Spain are only reporting DST results for pulmonary cases

**Table 18: Tuberculosis cases with HIV infection, European Region, 2013<sup>a</sup>**

Country	All TB cases (N)	Cases with known HIV-status		HIV-positive		HIV-positive cases started ART	
		N	%	N	% <sup>b</sup>	N	% <sup>b</sup>
<b>EU/EEA</b>							
Austria	-	-	-	-	-	-	-
Belgium	981	492	(50.2)	36	(7.3)	-	-
Bulgaria	1932	1874	(97.0)	4	(0.2)	3	(75.0)
Croatia	-	-	-	-	-	-	-
Cyprus	-	-	-	-	-	-	-
Czech Republic	501	125	(25.0)	0	(0.0)	-	-
Denmark <sup>c</sup>	-	-	-	-	-	-	-
Estonia	286	276	(96.5)	36	(13.0)	24	(66.7)
Finland	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-
Germany	-	-	-	-	-	-	-
Greece	540	363	(67.2)	35	(9.6)	26	(74.3)
Hungary	-	-	-	-	-	-	-
Iceland	11	8	(72.7)	0	(0.0)	-	-
Ireland	384	103	(26.8)	8	(7.8)	4	(50.0)
Italy	-	-	-	-	-	-	-
Latvia	904	420	(46.5)	95	(22.6)	47	(49.5)
Liechtenstein	-	-	-	-	-	-	-
Lithuania	1705	1144	(67.1)	39	(3.4)	-	-
Luxembourg	38	36	(94.7)	1	(2.8)	-	-
Malta	50	44	(88.0)	0	(0.0)	-	-
Netherlands <sup>d</sup>	848	432	(50.9)	17	(3.9)	-	-
Norway <sup>e</sup>	-	-	-	-	-	-	-
Poland <sup>e</sup>	-	-	-	-	-	-	-
Portugal	2393	1710	(71.5)	248	(14.5)	-	-
Romania	16 711	10 196	(61.0)	267	(2.6)	244	(91.4)
Slovakia	401	368	(91.8)	0	(0.0)	0	-
Slovenia	140	105	(75.0)	1	(1.0)	1	(100.0)
Spain	5539	4 069	(73.5)	273	(6.7)	-	-
Sweden <sup>f</sup>	-	-	-	-	-	-	-
United Kingdom	-	-	-	-	-	-	-
<b>Subtotal EU/EEA</b>	<b>33 364</b>	<b>21 765</b>	<b>(65.2)</b>	<b>1 060</b>	<b>(4.9)</b>	<b>349</b>	<b>(78.3)</b>
<b>Non-EU/EEA</b>							
Albania	474	109	(23.0)	2	(1.8)	2	(100.0)
Andorra	5	1	(20.0)	1	(100.0)	1	(100.0)
Armenia	1 417	1 417	(100.0)	67	(4.7)	48	(71.6)
Azerbaijan	8 597	8 329	(96.9)	131	(1.6)	78	(59.5)
Belarus	4 859	4 859	(100.0)	250	(5.1)	189	(75.6)
Bosnia and Herzegovina	1 261	74	(5.9)	0	(0.0)	0	-
former Yugoslav Republic of Macedonia, the	323	206	(63.8)	0	(0.0)	0	-
Georgia	4 319	2 698	(62.5)	56	(2.1)	50	(89.3)
Israel	308	292	(94.8)	15	(5.1)	0	(0.0)
Kazakhstan	19 857	18 104	(91.2)	466	(2.6)	271	(58.2)
Kyrgyzstan	7 209	6 358	(88.2)	203	(3.2)	110	(54.2)
Moldova	5 051	4 085	(80.9)	250	(6.1)	165	(66.0)
Monaco	-	-	-	-	-	-	-
Montenegro	120	98	(81.7)	2	(2.0)	2	(100.0)
Russia	142 533	69 724	(48.9)	4 990	(7.2)	-	-
San Marino	-	-	-	-	-	-	-
Serbia	1 181	106	(9.0)	19	(17.9)	19	(100.0)
Serbia excluding UN Administered Province of Kosovo <sup>g</sup>	1 181	106	(9.0)	19	(17.9)	19	(100.0)
UN Administered Province of Kosovo <sup>g</sup>	-	-	-	-	-	-	-
Switzerland	-	-	-	-	-	-	-
Tajikistan	6 495	5 200	(80.1)	165	(3.2)	162	(98.2)
Turkey	13 409	8 787	(65.5)	32	(0.4)	20	(62.5)
Turkmenistan	-	-	-	-	-	-	-
Ukraine	48 134	42 213	(87.7)	8 290	(19.6)	3 949	(47.6)
Uzbekistan	25 168	24 670	(98.0)	1 097	(4.4)	762	(69.5)
<b>Subtotal non-EU/EEA</b>	<b>290 720</b>	<b>197 330</b>	<b>(67.9)</b>	<b>16 036</b>	<b>(8.1)</b>	<b>5 828</b>	<b>(52.8)</b>
<b>Total European Region</b>	<b>324 084</b>	<b>219 095</b>	<b>(67.6)</b>	<b>17 096</b>	<b>(7.8)</b>	<b>6 177</b>	<b>(53.8)</b>
<b>Total 18 HPC</b>	<b>308 586</b>	<b>210 354</b>	<b>(68.2)</b>	<b>16 438</b>	<b>(7.8)</b>	<b>6 122</b>	<b>(53.7)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region TB High Priority Countries presented in italics.

<sup>b</sup> Countries were only included in this analysis if total of cases tested for HIV was provided.

<sup>c</sup> Data from WHO Global TB database (TME).

<sup>d</sup> Denmark, Norway and Poland reported HIV-positive cases, but not the number of tested cases for HIV and are therefore excluded from the current analysis.

<sup>e</sup> Netherlands reported aggregated HIV testing results to TME.

<sup>f</sup> Sweden reported HIV/TB-coinfected cases having started ARV, but not all HIV/TB coinfection cases and is therefore excluded from the current analysis.

<sup>g</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 19: TB in Prisons, European Region, 2012<sup>a</sup>

Country	Prison population (N)	New TB cases (all forms) notified in prisons		Proportion of new TB cases in prisons out of the country total <sup>b</sup> (%)	TB relative risk in prisons (RR)
		N	Rate		
<b>EU/EEA</b>					
Austria	-	-	-	-	-
Belgium	-	-	-	-	-
<i>Bulgaria</i>	9 387	44	468.7	(2.6)	20.2
Croatia	-	-	-	-	-
Cyprus	-	-	-	-	-
Czech Republic	22 644	20	88.3	(4.2)	20.1
Denmark	-	-	-	-	-
<i>Estonia</i>	3 300	4	121.2	(1.8)	6.9
Finland	-	-	-	-	-
France	-	-	-	-	-
Germany	-	-	-	-	-
Greece	-	-	-	-	-
Hungary	18 000	11	61.1	(1.1)	6.2
Iceland	-	-	-	-	-
Ireland	17 026	2	11.7	(0.6)	1.5
Italy	-	-	-	-	-
<i>Latvia</i>	10 085	49	485.9	(6.3)	12.8
Liechtenstein	-	-	-	-	-
<i>Lithuania</i>	9 729	31	318.6	(2.2)	6.9
Luxembourg	650	1	153.8	(2.6)	21.5
Malta	-	-	-	-	-
Netherlands	44 086	18	40.8	(2.2)	8.5
Norway	-	-	-	-	-
Poland	84 399	204	241.7	(3.2)	14.4
Portugal	13 614	46	337.9	(2.1)	16.2
<i>Romania</i>	32 282	112	346.9	(0.9)	5.9
Slovakia	-	-	-	-	-
Slovenia	-	-	-	-	-
Spain	-	-	-	-	-
Sweden	-	-	-	-	-
United Kingdom	84 065	35	41.6	(0.5)	3.6
<b>Subtotal EU/EEA</b>	<b>349 267</b>	<b>577</b>	<b>165.2</b>	<b>(1.6)</b>	<b>8.8</b>
<b>Non-EU/EEA</b>					
Albania	6 000	2	33.3	(0.4)	2.3
Andorra	-	-	-	-	-
<i>Armenia</i>	-	9	-	(0.9)	-
<i>Azerbaijan</i>	-	275	-	(6.1)	-
<i>Belarus</i>	-	127	-	(3.6)	-
Bosnia and Herzegovina	-	-	-	-	-
former Yugoslav Republic of Macedonia, the	2 600	1	38.5	(0.3)	2.8
<i>Georgia</i>	19 349	393	2 031.1	(12.5)	28.1
Israel	12 550	3	23.9	(1.0)	6.1
<i>Kazakhstan</i>	45 335	761	1 678.6	(6.1)	22.1
<i>Kyrgyzstan</i>	8 709	162	1 860.1	(2.8)	17.6
<i>Moldova</i>	22 000	130	590.9	(3.6)	5.7
Monaco	-	-	-	-	-
Montenegro	1 324	0	0.0	(0.0)	0.0
<i>Russia</i>	682 522	9 072	1 329.2	(10.0)	21.0
San Marino	-	-	-	-	-
Serbia	11 000	26	236.4	(2.4)	16.0
Serbia excluding UN Administered Province of Kosovo <sup>c</sup>	11 000	26	236.4	(2.4)	16.0
UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	-
Switzerland	-	-	-	-	-
<i>Tajikistan</i>	10 000	147	1 470.0	(2.8)	22.7
<i>Turkey</i>	136 020	126	92.6	(1.0)	5.6
<i>Turkmenistan</i>	-	-	-	-	-
<i>Ukraine</i>	147 145	1 582	1 075.1	(5.0)	15.5
<i>Uzbekistan</i>	-	-	-	-	-
<b>Subtotal non-EU/EEA<sup>c</sup></b>	<b>1 104 554</b>	<b>12 405</b>	<b>1 123.1</b>	<b>(7.4)</b>	<b>21.7</b>
<b>Total European Region<sup>c</sup></b>	<b>1 453 821</b>	<b>12 982</b>	<b>893.0</b>	<b>(6.4)</b>	<b>22.6</b>
<b>Subtotal 18 HPC<sup>c</sup></b>	<b>1 135 863</b>	<b>12 613</b>	<b>1 110.4</b>	<b>(6.9)</b>	<b>21.9</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region TB High Priority Countries presented in italics.

<sup>b</sup> Data obtained from WHO Tuberculosis Monitoring and Evaluation database (TME).

<sup>c</sup> In the calculation of summary results only countries reporting data on prison population and TB notification in prisons are included.

<sup>d</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 20: Treatment outcome of new TB cases and relapses started on treatment in 2012, European Region, 2013<sup>a</sup>**

Country	New TB cases and relapses started on treatment in 2012 <sup>b</sup>	Success		Died		Failed		Lost to follow-up <sup>c</sup>		Still on treatment		Not evaluated <sup>d</sup>	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA</b>													
Austria	586	422	(72.0)	41	(7.0)	0	(0.0)	52	(8.9)	71	(12.1)	0	(0.0)
Belgium	857	681	(79.5)	44	(5.1)	2	(0.2)	82	(9.6)	18	(2.1)	30	(3.5)
Bulgaria	2178	1892	(86.9)	163	(7.5)	20	(0.9)	91	(4.2)	3	(0.1)	9	(0.4)
Croatia	535	50	(9.3)	38	(7.1)	2	(0.4)	4	(0.7)	2	(0.4)	439	(82.1)
Cyprus	65	28	(43.1)	4	(6.2)	0	(0.0)	9	(13.8)	4	(6.2)	20	(30.8)
Czech Republic	519	412	(79.4)	60	(11.6)	1	(0.2)	30	(5.8)	13	(2.5)	3	(0.6)
Denmark	331	214	(64.7)	6	(1.8)	12	(3.6)	0	(0.0)	14	(4.2)	85	(25.7)
Estonia	200	165	(82.5)	12	(6.0)	3	(1.5)	15	(7.5)	5	(2.5)	0	(0.0)
Finland <sup>e</sup>	256	116	(45.3)	23	(9.0)	0	(0.0)	0	(0.0)	8	(3.1)	109	(42.6)
France	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	3929	2987	(76.0)	351	(8.9)	2	(0.1)	142	(3.6)	129	(3.3)	318	(8.1)
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	1146	823	(71.8)	111	(9.7)	0	(0.0)	98	(8.6)	59	(5.1)	55	(4.8)
Iceland	10	9	(90.0)	0	(0.0)	0	(0.0)	1	(10.0)	0	(0.0)	0	(0.0)
Ireland	324	200	(61.7)	6	(1.9)	0	(0.0)	4	(1.2)	14	(4.3)	100	(30.9)
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-
Latvia	863	758	(87.8)	50	(5.8)	1	(0.1)	42	(4.9)	6	(0.7)	6	(0.7)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	1459	1163	(79.7)	141	(9.7)	14	(1.0)	104	(7.1)	32	(2.2)	5	(0.3)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-
Malta	41	10	(24.4)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	31	(75.6)
Netherlands	898	770	(85.7)	18	(2.0)	0	(0.0)	33	(3.7)	20	(2.2)	57	(6.3)
Norway	328	267	(81.4)	9	(2.7)	4	(1.2)	3	(0.9)	12	(3.7)	33	(10.1)
Poland	7250	4385	(60.5)	569	(7.8)	7	(0.1)	539	(7.4)	18	(0.2)	1732	(23.9)
Portugal	2531	1970	(77.8)	148	(5.8)	1	(0.0)	64	(2.5)	273	(10.8)	75	(3.0)
Romania	16339	13892	(85.0)	1110	(6.8)	411	(2.5)	880	(5.4)	46	(0.3)	0	(0.0)
Slovakia	343	302	(88.0)	25	(7.3)	5	(1.5)	1	(0.3)	0	(0.0)	10	(2.9)
Slovenia	129	112	(86.8)	15	(11.6)	1	(0.8)	1	(0.8)	0	(0.0)	0	(0.0)
Spain <sup>f</sup>	5738	4087	(71.2)	339	(5.9)	7	(0.1)	69	(1.2)	50	(0.9)	1186	(20.7)
Sweden	575	482	(83.8)	19	(3.3)	4	(0.7)	9	(1.6)	3	(0.5)	58	(10.1)
United Kingdom	7956	6501	(81.7)	272	(3.4)	0	(0.0)	374	(4.7)	670	(8.4)	139	(1.7)
<b>Subtotal EU/EEA</b>	<b>55386</b>	<b>42698</b>	<b>(77.1)</b>	<b>3574</b>	<b>(6.5)</b>	<b>497</b>	<b>(0.9)</b>	<b>2647</b>	<b>(4.8)</b>	<b>1470</b>	<b>(2.7)</b>	<b>4500</b>	<b>(8.1)</b>
<b>Non-EU/EEA</b>													
Albania	407	373	(91.6)	11	(2.7)	1	(0.2)	12	(2.9)	-	-	10	(2.5)
Andorra	9	9	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Armenia	1350	1093	(81.0)	81	(6.0)	11	(0.8)	142	(10.5)	-	-	23	(1.7)
Azerbaijan	4616	3831	(83.0)	138	(3.0)	185	(4.0)	370	(8.0)	-	-	92	(2.0)
Belarus	3425	2902	(84.7)	221	(6.5)	194	(5.7)	54	(1.6)	-	-	54	(1.6)
Bosnia and Herzegovina	1301	722	(55.5)	82	(6.3)	5	(0.4)	37	(2.8)	-	-	455	(35.0)
former Yugoslav Republic of Macedonia, the	346	298	(86.1)	28	(8.1)	3	(0.9)	16	(4.6)	-	-	1	(0.3)
Georgia	3638	3103	(85.3)	73	(2.0)	99	(2.7)	224	(6.2)	-	-	139	(3.8)
Israel	509	412	(80.9)	30	(5.9)	0	(0.0)	14	(2.8)	-	-	53	(10.4)
Kazakhstan	16275	14068	(86.4)	923	(5.7)	612	(3.8)	439	(2.7)	-	-	233	(1.4)
Kyrgyzstan	-	-	-	-	-	-	-	-	-	-	-	-	-
Moldova	4203	3205	(76.3)	418	(9.9)	125	(3.0)	331	(7.9)	-	-	124	(3.0)
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	107	90	(84.1)	9	(8.4)	0	(0.0)	4	(3.7)	-	-	4	(3.7)
Russia	89666	61765	(68.9)	7215	(8.0)	8004	(8.9)	6398	(7.1)	-	-	6284	(7.0)
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	1851	1546	(83.5)	123	(6.6)	7	(0.4)	132	(7.1)	-	-	43	(2.3)
Serbia excluding UN Administered Province of Kosovo <sup>g</sup>	1197	968	(80.9)	105	(8.8)	6	(0.5)	80	(6.7)	-	-	38	(3.2)
UN Administered Province of Kosovo <sup>g</sup>	654	578	(88.4)	18	(2.8)	1	(0.2)	52	(8.0)	-	-	5	(0.8)
Switzerland	-	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan	5811	4845	(83.4)	276	(4.7)	422	(7.3)	208	(3.6)	-	-	60	(1.0)
Turkey	13535	11946	(88.3)	556	(4.1)	62	(0.5)	331	(2.4)	-	-	640	(4.7)
Turkmenistan	2804	2369	(84.5)	84	(3.0)	238	(8.5)	94	(3.4)	-	-	19	(0.7)
Ukraine	30928	21922	(70.9)	3282	(10.6)	2034	(6.6)	3350	(10.8)	-	-	340	(1.1)
Uzbekistan	14132	11905	(84.2)	653	(4.6)	310	(2.2)	687	(4.9)	-	-	577	(4.1)
<b>Subtotal non-EU/EEA</b>	<b>194913</b>	<b>146404</b>	<b>(75.1)</b>	<b>14203</b>	<b>(7.3)</b>	<b>12312</b>	<b>(6.3)</b>	<b>12843</b>	<b>(6.6)</b>	-	-	<b>9151</b>	<b>(4.7)</b>
<b>Total European Region</b>	<b>250299</b>	<b>189102</b>	<b>(75.6)</b>	<b>17777</b>	<b>(7.1)</b>	<b>12809</b>	<b>(5.1)</b>	<b>15490</b>	<b>(6.2)</b>	<b>1470</b>	<b>(0.6)</b>	<b>13651</b>	<b>(5.5)</b>
<b>Subtotal 18 HPC</b>	<b>211422</b>	<b>160824</b>	<b>(76.1)</b>	<b>15396</b>	<b>(7.3)</b>	<b>12745</b>	<b>(6.0)</b>	<b>13760</b>	<b>(6.5)</b>	<b>92</b>	<b>(0.0)</b>	<b>8605</b>	<b>(4.1)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> For countries that do not provide information on treatment start, all reported cases were used as proxy.

<sup>c</sup> Patients started on second-line treatment are excluded.

<sup>d</sup> In previous reports defined as 'defaulted'.

<sup>e</sup> In previous reports defined as 'transferred out and unknown'.

<sup>f</sup> Treatment outcome data collected consistently only for confirmed pulmonary cases.

<sup>g</sup> Includes MDR TB cases started on second-line treatment.

<sup>h</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 21: Treatment outcome of previously treated TB cases other than relapses started on treatment in 2012, European Region, 2013<sup>a</sup>**

Country	TB cases started on treatment in 2012 <sup>b</sup>	Success		Died		Failed		Lost to follow-up <sup>c</sup>		Still on treatment		Not evaluated <sup>d</sup>	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA</b>													
Austria	10	4	(40.0)	0	(0.0)	0	(0.0)	3	(30.0)	3	(30.0)	0	(0.0)
Belgium	70	51	(72.9)	6	(8.6)	0	(0.0)	7	(10.0)	3	(4.3)	3	(4.3)
Bulgaria	51	24	(47.1)	9	(17.6)	3	(5.9)	14	(27.5)	1	(2.0)	0	(0.0)
Croatia	36	8	(22.2)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	28	(77.8)
Cyprus	3	2	(66.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(33.3)
Czech Republic	37	29	(78.4)	5	(13.5)	0	(0.0)	3	(8.1)	0	(0.0)	0	(0.0)
Denmark	44	34	(77.3)	2	(4.5)	2	(4.5)	0	(0.0)	1	(2.3)	5	(11.4)
Estonia	4	1	(25.0)	1	(25.0)	0	(0.0)	2	(50.0)	0	(0.0)	0	(0.0)
Finland <sup>e</sup>	11	6	(54.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	5	(45.5)
France	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	109	66	(60.6)	13	(11.9)	1	(0.9)	9	(8.3)	4	(3.7)	16	(14.7)
Greece	32	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	32	(100.0)
Hungary	40	21	(52.5)	5	(12.5)	0	(0.0)	8	(20.0)	4	(10.0)	2	(5.0)
Iceland	0	0	-	0	-	0	-	0	-	0	-	0	-
Ireland	25	14	(56.0)	3	(12.0)	0	(0.0)	0	(0.0)	1	(4.0)	7	(28.0)
Italy	46	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	46	(100.0)
Latvia	14	7	(50.0)	1	(7.1)	0	(0.0)	6	(42.9)	0	(0.0)	0	(0.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	51	29	(56.9)	10	(19.6)	0	(0.0)	10	(19.6)	2	(3.9)	0	(0.0)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-
Malta	1	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(100.0)
Netherlands	20	14	(70.0)	0	(0.0)	0	(0.0)	3	(15.0)	1	(5.0)	2	(10.0)
Norway	31	24	(77.4)	2	(6.5)	0	(0.0)	1	(3.2)	0	(0.0)	4	(12.9)
Poland	250	113	(45.2)	19	(7.6)	0	(0.0)	28	(11.2)	1	(0.4)	89	(35.6)
Portugal	44	34	(77.3)	3	(6.8)	0	(0.0)	1	(2.3)	5	(11.4)	1	(2.3)
Romania	1070	490	(45.8)	126	(11.8)	155	(14.5)	286	(26.7)	13	(1.2)	0	(0.0)
Slovakia	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Slovenia	0	0	-	0	-	0	-	0	-	0	-	0	-
Spain <sup>f</sup>	332	199	(59.9)	25	(7.5)	1	(0.3)	8	(2.4)	8	(2.4)	91	(27.4)
Sweden	29	22	(75.9)	1	(3.4)	0	(0.0)	0	(0.0)	0	(0.0)	6	(20.7)
United Kingdom	498	364	(73.1)	34	(6.8)	0	(0.0)	28	(5.6)	62	(12.4)	10	(2.0)
<b>Subtotal EU/EEA</b>	<b>2859</b>	<b>1557</b>	<b>(54.5)</b>	<b>265</b>	<b>(9.3)</b>	<b>162</b>	<b>(5.7)</b>	<b>417</b>	<b>(14.6)</b>	<b>109</b>	<b>(3.8)</b>	<b>349</b>	<b>(12.2)</b>
<b>Non-EU/EEA</b>													
Albania	6	4	(66.7)	0	(0.0)	0	(0.0)	1	(16.7)	-	-	1	(16.7)
Andorra	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Armenia	15	7	(46.7)	2	(13.3)	1	(6.7)	5	(33.3)	-	-	0	(0.0)
Azerbaijan	2879	2120	(73.6)	111	(3.9)	126	(4.4)	402	(14.0)	-	-	120	(4.2)
Belarus	188	129	(68.6)	19	(10.1)	17	(9.0)	5	(2.7)	-	-	18	(9.6)
Bosnia and Herzegovina	119	66	(55.5)	10	(8.4)	2	(1.7)	3	(2.5)	-	-	38	(31.9)
former Yugoslav Republic of Macedonia, the	9	7	(77.8)	0	(0.0)	0	(0.0)	1	(11.1)	-	-	1	(11.1)
Georgia	886	654	(73.8)	42	(4.7)	34	(3.8)	109	(12.3)	-	-	47	(5.3)
Israel	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Kazakhstan	3171	2488	(78.5)	278	(8.8)	165	(5.2)	194	(6.1)	-	-	46	(1.5)
Kyrgyzstan	-	-	-	-	-	-	-	-	-	-	-	-	-
Moldova	455	177	(38.9)	52	(11.4)	42	(9.2)	145	(31.9)	-	-	39	(8.6)
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Russia	7961	2966	(37.3)	1266	(15.9)	1683	(21.1)	1137	(14.3)	-	-	909	(11.4)
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	37	27	(73.0)	2	(5.4)	0	(0.0)	8	(21.6)	-	-	0	(0.0)
Serbia excluding UN Administered Province of Kosovo <sup>g</sup>	15	8	(53.3)	2	(13.3)	0	(0.0)	5	(33.3)	-	-	0	(0.0)
UN Administered Province of Kosovo <sup>g</sup>	22	19	(86.4)	0	(0.0)	0	(0.0)	3	(13.6)	-	-	0	(0.0)
Switzerland	-	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan	1118	837	(74.9)	90	(8.1)	123	(11.0)	58	(5.2)	-	-	10	(0.9)
Turkey	1156	768	(66.4)	73	(6.3)	21	(1.8)	105	(9.1)	-	-	189	(16.3)
Turkmenistan	618	389	(62.9)	19	(3.1)	179	(29.0)	25	(4.0)	-	-	6	(1.0)
Ukraine	5586	2868	(51.3)	1017	(18.2)	566	(10.1)	1101	(19.7)	-	-	34	(0.6)
Uzbekistan	2633	1894	(71.9)	236	(9.0)	133	(5.1)	221	(8.4)	-	-	149	(5.7)
<b>Subtotal non-EU/EEA</b>	<b>26837</b>	<b>15401</b>	<b>(57.4)</b>	<b>3217</b>	<b>(12.0)</b>	<b>3092</b>	<b>(11.5)</b>	<b>3520</b>	<b>(13.1)</b>	<b>-</b>	<b>-</b>	<b>1607</b>	<b>(6.0)</b>
<b>Total European Region</b>	<b>29696</b>	<b>16958</b>	<b>(57.1)</b>	<b>3482</b>	<b>(11.7)</b>	<b>3254</b>	<b>(11.0)</b>	<b>3937</b>	<b>(13.3)</b>	<b>109</b>	<b>(0.4)</b>	<b>1956</b>	<b>(6.6)</b>
<b>Subtotal 18 HPC</b>	<b>27856</b>	<b>15848</b>	<b>(56.9)</b>	<b>3352</b>	<b>(12.0)</b>	<b>3248</b>	<b>(11.7)</b>	<b>3825</b>	<b>(13.7)</b>	<b>16</b>	<b>(0.1)</b>	<b>1567</b>	<b>(5.6)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

<sup>b</sup> WHO European Region 18 TB High Priority Countries presented in italics.

<sup>c</sup> For countries that do not provide information on treatment start, all reported cases were used as proxy.

<sup>d</sup> Patients started on second-line treatment are excluded.

<sup>e</sup> In previous reports defined as 'defaulted'.

<sup>f</sup> In previous reports defined as 'transferred out and unknown'.

<sup>g</sup> Treatment outcome data collected consistently only for confirmed pulmonary cases.

<sup>h</sup> Includes MDR TB cases started on second-line treatment.

<sup>i</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 22: Treatment outcome of HIV positive TB cases notified in 2012, European Region, 2013**

Country	HIV positive TB cases notified in 2012 <sup>a</sup>	Success		Died		Failed		Lost to follow-up <sup>b</sup>		Still on treatment		Not evaluated <sup>c</sup>	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA</b>													
Austria	-	-	-	-	-	-	-	-	-	-	-	-	-
Belgium	40	28	(70.0)	4	(10.0)	0	(0.0)	2	(5.0)	3	(7.5)	3	(7.5)
Bulgaria	3	1	(33.3)	2	(66.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Croatia	-	-	-	-	-	-	-	-	-	-	-	-	-
Cyprus	1	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(100.0)
Czech Republic	5	1	(20.0)	2	(40.0)	0	(0.0)	0	(0.0)	1	(20.0)	1	(20.0)
Denmark	10	3	(30.0)	1	(10.0)	1	(10.0)	0	(0.0)	1	(10.0)	4	(40.0)
Estonia	34	16	(47.1)	9	(26.5)	1	(2.9)	8	(23.5)	0	(0.0)	0	(0.0)
Finland	-	-	-	-	-	-	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	-	-	-	-	-	-	-	-	-	-	-	-	-
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	-	-	-	-	-	-	-	-	-	-	-	-	-
Iceland	0	0	-	0	-	0	-	0	-	0	-	0	-
Ireland	15	3	(20.0)	1	(6.7)	0	(0.0)	0	(0.0)	0	(0.0)	11	(73.3)
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-
Latvia	82	64	(78.0)	10	(12.2)	1	(1.2)	6	(7.3)	1	(1.2)	0	(0.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	19	11	(57.9)	5	(26.3)	1	(5.3)	2	(10.5)	0	(0.0)	0	(0.0)
Luxembourg	1	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(100.0)
Malta	4	2	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(50.0)
Netherlands	-	-	-	-	-	-	-	-	-	-	-	-	-
Norway	3	3	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Poland	-	-	-	-	-	-	-	-	-	-	-	-	-
Portugal	292	176	(60.3)	22	(7.5)	1	(0.3)	23	(7.9)	57	(19.5)	13	(4.5)
Romania	213	128	(60.1)	45	(21.1)	9	(4.2)	28	(13.1)	3	(1.4)	0	(0.0)
Slovakia	-	-	-	-	-	-	-	-	-	-	-	-	-
Slovenia	-	-	-	-	-	-	-	-	-	-	-	-	-
Spain	387	231	(59.7)	30	(7.8)	2	(0.5)	8	(2.1)	8	(2.1)	108	(27.9)
Sweden	-	-	-	-	-	-	-	-	-	-	-	-	-
United Kingdom	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Subtotal EU/EEA</b>	<b>1109</b>	<b>667</b>	<b>(60.1)</b>	<b>131</b>	<b>(11.8)</b>	<b>16</b>	<b>(1.4)</b>	<b>77</b>	<b>(6.9)</b>	<b>74</b>	<b>(6.7)</b>	<b>144</b>	<b>(13.0)</b>
<b>Non-EU/EEA</b>													
Albania	7	6	(85.7)	1	(14.3)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Andorra	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Armenia	-	-	-	-	-	-	-	-	-	-	-	-	-
Azerbaijan	69	55	(79.7)	11	(15.9)	2	(2.9)	1	(1.4)	-	-	0	(0.0)
Belarus	143	91	(63.6)	30	(21.0)	14	(9.8)	3	(2.1)	-	-	5	(3.5)
Bosnia and Herzegovina	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
former Yugoslav Republic of Macedonia, the	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Georgia	24	15	(62.5)	3	(12.5)	0	(0.0)	3	(12.5)	-	-	3	(12.5)
Israel	16	12	(75.0)	1	(6.3)	0	(0.0)	1	(6.3)	-	-	2	(12.5)
Kazakhstan	441	153	(34.7)	110	(24.9)	11	(2.5)	29	(6.6)	-	-	138	(31.3)
Kyrgyzstan	-	-	-	-	-	-	-	-	-	-	-	-	-
Moldova	264	123	(46.6)	76	(28.8)	13	(4.9)	34	(12.9)	-	-	18	(6.8)
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Russia	-	-	-	-	-	-	-	-	-	-	-	-	-
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	6	6	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Serbia excluding UN Administered Province of Kosovo <sup>d</sup>	6	6	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
UN Administered Province of Kosovo <sup>d</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	-	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan	88	50	(56.8)	28	(31.8)	9	(10.2)	0	(0.0)	-	-	1	(1.1)
Turkey	45	23	(51.1)	9	(20.0)	2	(4.4)	1	(2.2)	-	-	10	(22.2)
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	-	-	-	-	-	-	-	-	-	-	-	-	-
Uzbekistan	820	512	(62.4)	185	(22.6)	61	(7.4)	49	(6.0)	-	-	13	(1.6)
<b>Subtotal non-EU/EEA</b>	<b>1923</b>	<b>1046</b>	<b>(54.4)</b>	<b>454</b>	<b>(23.6)</b>	<b>112</b>	<b>(5.8)</b>	<b>121</b>	<b>(6.3)</b>	<b>-</b>	<b>-</b>	<b>190</b>	<b>(9.9)</b>
<b>Total European Region</b>	<b>3032</b>	<b>1713</b>	<b>(56.5)</b>	<b>585</b>	<b>(19.3)</b>	<b>128</b>	<b>(4.2)</b>	<b>198</b>	<b>(6.5)</b>	<b>74</b>	<b>(2.4)</b>	<b>334</b>	<b>(11.0)</b>
<b>Subtotal 18 HPC</b>	<b>2245</b>	<b>1242</b>	<b>(50.6)</b>	<b>523</b>	<b>(23.8)</b>	<b>124</b>	<b>(5.1)</b>	<b>164</b>	<b>(7.3)</b>	<b>4</b>	<b>(0.2)</b>	<b>188</b>	<b>(11.9)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in *italics*.

<sup>b</sup> For countries that do not provide information on treatment start, all reported cases were used as proxy.

<sup>c</sup> In previous reports defined as 'defaulted'.

<sup>d</sup> In previous reports defined as 'transferred out and unknown'.

<sup>e</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).



**Table 23: Treatment outcome of all TB cases notified in 2012, EU/EEA, 2013**

Country	Cases notified in 2012	Success		Died		Failed		Lost to follow-up <sup>a</sup>		Still on treatment		Not evaluated <sup>b</sup>	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA</b>													
<i>Austria</i>	647	428	(66.2)	57	(8.8)	0	(0.0)	70	(10.8)	92	(14.2)	0	(0.0)
<i>Belgium</i>	975	736	(75.5)	71	(7.3)	2	(0.2)	90	(9.2)	37	(3.8)	39	(4.0)
<i>Bulgaria</i>	2280	1916	(84.0)	179	(7.9)	23	(1.0)	116	(5.1)	37	(1.6)	9	(0.4)
<i>Croatia</i>	575	59	(10.3)	40	(7.0)	2	(0.3)	4	(0.7)	2	(0.3)	468	(81.4)
<i>Cyprus</i>	69	30	(43.5)	5	(7.2)	0	(0.0)	9	(13.0)	4	(5.8)	21	(30.4)
<i>Czech Republic</i>	598	444	(74.2)	100	(16.7)	1	(0.2)	35	(5.9)	15	(2.5)	3	(0.5)
<i>Denmark</i>	389	248	(63.8)	17	(4.4)	14	(3.6)	0	(0.0)	15	(3.9)	95	(24.4)
<i>Estonia</i>	288	167	(58.0)	45	(15.6)	4	(1.4)	23	(8.0)	49	(17.0)	0	(0.0)
<i>Finland<sup>c</sup></i>	276	122	(44.2)	27	(9.8)	0	(0.0)	0	(0.0)	8	(2.9)	119	(43.1)
<i>France</i>	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Germany</i>	4217	3073	(72.9)	457	(10.8)	4	(0.1)	157	(3.7)	148	(3.5)	378	(9.0)
<i>Greece</i>	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Hungary</i>	1223	847	(69.3)	146	(11.9)	0	(0.0)	108	(8.8)	65	(5.3)	57	(4.7)
<i>Iceland</i>	11	9	(81.8)	0	(0.0)	1	(9.1)	1	(9.1)	0	(0.0)	0	(0.0)
<i>Ireland</i>	359	214	(59.6)	15	(4.2)	0	(0.0)	4	(1.1)	17	(4.7)	109	(30.4)
<i>Italy</i>	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Latvia</i>	993	765	(77.0)	78	(7.9)	2	(0.2)	53	(5.3)	88	(8.9)	7	(0.7)
<i>Liechtenstein</i>	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	1781	1192	(66.9)	211	(11.8)	14	(0.8)	150	(8.4)	205	(11.5)	9	(0.5)
<i>Luxembourg</i>	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Malta</i>	42	10	(23.8)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	32	(76.2)
<i>Netherlands</i>	957	786	(82.1)	34	(3.6)	0	(0.0)	39	(4.1)	28	(2.9)	70	(7.3)
<i>Norway</i>	374	291	(77.8)	16	(4.3)	4	(1.1)	4	(1.1)	16	(4.3)	43	(11.5)
<i>Poland</i>	7542	4501	(59.7)	608	(8.1)	7	(0.1)	573	(7.6)	21	(0.3)	1832	(24.3)
<i>Portugal</i>	2605	2004	(76.9)	160	(6.1)	1	(0.0)	65	(2.5)	297	(11.4)	78	(3.0)
<i>Romania</i>	18190	14405	(79.2)	1439	(7.9)	755	(4.2)	1297	(7.1)	294	(1.6)	0	(0.0)
<i>Slovakia</i>	345	303	(87.8)	25	(7.2)	5	(1.4)	1	(0.3)	1	(0.3)	10	(2.9)
<i>Slovenia</i>	138	112	(81.2)	24	(17.4)	1	(0.7)	1	(0.7)	0	(0.0)	0	(0.0)
<i>Spain</i>	6070	4286	(70.6)	364	(6.0)	8	(0.1)	77	(1.3)	58	(1.0)	1277	(21.0)
<i>Sweden</i>	623	504	(80.9)	25	(4.0)	4	(0.6)	10	(1.6)	16	(2.6)	64	(10.3)
<i>United Kingdom</i>	8729	6866	(78.7)	428	(4.9)	0	(0.0)	456	(5.2)	799	(9.2)	180	(2.1)
<b>Subtotal EU/EEA</b>	<b>60296</b>	<b>44318</b>	<b>(73.5)</b>	<b>4571</b>	<b>(7.6)</b>	<b>852</b>	<b>(1.4)</b>	<b>3343</b>	<b>(5.5)</b>	<b>2312</b>	<b>(3.8)</b>	<b>4900</b>	<b>(8.1)</b>

EU/EEA countries designated as high-priority countries by WHO are presented in italics.

<sup>a</sup> In previous reports defined as 'defaulted'.

<sup>b</sup> In previous reports defined as 'transferred out and unknown'.

<sup>c</sup> Treatment outcome data collected consistently only for confirmed pulmonary cases.

**Table 24:** Treatment outcome after 24 months of RR TB/MDR TB cases started on second-line treatment in 2011, European Region, 2013

Country	RR TB/MDR TB cases started on second-line treatment in 2011 <sup>a</sup>	Success		Died		Failed		Lost to follow-up <sup>b</sup>		Still on treatment		Not evaluated <sup>c</sup>	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA</b>													
Austria	20	13	(65.0)	1	(5.0)	0	(0.0)	5	(25.0)	1	(5.0)	0	(0.0)
Belgium	15	11	(73.3)	0	(0.0)	0	(0.0)	1	(6.7)	2	(13.3)	1	(6.7)
Bulgaria	55	30	(54.5)	10	(18.2)	1	(1.8)	12	(21.8)	2	(3.6)	0	(0.0)
Croatia	-	-	-	-	-	-	-	-	-	-	-	-	-
Cyprus	-	-	-	-	-	-	-	-	-	-	-	-	-
Czech Republic	7	2	(28.6)	0	(0.0)	0	(0.0)	4	(57.1)	0	(0.0)	1	(14.3)
Denmark	3	0	(0.0)	0	(0.0)	1	(33.3)	0	(0.0)	0	(0.0)	2	(66.7)
Estonia	71	39	(54.9)	11	(15.5)	4	(5.6)	9	(12.7)	8	(11.3)	0	(0.0)
Finland	-	-	-	-	-	-	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	56	30	(53.6)	4	(7.1)	0	(0.0)	2	(3.6)	3	(5.4)	17	(30.4)
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	7	3	(42.9)	1	(14.3)	0	(0.0)	1	(14.3)	2	(28.6)	0	(0.0)
Iceland	-	-	-	-	-	-	-	-	-	-	-	-	-
Ireland	3	1	(33.3)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(66.7)
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-
Latvia	95	51	(53.7)	15	(15.8)	7	(7.4)	11	(11.6)	10	(10.5)	1	(1.1)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	296	104	(35.1)	63	(21.3)	20	(6.8)	87	(29.4)	20	(6.8)	2	(0.7)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-
Malta	0	0	-	0	-	0	-	0	-	0	-	0	-
Netherlands	17	11	(64.7)	0	(0.0)	0	(0.0)	3	(17.6)	2	(11.8)	1	(5.9)
Norway	4	3	(75.0)	0	(0.0)	1	(25.0)	0	(0.0)	0	(0.0)	0	(0.0)
Poland	41	14	(34.1)	10	(24.4)	0	(0.0)	7	(17.1)	1	(2.4)	9	(22.0)
Portugal	36	19	(52.8)	3	(8.3)	0	(0.0)	4	(11.1)	5	(13.9)	5	(13.9)
Romania	546	140	(25.6)	106	(19.4)	191	(35.0)	90	(16.5)	19	(3.5)	0	(0.0)
Slovakia	3	1	(33.3)	2	(66.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Slovenia	0	0	-	0	-	0	-	0	-	0	-	0	-
Spain	-	-	-	-	-	-	-	-	-	-	-	-	-
Sweden	16	12	(75.0)	0	(0.0)	1	(6.3)	0	(0.0)	0	(0.0)	3	(18.8)
United Kingdom	83	40	(48.2)	3	(3.6)	0	(0.0)	17	(20.5)	22	(26.5)	1	(1.2)
<b>Subtotal EU/EEA</b>	<b>1374</b>	<b>524</b>	<b>(38.1)</b>	<b>229</b>	<b>(16.7)</b>	<b>226</b>	<b>(16.4)</b>	<b>253</b>	<b>(18.4)</b>	<b>97</b>	<b>(7.1)</b>	<b>45</b>	<b>(3.3)</b>
<b>Non-EU/EEA</b>													
Albania	-	-	-	-	-	-	-	-	-	-	-	-	-
Andorra	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Armenia	121	61	(50.4)	1	(0.8)	6	(5.0)	32	(26.4)	-	-	21	(17.4)
Azerbaijan	565	339	(60.0)	94	(16.6)	98	(17.3)	34	(6.0)	-	-	0	(0.0)
Belarus	1600	807	(50.4)	376	(23.5)	174	(10.9)	152	(9.5)	-	-	91	(5.7)
Bosnia and Herzegovina	5	1	(20.0)	2	(40.0)	2	(40.0)	0	(0.0)	-	-	0	(0.0)
former Yugoslav Republic of Macedonia, the	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Georgia	611	305	(49.9)	18	(2.9)	31	(5.1)	221	(36.2)	-	-	36	(5.9)
Israel	11	7	(63.6)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	4	(36.4)
Kazakhstan	5261	3910	(74.3)	373	(7.1)	417	(7.9)	411	(7.8)	-	-	150	(2.9)
Kyrgyzstan	492	280	(56.9)	35	(7.1)	69	(14.0)	106	(21.5)	-	-	2	(0.4)
Moldova	761	413	(54.3)	72	(9.5)	100	(13.1)	176	(23.1)	-	-	0	(0.0)
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	1	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	1	(100.0)
Russia	15896	5895	(37.1)	2916	(18.3)	3037	(19.1)	2344	(14.7)	-	-	1704	(10.7)
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	14	9	(64.3)	0	(0.0)	3	(21.4)	2	(14.3)	-	-	0	(0.0)
Serbia excluding UN Administered Province of Kosovo <sup>d</sup>	14	9	(64.3)	0	(0.0)	3	(21.4)	2	(14.3)	-	-	0	(0.0)
UN Administered Province of Kosovo <sup>d</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	-	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan	380	242	(63.7)	37	(9.7)	57	(15.0)	35	(9.2)	-	-	9	(2.4)
Turkey	275	181	(65.8)	8	(2.9)	25	(9.1)	23	(8.4)	-	-	38	(13.8)
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	3810	1298	(34.1)	462	(12.1)	1127	(29.6)	681	(17.9)	-	-	242	(6.4)
Uzbekistan	855	455	(53.2)	81	(9.5)	112	(13.1)	190	(22.2)	-	-	17	(2.0)
<b>Subtotal non-EU/EEA</b>	<b>30659</b>	<b>14204</b>	<b>(46.3)</b>	<b>4475</b>	<b>(14.6)</b>	<b>5258</b>	<b>(17.1)</b>	<b>4407</b>	<b>(14.4)</b>	-	-	<b>2315</b>	<b>(7.6)</b>
<b>Total European Region</b>	<b>32033</b>	<b>14728</b>	<b>(46.0)</b>	<b>4704</b>	<b>(14.7)</b>	<b>5484</b>	<b>(17.1)</b>	<b>4660</b>	<b>(14.5)</b>	<b>97</b>	<b>(0.3)</b>	<b>2360</b>	<b>(7.4)</b>
<b>Subtotal 18 HPC</b>	<b>31690</b>	<b>14550</b>	<b>(45.9)</b>	<b>4678</b>	<b>(14.8)</b>	<b>5476</b>	<b>(17.3)</b>	<b>4614</b>	<b>(14.6)</b>	<b>59</b>	<b>(0.2)</b>	<b>2313</b>	<b>(7.3)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> For countries that do not provide information on treatment start - used all reported MDR TB cases as proxy. RR TB cases are not included to EU/EEA countries.

<sup>c</sup> In previous reports defined as 'defaulted'.

<sup>d</sup> In previous reports defined as 'transferred out and unknown'.

<sup>e</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 25: Treatment outcome after 24 months of all MDR TB cases notified in 2011, EU/EEA, 2013**

Country	Cases notified in 2012	Success		Died		Failed		Lost to follow-up <sup>a</sup>		Still on treatment		Not evaluated <sup>b</sup>	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA</b>													
Austria	20	13	(65.0)	1	(5.0)	0	(0.0)	5	(25.0)	1	(5.0)	0	(0.0)
Belgium	15	11	(73.3)	0	(0.0)	0	(0.0)	1	(6.7)	2	(13.3)	1	(6.7)
<i>Bulgaria</i>	55	30	(54.5)	10	(18.2)	1	(1.8)	12	(21.8)	2	(3.6)	0	(0.0)
Croatia	-	-	-	-	-	-	-	-	-	-	-	-	-
Cyprus	-	-	-	-	-	-	-	-	-	-	-	-	-
Czech Republic	7	2	(28.6)	0	(0.0)	0	(0.0)	4	(57.1)	0	(0.0)	1	(14.3)
Denmark	3	0	(0.0)	0	(0.0)	1	(33.3)	0	(0.0)	0	(0.0)	2	(66.7)
<i>Estonia</i>	78	39	(50.0)	15	(19.2)	5	(6.4)	11	(14.1)	8	(10.3)	0	(0.0)
Finland <sup>c</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	56	30	(53.6)	4	(7.1)	0	(0.0)	2	(3.6)	3	(5.4)	17	(30.4)
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	7	3	(42.9)	1	(14.3)	0	(0.0)	1	(14.3)	2	(28.6)	0	(0.0)
Iceland	-	-	-	-	-	-	-	-	-	-	-	-	-
Ireland	3	1	(33.3)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(66.7)
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Latvia</i>	95	51	(53.7)	15	(15.8)	7	(7.4)	11	(11.6)	10	(10.5)	1	(1.1)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	296	104	(35.1)	63	(21.3)	20	(6.8)	87	(29.4)	20	(6.8)	2	(0.7)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-
Malta	0	0	-	0	-	0	-	0	-	0	-	0	-
Netherlands	17	11	(64.7)	0	(0.0)	0	(0.0)	3	(17.6)	2	(11.8)	1	(5.9)
Norway	4	3	(75.0)	0	(0.0)	1	(25.0)	0	(0.0)	0	(0.0)	0	(0.0)
Poland	41	14	(34.1)	10	(24.4)	0	(0.0)	7	(17.1)	1	(2.4)	9	(22.0)
Portugal	36	19	(52.8)	3	(8.3)	0	(0.0)	4	(11.1)	5	(13.9)	5	(13.9)
<i>Romania</i>	547	140	(25.6)	106	(19.4)	191	(34.9)	90	(16.5)	20	(3.7)	0	(0.0)
Slovakia	3	1	(33.3)	2	(66.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Slovenia	0	0	-	0	-	0	-	0	-	0	-	0	-
Spain	-	-	-	-	-	-	-	-	-	-	-	-	-
Sweden	17	12	(70.6)	1	(5.9)	1	(5.9)	0	(0.0)	0	(0.0)	3	(17.6)
United Kingdom	86	40	(46.5)	4	(4.7)	0	(0.0)	19	(22.1)	22	(25.6)	1	(1.2)
<b>Subtotal EU/EEA</b>	<b>1386</b>	<b>524</b>	<b>(37.8)</b>	<b>235</b>	<b>(17.0)</b>	<b>227</b>	<b>(16.4)</b>	<b>257</b>	<b>(18.5)</b>	<b>98</b>	<b>(7.1)</b>	<b>45</b>	<b>(3.2)</b>

EU/EEA countries designated as high-priority countries by WHO are presented in italics.

<sup>a</sup> In previous reports defined as 'defaulted'.<sup>b</sup> In previous reports defined as 'transferred out and unknown'.

**Table 26:** Treatment outcome after 36 months of pulmonary XDR TB cases started on second-line treatment notified in 2010, European Region, 2013

Country	XDR TB cases started on second-line treatment in 2010 <sup>a</sup>	Success		Died		Failed		Lost to follow-up <sup>b</sup>		Still on treatment		Not evaluated <sup>c</sup>	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA</b>													
Austria	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Belgium	2	2	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Bulgaria	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Croatia	-	-	-	-	-	-	-	-	-	-	-	-	-
Cyprus	-	-	-	-	-	-	-	-	-	-	-	-	-
Czech Republic	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Denmark	-	-	-	-	-	-	-	-	-	-	-	-	-
Estonia	11	5	(45.5)	2	(18.2)	4	(36.4)	0	(0.0)	0	(0.0)	0	(0.0)
Finland	-	-	-	-	-	-	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	-	-	-	-	-	-	-	-	-	-	-	-	-
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	2	0	(0.0)	1	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(50.0)
Iceland	-	-	-	-	-	-	-	-	-	-	-	-	-
Ireland	-	-	-	-	-	-	-	-	-	-	-	-	-
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-
Latvia	13	9	(69.2)	3	(23.1)	0	(0.0)	1	(7.7)	0	(0.0)	0	(0.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	50	3	(6.0)	21	(42.0)	14	(28.0)	11	(22.0)	0	(0.0)	1	(2.0)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-
Malta	-	-	-	-	-	-	-	-	-	-	-	-	-
Netherlands	-	-	-	-	-	-	-	-	-	-	-	-	-
Norway	0	0	-	0	-	0	-	0	-	0	-	0	-
Poland	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Portugal	4	3	(75.0)	1	(25.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Romania	26	2	(7.7)	3	(11.5)	18	(69.2)	3	(11.5)	0	(0.0)	0	(0.0)
Slovakia	0	0	-	0	-	0	-	0	-	0	-	0	-
Slovenia	-	-	-	-	-	-	-	-	-	-	-	-	-
Spain	-	-	-	-	-	-	-	-	-	-	-	-	-
Sweden	0	0	-	0	-	0	-	0	-	0	-	0	-
United Kingdom	3	2	(66.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(33.3)
<b>Subtotal EU/EEA</b>	<b>115</b>	<b>30</b>	<b>(26.1)</b>	<b>31</b>	<b>(27.0)</b>	<b>36</b>	<b>(31.3)</b>	<b>15</b>	<b>(13.0)</b>	<b>0</b>	<b>(0.0)</b>	<b>3</b>	<b>(2.6)</b>
<b>Non-EU/EEA</b>													
Albania	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Andorra	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Armenia	3	1	(33.3)	0	(0.0)	0	(0.0)	2	(66.7)	-	-	0	(0.0)
Azerbaijan	-	-	-	-	-	-	-	-	-	-	-	-	-
Belarus	-	-	-	-	-	-	-	-	-	-	-	-	-
Bosnia and Herzegovina	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
former Yugoslav Republic of Macedonia, the	1	0	(0.0)	0	(0.0)	1	(100.0)	0	(0.0)	-	-	0	(0.0)
Georgia	35	8	(22.9)	9	(25.7)	7	(20.0)	10	(28.6)	-	-	1	(2.9)
Israel	1	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	1	(100.0)
Kazakhstan	-	-	-	-	-	-	-	-	-	-	-	-	-
Kyrgyzstan	7	1	(14.3)	1	(14.3)	2	(28.6)	1	(14.3)	-	-	2	(28.6)
Moldova	-	-	-	-	-	-	-	-	-	-	-	-	-
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Russia	-	-	-	-	-	-	-	-	-	-	-	-	-
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Serbia excluding UN Administered Province of Kosovo <sup>d</sup>	0	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
UN Administered Province of Kosovo <sup>d</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	-	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan	-	-	-	-	-	-	-	-	-	-	-	-	-
Turkey	3	2	(66.7)	1	(33.3)	0	(0.0)	0	(0.0)	-	-	0	(0.0)
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	-	-	-	-	-	-	-	-	-	-	-	-	-
Uzbekistan	16	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	-	-	16	(100.0)
<b>Subtotal non-EU/EEA</b>	<b>66</b>	<b>12</b>	<b>(18.2)</b>	<b>11</b>	<b>(16.7)</b>	<b>10</b>	<b>(15.2)</b>	<b>13</b>	<b>(19.7)</b>	<b>-</b>	<b>-</b>	<b>20</b>	<b>(30.3)</b>
<b>Total European Region</b>	<b>181</b>	<b>42</b>	<b>(23.2)</b>	<b>42</b>	<b>(23.2)</b>	<b>46</b>	<b>(25.4)</b>	<b>28</b>	<b>(15.5)</b>	<b>0</b>	<b>(0.0)</b>	<b>23</b>	<b>(12.7)</b>
<b>Subtotal 18 HPC</b>	<b>165</b>	<b>32</b>	<b>(19.4)</b>	<b>40</b>	<b>(24.2)</b>	<b>45</b>	<b>(27.3)</b>	<b>28</b>	<b>(17.0)</b>	<b>0</b>	<b>(0.0)</b>	<b>20</b>	<b>(12.1)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> For countries that do not provide information on treatment start, all reported MDR TB cases were used as proxy. Rifampicin-resistant TB cases are not included for EU/EEA countries.

<sup>c</sup> In previous reports defined as 'defaulted'.

<sup>d</sup> In previous reports defined as 'transferred out and unknown'.

<sup>e</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

**Table 27: Treatment outcome after 36 months of all XDR TB cases notified in 2010, European Region, 2013**

Country	Cases notified in 2012	Success		Died		Failed		Lost to follow-up <sup>a</sup>		Not evaluated <sup>b</sup>	
		N	(%)	N	(%)	N	(%)	N	(%)	N	(%)
<b>EU/EEA</b>											
Austria	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Belgium	2	2	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
<i>Bulgaria</i>	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Croatia	-	-	-	-	-	-	-	-	-	-	-
Cyprus	-	-	-	-	-	-	-	-	-	-	-
Czech Republic	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Denmark	-	-	-	-	-	-	-	-	-	-	-
<i>Estonia</i>	11	5	(45.5)	2	(18.2)	4	(36.4)	0	(0.0)	0	(0.0)
Finland	-	-	-	-	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-	-	-	-	-
Germany	-	-	-	-	-	-	-	-	-	-	-
Greece	-	-	-	-	-	-	-	-	-	-	-
Hungary	2	0	(0.0)	1	(50.0)	0	(0.0)	0	(0.0)	1	(50.0)
Iceland	-	-	-	-	-	-	-	-	-	-	-
Ireland	-	-	-	-	-	-	-	-	-	-	-
Italy	-	-	-	-	-	-	-	-	-	-	-
<i>Latvia</i>	13	9	(69.2)	3	(23.1)	0	(0.0)	1	(7.7)	0	(0.0)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	50	3	(6.0)	21	(42.0)	14	(28.0)	11	(22.0)	1	(2.0)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-
Malta	-	-	-	-	-	-	-	-	-	-	-
Netherlands	-	-	-	-	-	-	-	-	-	-	-
Norway	-	-	-	-	-	-	-	-	-	-	-
Poland	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Portugal	4	3	(75.0)	1	(25.0)	0	(0.0)	0	(0.0)	0	(0.0)
<i>Romania</i>	27	2	(7.4)	4	(14.8)	18	(66.7)	3	(11.1)	0	(0.0)
Slovakia	-	-	-	-	-	-	-	-	-	-	-
Slovenia	-	-	-	-	-	-	-	-	-	-	-
Spain	-	-	-	-	-	-	-	-	-	-	-
Sweden	-	-	-	-	-	-	-	-	-	-	-
United Kingdom	3	2	(66.7)	0	(0.0)	0	(0.0)	0	(0.0)	1	(33.3)
<b>Subtotal EU/EEA</b>	<b>116</b>	<b>30</b>	<b>(25.9)</b>	<b>32</b>	<b>(27.6)</b>	<b>36</b>	<b>(31.0)</b>	<b>15</b>	<b>(12.9)</b>	<b>3</b>	<b>(2.6)</b>

EU/EEA countries designated as high-priority countries by WHO are presented in italics.

<sup>a</sup> In previous reports defined as 'defaulted'.

<sup>b</sup> In previous reports defined as 'transferred out and unknown'.



## 7. Trend tables

Table I. All laboratory confirmed<sup>a</sup> tuberculosis cases, European Region, 2004–2013

Country	2004		2005		2006		2007		2008		2009	
	N	% among all TB	N	% among all TB	N	% among all TB	N	% among all TB	N	% among all TB	N	% among all TB
<b>EU/EEA</b>												
Austria	675	(62.8)	654	(65.5)	569	(62.8)	541	(61.9)	488	(59.7)	445	(63.9)
Belgium	937	(78.2)	834	(75.3)	884	(79.1)	800	(78.4)	810	(81.8)	802	(80.7)
Bulgaria	1283	(39.7)	1254	(38.0)	1360	(42.1)	1385	(45.6)	1360	(43.2)	1281	(44.0)
Croatia	758	(58.4)	563	(49.3)	583	(51.4)	575	(58.6)	440	(44.9)	450	(52.6)
Cyprus	19	(63.3)	19	(51.4)	23	(62.2)	33	(78.6)	36	(72.0)	40	(72.7)
Czech Republic	666	(63.0)	644	(65.4)	621	(65.3)	557	(65.8)	560	(64.8)	477	(68.7)
Denmark	291	(75.6)	328	(76.6)	301	(77.8)	293	(74.9)	291	(76.6)	242	(72.5)
Estonia	452	(76.1)	389	(75.1)	352	(76.5)	385	(78.4)	348	(78.4)	308	(74.9)
Finland	291	(90.4)	325	(91.8)	271	(93.1)	251	(72.3)	247	(72.4)	303	(73.4)
France	2570	(46.1)	2412	(44.9)	2412	(45.3)	2535	(45.5)	2532	(44.0)	2427	(46.0)
Germany	4362	(66.7)	4141	(68.8)	3814	(70.9)	3503	(70.1)	3193	(70.6)	3217	(72.4)
Greece	206	(26.6)	214	(27.8)	210	(30.8)	210	(32.9)	248	(37.3)	303	(51.4)
Hungary	990	(42.3)	777	(39.6)	832	(44.8)	772	(45.8)	760	(46.9)	706	(50.2)
Iceland	8	(66.7)	8	(72.7)	12	(92.3)	11	(78.6)	5	(83.3)	8	(88.9)
Ireland	279	(64.6)	283	(62.9)	316	(68.3)	315	(65.6)	312	(66.7)	341	(71.2)
Italy	1954	(46.3)	1662	(39.5)	1735	(38.5)	1840	(40.7)	1529	(34.6)	1381	(32.5)
Latvia	1157	(71.9)	1109	(76.9)	995	(74.9)	994	(79.2)	838	(78.3)	773	(79.1)
Liechtenstein	-	-	-	-	-	-	5	(100.0)	-	-	-	-
Lithuania	1598	(63.6)	1739	(67.6)	1787	(69.8)	1686	(70.0)	1616	(71.8)	1478	(71.0)
Luxembourg	31	(100.0)	37	(100.0)	33	(100.0)	26	(66.7)	0	(0.0)	27	(100.0)
Malta	8	(42.1)	11	(44.0)	15	(50.0)	19	(50.0)	25	(47.2)	20	(45.5)
Netherlands	759	(56.5)	852	(75.5)	755	(73.2)	721	(72.2)	745	(73.4)	761	(65.7)
Norway	246	(81.5)	214	(74.3)	225	(77.6)	245	(81.1)	226	(72.2)	287	(80.2)
Poland	5044	(53.2)	5399	(58.2)	5229	(60.9)	5410	(62.8)	5093	(63.0)	5223	(63.4)
Portugal	2317	(60.1)	-	-	2234	(64.6)	2076	(66.1)	2085	(69.5)	1981	(69.0)
Romania	18605	(60.0)	18483	(63.1)	16844	(63.3)	16189	(65.2)	14741	(59.7)	15243	(65.8)
Slovakia	357	(50.6)	357	(47.0)	401	(54.9)	397	(58.2)	383	(60.5)	235	(46.4)
Slovenia	231	(87.8)	245	(88.1)	184	(85.6)	189	(86.7)	201	(94.4)	179	(95.2)
Spain	3457	(44.5)	3686	(47.1)	3651	(45.5)	3950	(50.8)	4493	(54.7)	4095	(53.9)
Sweden	370	(80.3)	444	(79.4)	397	(79.9)	365	(75.7)	436	(79.9)	515	(83.5)
United Kingdom	4547	(59.9)	5018	(60.5)	5125	(61.6)	4923	(59.5)	5007	(58.9)	5162	(58.1)
<b>Subtotal EU/EEA</b>	<b>54468</b>	<b>(56.7)</b>	<b>54378</b>	<b>(58.5)</b>	<b>52283</b>	<b>(59.1)</b>	<b>51201</b>	<b>(60.2)</b>	<b>49048</b>	<b>(58.3)</b>	<b>48710</b>	<b>(60.5)</b>
<b>Non-EU/EEA</b>												
Albania	-	-	-	-	-	-	-	-	-	-	-	-
Andorra	-	-	-	-	-	-	-	-	-	-	-	-
Armenia	-	-	-	-	-	-	-	-	-	-	-	-
Azerbaijan	-	-	-	-	-	-	-	-	-	-	-	-
Belarus	-	-	-	-	-	-	-	-	-	-	-	-
Bosnia and Herzegovina	-	-	-	-	-	-	-	-	-	-	-	-
former Yugoslav Republic of Macedonia, the	-	-	-	-	-	-	-	-	-	-	-	-
Georgia	-	-	-	-	-	-	-	-	-	-	-	-
Israel	-	-	-	-	-	-	-	-	-	-	-	-
Kazakhstan	-	-	-	-	-	-	-	-	-	-	-	-
Kyrgyzstan	-	-	-	-	-	-	-	-	-	-	-	-
Moldova	-	-	-	-	-	-	-	-	-	-	-	-
Monaco	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	-	-	-	-	-	-	-	-	-	-	-	-
Russia	-	-	-	-	-	-	-	-	-	-	-	-
San Marino	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	-	-	-	-	-	-	-	-	-	-	-	-
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>	-	-	-	-	-	-	-	-	-	-	-	-
UN Administered Province of Kosovo <sup>b</sup>	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan	-	-	-	-	-	-	-	-	-	-	-	-
Turkey	-	-	-	-	-	-	-	-	-	-	-	-
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	-	-	-	-	-	-	-	-	-	-	-	-
Uzbekistan	-	-	-	-	-	-	-	-	-	-	-	-
<b>Subtotal non-EU/EEA</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total European Region</b>	<b>54468</b>	<b>(56.7)</b>	<b>54378</b>	<b>(58.5)</b>	<b>52283</b>	<b>(59.1)</b>	<b>51201</b>	<b>(60.2)</b>	<b>49048</b>	<b>(58.3)</b>	<b>48710</b>	<b>(60.5)</b>
<b>Subtotal 18 HPC</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein WHO European Region 18 TB high-priority countries presented in italics.

<sup>b</sup> Laboratory-confirmed cases consist of culture-confirmed or smear-positive and nucleic-acid-amplification-test-positive cases for EU/EEA countries, culture-positive or smear-positive for non-EU/EEA countries.

<sup>c</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).



	2010		2011		2012		2013	
	N	% among all TB	N	% among all TB	N	% among all TB	N	% among all TB
	480	(69.5)	467	(68.3)	411	(63.5)	467	(72.0)
	854	(78.6)	786	(77.1)	768	(78.8)	770	(78.5)
	1174	(44.3)	1071	(44.5)	1095	(48.0)	951	(49.2)
	456	(65.6)	-	-	299	(52.0)	346	(66.9)
	57	(93.4)	44	(81.5)	50	(72.5)	30	(73.2)
	434	(65.0)	428	(71.3)	421	(70.4)	349	(69.7)
	287	(78.4)	272	(71.4)	301	(77.4)	278	(78.1)
	266	(79.9)	263	(77.6)	237	(82.3)	223	(78.0)
	251	(79.2)	253	(78.1)	223	(80.8)	205	(75.6)
	2386	(46.6)	2339	(46.9)	2338	(47.0)	2335	(47.3)
	3086	(70.3)	3129	(72.6)	3104	(73.6)	3150	(73.0)
	269	(55.2)	282	(57.7)	285	(51.1)	339	(62.8)
	623	(35.8)	597	(41.3)	538	(44.0)	448	(42.9)
	19	(86.4)	4	(44.4)	5	(45.5)	7	(63.6)
	281	(66.9)	278	(67.3)	284	(79.1)	282	(73.4)
	1651	(35.2)	982	(27.9)	677	(21.5)	675	(21.4)
	733	(78.4)	671	(75.8)	779	(78.4)	702	(77.7)
	-	-	-	-	-	-	-	-
	1363	(70.3)	1403	(73.7)	1368	(76.8)	1354	(79.4)
	20	(69.0)	19	(73.1)	33	(73.3)	33	(86.8)
	16	(50.0)	24	(72.7)	16	(38.1)	27	(54.0)
	787	(73.7)	732	(72.9)	664	(69.4)	609	(71.8)
	276	(82.1)	262	(74.0)	281	(75.1)	319	(79.6)
	4756	(63.3)	5581	(65.8)	5070	(67.2)	4825	(66.6)
	1869	(68.8)	1741	(66.7)	1810	(69.5)	1453	(60.7)
	13673	(64.9)	13060	(68.0)	12375	(68.0)	10890	(65.2)
	234	(53.3)	188	(47.1)	181	(52.5)	212	(52.9)
	155	(90.1)	182	(94.8)	126	(91.3)	132	(94.3)
	4890	(67.6)	4544	(66.8)	4046	(66.7)	3631	(65.6)
	524	(78.6)	476	(82.1)	504	(80.9)	523	(80.7)
	5091	(60.6)	5463	(61.2)	5331	(61.1)	4684	(59.4)
	<b>46961</b>	<b>(61.6)</b>	<b>45541</b>	<b>(62.9)</b>	<b>43620</b>	<b>(63.2)</b>	<b>40249</b>	<b>(62.1)</b>
	231	(51.9)	235	(54.5)	247	(58.8)	238	(50.2)
	4	(57.1)	2	(50.0)	4	(50.0)	0	-
	548	(30.8)	554	(35.0)	561	(37.0)	492	(34.7)
	3839	(45.7)	3542	(35.1)	0	-	0	-
	3272	(58.9)	3208	(62.7)	3662	(69.8)	3470	(71.4)
	647	(46.5)	749	(52.6)	811	(57.1)	708	(56.1)
	239	(56.9)	218	(60.2)	219	(61.7)	211	(65.3)
	3410	(58.9)	3472	(62.8)	3028	(60.9)	2680	(62.1)
	249	(72.6)	287	(68.7)	330	(64.8)	217	(70.5)
	12786	(51.4)	12379	(53.7)	11203	(52.1)	15874	(79.9)
	2133	(33.9)	1886	(30.3)	2013	(29.1)	2298	(31.9)
	2859	(52.5)	2882	(54.0)	2934	(54.9)	2878	(57.0)
	1	(100.0)	0	-	0	-	0	-
	72	(63.2)	70	(58.8)	64	(59.8)	73	(60.8)
	65846	(42.2)	64975	(40.7)	61036	(40.7)	57751	(40.6)
	0	-	0	-	0	-	0	-
	1458	(61.2)	1055	(78.8)	955	(78.7)	1133	(53.9)
	1142	(76.2)	1055	(78.8)	955	(78.7)	890	(75.4)
	316	(35.7)	0	-	0	-	243	(26.4)
	456	(83.1)	467	(80.8)	381	(82.3)	432	(82.1)
	3275	(42.9)	3103	(40.8)	2789	(40.3)	2842	(43.8)
	8038	(48.6)	7570	(48.3)	7533	(51.3)	7024	(52.4)
	1235	(38.2)	1395	(45.9)	1537	(44.9)	1773	(48.2)
	12720	(34.9)	23470	(55.0)	22799	(50.0)	26786	(55.6)
	6561	(32.4)	5993	(37.8)	6258	(37.3)	9765	(38.8)
	<b>129879</b>	<b>(42.8)</b>	<b>137512</b>	<b>(44.9)</b>	<b>128364</b>	<b>(44.7)</b>	<b>136645</b>	<b>(47.6)</b>
	<b>176840</b>	<b>(47.4)</b>	<b>183053</b>	<b>(49.1)</b>	<b>171984</b>	<b>(48.9)</b>	<b>176894</b>	<b>(51.3)</b>
	<b>143731</b>	<b>(44.5)</b>	<b>150897</b>	<b>(46.5)</b>	<b>141207</b>	<b>(46.3)</b>	<b>147753</b>	<b>(49.0)</b>

Table II. Tuberculosis cases in children under 15 years, European Region, 2004–2013

Country	2004			2005			2006			2007			2008		
	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate
<b>EU/EEA</b>															
Austria	53	(4.9)	4.0	42	(4.2)	3.2	61	(6.7)	4.6	25	(2.9)	1.9	39	(4.8)	3.1
Belgium	70	(5.8)	3.9	73	(6.6)	4.1	63	(5.6)	3.5	67	(6.6)	3.7	52	(5.3)	2.9
Bulgaria	199	(6.2)	18.0	180	(5.5)	16.8	197	(6.1)	18.8	196	(6.5)	19.6	227	(7.2)	23.0
Croatia	4	(0.3)	0.6	2	(0.2)	0.3	28	(2.5)	4.1	0	(0.0)	0.0	27	(2.8)	4.0
Cyprus	0	(0.0)	0.0	3	(8.1)	2.1	3	(8.1)	2.1	1	(2.4)	0.7	3	(6.0)	2.1
Czech Republic	7	(0.7)	0.5	5	(0.5)	0.3	4	(0.4)	0.3	4	(0.5)	0.3	4	(0.5)	0.3
Denmark	28	(7.3)	2.8	39	(9.1)	3.8	26	(6.7)	2.6	27	(6.9)	2.7	22	(5.8)	2.2
Estonia	2	(0.3)	0.9	1	(0.2)	0.5	8	(1.7)	3.9	1	(0.2)	0.5	2	(0.5)	1.0
Finland	5	(1.6)	0.5	5	(1.4)	0.5	1	(0.3)	0.1	4	(1.2)	0.4	4	(1.2)	0.4
France	330	(5.9)	2.8	299	(5.6)	2.6	298	(5.6)	2.5	331	(5.9)	2.8	292	(5.1)	2.5
Germany	264	(4.0)	2.2	228	(3.8)	1.9	192	(3.6)	1.6	180	(3.6)	1.6	124	(2.7)	1.1
Greece	58	(7.5)	3.5	62	(8.1)	3.8	45	(6.6)	2.8	35	(5.5)	2.2	37	(5.6)	2.3
Hungary	9	(0.4)	0.6	5	(0.3)	0.3	9	(0.5)	0.6	7	(0.4)	0.5	4	(0.2)	0.3
Iceland	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0
Ireland	10	(2.3)	1.2	28	(6.2)	3.3	21	(4.5)	2.4	41	(8.5)	4.7	15	(3.2)	1.7
Italy	197	(4.7)	2.4	191	(4.5)	2.3	170	(3.8)	2.1	154	(3.4)	1.9	229	(5.2)	2.8
Latvia	110	(6.8)	31.2	68	(4.7)	20.2	84	(6.3)	26.0	57	(4.5)	18.2	48	(4.5)	15.6
Liechtenstein	-	-	-	-	-	-	-	-	-	0	(0.0)	0.0	-	-	-
Lithuania	119	(4.7)	19.9	90	(3.5)	15.7	106	(4.1)	19.5	85	(3.5)	16.3	100	(4.4)	20.1
Luxembourg	0	(0.0)	0.0	1	(2.7)	1.2	0	(0.0)	0.0	2	(5.1)	2.3	0	(0.0)	0.0
Malta	0	(0.0)	0.0	0	(0.0)	0.0	1	(3.3)	1.4	2	(5.3)	3.0	0	(0.0)	0.0
Netherlands	76	(5.7)	2.5	55	(4.9)	1.8	51	(4.9)	1.7	49	(4.9)	1.7	50	(4.9)	1.7
Norway	23	(7.6)	2.5	18	(6.3)	2.0	23	(7.9)	2.5	19	(6.3)	2.1	23	(7.3)	2.5
Poland	120	(1.3)	1.8	99	(1.1)	1.6	69	(0.8)	1.1	74	(0.9)	1.2	76	(0.9)	1.3
Portugal	75	(1.9)	-	86	(2.4)	5.1	94	(2.7)	5.6	71	(2.3)	4.3	65	(2.2)	4.0
Romania	1413	(4.6)	40.2	1105	(3.8)	32.7	1055	(4.0)	32.1	1007	(4.1)	31.2	924	(3.7)	29.4
Slovakia	19	(2.7)	2.0	22	(2.9)	2.4	23	(3.2)	2.6	16	(2.3)	1.8	14	(2.2)	1.6
Slovenia	5	(1.9)	1.7	7	(2.5)	2.4	8	(3.7)	2.8	6	(2.8)	2.1	3	(1.4)	1.1
Spain	511	(6.6)	8.3	498	(6.4)	8.0	544	(6.8)	8.5	477	(6.1)	7.3	600	(7.3)	9.0
Sweden	20	(4.3)	1.3	37	(6.6)	2.3	29	(5.8)	1.9	36	(7.5)	2.3	27	(4.9)	1.8
United Kingdom	438	(5.8)	4.0	444	(5.4)	4.1	383	(4.6)	3.5	486	(5.9)	4.5	487	(5.7)	4.5
<b>Subtotal EU/EEA</b>	<b>4165</b>	<b>(4.4)</b>	<b>5.1</b>	<b>3693</b>	<b>(4.0)</b>	<b>4.6</b>	<b>3596</b>	<b>(4.1)</b>	<b>4.5</b>	<b>3460</b>	<b>(4.1)</b>	<b>4.3</b>	<b>3498</b>	<b>(4.2)</b>	<b>4.4</b>
<b>Non-EU/EEA</b>															
Albania	7	(1.2)	0.8	0	(0.0)	0	42	(8.4)	5.1	27	(6.0)	3.4	19	(4.4)	2.5
Andorra	0	0	0	0	(0.0)	0	0	0	0	0	0	0	0	0	0
Armenia	3	(0.2)	0.4	6	(0.3)	0.9	92	(4.3)	14.3	41	(1.9)	6.5	85	(4.0)	13.7
Azerbaijan	16	(0.2)	0.7	167	(2.1)	7.5	217	(2.9)	10.0	-	-	-	-	-	-
Belarus	1	(0.0)	0.1	0	(0.0)	0.0	61	(1.0)	4.2	31	(0.5)	2.2	38	(0.7)	2.7
Bosnia and Herzegovina	6	(0.3)	0.8	3	(0.1)	0.4	24	(1.3)	3.3	0	0	0	17	(1.0)	2.4
former Yugoslav Republic of Macedonia, the	2	(0.3)	0.5	4	(0.6)	1.0	78	(12.4)	19.4	55	(9.8)	14.0	40	(8.3)	10.4
Georgia	6	(0.1)	0.7	4	(0.1)	0.5	347	(5.5)	43.6	306	(5.2)	39.4	267	(4.6)	34.9
Israel	25	(5.5)	1.4	29	(7.8)	1.6	30	(8.8)	1.6	27	(6.8)	1.4	14	(4.3)	0.7
Kazakhstan	86	(0.2)	2.3	77	(0.2)	2.1	5156	(13.4)	138.4	1884	(5.0)	50.1	981	(3.4)	25.7
Kyrgyzstan	14	(0.2)	0.9	16	(0.2)	1.0	16	(0.2)	1.0	14	(0.2)	0.9	630	(8.8)	40.1
Moldova	19	(0.3)	2.5	5	(0.1)	0.7	9	(0.1)	1.3	176	(2.8)	27.1	160	(2.7)	25.6
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	-	-	-	0	0	0	1	(0.6)	0.8	2	(1.3)	1.6	1	(0.8)	0.8
Russia	63	(0.0)	0.3	-	-	-	58	(0.0)	0.3	3422	(1.6)	16.2	3203	(1.5)	15.2
San Marino	0	(0.0)	0	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	-	-	-	9	(0.3)	0.5	28	(0.9)	1.6	28	(0.9)	1.6	24	(0.9)	1.4
Serbia excluding UN Administered Province of Kosovo <sup>a</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
UN Administered Province of Kosovo <sup>a</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	10	(1.7)	0.8	17	(3.0)	1.4	9	(1.7)	0.8	15	(3.2)	1.3	11	(2.1)	0.9
Tajikistan	18	(0.4)	0.7	34	(0.5)	1.3	0	(0.0)	0.0	585	(7.2)	22.2	547	(6.8)	20.6
Turkey	2	(0.0)	0.0	83	(0.4)	0.4	1113	(5.4)	5.8	952	(4.8)	4.9	949	(5.1)	4.9
Turkmenistan	2	(0.0)	0.1	5	(0.2)	0.3	38	(1.1)	2.5	8	(0.2)	0.5	7	(0.2)	0.5
Ukraine	-	-	-	-	-	-	463	(1.1)	6.9	34	(0.1)	0.5	581	(1.5)	9.0
Uzbekistan	54	(0.2)	0.6	65	(0.2)	0.8	2833	(11.2)	33.2	2583	(11.0)	30.6	2008	(9.5)	24.0
<b>Subtotal non-EU/EEA</b>	<b>334</b>	<b>(0.1)</b>	<b>0.6</b>	<b>524</b>	<b>(0.4)</b>	<b>0.9</b>	<b>10615</b>	<b>(3.2)</b>	<b>13.6</b>	<b>10190</b>	<b>(2.6)</b>	<b>13.2</b>	<b>9582</b>	<b>(2.5)</b>	<b>12.4</b>
<b>Total European Region</b>	<b>4499</b>	<b>(1.2)</b>	<b>2.8</b>	<b>4217</b>	<b>(1.0)</b>	<b>2.6</b>	<b>14211</b>	<b>(3.4)</b>	<b>9.0</b>	<b>13650</b>	<b>(2.9)</b>	<b>8.7</b>	<b>13080</b>	<b>(2.8)</b>	<b>8.3</b>
<b>Subtotal 18 HPC</b>	<b>2127</b>	<b>(0.7)</b>	<b>2.7</b>	<b>1906</b>	<b>(0.5)</b>	<b>2.5</b>	<b>11853</b>	<b>(3.3)</b>	<b>15.5</b>	<b>11382</b>	<b>(2.7)</b>	<b>15.0</b>	<b>10757</b>	<b>(2.7)</b>	<b>14.2</b>

<sup>a</sup> "European Region" comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	2009			2010			2011			2012			2013		
	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate
	18	(2.6)	1.4	25	(3.6)	2.0	24	(3.5)	1.9	27	(4.2)	2.2	23	(3.5)	1.9
	64	(6.4)	3.5	71	(6.5)	3.9	79	(7.8)	4.2	63	(6.5)	3.3	59	(6.0)	3.1
	210	(7.2)	21.5	217	(8.2)	22.2	176	(7.3)	18.0	178	(7.8)	18.2	146	(7.6)	14.7
	25	(2.9)	3.8	18	(2.6)	2.7	25	(4.0)	3.8	12	(2.1)	1.9	4	(0.8)	0.6
	2	(3.6)	1.4	2	(3.3)	1.4	0	(0.0)	0.0	3	(4.3)	2.1	0	(0.0)	0.0
	7	(1.0)	0.5	3	(0.4)	0.2	6	(1.0)	0.4	5	(0.8)	0.3	5	(1.0)	0.3
	22	(6.6)	2.2	21	(5.7)	2.1	16	(4.2)	1.6	17	(4.4)	1.7	22	(6.2)	2.3
	3	(0.7)	1.5	6	(1.8)	3.0	1	(0.3)	0.5	2	(0.7)	1.0	1	(0.3)	0.5
	7	(1.7)	0.8	6	(1.9)	0.7	11	(3.4)	1.2	5	(1.8)	0.6	2	(0.7)	0.2
	253	(4.8)	2.1	232	(4.5)	1.9	251	(5.0)	2.1	255	(5.1)	2.1	263	(5.3)	2.2
	146	(3.3)	1.3	162	(3.7)	1.5	176	(4.1)	1.6	173	(4.1)	1.6	169	(3.9)	1.6
	36	(6.1)	2.2	33	(6.8)	2.0	38	(7.8)	2.3	41	(7.3)	2.5	30	(5.6)	1.8
	5	(0.4)	0.3	11	(0.6)	0.7	4	(0.3)	0.3	9	(0.7)	0.6	8	(0.8)	0.6
	1	(11.1)	1.5	0	(0.0)	0.0	1	(11.1)	1.5	0	(0.0)	0.0	0	(0.0)	0.0
	18	(3.8)	1.9	21	(5.0)	2.2	19	(4.6)	2.0	10	(2.8)	1.0	9	(2.3)	0.9
	184	(4.3)	2.2	282	(6.0)	3.4	209	(5.9)	2.5	149	(4.7)	1.8	126	(4.0)	1.5
	40	(4.1)	13.1	46	(4.9)	15.3	61	(6.9)	20.7	57	(5.7)	19.5	45	(5.0)	15.4
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	74	(3.6)	15.4	92	(4.7)	19.6	88	(4.6)	19.4	56	(3.1)	12.6	37	(2.2)	8.5
	1	(3.7)	1.1	1	(3.4)	1.1	1	(3.8)	1.1	3	(6.7)	3.3	1	(2.6)	1.1
	1	(2.3)	1.6	0	(0.0)	0.0	0	(0.0)	0.0	2	(4.8)	3.2	0	(0.0)	0.0
	58	(5.0)	2.0	34	(3.2)	1.2	56	(5.6)	1.9	50	(5.2)	1.7	32	(3.8)	1.1
	14	(3.9)	1.5	13	(3.9)	1.4	17	(4.8)	1.8	19	(5.1)	2.1	17	(4.2)	1.8
	99	(1.2)	1.7	62	(0.8)	1.1	111	(1.3)	1.9	95	(1.3)	1.6	116	(1.6)	2.0
	78	(2.7)	4.8	59	(2.2)	3.6	49	(1.9)	3.1	75	(2.9)	4.8	51	(2.1)	3.3
	965	(4.2)	31.1	823	(3.9)	26.6	775	(4.0)	25.2	717	(3.9)	23.4	697	(4.2)	22.2
	11	(2.2)	1.3	11	(2.5)	1.3	17	(4.3)	2.0	19	(5.5)	2.3	38	(9.5)	4.6
	6	(3.2)	2.1	3	(1.7)	1.0	4	(2.1)	1.4	5	(3.6)	1.7	2	(1.4)	0.7
	537	(7.1)	7.9	484	(6.7)	7.0	543	(8.0)	7.7	388	(6.4)	5.5	382	(6.9)	5.4
	31	(5.0)	2.0	47	(7.0)	3.0	35	(6.0)	2.2	25	(4.0)	1.6	51	(7.9)	3.2
	424	(4.8)	3.9	380	(4.5)	3.4	408	(4.6)	3.7	413	(4.7)	3.7	319	(4.0)	2.8
	<b>3340</b>	<b>(4.2)</b>	<b>4.2</b>	<b>3165</b>	<b>(4.2)</b>	<b>4.0</b>	<b>3201</b>	<b>(4.4)</b>	<b>4.0</b>	<b>2873</b>	<b>(4.2)</b>	<b>3.6</b>	<b>2655</b>	<b>(4.1)</b>	<b>3.3</b>
	17	(3.8)	2.3	18	(4.0)	2.5	7	(1.6)	1.0	3	(0.7)	0.4	19	(4.0)	2.9
	0	0	0	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0
	65	(3.2)	10.6	60	(3.4)	9.9	51	(3.2)	8.4	41	(2.7)	6.8	42	(3.0)	7.0
	271	(2.6)	13.0	244	(2.9)	11.8	186	(1.8)	9.0	212	(4.6)	10.2	215	(3.7)	10.3
	11	(0.2)	0.8	32	(0.6)	2.3	27	(0.6)	1.9	21	(0.4)	1.5	15	(0.3)	1.0
	14	(0.8)	2.0	13	(0.9)	1.9	17	(1.2)	2.6	18	(1.3)	2.9	12	(1.0)	2.0
	31	(6.6)	8.3	33	(7.9)	9.0	33	(9.1)	9.2	29	(8.2)	8.2	23	(7.1)	6.5
	281	(4.7)	36.9	256	(4.4)	33.7	206	(3.7)	27.0	215	(4.3)	28.0	188	(4.4)	24.2
	10	(2.9)	0.5	19	(5.5)	0.9	20	(4.8)	1.0	19	(3.7)	0.9	15	(4.9)	0.7
	818	(2.7)	21.0	773	(3.1)	19.5	659	(2.9)	16.3	653	(3.0)	15.8	514	(2.6)	12.1
	541	(8.5)	34.2	531	(10.0)	33.1	504	(9.6)	31.0	640	(10.9)	38.7	594	(10.1)	35.2
	161	(2.9)	26.4	140	(2.6)	23.5	159	(3.0)	27.1	150	(2.8)	25.8	137	(2.7)	23.7
	-	-	-	0	(0.0)	0.0	0	-	0.0	0	-	0.0	0	-	0.0
	2	(1.7)	1.6	3	(2.6)	2.5	3	(2.5)	2.5	0	(0.0)	0.0	1	(0.8)	0.9
	3111	(2.0)	14.7	3263	(3.0)	15.2	3545	(3.4)	16.3	3688	(3.8)	16.7	3298	(3.6)	14.6
	-	-	-	0	-	0.0	0	-	0.0	0	-	0.0	0	-	0.0
	25	(1.0)	1.5	45	(1.9)	2.8	50	(2.3)	3.1	38	(2.0)	2.4	14	(1.2)	0.9
	-	-	-	16	(1.1)	4.0	13	(1.0)	3.3	18	(1.5)	4.7	14	(1.2)	0.9
	-	-	-	29	(3.3)	2.4	37	(4.2)	3.1	20	(2.8)	1.7			
	16	(2.9)	1.4	19	(3.5)	1.6	26	(4.5)	2.2	16	(3.5)	1.4	22	(4.2)	1.9
	456	(6.1)	16.9	491	(8.2)	17.9	569	(9.6)	20.3	360	(5.2)	12.6	389	(7.3)	13.2
	940	(5.4)	4.9	900	(5.4)	4.7	761	(4.9)	4.0	686	(4.7)	3.6	584	(4.4)	3.0
	5	(0.2)	0.3	3	(0.1)	0.2	0	-	-	0	-	-	0	-	-
	580	(1.5)	9.0	302	(0.8)	4.7	520	(1.7)	8.1	550	(1.2)	8.5	650	(1.4)	10.0
	2263	(10.5)	27.2	2000	(9.8)	24.2	1751	(11.0)	21.2	1852	(11.0)	22.5	2042	(8.1)	24.7
	<b>9618</b>	<b>(3.0)</b>	<b>12.5</b>	<b>9145</b>	<b>(2.9)</b>	<b>11.8</b>	<b>9094</b>	<b>(3.0)</b>	<b>11.9</b>	<b>9191</b>	<b>(3.9)</b>	<b>12.2</b>	<b>8774</b>	<b>(3.8)</b>	<b>11.3</b>
	<b>12958</b>	<b>(3.3)</b>	<b>8.3</b>	<b>12310</b>	<b>(3.2)</b>	<b>7.8</b>	<b>12295</b>	<b>(3.2)</b>	<b>7.8</b>	<b>12064</b>	<b>(4.0)</b>	<b>7.7</b>	<b>11429</b>	<b>(3.8)</b>	<b>7.3</b>
	<b>10795</b>	<b>(3.2)</b>	<b>14.3</b>	<b>10179</b>	<b>(3.0)</b>	<b>13.4</b>	<b>10039</b>	<b>(3.0)</b>	<b>13.4</b>	<b>10078</b>	<b>(4.0)</b>	<b>13.4</b>	<b>9594</b>	<b>(3.8)</b>	<b>13.0</b>

Table III. Tuberculosis cases of foreign origin, EU/EEA, 2004–2013

Country	2004			2005			2006			2007			2008		
	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate
<b>EU/EEA</b>															
Austria <sup>a</sup>	447	(41.6)	5.5	436	(43.7)	5.3	335	(37.0)	4.1	319	(36.5)	3.9	299	(36.6)	3.6
Belgium <sup>a</sup>	634	(52.9)	6.1	571	(51.6)	5.5	574	(51.4)	5.5	482	(47.3)	4.6	473	(47.8)	4.4
Bulgaria	-	-	-	-	-	-	-	-	-	5	(0.2)	0.1	6	(0.2)	0.1
Croatia	126	(9.7)	2.9	101	(8.9)	2.4	119	(10.5)	2.8	-	-	-	45	(5.3)	1.1
Cyprus	23	(76.7)	3.2	25	(67.6)	3.4	28	(75.7)	3.8	31	(73.8)	4.1	44	(88.0)	5.7
Czech Republic	149	(14.1)	1.5	129	(13.1)	1.3	130	(13.7)	1.3	151	(17.8)	1.5	185	(21.4)	1.8
Denmark	237	(61.6)	4.4	252	(58.9)	4.7	225	(58.1)	4.1	242	(61.9)	4.4	227	(59.7)	4.1
Estonia	138	(23.2)	10.1	83	(16.0)	6.1	73	(15.9)	5.4	80	(16.3)	6.0	83	(18.7)	6.2
Finland	33	(10.2)	0.6	41	(11.6)	0.8	45	(15.5)	0.9	67	(19.3)	1.3	46	(13.5)	0.9
France	2526	(45.3)	4.1	2422	(45.1)	3.9	2310	(43.4)	3.7	2498	(44.8)	3.9	2587	(44.9)	4.0
Germany	2884	(44.1)	3.5	2633	(43.8)	3.2	2248	(41.8)	2.7	2100	(42.0)	2.6	1935	(42.8)	2.4
Greece <sup>a</sup>	180	(23.3)	1.6	219	(28.5)	2.0	215	(31.6)	1.9	212	(33.2)	1.9	249	(37.5)	2.2
Hungary <sup>a</sup>	44	(1.9)	0.4	62	(3.2)	0.6	41	(2.2)	0.4	48	(2.8)	0.5	47	(2.9)	0.5
Iceland	8	(66.7)	2.8	7	(63.6)	2.4	9	(69.2)	3.0	9	(64.3)	2.9	4	(66.7)	1.3
Ireland	129	(29.9)	3.2	152	(33.8)	3.7	160	(34.6)	3.8	192	(40.0)	4.4	203	(43.4)	4.6
Italy	1664	(39.4)	2.9	1854	(44.0)	3.2	2108	(46.8)	3.6	1960	(43.3)	3.4	2026	(45.9)	3.5
Latvia	119	(7.4)	5.2	84	(5.8)	3.7	69	(5.2)	3.1	66	(5.3)	3.0	56	(5.2)	2.6
Liechtenstein	-	-	-	-	-	-	-	-	-	1	(20.0)	2.8	-	-	-
Lithuania	87	(3.5)	2.6	90	(3.5)	2.7	74	(2.9)	2.2	76	(3.2)	2.3	49	(2.2)	1.5
Luxembourg	25	(80.6)	5.5	25	(67.6)	5.4	20	(60.6)	4.3	24	(61.5)	5.0	0	(0.0)	0.0
Malta	12	(63.2)	3.0	17	(68.0)	4.2	17	(56.7)	4.2	24	(63.2)	5.9	42	(79.2)	10.3
Netherlands	721	(53.6)	4.4	758	(67.2)	4.6	659	(63.9)	4.0	626	(62.7)	3.8	708	(69.8)	4.3
Norway	239	(79.1)	5.2	225	(78.1)	4.9	235	(81.0)	5.1	239	(79.1)	5.1	261	(83.4)	5.5
Poland <sup>a</sup>	22	(0.2)	0.1	17	(0.2)	0.0	47	(0.5)	0.1	55	(0.6)	0.1	53	(0.7)	0.1
Portugal	455	(11.8)	4.4	420	(11.8)	4.1	398	(11.5)	3.8	423	(13.5)	4.1	443	(14.8)	4.3
Romania	2	(0.0)	0.0	2	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0
Slovakia	15	(2.1)	0.3	27	(3.6)	0.5	11	(1.5)	0.2	12	(1.8)	0.2	9	(1.4)	0.2
Slovenia	54	(20.5)	2.7	48	(17.3)	2.4	34	(15.8)	1.7	38	(17.4)	1.9	56	(26.3)	2.8
Spain	787	(10.1)	1.8	1448	(18.5)	3.3	1552	(19.3)	3.5	2029	(26.1)	4.5	2495	(30.4)	5.5
Sweden	343	(74.4)	3.8	410	(73.3)	4.5	357	(71.8)	3.9	374	(77.6)	4.1	442	(81.0)	4.8
United Kingdom	4789	(63.1)	8.1	5411	(65.3)	9.1	5429	(65.3)	9.0	5445	(65.9)	9.0	5742	(67.6)	9.4
<b>Total EU/EEA</b>	<b>16 892</b>	<b>(18.2)</b>	<b>3.4</b>	<b>17 969</b>	<b>(19.4)</b>	<b>3.6</b>	<b>17 522</b>	<b>(20.6)</b>	<b>3.5</b>	<b>17 828</b>	<b>(21.2)</b>	<b>3.5</b>	<b>18 815</b>	<b>(22.4)</b>	<b>3.7</b>

<sup>a</sup>European Region<sup>a</sup> comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

Notification rates are calculated from all population.

<sup>a</sup> Criterion for definition of origin is nationality (citizenship), otherwise birthplace.

	2009			2010			2011			2012			2013		
	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate	N	% among all TB cases	Rate
	230	(33.0)	2.8	300	(43.4)	3.6	325	(47.5)	3.9	315	(48.7)	3.7	332	(51.2)	3.9
	485	(48.8)	4.5	594	(54.7)	5.5	532	(52.2)	4.8	517	(53.0)	4.7	512	(52.2)	4.6
	8	(0.3)	0.1	2	(0.1)	0.0	9	(0.4)	0.1	4	(0.2)	0.1	10	(0.5)	0.1
	99	(11.6)	2.3	4	(0.6)	0.1	75	(12.1)	1.8	49	(8.5)	1.2	63	(12.2)	1.5
	46	(83.6)	5.8	50	(82.0)	6.1	45	(83.3)	5.4	52	(75.4)	6.0	35	(85.4)	4.0
	135	(19.5)	1.3	117	(17.5)	1.1	112	(18.7)	1.1	105	(17.6)	1.0	79	(15.8)	0.8
	202	(60.5)	3.7	220	(60.1)	4.0	233	(61.2)	4.2	236	(60.7)	4.2	215	(60.4)	3.8
	79	(19.2)	5.9	61	(18.3)	4.6	48	(14.2)	3.6	47	(16.3)	3.5	43	(15.0)	3.3
	116	(28.1)	2.2	101	(31.9)	1.9	79	(24.4)	1.5	80	(29.0)	1.5	85	(31.4)	1.6
	2427	(46.0)	3.8	2469	(48.3)	3.8	2474	(49.6)	3.8	2539	(51.0)	3.9	2553	(51.7)	3.9
	1946	(43.8)	2.4	2012	(45.8)	2.5	2046	(47.5)	2.5	2044	(48.5)	2.5	2309	(53.5)	2.8
	255	(43.3)	2.3	231	(47.4)	2.1	216	(44.2)	1.9	210	(37.6)	1.9	229	(42.4)	2.1
	32	(2.3)	0.3	21	(1.2)	0.2	27	(1.9)	0.3	21	(1.7)	0.2	34	(3.3)	0.3
	5	(55.6)	1.6	16	(72.7)	5.0	7	(77.8)	2.2	9	(81.8)	2.8	5	(45.5)	1.6
	206	(43.0)	4.6	171	(40.7)	3.8	193	(46.7)	4.2	160	(44.6)	3.5	171	(44.5)	3.7
	2052	(48.4)	3.5	2284	(48.7)	3.9	1677	(47.6)	2.8	1832	(58.3)	3.1	1973	(62.6)	3.3
	60	(6.1)	2.8	62	(6.6)	2.9	59	(6.7)	2.8	42	(4.2)	2.1	40	(4.4)	2.0
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	61	(2.9)	1.9	48	(2.5)	1.5	45	(2.4)	1.5	41	(2.3)	1.4	40	(2.3)	1.3
	16	(59.3)	3.2	17	(58.6)	3.4	21	(80.8)	4.1	32	(71.1)	6.1	36	(94.7)	6.7
	34	(77.3)	8.3	25	(78.1)	6.0	28	(84.8)	6.7	36	(85.7)	8.6	44	(88.0)	10.4
	842	(72.7)	5.1	789	(73.9)	4.8	712	(70.9)	4.3	701	(73.2)	4.2	627	(73.9)	3.7
	323	(90.2)	6.7	289	(86.0)	5.9	313	(88.4)	6.4	320	(85.6)	6.4	345	(86.0)	6.8
	53	(0.6)	0.1	46	(0.6)	0.1	38	(0.4)	0.1	48	(0.6)	0.1	52	(0.7)	0.1
	441	(15.4)	4.3	439	(16.2)	4.2	404	(15.5)	3.9	408	(15.7)	3.9	389	(16.3)	3.7
	35	(0.2)	0.2	37	(0.2)	0.2	51	(0.3)	0.3	42	(0.2)	0.2	48	(0.3)	0.2
	7	(1.4)	0.1	8	(1.8)	0.1	3	(0.8)	0.1	3	(0.9)	0.1	6	(1.5)	0.1
	55	(29.3)	2.7	41	(23.8)	2.0	57	(29.7)	2.8	48	(34.8)	2.3	46	(32.9)	2.2
	2330	(30.7)	5.0	2383	(32.9)	5.1	2169	(31.9)	4.6	1897	(31.3)	4.1	1755	(31.7)	3.8
	507	(82.2)	5.5	572	(85.8)	6.1	519	(89.5)	5.5	529	(84.9)	5.6	575	(88.7)	6.0
	5982	(67.4)	9.7	5837	(69.5)	9.4	6335	(71.0)	10.1	6174	(70.7)	9.7	5529	(70.1)	8.7
	<b>19069</b>	<b>(23.7)</b>	<b>3.8</b>	<b>19246</b>	<b>(25.2)</b>	<b>3.8</b>	<b>18852</b>	<b>(25.8)</b>	<b>3.7</b>	<b>18541</b>	<b>(26.9)</b>	<b>3.6</b>	<b>18180</b>	<b>(28.0)</b>	<b>3.5</b>

**Table IV. MDR TB notification among new pulmonary culture-positive TB cases with available DST results, European Region, 2004–2013**

Country	2004		2005		2006		2007		2008	
	N	%	N	%	N	%	N	%	N	%
<b>EU/EEA</b>										
Austria	17	(3.3)	11	(2.3)	7	(1.6)	8	(2.0)	11	(2.9)
Belgium <sup>a</sup>	3	(0.6)	5	(1.1)	8	(1.8)	5	(1.1)	11	(2.3)
Bulgaria	11	(2.3)	22	(4.6)	24	(2.2)	31	(3.5)	13	(1.6)
Croatia	3	(0.4)	3	(0.5)	1	(0.2)	5	(100.0)	-	-
Cyprus	0	(0.0)	1	(6.3)	0	(0.0)	2	(8.3)	0	(0.0)
Czech Republic	4	(1.0)	7	(1.4)	8	(1.6)	5	(1.1)	10	(2.3)
Denmark <sup>a</sup>	0	(0.0)	5	(1.6)	2	(1.0)	0	(0.0)	0	(0.0)
Estonia	50	(14.9)	41	(13.9)	36	(13.2)	49	(16.3)	42	(16.3)
Finland	0	(0.0)	2	(0.9)	0	(0.0)	1	(0.6)	1	(0.6)
France	14	(1.0)	14	(1.1)	19	(1.4)	12	(1.0)	16	(1.2)
Germany	38	(1.5)	54	(2.2)	53	(2.2)	31	(1.3)	20	(1.0)
Greece	-	-	12	(2.4)	13	(2.6)	13	(2.7)	-	-
Hungary	7	(1.7)	9	(2.6)	12	(2.6)	9	(2.4)	7	(1.8)
Iceland	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(100.0)
Ireland <sup>a</sup>	2	(1.3)	1	(0.6)	0	(0.0)	4	(2.4)	2	(1.0)
Italy	6	(1.2)	8	(1.6)	28	(3.3)	16	(2.5)	27	(2.7)
Latvia	107	(12.9)	90	(11.0)	81	(10.7)	57	(7.4)	76	(11.9)
Liechtenstein	-	-	-	-	-	-	0	(0.0)	-	-
Lithuania	103	(9.5)	126	(10.1)	125	(9.7)	123	(10.2)	111	(9.2)
Luxembourg	1	(3.4)	0	(0.0)	0	(0.0)	0	-	0	-
Malta	0	(0.0)	0	(0.0)	2	(20.0)	1	(8.3)	0	(0.0)
Netherlands	1	(0.2)	4	(0.7)	3	(0.6)	4	(0.9)	11	(2.4)
Norway <sup>a</sup>	2	(1.5)	2	(1.8)	0	(0.0)	1	(0.9)	0	(0.0)
Poland	8	(0.3)	29	(0.8)	19	(0.6)	12	(0.4)	9	(0.3)
Portugal	21	(1.6)	-	(1.2)	14	(1.0)	19	(1.3)	19	(1.3)
Romania	219	(8.2)	147	(5.4)	99	(4.2)	90	(4.4)	117	(3.9)
Slovakia	1	(0.4)	4	(1.8)	3	(1.0)	3	(1.0)	1	(0.4)
Slovenia	0	(0.0)	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.6)
Spain	-	-	-	-	36	(2.8)	-	-	31	(2.9)
Sweden	4	(1.7)	1	(0.4)	1	(0.4)	11	(4.6)	6	(2.7)
United Kingdom <sup>a</sup>	25	(1.1)	16	(0.7)	19	(0.8)	24	(1.0)	28	(1.1)
<b>Subtotal EU/EEA</b>	<b>647</b>	<b>(3.2)</b>	<b>630</b>	<b>(2.9)</b>	<b>614</b>	<b>(2.6)</b>	<b>536</b>	<b>(2.6)</b>	<b>571</b>	<b>(2.6)</b>
<b>Non-EU/EEA</b>										
Albania	0	(0.0)	0	(0.0)	1	(0.7)	1	(0.6)	1	(0.5)
Andorra	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Armenia	79	(17.0)	86	(14.9)	65	(12.4)	50	(11.7)	60	(14.4)
Azerbaijan	-	-	270	(59.6)	97	(24.0)	13	(6.1)	-	-
Belarus	110	(6.1)	-	-	224	(11.7)	302	(16.1)	301	(16.7)
Bosnia and Herzegovina	4	(0.4)	4	(0.4)	3	(0.3)	3	(0.2)	3	(0.4)
former Yugoslav Republic of Macedonia, the	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Georgia	-	-	54	(6.8)	111	(8.6)	87	(6.4)	190	(11.3)
Israel	11	(3.5)	14	(5.4)	18	(7.5)	12	(4.3)	12	(5.3)
Kazakhstan	1339	(15.9)	-	-	1028	(13.1)	1596	(20.0)	1384	(24.7)
Kyrgyzstan	169	(22.0)	169	(20.2)	248	(25.8)	168	(16.5)	97	(20.0)
Moldova	-	-	68	(12.7)	160	(19.4)	311	(23.7)	300	(24.8)
Monaco	-	-	-	-	-	-	-	-	-	-
Montenegro	-	-	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Russia	-	-	-	-	-	-	3959	(13.0)	5061	(14.0)
San Marino	-	-	-	-	-	-	-	-	-	-
Serbia	-	-	4	(0.4)	0	(0.0)	7	(0.6)	6	(0.7)
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>										
UN Administered Province of Kosovo <sup>b</sup>										
Switzerland	3	(0.9)	2	(0.6)	4	(1.0)	5	(1.9)	3	(1.2)
Tajikistan	-	-	-	-	-	-	-	-	-	-
Turkey	-	-	101	(3.1)	133	(3.2)	120	(2.9)	125	(3.0)
Turkmenistan	-	-	-	-	-	-	-	-	-	-
Ukraine	-	-	-	-	-	-	-	-	-	-
Uzbekistan	-	-	-	-	29	(14.1)	119	(30.9)	52	(19.0)
<b>Subtotal non-EU/EEA</b>	<b>1715</b>	<b>(12.6)</b>	<b>772</b>	<b>(8.1)</b>	<b>2121</b>	<b>(10.1)</b>	<b>6753</b>	<b>(12.9)</b>	<b>7595</b>	<b>(13.9)</b>
<b>Total European Region</b>	<b>2362</b>	<b>(7.0)</b>	<b>1402</b>	<b>(4.0)</b>	<b>2735</b>	<b>(6.4)</b>	<b>7289</b>	<b>(9.6)</b>	<b>8166</b>	<b>(10.2)</b>
<b>Subtotal 18 HPC</b>	<b>2187</b>	<b>(15.1)</b>	<b>1174</b>	<b>(10.7)</b>	<b>2460</b>	<b>(11.4)</b>	<b>7075</b>	<b>(12.9)</b>	<b>7929</b>	<b>(13.7)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in *italics*.

<sup>b</sup> Criterion for definition of previous TB history is previous diagnosis, otherwise treatment.

<sup>c</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	2009		2010		2011		2012		2013	
	N	%	N	%	N	%	N	%	N	%
	4	(1.8)	5	(2.5)	8	(3.7)	9	(4.2)	7	(2.5)
	2	(0.4)	7	(1.5)	4	(1.0)	5	(1.3)	7	(1.8)
	11	(1.6)	15	(1.9)	17	(2.9)	15	(2.2)	12	(1.9)
	7	(1.5)	0	-	1	(0.3)	1	(0.4)	0	(0.0)
	3	(13.6)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
	5	(1.3)	7	(2.0)	6	(1.6)	2	(0.6)	0	(0.0)
	1	(0.6)	1	(0.5)	2	(0.9)	0	(0.0)	1	(0.5)
	53	(22.6)	35	(18.4)	47	(23.3)	38	(20.5)	29	(17.3)
	3	(1.4)	4	(2.3)	5	(2.9)	3	(2.1)	2	(1.2)
	13	(0.4)	13	(1.1)	25	(2.0)	-	-	-	-
	36	(1.7)	11	(1.2)	14	(1.5)	14	(1.8)	14	(2.2)
	8	(6.3)	1	(0.9)	3	(2.2)	1	(0.8)	7	(4.0)
	14	(3.6)	10	(2.1)	2	(0.5)	9	(2.2)	6	(1.8)
	0	(0.0)	0	(0.0)	0	-	0	(0.0)	0	(0.0)
	0	(0.0)	2	(1.2)	0	(0.0)	2	(1.3)	2	(1.5)
	34	(3.2)	23	(2.8)	30	(3.9)	12	(2.6)	-	-
	80	(13.7)	64	(10.9)	69	(12.7)	73	(11.4)	48	(8.8)
	-	-	-	-	-	-	-	-	0	(0.0)
	113	(10.9)	121	(12.6)	111	(11.1)	116	(11.8)	116	(11.5)
	0	-	0	(0.0)	0	-	0	-	0	(0.0)
	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
	10	(2.2)	8	(1.7)	9	(2.1)	5	(1.3)	7	(2.0)
	5	(3.4)	4	(2.9)	2	(1.5)	2	(1.2)	4	(2.2)
	13	(0.4)	11	(0.4)	23	(0.5)	19	(0.5)	19	(0.5)
	12	(0.9)	18	(1.4)	23	(1.9)	14	(1.1)	9	(1.0)
	148	(3.9)	116	(3.1)	119	(3.0)	153	(3.1)	151	(3.2)
	0	(0.0)	0	(0.0)	2	(1.4)	0	(0.0)	1	(0.7)
	1	(0.7)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
	6	(0.5)	20	(2.0)	15	(1.5)	26	(3.2)	27	(1.9)
	4	(1.6)	9	(3.1)	5	(2.0)	6	(2.1)	5	(1.8)
	27	(1.0)	31	(1.1)	39	(1.3)	44	(1.6)	36	(1.4)
	<b>613</b>	<b>(2.5)</b>	<b>536</b>	<b>(2.6)</b>	<b>581</b>	<b>(2.6)</b>	<b>569</b>	<b>(2.7)</b>	<b>510</b>	<b>(2.6)</b>
	0	(0.0)	1	(0.5)	2	(1.0)	1	(0.6)	1	(3.7)
	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
	80	(16.7)	40	(11.1)	66	(15.0)	57	(13.6)	43	(11.6)
	-	-	93	(11.6)	55	(9.7)	128	(13.5)	187	(15.2)
	464	(22.4)	507	(25.7)	542	(26.0)	753	(34.8)	755	(35.2)
	0	(0.0)	1	(0.2)	1	(0.1)	4	(0.6)	0	(0.0)
	0	(0.0)	2	(1.3)	0	(0.0)	0	(0.0)	0	(0.0)
	183	(10.3)	188	(9.5)	239	(10.9)	177	(9.2)	183	(11.2)
	4	(1.6)	12	(4.9)	10	(3.6)	15	(4.7)	6	(3.8)
	981	(23.7)	1408	(27.0)	1604	(30.3)	1864	(22.9)	1997	(26.3)
	225	(33.2)	-	-	-	-	433	(26.1)	613	(28.4)
	289	(22.5)	336	(24.3)	359	(26.0)	299	(23.7)	343	(24.5)
	-	-	-	-	-	-	-	-	-	-
	0	(0.0)	0	(0.0)	1	(1.8)	0	(0.0)	0	(0.0)
	5816	(15.8)	6218	(17.3)	6596	(19.4)	6537	(20.0)	6726	(21.2)
	-	-	-	-	-	-	-	-	-	-
	0	(0.0)	4	(0.5)	3	(0.3)	6	(0.8)	6	(0.9)
	2	(0.7)	1	(0.4)	1	(0.3)	3	(1.2)	3	(1.5)
	62	(7.4)	92	(57.5)	72	(44.7)	286	(31.1)	143	(34.5)
	99	(2.7)	110	(2.5)	116	(2.7)	151	(3.2)	123	(2.5)
	21	(12.8)	19	(23.5)	-	-	-	-	-	-
	1437	(12.0)	1492	(16.2)	1367	(13.2)	1614	(14.4)	2479	(19.2)
	115	(20.1)	430	(15.1)	170	(35.1)	703	(27.9)	1535	(36.3)
	<b>9778</b>	<b>(14.7)</b>	<b>10954</b>	<b>(16.4)</b>	<b>11204</b>	<b>(17.6)</b>	<b>13031</b>	<b>(18.4)</b>	<b>15143</b>	<b>(20.8)</b>
	<b>10391</b>	<b>(11.0)</b>	<b>11490</b>	<b>(12.5)</b>	<b>11785</b>	<b>(13.0)</b>	<b>13600</b>	<b>(14.3)</b>	<b>15653</b>	<b>(16.8)</b>
	<b>10177</b>	<b>(14.3)</b>	<b>11284</b>	<b>(15.9)</b>	<b>11549</b>	<b>(17.1)</b>	<b>13397</b>	<b>(17.8)</b>	<b>15483</b>	<b>(19.9)</b>

**Table V. MDR TB notification among pulmonary previously treated culture-positive TB cases with available DST results, European Region, 2004–2013**

Country	2004		2005		2006		2007		2008	
	N	%	N	%	N	%	N	%	N	%
<b>EU/EEA</b>										
Austria	0	(0.0)	2	(11.8)	1	(9.1)	1	(14.3)	1	(12.5)
Belgium <sup>a</sup>	5	(9.3)	2	(6.3)	8	(17.8)	6	(13.0)	6	(14.3)
Bulgaria	-	-	25	(3.6)	29	(13.1)	45	(37.5)	18	(17.1)
Croatia	0	(0.0)	3	(4.9)	2	(2.4)	2	(100.0)	-	-
Cyprus	0	-	0	-	0	-	1	(100.0)	1	(33.3)
Czech Republic	2	(25.0)	6	(11.8)	4	(11.8)	3	(7.5)	1	(2.8)
Denmark <sup>a</sup>	0	(0.0)	-	-	0	(0.0)	0	(0.0)	0	(0.0)
Estonia	39	(43.3)	36	(53.7)	18	(27.7)	31	(44.9)	31	(41.3)
Finland	0	(0.0)	0	(0.0)	1	(8.3)	0	(0.0)	0	(0.0)
France	11	(8.0)	8	(7.1)	11	(10.0)	7	(6.9)	10	(9.6)
Germany	27	(12.6)	29	(13.1)	11	(5.6)	19	(11.4)	20	(14.1)
Greece	-	-	-	-	-	-	-	-	-	-
Hungary	4	(5.6)	8	(13.6)	2	(3.1)	3	(4.4)	6	(9.2)
Iceland	0	-	0	-	0	-	1	(100.0)	0	-
Ireland <sup>a</sup>	0	(0.0)	1	(4.8)	3	(15.0)	2	(7.1)	0	(0.0)
Italy	15	(17.0)	14	(17.7)	-	-	21	(26.6)	24	(14.5)
Latvia	81	(39.3)	66	(36.3)	57	(33.3)	40	(24.8)	46	(32.2)
Liechtenstein	-	-	-	-	-	-	0	-	-	-
Lithuania	209	(46.5)	209	(48.0)	203	(46.6)	188	(44.4)	161	(45.5)
Luxembourg	0	-	0	-	0	-	0	-	0	-
Malta	0	-	0	-	0	-	0	(0.0)	0	(0.0)
Netherlands	0	(0.0)	1	(3.7)	2	(10.0)	0	(0.0)	2	(9.1)
Norway <sup>a</sup>	0	(0.0)	0	(0.0)	2	(13.3)	1	(5.9)	1	(6.7)
Poland	43	(8.2)	16	(3.4)	13	(2.8)	10	(1.8)	6	(1.3)
Portugal	14	(7.8)	-	(7.1)	5	(2.9)	14	(9.1)	10	(6.5)
Romania	588	(30.6)	702	(31.0)	574	(26.2)	583	(32.5)	675	(26.8)
Slovakia	0	(0.0)	4	(7.4)	4	(6.7)	4	(9.5)	2	(3.4)
Slovenia	0	(0.0)	1	(3.8)	0	(0.0)	0	(0.0)	1	(8.3)
Spain	-	-	-	-	14	(25.9)	-	-	23	(13.2)
Sweden	1	(6.7)	1	(9.1)	1	(16.7)	2	(15.4)	3	(12.5)
United Kingdom <sup>a</sup>	4	(2.1)	9	(4.5)	13	(7.5)	12	(6.5)	8	(4.2)
<b>Subtotal EU/EEA</b>	<b>1043</b>	<b>(23.8)</b>	<b>1155</b>	<b>(21.8)</b>	<b>978</b>	<b>(21.0)</b>	<b>996</b>	<b>(24.2)</b>	<b>1056</b>	<b>(21.5)</b>
<b>Non-EU/EEA</b>										
Albania	0	(0.0)	1	(8.3)	0	(0.0)	2	(11.1)	1	(4.5)
Andorra	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	-
Armenia	78	(46.4)	76	(41.8)	150	(43.4)	75	(35.2)	68	(35.8)
Azerbaijan	-	-	58	(15.8)	301	(81.6)	183	(71.2)	-	-
Belarus	206	(16.1)	-	-	427	(35.8)	455	(36.6)	516	(42.0)
Bosnia and Herzegovina	6	(7.8)	7	(6.6)	4	(4.3)	3	(1.9)	9	(11.7)
former Yugoslav Republic of Macedonia, the	2	(13.3)	4	(21.1)	6	(20.7)	9	(34.6)	2	(11.8)
Georgia	-	-	141	(27.4)	155	(26.4)	182	(32.7)	290	(40.3)
Israel	3	(42.9)	2	(33.3)	1	(100.0)	2	(33.3)	1	(33.3)
Kazakhstan	3 489	(39.8)	-	-	3 089	(39.1)	3 972	(52.9)	1 950	(43.6)
Kyrgyzstan	90	(52.0)	96	(63.2)	88	(56.8)	154	(77.0)	172	(52.9)
Moldova	-	-	270	(41.4)	1 044	(50.8)	585	(62.6)	748	(61.0)
Monaco	-	-	-	-	-	-	-	-	-	-
Montenegro	-	-	2	(14.3)	2	(13.3)	2	(18.2)	0	(0.0)
Russia	-	-	0	-	-	-	1 338	(27.7)	1 899	(29.7)
San Marino	-	-	0	-	-	-	-	-	-	-
Serbia	-	-	5	(4.1)	10	(7.1)	18	(9.7)	10	(7.7)
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>										
UN Administered Province of Kosovo <sup>b</sup>										
Switzerland	1	(3.4)	2	(6.7)	0	(0.0)	3	(8.1)	1	(2.9)
Tajikistan	-	-	-	-	-	-	-	-	-	-
Turkey	-	-	90	(17.7)	116	(16.6)	120	(15.5)	138	(18.6)
Turkmenistan	-	-	-	-	16	(15.5)	-	-	-	-
Ukraine	-	-	-	-	-	-	-	-	-	-
Uzbekistan	9	(1.5)	86	(19.8)	54	(60.7)	365	(78.8)	290	(61.7)
<b>Subtotal non-EU/EEA</b>	<b>3 884</b>	<b>(34.9)</b>	<b>840</b>	<b>(26.9)</b>	<b>5 463</b>	<b>(39.5)</b>	<b>7 468</b>	<b>(42.9)</b>	<b>6 095</b>	<b>(37.9)</b>
<b>Total European Region</b>	<b>4 349</b>	<b>(30.9)</b>	<b>1 995</b>	<b>(28.1)</b>	<b>6 441</b>	<b>(40.4)</b>	<b>8 464</b>	<b>(38.1)</b>	<b>7 151</b>	<b>(33.6)</b>
<b>Subtotal 18 HPC</b>	<b>4 789</b>	<b>(39.7)</b>	<b>1 855</b>	<b>(33.8)</b>	<b>6 321</b>	<b>(43.9)</b>	<b>8 316</b>	<b>(41.4)</b>	<b>7 002</b>	<b>(36.9)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in *italics*.

<sup>b</sup> Criterion for definition of previous TB history is previous diagnosis, otherwise treatment.

<sup>c</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).



	2009		2010		2011		2012		2013	
	N	%	N	%	N	%	N	%	N	%
	8	(36.4)	3	(20.0)	2	(22.2)	9	(37.5)	9	(37.5)
	3	(6.3)	9	(17.6)	4	(13.8)	5	(10.9)	1	(2.4)
	31	(24.4)	40	(24.4)	37	(25.5)	33	(23.4)	14	(12.8)
	0	(0.0)	-	-	1	(2.5)	0	(0.0)	0	(0.0)
	0	(0.0)	0	-	0	(0.0)	0	(0.0)	1	(100.0)
	3	(8.3)	2	(7.1)	1	(6.3)	2	(9.1)	0	(0.0)
	1	(3.6)	0	(0.0)	0	(0.0)	0	(0.0)	1	(5.0)
	31	(49.2)	28	(45.2)	30	(58.8)	22	(52.4)	21	(47.7)
	0	(0.0)	1	(14.3)	0	(0.0)	0	(0.0)	0	(0.0)
	14	(13.2)	8	(8.8)	9	(8.2)	-	-	-	-
	18	(11.0)	13	(7.9)	17	(14.2)	13	(10.9)	25	(21.2)
	4	(28.6)	1	(6.7)	2	(18.2)	0	(0.0)	2	(11.8)
	4	(8.2)	7	(8.2)	5	(7.4)	2	(6.5)	4	(19.0)
	0	(0.0)	0	-	0	-	0	-	0	-
	1	(4.2)	0	(0.0)	1	(7.7)	0	(0.0)	0	(0.0)
	33	(12.5)	29	(10.4)	24	(5.4)	12	(8.8)	-	-
	47	(35.3)	24	(23.5)	23	(28.8)	32	(33.0)	27	(25.7)
	-	-	-	-	-	-	-	-	0	(0.0)
	208	(51.9)	181	(50.3)	179	(48.9)	153	(44.3)	135	(44.1)
	0	-	0	-	0	(0.0)	0	(0.0)	0	(0.0)
	0	-	1	(50.0)	0	-	0	(0.0)	0	-
	3	(12.0)	1	(3.3)	4	(16.0)	1	(5.0)	7	(33.3)
	0	(0.0)	2	(9.1)	0	(0.0)	1	(7.7)	1	(6.3)
	8	(1.7)	17	(3.7)	18	(3.2)	11	(2.1)	21	(4.3)
	10	(6.7)	6	(5.7)	8	(7.5)	6	(5.3)	5	(8.9)
	476	(19.4)	458	(19.7)	423	(18.9)	527	(20.8)	396	(17.5)
	1	(2.9)	1	(3.4)	1	(3.4)	1	(3.8)	1	(2.9)
	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
	45	(11.7)	13	(11.8)	16	(16.7)	11	(15.9)	7	(6.8)
	2	(8.0)	5	(20.8)	5	(23.8)	2	(13.3)	2	(12.5)
	10	(3.9)	9	(4.6)	12	(6.9)	13	(7.1)	7	(3.6)
	<b>961</b>	<b>(17.9)</b>	<b>859</b>	<b>(17.9)</b>	<b>822</b>	<b>(17.1)</b>	<b>856</b>	<b>(18.5)</b>	<b>687</b>	<b>(17.0)</b>
	0	(0.0)	1	(5.3)	3	(27.3)	0	(0.0)	0	(0.0)
	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
	76	(38.0)	28	(28.3)	13	(14.4)	35	(38.5)	23	(34.3)
	-	-	459	(47.8)	35	(23.2)	468	(30.0)	778	(48.8)
	840	(47.9)	1021	(60.2)	622	(65.6)	811	(68.6)	598	(54.5)
	2	(3.0)	1	(2.1)	4	(9.8)	3	(4.5)	1	(1.6)
	1	(3.6)	5	(17.9)	1	(4.0)	4	(15.4)	1	(6.3)
	185	(31.1)	171	(30.6)	214	(31.7)	169	(31.2)	201	(38.1)
	2	(25.0)	0	(0.0)	1	(11.1)	2	(33.3)	1	(100.0)
	2329	(52.8)	2099	(45.1)	2456	(51.3)	5744	(55.0)	4035	(57.8)
	161	(61.2)	-	-	-	-	453	(54.5)	547	(55.1)
	780	(69.1)	746	(65.4)	642	(63.8)	581	(62.3)	561	(62.1)
	-	-	-	-	-	-	-	-	-	-
	1	(11.1)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
	2314	(34.0)	6169	(46.0)	7189	(52.8)	7075	(57.4)	6795	(56.3)
	-	-	-	-	-	-	-	-	-	-
	-	-	8	(7.1)	6	(6.0)	3	(3.6)	4	(4.7)
	1	(2.4)	3	(9.1)	4	(10.0)	4	(12.9)	8	(23.5)
	257	(44.3)	174	(78.0)	308	(74.2)	278	(56.0)	16	(34.8)
	123	(20.5)	140	(22.8)	146	(24.3)	140	(21.8)	105	(17.8)
	18	(16.2)	19	(30.2)	-	-	-	-	-	-
	2045	(32.2)	3844	(79.4)	2283	(51.7)	1908	(32.2)	3365	(40.7)
	539	(73.6)	593	(50.3)	89	(72.4)	479	(46.7)	1495	(56.1)
	<b>9674</b>	<b>(40.8)</b>	<b>15481</b>	<b>(51.7)</b>	<b>14016</b>	<b>(51.8)</b>	<b>18157</b>	<b>(50.1)</b>	<b>18534</b>	<b>(51.5)</b>
	<b>10635</b>	<b>(36.4)</b>	<b>16340</b>	<b>(46.8)</b>	<b>14838</b>	<b>(46.3)</b>	<b>19013</b>	<b>(47.0)</b>	<b>19221</b>	<b>(48.0)</b>
	<b>10460</b>	<b>(39.2)</b>	<b>16194</b>	<b>(49.5)</b>	<b>14689</b>	<b>(49.4)</b>	<b>18908</b>	<b>(48.9)</b>	<b>19112</b>	<b>(49.5)</b>

Table VI. MDR TB notification among all laboratory confirmed TB cases with available DST results, EU/EEA 2004–2013

Country	2004			2005			2006			2007			2008		
	N	%	Rate	N	%	Rate	N	%	Rate	N	%	Rate	N	%	Rate
<b>EU/EEA</b>															
Austria	19	(3.0)	0.2	13	(2.1)	0.2	10	(1.9)	0.1	9	(1.8)	0.1	15	(3.1)	0.2
Belgium	12	(1.4)	0.1	11	(1.5)	0.1	18	(2.2)	0.2	14	(1.9)	0.1	21	(2.7)	0.2
<i>Bulgaria</i>	47	(5.7)	0.6	47	(4.0)	0.6	53	(4.0)	0.7	76	(7.5)	1.0	31	(3.3)	0.4
Croatia	3	(0.4)	0.1	6	(0.9)	0.1	3	(0.4)	0.1	7	(1.0)	0.2	0	-	0.0
Cyprus	0	(0.0)	0.0	1	(5.9)	0.1	0	(0.0)	0.0	3	(10.3)	0.4	1	(2.8)	0.1
Czech Republic	6	(1.2)	0.1	13	(2.2)	0.1	12	(2.1)	0.1	8	(1.5)	0.1	11	(2.1)	0.1
Denmark	0	(0.0)	0.0	5	(1.5)	0.1	3	(1.0)	0.1	2	(0.7)	0.0	0	(0.0)	0.0
<i>Estonia</i>	90	(19.9)	6.6	78	(20.2)	5.7	55	(15.6)	4.1	82	(21.4)	6.1	73	(21.0)	5.5
Finland	0	(0.0)	0.0	3	(0.9)	0.1	2	(0.7)	0.0	1	(0.4)	0.0	2	(0.8)	0.0
France	26	(1.5)	0.0	24	(1.6)	0.0	30	(2.0)	0.0	20	(1.3)	0.0	27	(1.7)	0.0
Germany	98	(2.5)	0.1	103	(2.7)	0.1	82	(2.3)	0.1	66	(2.0)	0.1	49	(1.6)	0.1
Greece	16	(3.2)	0.1	12	(2.0)	0.1	13	(2.6)	0.1	-	-	-	-	-	-
Hungary	11	(2.2)	0.1	17	(4.1)	0.2	14	(2.6)	0.1	12	(2.6)	0.1	13	(2.8)	0.1
Iceland	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	1	(9.1)	0.3	1	(20.0)	0.3
Ireland	2	(0.8)	0.0	3	(1.1)	0.1	4	(1.4)	0.1	7	(2.4)	0.2	2	(0.7)	0.0
Italy	24	(3.1)	0.0	22	(3.8)	0.0	28	(3.3)	0.2	56	(3.3)	0.1	71	(3.7)	0.1
<i>Latvia</i>	195	(17.7)	8.6	161	(15.3)	7.2	142	(14.7)	6.4	99	(10.1)	4.5	128	(15.5)	5.8
Liechtenstein	-	-	-	-	-	-	-	-	-	0	(0.0)	0.0	-	-	-
<i>Lithuania</i>	318	(20.0)	9.4	338	(19.4)	10.1	332	(18.6)	10.1	314	(18.6)	9.7	276	(17.1)	8.6
Luxembourg	1	(3.2)	0.2	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	-	-	-
Malta	0	(0.0)	0.0	0	(0.0)	0.0	2	(14.3)	0.5	1	(5.3)	0.2	0	(0.0)	0.0
Netherlands	3	(0.4)	0.0	8	(0.9)	0.0	6	(0.8)	0.0	6	(0.8)	0.0	15	(2.0)	0.1
Norway	4	(1.6)	0.1	3	(1.4)	0.1	3	(1.3)	0.1	3	(1.2)	0.1	4	(1.8)	0.1
Poland	51	(1.6)	0.1	46	(1.2)	0.1	32	(0.9)	0.1	22	(0.6)	0.1	19	(0.5)	0.0
Portugal	35	(2.3)	0.3	31	(1.9)	0.3	22	(1.3)	0.2	34	(2.0)	0.3	32	(1.8)	0.3
<i>Romania</i>	810	(17.5)	3.8	849	(17.1)	4.0	673	(14.8)	3.2	673	(17.6)	3.2	792	(14.3)	3.9
Slovakia	1	(0.3)	0.0	8	(2.6)	0.1	7	(1.7)	0.1	7	(1.8)	0.1	4	(1.0)	0.1
Slovenia	0	(0.0)	0.0	1	(0.4)	0.1	1	(0.5)	0.0	0	(0.0)	0.0	2	(1.0)	0.1
Spain	59	(3.8)	0.1	80	(4.7)	0.2	50	(3.8)	0.1	-	-	-	76	(4.7)	0.2
Sweden	6	(1.6)	0.1	4	(0.9)	0.0	3	(0.8)	0.0	15	(4.1)	0.2	11	(2.6)	0.1
United Kingdom	49	(1.1)	0.1	43	(0.9)	0.1	58	(1.1)	0.1	62	(1.3)	0.1	55	(1.1)	0.1
<b>Total EU/EEA</b>	<b>1886</b>	<b>(5.8)</b>	<b>0.4</b>	<b>1930</b>	<b>(5.7)</b>	<b>0.4</b>	<b>1658</b>	<b>(5.0)</b>	<b>0.3</b>	<b>1600</b>	<b>(5.2)</b>	<b>0.3</b>	<b>1731</b>	<b>(5.2)</b>	<b>0.3</b>

EU/EEA countries designated as high-priority countries by WHO are presented in italics.

	2009			2010			2011			2012			2013			Mean annual % change in rate, 2004–2013
	N	%	Rate	N	%	Rate	N	%	Rate	N	%	Rate	N	%	Rate	
	23	(5.3)	0.3	16	(3.4)	0.2	20	(4.4)	0.2	27	(6.9)	0.3	16	(3.6)	0.2	4.5%
	10	(1.3)	0.1	19	(2.3)	0.2	15	(2.0)	0.1	19	(2.6)	0.2	13	(1.8)	0.1	9.7%
	43	(5.1)	0.6	56	(5.8)	0.8	55	(7.5)	0.7	49	(5.9)	0.7	27	(3.7)	0.4	1.8%
	7	(1.4)	0.2	0	(0.0)	0.0	2	(0.5)	0.0	1	(0.3)	0.0	0	(0.0)	0.0	-
	4	(12.5)	0.5	0	(0.0)	0.0	1	(2.5)	0.1	0	(0.0)	0.0	1	(3.3)	0.1	-
	8	(1.8)	0.1	9	(2.1)	0.1	7	(1.7)	0.1	4	(1.0)	0.0	0	(0.0)	0.0	-7.7%
	2	(0.8)	0.0	2	(0.7)	0.0	3	(1.1)	0.1	1	(0.3)	0.0	2	(0.7)	0.0	-
	85	(28.0)	6.4	64	(24.2)	4.8	78	(29.8)	5.9	61	(25.7)	4.6	50	(22.7)	3.8	-3.1%
	4	(1.3)	0.1	6	(2.4)	0.1	5	(2.0)	0.1	3	(1.4)	0.1	2	(1.0)	0.0	-
	30	(1.0)	0.0	23	(1.6)	0.0	40	(2.6)	0.1	-	-	-	83	(1.9)	0.1	-
	62	(2.0)	0.1	51	(1.8)	0.1	56	(1.9)	0.1	61	(2.1)	0.1	100	(3.4)	0.1	3.5%
	12	(7.1)	0.1	2	(1.2)	0.0	5	(3.1)	0.0	3	(1.7)	0.0	10	(4.3)	0.1	-
	18	(4.0)	0.2	19	(3.3)	0.2	7	(1.5)	0.1	11	(2.4)	0.1	10	(2.8)	0.1	6.8%
	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	1	(20.0)	0.3	0	(0.0)	0.0	-
	1	(0.3)	0.0	2	(0.7)	0.0	3	(1.2)	0.1	5	(1.8)	0.1	4	(1.5)	0.1	24.2%
	82	(3.3)	0.1	87	(3.4)	0.1	81	(3.2)	0.1	74	(3.0)	0.1	78	(3.3)	0.1	-
	131	(17.4)	6.1	88	(12.3)	4.2	95	(14.8)	4.6	107	(14.0)	5.2	79	(11.6)	3.9	-6.1%
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	322	(21.8)	10.1	310	(22.7)	9.9	296	(21.1)	9.7	271	(19.8)	9.0	256	(18.9)	8.6	-0.6%
	0	(0.0)	0.0	0	(0.0)	0.0	2	(10.5)	0.4	0	(0.0)	0.0	0	(0.0)	0.0	-
	0	(0.0)	0.0	1	(6.3)	0.2	0	(0.0)	0.0	0	(0.0)	0.0	1	(3.7)	0.2	-
	20	(2.6)	0.1	11	(1.4)	0.1	17	(2.3)	0.1	11	(1.7)	0.1	17	(2.8)	0.1	38.8%
	8	(2.8)	0.2	8	(2.9)	0.2	4	(1.6)	0.1	6	(2.1)	0.1	6	(1.9)	0.1	10.8%
	21	(0.5)	0.1	30	(0.8)	0.1	41	(0.8)	0.1	31	(0.7)	0.1	40	(0.9)	0.1	0.9%
	24	(1.4)	0.2	28	(1.7)	0.3	36	(2.4)	0.3	22	(1.4)	0.2	15	(1.5)	0.1	-4.8%
	624	(10.0)	3.1	574	(9.4)	2.9	547	(8.6)	2.7	684	(9.0)	3.4	555	(7.8)	2.8	-2.2%
	1	(0.4)	0.0	1	(0.4)	0.0	3	(1.6)	0.1	1	(0.6)	0.0	3	(1.4)	0.1	100.2%
	1	(0.6)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	0	(0.0)	0.0	-
	56	(3.2)	0.1	49	(3.5)	0.1	41	(3.2)	0.1	37	(4.2)	0.1	34	(2.2)	0.1	-4.2%
	13	(2.5)	0.1	18	(3.4)	0.2	17	(3.6)	0.2	14	(2.8)	0.1	8	(1.5)	0.1	33.0%
	61	(1.2)	0.1	67	(1.3)	0.1	86	(1.6)	0.1	82	(1.6)	0.1	74	(1.6)	0.1	5.0%
	<b>1673</b>	<b>(4.6)</b>	<b>0.3</b>	<b>1541</b>	<b>(4.6)</b>	<b>0.3</b>	<b>1563</b>	<b>(4.5)</b>	<b>0.3</b>	<b>1586</b>	<b>(4.7)</b>	<b>0.3</b>	<b>1484</b>	<b>(4.1)</b>	<b>0.3</b>	<b>-2.8%</b>

**Table VII. XDR TB notification among pulmonary MDR TB cases with second line DST results, European Region, 2006–2013<sup>a</sup>**

Country	2006			2007			2008			2009			2010		
	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested
<b>EU/EEA</b>															
Austria	-	-	-	-	-	-	13	4	(30.8)	20	2	(10.0)	15	1	(6.7)
Belgium	18	2	(11.1)	12	1	(8.3)	18	2	(11.1)	8	3	(37.5)	16	2	(12.5)
Bulgaria	-	-	-	42	6	(14.3)	27	7	(3.7)	23	1	(4.3)	35	1	(2.9)
Croatia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cyprus	-	-	-	2	0	(0.0)	1	0	(0.0)	1	0	(0.0)	0	0	-
Czech Republic	4	3	(75.0)	4	0	(0.0)	10	1	(10.0)	7	1	(14.3)	4	1	(25.0)
Denmark	-	-	-	-	-	-	-	-	-	2	0	(0.0)	1	0	(0.0)
Estonia	51	5	(9.8)	80	14	(17.5)	69	6	(8.7)	78	8	(10.3)	62	11	(17.7)
Finland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Greece	-	-	-	-	-	-	-	-	-	11	2	(18.2)	2	0	(0.0)
Hungary	-	-	-	-	-	-	-	-	-	-	-	-	16	2	(12.5)
Iceland	-	-	-	1	0	(0.0)	1	0	(0.0)	0	0	-	0	0	-
Ireland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Italy	-	-	-	-	-	-	-	-	-	32	1	(3.1)	10	0	(0.0)
Latvia	-	-	-	93	6	(6.5)	121	19	(15.7)	126	14	(11.1)	87	13	(14.9)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	-	-	-	-	-	-	-	-	-	4	4	(100.0)	303	50	(16.5)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Malta	-	-	-	1	0	(0.0)	0	0	-	0	0	-	1	0	(0.0)
Netherlands	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Norway	-	-	-	-	-	-	-	-	-	4	0	(0.0)	6	0	(0.0)
Poland	-	-	-	-	-	-	4	3	(75.0)	5	1	(20.0)	11	1	(9.1)
Portugal	-	-	-	-	-	-	-	-	-	-	-	-	14	3	(21.4)
Romania	1	1	(100.0)	48	48	(100.0)	78	53	(67.9)	217	26	(12.0)	215	27	(12.6)
Slovakia	-	-	-	5	0	(0.0)	4	0	(0.0)	1	0	(0.0)	1	0	(0.0)
Slovenia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Spain	-	-	-	-	-	-	63	3	(4.8)	56	5	(8.9)	49	3	(6.1)
Sweden	-	-	-	12	1	(8.3)	8	1	(12.5)	7	0	(0.0)	0	0	-
United Kingdom	37	0	(0.0)	40	0	(0.0)	36	3	(8.3)	37	2	(5.4)	39	3	(7.7)
<b>Subtotal EU/EEA</b>	<b>111</b>	<b>11</b>	<b>(9.9)</b>	<b>340</b>	<b>76</b>	<b>(22.4)</b>	<b>453</b>	<b>96</b>	<b>(21.2)</b>	<b>639</b>	<b>70</b>	<b>(11.0)</b>	<b>887</b>	<b>118</b>	<b>(13.3)</b>
<b>Non-EU/EEA</b>															
Albania	-	-	-	0	0	(0.0)	-	-	-	0	0	(0.0)	2	0	(0.0)
Andorra	-	-	-	0	0	(0.0)	-	-	-	0	0	(0.0)	0	0	(0.0)
Armenia	-	-	-	125	10	(8.0)	-	-	-	-	-	-	60	1	(1.7)
Azerbaijan	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Belarus	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bosnia and Herzegovina	-	-	-	0	0	(0.0)	-	-	-	-	-	-	-	-	-
former Yugoslav Republic of Macedonia, the	0	0	(0.0)	-	-	-	0	0	(0.0)	0	0	(0.0)	5	1	(20.0)
Georgia	-	-	-	140	13	(9.3)	-	-	-	306	32	(10.5)	313	30	(9.6)
Israel	19	0	(0.0)	14	0	(0.0)	13	1	(7.7)	6	0	(0.0)	12	1	(8.3)
Kazakhstan	-	-	-	-	-	-	-	-	-	282	216	(76.6)	-	-	-
Kyrgyzstan	-	-	-	-	-	-	-	-	-	-	-	-	32	32	(100.0)
Moldova	47	3	(6.4)	-	-	-	-	-	-	-	-	-	-	-	-
Monaco	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	-	-	(0.0)	2	0	(0.0)	-	-	-	1	0	(0.0)	0	0	(0.0)
Russia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	-	-	-	0	0	(0.0)	-	-	-	-	-	-	-	-	-
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
UN Administered Province of Kosovo <sup>b</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	-	-	-	8	0	(0.0)	5	0	(0.0)	-	-	-	9	0	(0.0)
Tajikistan	-	-	-	-	-	-	-	-	-	52	11	(21.2)	-	-	-
Turkey	-	-	-	0	0	(0.0)	0	0	-	-	-	-	5	3	(60.0)
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Uzbekistan	-	-	-	19	9	(47.4)	45	8	(17.8)	58	13	(22.4)	364	16	(4.4)
<b>Subtotal non-EU/EEA</b>	<b>66</b>	<b>3</b>	<b>(4.5)</b>	<b>308</b>	<b>32</b>	<b>(10.4)</b>	<b>63</b>	<b>9</b>	<b>(14.3)</b>	<b>705</b>	<b>272</b>	<b>(38.6)</b>	<b>802</b>	<b>84</b>	<b>(10.5)</b>
<b>Total European Region</b>	<b>177</b>	<b>14</b>	<b>(7.9)</b>	<b>648</b>	<b>108</b>	<b>(16.7)</b>	<b>516</b>	<b>105</b>	<b>(20.3)</b>	<b>1344</b>	<b>342</b>	<b>(25.4)</b>	<b>1689</b>	<b>202</b>	<b>(12.0)</b>
<b>Subtotal 18 HPC</b>	<b>99</b>	<b>9</b>	<b>(9.1)</b>	<b>547</b>	<b>106</b>	<b>(19.4)</b>	<b>340</b>	<b>87</b>	<b>(25.6)</b>	<b>1146</b>	<b>325</b>	<b>(28.4)</b>	<b>1476</b>	<b>184</b>	<b>(12.5)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> Includes only countries reporting second-line anti-TB drug susceptibility testing – at least one fluoroquinolone (ofloxacin, moxifloxacin and ciprofloxacin) and one injectable drug (amikacin, kanamycin and capreomycin).

<sup>c</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	2011			2012			2013		
	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested
	19	5	(26.3)	26	7	(26.9)	16	3	(18.8)
	12	3	(25.0)	15	2	(13.3)	10	0	(0.0)
	45	0	(0.0)	48	5	(10.4)	26	4	(15.4)
	-	-	-	-	-	-	-	-	-
	0	0	-	0	0	-	1	1	(100.0)
	5	2	(40.0)	2	1	(50.0)	0	0	-
	1	0	(0.0)	0	0	-	2	1	(50.0)
	74	14	(18.9)	55	5	(9.1)	49	8	(16.3)
	-	-	-	3	1	(33.3)	2	0	(0.0)
	-	-	-	-	-	-	-	-	-
	6	1	(16.7)	12	1	(8.3)	26	2	(7.7)
	5	2	(40.0)	2	0	(0.0)	10	0	(0.0)
	5	0	(0.0)	10	2	(20.0)	9	1	(11.1)
	0	0	-	0	0	-	0	0	-
	1	0	(0.0)	1	0	(0.0)	3	1	(33.3)
	50	6	(12.0)	50	5	(10.0)	-	-	-
	92	12	(13.0)	104	17	(16.3)	69	15	(21.7)
	-	-	-	-	-	-	-	-	-
	292	51	(17.5)	210	52	(24.8)	186	46	(24.7)
	-	-	-	-	-	-	-	-	-
	0	0	-	0	0	-	1	1	(100.0)
	-	-	-	-	-	-	0	0	-
	2	0	(0.0)	4	0	(0.0)	5	1	(20.0)
	9	1	(11.1)	4	0	(0.0)	4	1	(25.0)
	21	9	(42.9)	15	3	(20.0)	11	4	(36.4)
	259	34	(13.1)	369	41	(11.1)	264	44	(16.7)
	3	0	(0.0)	1	0	(0.0)	2	0	(0.0)
	-	-	-	-	-	-	-	-	-
	41	1	(2.4)	37	1	(2.7)	34	2	(5.9)
	11	0	(0.0)	9	1	(11.1)	7	2	(28.6)
	54	6	(11.1)	61	2	(3.3)	43	2	(4.7)
	<b>1007</b>	<b>147</b>	<b>(14.6)</b>	<b>1038</b>	<b>146</b>	<b>(14.1)</b>	<b>780</b>	<b>139</b>	<b>(17.8)</b>
	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)
	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)
	79	0	(0.0)	92	2	(2.2)	66	7	(10.6)
	84	3	(3.6)	319	38	(11.9)	-	-	-
	-	-	-	-	-	-	1353	80	(5.9)
	5	0	(0.0)	5	0	(0.0)	-	-	-
	0	0	(0.0)	1	1	(100.0)	0	0	(0.0)
	440	28	(6.4)	341	30	(8.8)	369	71	(19.2)
	11	0	(0.0)	17	4	(23.5)	7	1	(14.3)
	825	187	(22.7)	-	-	-	-	-	-
	357	-	-	511	18	(3.5)	-	-	-
	-	-	-	761	33	(4.3)	782	35	(4.5)
	-	-	-	-	-	-	-	-	-
	1	0	(0.0)	0	0	(0.0)	0	0	(0.0)
	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-
	9	2	(22.2)	9	0	(0.0)	6	0	(0.0)
	8	0	(0.0)	8	0	(0.0)	12	1	(8.3)
	122	12	(9.8)	345	49	(14.2)	159	28	(17.6)
	13	1	(7.7)	104	6	(5.8)	114	3	(2.6)
	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-
	834	12	(1.4)	356	31	(8.7)	528	167	(31.6)
	<b>2788</b>	<b>245</b>	<b>(8.8)</b>	<b>2869</b>	<b>212</b>	<b>(7.4)</b>	<b>3396</b>	<b>393</b>	<b>(11.6)</b>
	<b>3795</b>	<b>392</b>	<b>(10.3)</b>	<b>3907</b>	<b>358</b>	<b>(9.2)</b>	<b>4176</b>	<b>532</b>	<b>(12.7)</b>
	<b>3516</b>	<b>354</b>	<b>(10.1)</b>	<b>3615</b>	<b>327</b>	<b>(9.0)</b>	<b>3965</b>	<b>508</b>	<b>(12.8)</b>

Table VIII. XDR TB notification among all MDR TB cases with second line DST results, EU/EEA, 2006–2013<sup>a</sup>

Country	2006			2007			2008			2009			2010		
	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested
<b>EU/EEA</b>															
Austria	-	-	-	-	-	-	13	4	(30.8)	21	2	(9.5)	16	1	(6.3)
Belgium	18	2	(11.1)	14	1	(7.1)	21	2	(9.5)	10	3	(30.0)	19	2	(10.5)
<i>Bulgaria</i>	-	-	-	42	6	(14.3)	27	1	(3.7)	24	1	(4.2)	35	1	(2.9)
Croatia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cyprus	-	-	-	2	0	(0.0)	1	0	(0.0)	2	0	(0.0)	0	0	-
Czech Republic	4	3	(75.0)	4	0	(0.0)	10	1	(10.0)	7	1	(14.3)	4	1	(25.0)
Denmark	-	-	-	-	-	-	-	-	-	2	0	(0.0)	2	0	(0.0)
<i>Estonia</i>	52	5	(9.6)	82	14	(17.1)	69	6	(8.7)	79	8	(10.1)	63	11	(17.5)
Finland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Greece	-	-	-	-	-	-	-	-	-	11	2	(18.2)	2	0	(0.0)
Hungary	-	-	-	-	-	-	-	-	-	-	-	-	18	2	(11.1)
Iceland	-	-	-	1	0	(0.0)	1	0	(0.0)	0	0	-	0	0	-
Ireland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Italy	-	-	-	-	-	-	-	-	-	32	1	(3.1)	10	0	(0.0)
<i>Latvia</i>	-	-	-	95	6	(6.3)	127	19	(15.0)	130	16	(12.3)	87	13	(14.9)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	-	-	-	-	-	-	-	-	-	4	4	(100.0)	310	50	(16.1)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Malta	-	-	-	1	0	(0.0)	0	0	-	0	0	-	1	0	(0.0)
Netherlands	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Norway	-	-	-	-	-	-	-	-	-	4	0	(0.0)	8	0	(0.0)
Poland	-	-	-	-	-	-	4	3	(75.0)	5	1	(20.0)	12	1	(8.3)
Portugal	-	-	-	-	-	-	-	-	-	-	-	-	16	4	(25.0)
<i>Romania</i>	1	1	(100.0)	48	48	(100.0)	78	53	(67.9)	217	26	(12.0)	215	27	(12.6)
Slovakia	-	-	-	5	0	(0.0)	4	0	(0.0)	1	0	(0.0)	1	0	(0.0)
Slovenia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Spain	-	-	-	-	-	-	63	3	(4.8)	56	5	(8.9)	49	3	(6.1)
Sweden	-	-	-	14	1	(7.1)	10	1	(10.0)	13	0	(0.0)	0	0	-
United Kingdom	57	0	(0.0)	57	0	(0.0)	52	3	(5.8)	58	2	(3.4)	62	3	(4.8)
<b>Total EU/EEA</b>	<b>132</b>	<b>11</b>	<b>(8.3)</b>	<b>365</b>	<b>76</b>	<b>(20.8)</b>	<b>480</b>	<b>96</b>	<b>(20.0)</b>	<b>676</b>	<b>72</b>	<b>(10.7)</b>	<b>930</b>	<b>119</b>	<b>(12.8)</b>

EU/EEA countries designated as high-priority countries by WHO are presented in italics.

<sup>a</sup> Includes only countries reporting second-line anti-TB drug susceptibility testing – at least one fluoroquinolone (ofloxacin, moxifloxacin and ciprofloxacin) and one injectable drug (amikacin, kanamycin and capreomycin).

	2011			2012			2013		
	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested	MDR TB tested for 2nd LDs (N)	XDR TB (N)	% among tested
	20	6	(30.0)	27	7	(25.9)	16	3	(18.8)
	15	3	(20.0)	19	2	(10.5)	13	0	(0.0)
	46	0	(0.0)	49	5	(10.2)	27	4	(14.8)
	-	-	-	-	-	-	-	-	-
	1	0	(0.0)	0	0	-	1	1	(100.0)
	5	2	(40.0)	2	1	(50.0)	0	0	-
	2	0	(0.0)	1	0	(0.0)	2	1	(50.0)
	75	14	(18.7)	56	5	(8.9)	49	8	(16.3)
	-	-	-	3	1	(33.3)	2	0	(0.0)
	-	-	-	-	-	-	81	21	(25.9)
	6	1	(16.7)	12	1	(8.3)	29	2	(6.9)
	5	2	(40.0)	3	0	(0.0)	10	0	(0.0)
	5	0	(0.0)	10	2	(20.0)	9	1	(11.1)
	0	0	-	1	0	(0.0)	0	0	-
	1	0	(0.0)	2	0	(0.0)	3	1	(33.3)
	50	6	(12.0)	50	5	(10.0)	55	7	-
	95	12	(12.6)	106	17	(16.0)	73	15	(20.5)
	-	-	-	-	-	-	0	0	-
	296	52	(17.6)	210	52	(24.8)	188	47	(25.0)
	-	-	-	-	-	-	-	-	-
	0	0	-	0	0	-	1	1	(100.0)
	-	-	-	-	-	-	-	-	-
	4	0	(0.0)	6	0	(0.0)	6	1	(16.7)
	9	1	(11.1)	4	0	(0.0)	4	1	(25.0)
	21	9	(42.9)	16	4	(25.0)	11	4	(36.4)
	260	34	(13.1)	369	41	(11.1)	268	44	(16.4)
	3	0	(0.0)	1	0	(0.0)	2	0	(0.0)
	-	-	-	-	-	-	0	0	-
	41	1	(2.4)	37	1	(2.7)	34	2	-
	17	0	(0.0)	14	2	(14.3)	8	2	(25.0)
	85	6	(7.1)	81	2	(2.5)	71	3	(4.2)
	<b>1062</b>	<b>149</b>	<b>(14.0)</b>	<b>1079</b>	<b>148</b>	<b>(13.7)</b>	<b>963</b>	<b>169</b>	<b>(17.5)</b>

Table IX. Tuberculosis cases with HIV infection, European Region, 2004–2013<sup>a</sup>

## Part a: 2004–2009

Country	2004					2005					2006				
	All TB cases (N)	Cases with known HIV status		HIV positive		All TB cases (N)	Cases with known HIV status		HIV positive		All TB cases (N)	Cases with known HIV status		HIV positive	
		N	%	N	% <sup>b</sup>		N	%	N	% <sup>b</sup>		N	%	N	% <sup>b</sup>
<b>EU/EEA</b>															
Austria	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Belgium	1198	751	(62.7)	53	(7.1)	1107	937	(84.6)	52	(5.5)	1117	927	(83.0)	55	(5.9)
Bulgaria	3232	19	(0.6)	-	-	-	-	-	-	-	3232	247	(7.6)	6	-
Croatia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cyprus	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Czech Republic	1057	234	(22.1)	2	(0.9)	984	189	(19.2)	2	(1.1)	951	163	(17.1)	4	(2.5)
Denmark	385	385	(100.0)	7	(1.8)	-	-	-	-	-	-	-	-	-	-
Estonia	594	477	(80.3)	26	(5.5)	518	490	95	33	(6.7)	460	414	(90.0)	41	(9.9)
Finland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Iceland	12	8	(66.7)	1	(12.5)	11	10	(90.9)	1	(10.0)	13	10	(76.9)	2	(20.0)
Ireland	-	-	-	-	-	450	28	(6.2)	11	(39.3)	463	45	(9.7)	13	(28.9)
Italy	4220	404	(9.6)	11	(2.7)	-	-	-	-	-	-	-	-	-	-
Latvia	1610	1449	(90.0)	40	(2.8)	1443	1226	85	53	(4.3)	1328	1128	(84.9)	47	(4.2)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	2514	2514	(100.0)	8	(0.3)	-	-	-	-	-	-	-	-	-	-
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Malta	19	19	(100.0)	1	(5.3)	-	-	-	-	-	-	-	-	-	-
Netherlands	1344	1344	(100.0)	46	(3.4)	1128	252	(22.3)	61	(24.2)	1031	201	(19.5)	43	(21.4)
Norway	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Poland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Portugal	3854	2504	(65.0)	626	(25.0)	3558	2485	(69.8)	571	(23.0)	3456	2677	(77.5)	508	(19.0)
Romania	31034	1710	(5.5)	5	(0.3)	29288	10860	(37.1)	160	(1.5)	26600	8402	(31.6)	60	(0.7)
Slovakia	705	700	(99.3)	0	(0.0)	760	720	(94.7)	1	(0.1)	730	708	(97.0)	0	(0.0)
Slovenia	263	89	(33.8)	3	(3.4)	278	107	(38.5)	0	(0.0)	215	70	(32.6)	1	(1.4)
Spain	6392	2453	(38.4)	328	(13.4)	-	-	-	-	-	-	-	-	-	-
Sweden	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
United Kingdom	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Subtotal EU/EEA</b>	<b>58433</b>	<b>15060</b>	<b>(25.8)</b>	<b>1157</b>	<b>(7.7)</b>	<b>39525</b>	<b>17304</b>	<b>(43.8)</b>	<b>945</b>	<b>(5.5)</b>	<b>39596</b>	<b>14992</b>	<b>(37.9)</b>	<b>780</b>	<b>(5.2)</b>
<b>Non-EU/EEA</b>															
Albania	581	145	(25.0)	0	(0.0)	540	81	(15.0)	1	(0.2)	502	51	(10.2)	3	(0.6)
Andorra	7	0	(0.0)	0	(0.0)	10	0	(0.0)	0	(0.0)	13	0	(0.0)	0	(0.0)
Armenia	1701	270	(15.9)	6	(0.4)	2322	270	(11.6)	6	(0.3)	2155	332	(15.4)	25	(1.2)
Azerbaijan	6501	3295	(50.7)	0	(0.0)	7920	0	(0.0)	0	(0.0)	7498	0	(0.0)	0	(0.0)
Belarus	6490	6457	(99.5)	77	(1.2)	6357	0	(0.0)	139	(2.2)	6065	0	(0.0)	0	(0.0)
Bosnia and Herzegovina	2382	0	(0.0)	0	(0.0)	2160	0	(0.0)	0	(0.0)	1800	0	(0.0)	0	(0.0)
former Yugoslav Republic of Macedonia, the	680	10	(1.5)	0	(0.0)	658	2	(0.3)	2	(0.3)	627	96	(15.3)	0	(0.0)
Georgia	5967	726	(12.2)	9	(0.2)	6448	674	(10.5)	13	(0.2)	6311	649	(10.3)	17	(0.3)
Israel	456	387	(84.9)	12	(2.6)	372	316	(84.9)	17	(4.6)	340	289	(85.0)	12	(3.5)
Kazakhstan	39380	0	(0.0)	0	(0.0)	40429	31187	(77.1)	183	(0.5)	38556	43204	(112.1)	234	(0.6)
Kyrgyzstan	6591	0	(0.0)	0	(0.0)	6765	0	(0.0)	0	(0.0)	6656	0	(0.0)	0	(0.0)
Moldova	6008	0	(0.0)	0	(0.0)	6278	6469	(103.0)	9	(0.1)	6118	2523	(41.2)	20	(0.3)
Monaco	0	0	-	0	-	0	0	-	-	-	-	-	-	-	-
Montenegro	0	0	-	-	-	170	8	(4.7)	0	(0.0)	171	17	(9.9)	1	(0.6)
Russia	152438	0	(0.0)	4506	(3.0)	154379	85537	(55.4)	3533	(2.3)	152265	87041	(57.2)	1979	(1.3)
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	-	-	-	-	-	3468	3	(0.1)	3	(0.1)	3272	5	(0.2)	5	(0.2)
Serbia excluding UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	-	3468	3	(0.1)	3	(0.1)	3272	0	(0.0)	5	(0.2)
UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	602	0	(0.0)	0	(0.0)	563	0	(0.0)	0	(0.0)	519	0	(0.0)	0	(0.0)
Tajikistan	5122	0	(0.0)	0	(0.0)	7526	670	(8.9)	1	(0.0)	6671	1639	(24.6)	3	(0.0)
Turkey	8444	0	(0.0)	0	(0.0)	21303	0	(0.0)	0	(0.0)	20526	0	(0.0)	0	(0.0)
Turkmenistan	4182	0	(0.0)	0	(0.0)	3291	0	(0.0)	0	(0.0)	3369	0	(0.0)	0	(0.0)
Ukraine	0	0	-	-	-	0	0	-	1526	-	41265	0	(0.0)	1987	(4.8)
Uzbekistan	25714	31579	(122.8)	138	(0.5)	28891	35801	(123.9)	147	(0.5)	25310	37565	(148.4)	238	(0.9)
<b>Subtotal non-EU/EEA</b>															
<b>Total European Region</b>	<b>272644</b>	<b>42869</b>	<b>(15.7)</b>	<b>4748</b>	<b>(1.7)</b>	<b>299287</b>	<b>161018</b>	<b>(53.8)</b>	<b>5580</b>	<b>(1.9)</b>	<b>329490</b>	<b>173411</b>	<b>(52.6)</b>	<b>4524</b>	<b>(2.6)</b>
<b>Subtotal 18 HPC</b>	<b>331077</b>	<b>57929</b>	<b>(17.5)</b>	<b>5905</b>	<b>(2.0)</b>	<b>338812</b>	<b>178322</b>	<b>(52.6)</b>	<b>6525</b>	<b>(2.1)</b>	<b>369086</b>	<b>188403</b>	<b>(51.0)</b>	<b>5304</b>	<b>(2.8)</b>
	<b>307522</b>	<b>48496</b>	<b>(15.8)</b>	<b>4815</b>	<b>(1.6)</b>	<b>323158</b>	<b>173184</b>	<b>(53.6)</b>	<b>5803</b>	<b>(1.8)</b>	<b>354385</b>	<b>183144</b>	<b>(51.7)</b>	<b>4657</b>	<b>(2.5)</b>

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> HIV prevalence may be underestimated due to incomplete HIV testing and/or reporting of HIV serostatus. Countries reporting only HIV positive cases and untested cases are excluded.

<sup>c</sup> Percentages calculated from TB cases with known HIV test results.

<sup>d</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).



	2007					2008					2009				
	All TB cases (N)	Cases with known HIV status		HIV positive		All TB cases (N)	Cases with known HIV status		HIV positive		All TB cases (N)	Cases with known HIV status		HIV positive	
		N	%	N	% <sup>b</sup>		N	%	N	% <sup>b</sup>		N	%	N	% <sup>b</sup>
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
1020	871	(85.4)	52	(6.0)	990	913	(92.2)	56	(6.1)	994	930	(93.6)	43	(4.6)	
3038	199	(6.6)	0	(0.0)	3150	732	(23.2)	0	(0.0)	2910	1155	(39.7)	1	(0.1)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
42	42	(100.0)	0	(0.0)	50	36	(72.0)	2	(5.6)	-	-	-	-	-	
846	159	(18.8)	6	(3.8)	864	171	(19.8)	6	(3.5)	694	161	(23.2)	6	(3.7)	
391	158	(40.4)	13	(8.2)	380	177	(46.6)	11	(6.2)	334	207	(62.0)	9	(3.4)	
491	453	(92.3)	53	(11.7)	444	401	(90.3)	41	(10.2)	411	380	(92.5)	39	(10.3)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
480	51	(10.6)	16	(31.4)	468	86	(18.4)	17	(19.8)	479	136	(28.4)	11	(8.1)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
1255	1066	(84.9)	56	(5.3)	1070	910	(85.0)	72	(7.9)	977	830	(85.0)	73	(8.8)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
38	27	(71.1)	2	(7.4)	53	45	(84.9)	5	(11.1)	44	38	(86.4)	4	(10.5)	
998	205	(20.5)	32	(15.6)	1015	285	(28.1)	46	(16.1)	1158	380	(32.8)	42	(11.1)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8614	33	(0.4)	15	(45.5)	-	-	-	-	-	-	-	-	-	-	
3139	2664	(84.9)	467	(17.5)	3002	2648	(88.2)	626	(23.6)	2871	2455	(85.5)	392	(16.0)	
24837	6367	(25.6)	178	(2.8)	24680	6123	(24.8)	202	(3.3)	23164	6443	(27.8)	214	(3.3)	
682	682	(100.0)	0	(0.0)	633	537	(84.8)	0	(0.0)	506	500	(98.8)	1	(0.2)	
218	98	(45.0)	0	(0.0)	213	131	(61.5)	3	(2.3)	188	134	(71.3)	0	(0.0)	
7768	3969	(51.1)	548	(13.8)	8216	3991	(48.6)	328	(8.2)	7592	3599	(47.4)	425	(11.8)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<b>53857</b>	<b>17044</b>	<b>(31.6)</b>	<b>1438</b>	<b>(8.4)</b>	<b>45234</b>	<b>17191</b>	<b>(38.0)</b>	<b>1402</b>	<b>(8.2)</b>	<b>42331</b>	<b>17355</b>	<b>(41.0)</b>	<b>1260</b>	<b>(7.2)</b>	
447	37	(8.3)	1	(2.7)	434	177	(40.8)	4	(2.3)	447	211	(47.2)	6	(2.8)	
6	0	(0.0)	0	-	4	0	(0.0)	0	-	9	0	(0.0)	0	-	
2129	335	(15.7)	8	(2.4)	2125	335	(15.8)	12	(3.6)	2006	521	(26.0)	17	(3.3)	
7347	0	(0.0)	31	-	10078	5945	(59.0)	0	(0.0)	10417	0	(0.0)	0	-	
5756	5756	(100.0)	152	(2.6)	5483	5227	(95.3)	156	(3.0)	5511	5227	(94.8)	190	(3.6)	
2400	0	(0.0)	0	-	1736	0	(0.0)	0	-	1772	0	(0.0)	0	-	
563	97	(17.2)	1	(1.0)	483	99	(20.5)	2	(2.0)	473	43	(9.1)	0	(0.0)	
5912	842	(14.2)	32	(3.8)	5836	1482	(25.4)	20	(1.3)	5978	1289	(21.6)	33	(2.6)	
397	397	(100.0)	16	(4.0)	322	283	(87.9)	12	(4.2)	347	288	(83.0)	22	(7.6)	
37658	24532	(65.1)	213	(0.9)	28913	28237	(97.7)	238	(0.8)	30578	29597	(96.8)	325	(1.1)	
6707	0	(0.0)	0	-	7127	6508	(91.3)	117	(1.8)	6358	6358	(100.0)	88	(1.4)	
6367	5123	(80.5)	194	(3.8)	5838	5171	(88.6)	260	(5.0)	5591	5107	(91.3)	260	(5.1)	
0	-	-	0	-	0	0	-	0	-	0	0	-	-	-	
159	32	(20.1)	0	(0.0)	133	73	(54.9)	0	(0.0)	120	91	(75.8)	0	(0.0)	
214924	218866	(101.8)	4828	(2.2)	214905	214905	(100.0)	5892	(2.7)	156222	156222	(100.0)	7064	(4.5)	
0	0	-	0	-	0	0	-	0	-	0	0	-	-	-	
2981	9	(0.3)	9	(100.0)	2813	5	(0.2)	5	(100.0)	2595	5	(0.2)	5	(100.0)	
2981	9	(0.3)	9	(100.0)	2813	5	(0.2)	5	(100.0)	2595	5	(0.2)	5	(100.0)	
-	-	-	-	-	-	-	-	0	-	0	0	-	0	-	
472	0	(0.0)	0	-	516	0	(0.0)	0	-	554	0	(0.0)	0	-	
8081	2763	(34.2)	43	(1.6)	7996	3949	(49.4)	48	(1.2)	7482	3714	(49.6)	49	(1.3)	
19694	0	(0.0)	0	-	18452	0	(0.0)	0	-	17402	1	(0.0)	1	(100.0)	
3698	0	(0.0)	0	-	3909	0	(0.0)	0	-	3157	0	(0.0)	0	-	
40643	34300	(84.4)	2345	(6.8)	37832	35739	(94.5)	3375	(9.4)	38901	33424	(85.9)	3771	(11.3)	
23390	31682	(135.5)	371	(1.2)	21194	21194	(100.0)	256	(1.2)	21453	21453	(100.0)	357	(1.7)	
<b>389259</b>	<b>324771</b>	<b>(83.4)</b>	<b>8244</b>	<b>(2.5)</b>	<b>375613</b>	<b>329329</b>	<b>(87.7)</b>	<b>10397</b>	<b>(3.2)</b>	<b>316819</b>	<b>263551</b>	<b>(83.2)</b>	<b>12188</b>	<b>(4.6)</b>	
<b>443116</b>	<b>341815</b>	<b>(77.1)</b>	<b>9682</b>	<b>(2.8)</b>	<b>420847</b>	<b>346520</b>	<b>(82.3)</b>	<b>11799</b>	<b>(3.4)</b>	<b>359150</b>	<b>280906</b>	<b>(78.2)</b>	<b>13448</b>	<b>(4.8)</b>	
<b>411927</b>	<b>332284</b>	<b>(80.7)</b>	<b>8504</b>	<b>(2.6)</b>	<b>399032</b>	<b>336858</b>	<b>(84.4)</b>	<b>10689</b>	<b>(3.2)</b>	<b>338518</b>	<b>271721</b>	<b>(80.3)</b>	<b>12482</b>	<b>(4.6)</b>	

Table IX. continued

## Part b: 2010–2013

Country	2010					2011					2012				
	All TB cases (N)	Cases with known HIV status		HIV positive		All TB cases (N)	Cases with known HIV status		HIV positive		All TB cases (N)	Cases with known HIV status		HIV positive	
		N	%	N	% <sup>b</sup>		N	%	N	% <sup>b</sup>		N	%	N	% <sup>b</sup>
<b>EU/EEA</b>															
Austria	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Belgium	1086	943	(86.8)	62	(6.6)	1019	829	(81.4)	44	(5.3)	975	549	(56.3)	40	(7.3)
Bulgaria	2649	1773	(66.9)	2	(0.1)	2406	1697	(70.5)	5	(0.3)	2280	1513	(66.4)	3	(0.2)
Croatia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cyprus	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Czech Republic	668	175	(26.2)	5	(2.9)	600	153	(25.5)	4	(2.6)	598	135	(22.6)	5	(3.7)
Denmark	-	-	-	-	-	381	277	(72.7)	10	(3.6)	-	-	-	-	-
Estonia	333	300	(90.1)	34	(11.3)	339	317	(93.5)	46	(14.5)	288	272	(94.4)	45	(16.5)
Finland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
France	5116	1233	(24.1)	121	(9.8)	4991	1354	(27.1)	95	(7.0)	-	-	-	-	-
Germany	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Iceland	22	21	(95.5)	1	(4.8)	9	8	(88.9)	0	(0.0)	11	11	(100.0)	0	(0.0)
Ireland	420	98	(23.3)	15	(15.3)	413	137	(33.2)	21	(15.3)	359	100	(27.9)	15	(15.0)
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Latvia	935	794	(7.4)	71	(8.9)	885	752	(85.0)	71	(9.4)	993	844	(85.0)	114	(13.5)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	1938	929	(47.9)	20	(2.2)	1904	1358	(71.3)	22	(1.6)	1781	1213	(68.1)	29	(2.4)
Luxembourg	29	29	(100.0)	0	(0.0)	26	5	(19.2)	2	(40.0)	45	44	(97.8)	1	(2.3)
Malta	32	26	(81.3)	3	(11.5)	33	30	(90.9)	5	(16.7)	42	42	(100.0)	4	(9.5)
Netherlands	1068	413	(38.7)	48	(11.6)	1004	490	(48.8)	31	(6.3)	957	458	(47.9)	30	(6.6)
Norway	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Poland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Portugal	2715	2354	(86.7)	335	(14.2)	2611	2185	(83.7)	316	(14.5)	2605	2262	(86.8)	302	(13.4)
Romania	21059	7833	(37.2)	241	(3.1)	19202	9608	(50.0)	244	(2.5)	18190	10402	(57.2)	237	(2.3)
Slovakia	439	439	(97.9)	1	(0.2)	399	395	(99.0)	0	(0.0)	345	322	(93.3)	0	(0.0)
Slovenia	172	130	(76.2)	1	(0.8)	192	147	(76.6)	0	(0.0)	138	103	(74.6)	0	(0.0)
Spain	7239	4909	(67.8)	456	(9.3)	6798	4569	(67.2)	412	(9.0)	6070	4425	(72.9)	387	(8.7)
Sweden	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
United Kingdom	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Subtotal EU/EEA</b>	<b>45 920</b>	<b>22 399</b>	<b>(48.8)</b>	<b>1 416</b>	<b>(6.3)</b>	<b>43 212</b>	<b>24 311</b>	<b>(56.3)</b>	<b>1 328</b>	<b>(5.5)</b>	<b>35 677</b>	<b>22 695</b>	<b>(63.6)</b>	<b>1 212</b>	<b>(5.3)</b>
<b>Non-EU/EEA</b>															
Albania	445	186	(41.8)	6	(0.0)	431	170	(39.4)	2	(1.2)	420	233	(55.5)	7	(3.0)
Andorra	7	0	(0.0)	0	-	-	-	-	-	-	9	1	(11.1)	0	(0.0)
Armenia	1780	1242	(69.8)	17	(1.4)	1582	1499	(94.8)	49	(3.3)	1518	1518	(100.0)	79	(5.2)
Azerbaijan	8394	0	(0.0)	0	-	10100	6179	(61.2)	76	(1.2)	8140	7849	(96.4)	129	(1.6)
Belarus	5554	5153	(92.8)	190	(3.7)	5118	4747	(92.8)	217	(4.6)	5246	5246	(100.0)	229	(4.4)
Bosnia and Herzegovina	1390	0	(0.0)	0	-	1385	0	(0.0)	0	-	1420	56	(3.9)	0	(0.0)
former Yugoslav Republic of Macedonia, the	420	39	(9.3)	0	(0.0)	362	45	(12.4)	0	(0.0)	355	145	(40.8)	0	(0.0)
Georgia	5796	1841	(31.8)	33	(1.9)	5533	2550	(46.1)	50	(2.0)	4974	1881	(37.8)	33	(1.8)
Israel	343	308	(89.8)	22	(4.2)	418	384	(91.9)	24	(6.3)	509	503	(98.8)	16	(3.2)
Kazakhstan	28550	23854	(83.6)	325	(1.4)	26211	22480	(85.8)	352	(1.6)	21523	21184	(98.4)	441	(2.1)
Kyrgyzstan	6295	6295	(100.0)	88	(2.9)	6254	153	(2.4)	0	(0.0)	6916	6916	(100.0)	151	(2.2)
Moldova	5447	5192	(95.3)	260	(5.9)	5341	5017	(93.9)	285	(5.7)	5348	5348	(100.0)	303	(5.7)
Monaco	1	0	(0.0)	0	-	-	-	-	-	-	-	-	-	-	-
Montenegro	114	84	(73.7)	0	(1.2)	112	92	(82.1)	0	(0.0)	107	82	(76.6)	0	(0.0)
Russia	102823	84669	(82.3)	7064	(5.3)	104320	79494	(76.2)	4104	(5.2)	97542	75995	(77.9)	4880	(6.4)
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	2385	16	(0.7)	5	(75.0)	2216	67	(3.0)	6	(9.0)	1215	39	(3.2)	6	(15.4)
Serbia excluding UN Administered Province of Kosovo <sup>c</sup>	2385	16	(0.7)	0	(75.0)	1341	67	(5.0)	6	(9.0)	1215	39	(3.2)	6	(15.4)
UN Administered Province of Kosovo <sup>c</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	548	0	(0.0)	0	-	578	-	-	-	-	-	-	-	-	-
Tajikistan	7641	4049	(53.0)	49	(2.5)	7609	6241	(82.0)	115	(1.8)	6929	6375	(92.0)	88	(1.4)
Turkey	16551	581	(3.5)	1	(2.4)	15679	7241	(46.2)	29	(0.4)	14691	8646	(58.9)	45	(0.5)
Turkmenistan	3230	3230	(100.0)	0	(0.0)	-	-	-	-	-	-	-	-	-	-
Ukraine	36409	34621	(95.1)	3771	(16.6)	42676	31776	(74.5)	4157	(13.1)	45569	34181	(75.0)	4726	(13.8)
Uzbekistan	20330	20330	(100.0)	357	(2.1)	15913	15913	(100.0)	546	(3.4)	16810	16810	(100.0)	820	(4.9)
<b>Subtotal non-EU/EEA</b>	<b>255 845</b>	<b>191 690</b>	<b>(74.9)</b>	<b>12 188</b>	<b>(6.4)</b>	<b>251 260</b>	<b>184 048</b>	<b>(73.3)</b>	<b>10 012</b>	<b>(5.4)</b>	<b>239 241</b>	<b>193 008</b>	<b>(80.7)</b>	<b>11 953</b>	<b>(6.2)</b>
<b>Total European Region</b>	<b>255 845</b>	<b>214 089</b>	<b>(83.7)</b>	<b>13 604</b>	<b>(6.4)</b>	<b>294 472</b>	<b>208 359</b>	<b>(70.8)</b>	<b>11 339</b>	<b>(5.4)</b>	<b>274 918</b>	<b>215 703</b>	<b>(78.5)</b>	<b>13 165</b>	<b>(6.1)</b>
<b>Subtotal 18 HPC</b>	<b>275 714</b>	<b>202 686</b>	<b>(73.5)</b>	<b>12 523</b>	<b>(6.2)</b>	<b>271 072</b>	<b>197 022</b>	<b>(72.7)</b>	<b>10 368</b>	<b>(5.3)</b>	<b>258 738</b>	<b>206 193</b>	<b>(79.7)</b>	<b>12 352</b>	<b>(6.0)</b>

<sup>a</sup> "European Region" comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> HIV prevalence may be underestimated due to incomplete HIV testing and/or reporting of HIV serostatus. Countries reporting only HIV positive cases and untested cases are excluded.

<sup>c</sup> Percentages calculated from TB cases with known HIV test results.

<sup>d</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	2013				
	All TB cases (N)	Cases with known HIV status		HIV positive	
		N	%	N	% <sup>b</sup>
-	-	-	-	-	-
981	492	(50.2)	36	(7.3)	
1932	1874	(97.0)	4	(0.2)	
-	-	-	-	-	
-	-	-	-	-	
501	125	(25.0)	0	(0.0)	
-	-	-	-	-	
286	276	(96.5)	36	(13.0)	
-	-	-	-	-	
-	-	-	-	-	
-	-	-	-	-	
540	363	(67.2)	35	(9.6)	
-	-	-	-	-	
11	8	(72.7)	0	(0.0)	
384	103	(26.8)	8	(7.8)	
-	-	-	-	-	
904	420	(46.5)	95	(22.6)	
-	-	-	-	-	
1705	1144	(67.1)	39	(3.4)	
38	36	(94.7)	1	(2.8)	
50	44	(88.0)	0	(0.0)	
848	432	(50.9)	17	(3.9)	
-	-	-	-	-	
-	-	-	-	-	
2393	1710	(71.5)	248	(14.5)	
16711	10196	(61.0)	267	(2.6)	
401	368	(91.8)	0	(0.0)	
140	105	(75.0)	1	(1.0)	
5539	4069	(73.5)	273	(6.7)	
-	-	-	-	-	
-	-	-	-	-	
<b>33364</b>	<b>21765</b>	<b>(65.2)</b>	<b>1060</b>	<b>(4.9)</b>	
474	109	(23.0)	2	(1.8)	
5	1	(20.0)	1	(100.0)	
1417	1417	(100.0)	67	(4.7)	
8597	8329	(96.9)	131	(1.6)	
4859	4859	(100.0)	250	(5.1)	
1261	74	(5.9)	0	(0.0)	
323	206	(63.8)	0	(0.0)	
4319	2698	(62.5)	56	(2.1)	
308	292	(94.8)	15	(5.1)	
19857	18104	(91.2)	466	(2.6)	
7209	7209	(100.0)	203	(2.8)	
5051	4085	(80.9)	250	(6.1)	
-	-	-	-	-	
120	98	(81.7)	2	(2.0)	
142533	69724	(48.9)	4990	(7.2)	
-	-	-	-	-	
1181	106	(9.0)	19	(17.9)	
1181	106	(9.0)	19	(17.9)	
-	-	-	-	-	
-	-	-	-	-	
6495	5200	(80.1)	165	(3.2)	
13409	8787	(65.5)	32	(0.4)	
-	-	-	-	-	
48134	42213	(87.7)	8290	(19.6)	
25168	24670	(98.0)	1097	(4.4)	
<b>290720</b>	<b>198181</b>	<b>(68.2)</b>	<b>16036</b>	<b>(8.1)</b>	
<b>324084</b>	<b>219946</b>	<b>(67.9)</b>	<b>17096</b>	<b>(7.8)</b>	
<b>308586</b>	<b>211205</b>	<b>(68.4)</b>	<b>16438</b>	<b>(7.8)</b>	

Table X. Treatment success after 12 months of new TB cases and relapses, European Region, 2003–2012

Country	2003			2004			2005			2006			2007		
	Cases reported	Success N (%)		Cases reported	Success N (%)		Cases reported	Success N (%)		Cases reported	Success N (%)		Cases reported	Success N (%)	
<b>EU/EEA</b>															
Austria	915	748 (81.7)		1024	799 (78.0)		936	724 (77.4)		839	622 (74.1)		818	359 (43.9)	
Belgium	1020	438 (42.9)		1108	470 (42.4)		1042	417 (40.0)		1034	418 (40.4)		940	387 (41.2)	
Bulgaria	1254	1140 (90.9)		1315	1047 (79.6)		1342	1152 (85.8)		1308	1043 (79.7)		2967	2401 (80.9)	
Croatia	438	168 (38.4)		423	193 (45.6)		391	181 (46.3)		898	265 (29.5)		637	389 (61.1)	
Cyprus	35	27 (77.1)		30	12 (40.0)		36	24 (66.7)		36	26 (72.2)		-	-	
Czech Republic	1110	853 (76.8)		1027	754 (73.4)		831	641 (77.1)		830	627 (75.5)		732	560 (76.5)	
Denmark	368	319 (86.7)		355	305 (85.9)		-	-		351	297 (84.6)		354	281 (79.4)	
Estonia	582	421 (72.3)		561	408 (72.7)		500	355 (71.0)		431	311 (72.2)		455	306 (67.3)	
Finland	-	-		-	-		-	-		-	-		328	139 (42.4)	
France	-	-		-	-		-	-		-	-		-	-	
Germany	6912	4722 (68.3)		6331	4308 (68.0)		5778	4073 (70.5)		5197	3895 (74.9)		4855	3632 (74.8)	
Greece	-	-		-	-		-	-		-	-		-	-	
Hungary	2532	1644 (64.9)		2301	1487 (64.6)		1923	1183 (61.5)		1825	1106 (60.6)		1639	971 (59.2)	
Iceland	5	4 (80.0)		12	11 (91.7)		10	10 (100.0)		13	11 (84.6)		12	11 (91.7)	
Ireland	367	237 (64.6)		396	260 (65.7)		404	276 (68.3)		414	231 (55.8)		419	302 (72.1)	
Italy	-	-		-	-		-	-		-	-		-	-	
Latvia	1686	1295 (76.8)		1579	1187 (75.2)		1383	1058 (76.5)		1263	974 (77.1)		1220	987 (80.9)	
Liechtenstein	-	-		-	-		-	-		-	-		5	0 (0.0)	
Lithuania	2597	1991 (76.7)		2036	1643 (80.7)		2377	1827 (76.9)		2367	1811 (76.5)		2237	1635 (73.1)	
Luxembourg	-	-		-	-		-	-		-	-		-	-	
Malta	6	6 (100.0)		19	17 (89.5)		24	23 (95.8)		30	30 (100.0)		38	28 (73.7)	
Netherlands	1293	1007 (77.9)		1330	1075 (80.8)		1063	904 (85.0)		973	823 (84.6)		942	818 (86.8)	
Norway	297	262 (88.2)		264	228 (86.4)		254	233 (91.7)		258	230 (89.1)		256	214 (83.6)	
Poland	8901	6446 (72.4)		8918	6289 (70.5)		8819	6158 (69.8)		8157	6245 (76.6)		8243	6377 (77.4)	
Portugal	3961	3300 (83.3)		3661	3034 (82.9)		-	-		3307	2854 (86.3)		3033	2570 (84.7)	
Romania	28889	22801 (78.9)		28612	22576 (78.9)		26584	21707 (81.7)		24542	20542 (83.7)		22860	18897 (82.7)	
Slovakia	966	876 (90.7)		699	624 (89.3)		742	684 (92.2)		715	612 (85.6)		673	601 (89.3)	
Slovenia	283	235 (83.0)		256	211 (82.4)		272	223 (82.0)		205	177 (86.3)		214	180 (84.1)	
Spain	-	-		-	-		-	-		-	-		-	-	
Sweden	387	326 (84.2)		430	146 (34.0)		531	368 (69.3)		-	-		440	371 (84.3)	
United Kingdom	6626	4563 (68.9)		6953	4850 (69.8)		7681	5307 (69.1)		7713	5705 (74.0)		7715	5823 (75.5)	
<b>Subtotal EU/EEA</b>	<b>71430</b>	<b>53829 (75.4)</b>		<b>69640</b>	<b>51934 (74.6)</b>		<b>62923</b>	<b>47528 (75.5)</b>		<b>62706</b>	<b>48855 (77.9)</b>		<b>62032</b>	<b>48239 (77.8)</b>	
<b>Non-EU/EEA</b>															
Albania	212	186 (87.7)		544	406 (74.6)		497	403 (81.1)		467	408 (87.4)		422	369 (87.4)	
Andorra	6	6 (100.0)		5	4 (80.0)		9	8 (88.9)		10	8 (80.0)		4	4 (100.0)	
Armenia	406	312 (76.8)		1088	813 (74.7)		1868	1444 (77.3)		1565	1176 (75.1)		1471	1135 (77.2)	
Azerbaijan	1889	1321 (69.9)		4313	2827 (65.5)		1561	922 (59.1)		1454	867 (59.6)		4466	2600 (58.2)	
Belarus	2236	1630 (72.9)		2284	1699 (74.4)		362	336 (92.8)		5085	4072 (80.1)		4811	3948 (82.1)	
Bosnia and Herzegovina	272	255 (93.8)		1025	1007 (98.2)		1035	999 (96.5)		993	960 (96.7)		1267	1227 (96.8)	
former Yugoslav Republic of Macedonia, the	200	167 (83.5)		596	481 (80.7)		555	429 (77.3)		529	437 (82.6)		374	331 (88.5)	
Georgia	989	657 (66.4)		3819	2653 (69.5)		4231	3252 (76.9)		4282	3426 (80.0)		4061	3251 (80.1)	
Israel	457	382 (83.6)		443	384 (86.7)		365	313 (85.8)		335	280 (83.6)		389	319 (82.0)	
Kazakhstan	8660	6452 (74.5)		22241	18725 (84.2)		21302	17949 (84.3)		20276	16872 (83.2)		19582	16182 (82.6)	
Kyrgyzstan	1634	1380 (84.5)		5660	5120 (90.5)		5724	5183 (90.5)		5707	5061 (88.7)		5566	4970 (89.3)	
Moldova	1025	668 (65.2)		2176	1518 (69.8)		4426	3262 (73.7)		4307	3150 (73.1)		4024	2992 (74.4)	
Monaco	-	-		-	-		-	-		-	-		-	-	
Montenegro	0	0		0	0		141	36 (25.5)		151	66 (43.7)		138	107 (77.5)	
Russia	6311	3873 (61.4)		38516	24984 (64.9)		74146	49825 (67.2)		96832	66461 (68.6)		98737	67780 (68.6)	
San Marino	-	-		-	-		-	-		-	-		-	-	
Serbia	0	0		0	0		2342	1943 (83.0)		2688	2196 (81.7)		2411	1996 (82.8)	
Serbia excluding UN Administered Province of Kosovo <sup>a</sup>	-	-		-	-		-	-		-	-		-	-	
UN Administered Province of Kosovo <sup>b</sup>	-	-		-	-		-	-		-	-		-	-	
Switzerland	-	-		-	-		-	-		-	-		-	-	
Tajikistan	927	423 (45.6)		3055	2035 (66.6)		5015	4002 (79.8)		4949	3270 (66.1)		5618	4971 (88.5)	
Turkey	6082	4372 (71.9)		17223	13931 (80.9)		18753	16410 (87.5)		18239	16571 (90.9)		17781	16268 (91.5)	
Turkmenistan	1197	844 (70.5)		743	678 (91.3)		3147	2793 (88.8)		2750	2488 (90.5)		2387	2080 (87.1)	
Ukraine	0	0		0	0		0	0		31620	22025 (69.7)		31075	22030 (70.9)	
Uzbekistan	4674	3971 (85.0)		18926	16855 (89.1)		16564	14065 (84.9)		17241	14780 (85.7)		18773	15167 (80.8)	
<b>Subtotal non-EU/EEA</b>	<b>37177</b>	<b>26899 (72.4)</b>		<b>122657</b>	<b>94120 (76.7)</b>		<b>162043</b>	<b>123574 (76.3)</b>		<b>219480</b>	<b>164574 (75.0)</b>		<b>223357</b>	<b>167727 (75.1)</b>	
<b>Total European Region</b>	<b>108607</b>	<b>80728 (74.3)</b>		<b>192297</b>	<b>146054 (76.0)</b>		<b>224966</b>	<b>171102 (76.1)</b>		<b>282186</b>	<b>213429 (75.6)</b>		<b>285389</b>	<b>215966 (75.7)</b>	
<b>Subtotal 18 HPC</b>	<b>71038</b>	<b>53551 (75.4)</b>		<b>154147</b>	<b>118699 (77.0)</b>		<b>189285</b>	<b>145542 (76.9)</b>		<b>244218</b>	<b>184900 (75.7)</b>		<b>248091</b>	<b>187600 (75.6)</b>	

<sup>a</sup> "European Region" comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> MDR TB cases reported by non-EU/EEA countries excluded for 2012.

<sup>c</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	2008			2009			2010			2011			2012 <sup>1</sup>		
	Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success	
		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
	779	560	(71.9)	651	436	(67.0)	651	470	(72.2)	666	474	(71.2)	605	424	(70.1)
	910	435	(47.8)	917	709	(77.3)	1000	766	(76.6)	955	754	(79.0)	887	685	(77.2)
	3067	2564	(83.6)	2813	2407	(85.6)	2550	2195	(86.1)	2309	1950	(84.5)	2210	1892	(85.6)
	602	347	(57.6)	234	148	(63.2)	181	136	(75.1)	-	-	-	536	50	(9.3)
	48	24	(50.0)	52	11	(21.2)	61	13	(21.3)	52	32	(61.5)	65	28	(43.1)
	748	566	(75.7)	595	442	(74.3)	588	449	(76.4)	541	398	(73.6)	521	412	(79.1)
	340	266	(78.2)	272	220	(80.9)	316	249	(78.8)	351	260	(74.1)	332	214	(64.5)
	385	261	(67.8)	364	241	(66.2)	283	190	(67.1)	292	187	(64.0)	238	165	(69.3)
	326	137	(42.0)	392	169	(43.1)	301	143	(47.5)	310	131	(42.3)	259	116	(44.8)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	4376	3362	(76.8)	4196	3178	(75.7)	4089	2680	(65.5)	4095	2700	(65.9)	3997	3005	(75.2)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	1583	979	(61.8)	1381	924	(66.9)	1596	1200	(75.2)	1360	1027	(75.5)	1156	826	(71.5)
	6	5	(83.3)	9	7	(77.8)	22	20	(90.9)	8	8	(100.0)	11	9	(81.8)
	422	311	(73.7)	421	275	(65.3)	384	286	(74.5)	385	236	(61.3)	328	200	(61.0)
	-	-	-	-	-	-	-	-	-	-	-	-	3096	0	(0.0)
	1039	780	(75.1)	936	696	(74.4)	904	699	(77.3)	862	646	(74.9)	962	758	(78.8)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	2098	1558	(74.3)	1898	1375	(72.4)	1755	1249	(71.2)	1751	1297	(74.1)	1640	1163	(70.9)
	-	-	-	-	-	-	29	0	(0.0)	25	0	(0.0)	45	0	(0.0)
	50	37	(74.0)	43	33	(76.7)	29	17	(58.6)	32	22	(68.8)	41	10	(24.4)
	962	819	(85.1)	1128	954	(84.6)	1017	868	(85.3)	971	842	(86.7)	909	772	(84.9)
	273	234	(85.7)	326	279	(85.6)	290	259	(89.3)	318	281	(88.4)	333	267	(80.2)
	7660	5758	(75.2)	7843	5364	(68.4)	7216	4835	(67.0)	8163	5058	(62.0)	7274	4388	(60.3)
	2905	2534	(87.2)	2768	2281	(82.4)	-	-	-	2547	1984	(77.9)	2549	1970	(77.3)
	22644	18694	(82.6)	21298	17850	(83.8)	19270	15727	(81.6)	17559	14728	(83.9)	16675	13911	(83.4)
	613	554	(90.4)	489	424	(86.7)	430	378	(87.9)	396	364	(91.9)	344	302	(87.8)
	196	163	(83.2)	179	157	(87.7)	162	138	(85.2)	179	155	(86.6)	129	112	(86.8)
	-	-	-	-	-	-	6888	4664	(67.7)	6410	4541	(70.8)	5738	4087	(71.2)
	508	459	(90.4)	568	504	(88.7)	614	538	(87.6)	534	463	(86.7)	587	482	(82.1)
	7932	6119	(77.1)	8073	6371	(78.9)	7781	6221	(80.0)	8317	6500	(78.2)	8126	6502	(80.0)
	<b>60469</b>	<b>47526</b>	<b>(78.6)</b>	<b>57846</b>	<b>45455</b>	<b>(78.6)</b>	<b>58407</b>	<b>44390</b>	<b>(76.0)</b>	<b>59388</b>	<b>45038</b>	<b>(75.8)</b>	<b>59593</b>	<b>42750</b>	<b>(71.7)</b>
	402	354	(88.1)	416	358	(86.1)	415	371	(89.4)	413	382	(92.5)	407	373	(91.6)
	4	4	(100.0)	8	7	(87.5)	7	6	(85.7)	3	3	(100.0)	9	9	(100.0)
	1507	1173	(77.8)	1464	1156	(79.0)	1329	1087	(81.8)	1200	934	(77.8)	1350	1093	(81.0)
	1392	782	(56.2)	4624	3029	(65.5)	4458	3252	(72.9)	2208	1717	(77.8)	4616	3831	(83.0)
	4609	3700	(80.3)	4583	3541	(77.3)	4299	3356	(78.1)	4926	3480	(70.6)	3425	2902	(84.7)
	757	697	(92.1)	1656	1583	(95.6)	970	955	(98.5)	1321	945	(71.5)	1301	1096	(84.2)
	427	379	(88.8)	417	371	(89.0)	368	313	(85.1)	307	272	(88.6)	346	298	(86.1)
	4148	3196	(77.0)	4445	3516	(79.1)	4386	3481	(79.4)	4237	3414	(80.6)	3638	3103	(85.3)
	318	280	(88.1)	338	299	(88.5)	341	288	(84.5)	514	403	(78.4)	509	412	(80.9)
	19677	15818	(80.4)	14529	11319	(77.9)	13449	10269	(76.4)	12400	9430	(76.0)	16275	14068	(86.4)
	5303	4760	(89.8)	5389	4797	(89.0)	-	-	-	3662	3091	(84.4)	-	-	-
	3951	2813	(71.2)	3804	2620	(68.9)	3745	2519	(67.3)	3836	2815	(73.4)	4203	3205	(76.3)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	124	103	(83.1)	133	113	(85.0)	102	89	(87.3)	100	86	(86.0)	107	90	(84.1)
	102742	71019	(69.1)	100991	68313	(67.6)	93995	62400	(66.4)	88554	57801	(65.3)	89666	61765	(68.9)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	2462	2157	(87.6)	2068	1790	(86.6)	1915	1676	(87.5)	1794	1537	(85.7)	1851	1546	(83.5)
	-	-	-	-	-	-	-	-	-	-	-	-	1197	968	(80.9)
	-	-	-	-	-	-	-	-	-	-	-	-	654	578	(88.4)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	6080	5324	(87.6)	5864	5126	(87.4)	5959	5134	(86.2)	5935	5145	(86.7)	5811	4845	(83.4)
	16760	15328	(91.5)	15943	14310	(89.8)	15183	13573	(89.4)	14417	12915	(89.6)	13535	11946	(88.3)
	3235	2891	(89.4)	1375	1152	(83.8)	2401	2080	(86.6)	2140	1852	(86.5)	2804	2369	(84.5)
	33906	24079	(71.0)	13111	7822	(59.7)	30487	21043	(69.0)	27793	18620	(67.0)	30928	21922	(70.9)
	15971	13677	(85.6)	16569	14298	(86.3)	15734	13538	(86.0)	13995	11836	(84.6)	14132	11905	(84.2)
	<b>223775</b>	<b>168534</b>	<b>(75.3)</b>	<b>197727</b>	<b>145520</b>	<b>(73.6)</b>	<b>199543</b>	<b>145430</b>	<b>(72.9)</b>	<b>189755</b>	<b>136678</b>	<b>(72.0)</b>	<b>194913</b>	<b>146778</b>	<b>(75.3)</b>
	<b>284244</b>	<b>216060</b>	<b>(76.0)</b>	<b>255573</b>	<b>190975</b>	<b>(74.7)</b>	<b>257950</b>	<b>189820</b>	<b>(73.6)</b>	<b>249143</b>	<b>181716</b>	<b>(72.9)</b>	<b>254506</b>	<b>189528</b>	<b>(74.5)</b>
	<b>248511</b>	<b>188417</b>	<b>(75.8)</b>	<b>220000</b>	<b>163568</b>	<b>(74.3)</b>	<b>220187</b>	<b>161792</b>	<b>(73.5)</b>	<b>208076</b>	<b>151858</b>	<b>(73.0)</b>	<b>212108</b>	<b>160843</b>	<b>(75.8)</b>

**Table Xa.** Treatment success after 12 months of all TB cases, EU/EEA 2003–2012

Country	2003			2004			2005			2006			2007		
	Cases reported	Success N	(%)	Cases reported	Success N	(%)	Cases reported	Success N	(%)	Cases reported	Success N	(%)	Cases reported	Success N	(%)
<b>EU/EEA</b>															
Austria	990	769	(77.7)	1075	816	(75.9)	998	748	(74.9)	906	642	(70.9)	874	367	(42.0)
Belgium	1117	477	(42.7)	1198	500	(41.7)	1107	435	(39.3)	1117	444	(39.7)	1020	415	(40.7)
<i>Bulgaria</i>	2748	2445	(89.0)	1417	1102	(77.8)	1464	1233	(84.2)	3232	1043	(32.3)	3038	2415	(79.5)
Croatia	1292	373	(28.9)	1197	516	(43.1)	1053	479	(45.5)	1117	367	(32.9)	637	389	(61.1)
Cyprus	35	27	(77.1)	30	12	(40.0)	37	25	(67.6)	37	27	(73.0)	42	0	(0.0)
Czech Republic	1162	897	(77.2)	1057	775	(73.3)	984	710	(72.2)	951	679	(71.4)	846	618	(73.0)
Denmark	393	338	(86.0)	385	326	(84.7)	428	400	(93.5)	387	316	(81.7)	391	298	(76.2)
<i>Estonia</i>	623	429	(68.9)	594	413	(69.5)	518	359	(69.3)	460	317	(68.9)	491	311	(63.3)
Finland	-	-	-	-	-	-	-	-	-	-	-	-	347	141	(40.6)
France	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	7166	4881	(68.1)	6542	4431	(67.7)	6018	4196	(69.7)	5378	3995	(74.3)	5000	3726	(74.5)
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	2582	1662	(64.4)	2340	1498	(64.0)	1964	1195	(60.8)	1859	1119	(60.2)	1685	987	(58.6)
Iceland	5	4	(80.0)	12	11	(91.7)	11	11	(100.0)	13	11	(84.6)	14	12	(85.7)
Ireland	407	261	(64.1)	432	281	(65.0)	450	303	(67.3)	463	253	(54.6)	480	338	(70.4)
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Latvia</i>	1726	1311	(76.0)	1610	1201	(74.6)	1443	1080	(74.8)	1328	993	(74.8)	1255	1003	(79.9)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<i>Lithuania</i>	2821	2044	(72.5)	2514	1796	(71.4)	2574	1873	(72.8)	2559	1868	(73.0)	2408	1660	(68.9)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Malta	7	7	(100.0)	19	17	(89.5)	25	24	(96.0)	30	30	(100.0)	38	28	(73.7)
Netherlands	1321	1022	(77.4)	1344	1086	(80.8)	1128	940	(83.3)	1031	845	(82.0)	998	853	(85.5)
Norway	337	294	(87.2)	302	260	(86.1)	288	260	(90.3)	290	250	(86.2)	302	250	(82.8)
Poland	10124	7291	(72.0)	9485	6543	(69.0)	9269	6354	(68.6)	8587	6446	(75.1)	8614	6582	(76.4)
Portugal	4148	3424	(82.5)	3854	3156	(81.9)	-	-	-	3456	2959	(85.6)	3139	2639	(84.1)
<i>Romania</i>	31039	23476	(75.6)	31034	23320	(75.1)	29288	22607	(77.2)	26600	21241	(79.9)	24837	19415	(78.2)
Slovakia	983	893	(90.8)	705	630	(89.4)	760	697	(91.7)	730	623	(85.3)	682	606	(88.9)
Slovenia	293	242	(82.6)	263	216	(82.1)	278	228	(82.0)	215	178	(82.8)	218	181	(83.0)
Spain	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sweden	408	343	(84.1)	-	-	-	559	389	(69.6)	-	-	-	482	398	(82.6)
United Kingdom	7221	4868	(67.4)	7594	5154	(67.9)	8290	5613	(67.7)	8314	6018	(72.4)	8268	6123	(74.1)
<b>Total EU/EEA</b>	<b>78 948</b>	<b>57 778</b>	<b>(73.2)</b>	<b>75 003</b>	<b>54 060</b>	<b>(72.1)</b>	<b>68 934</b>	<b>50 159</b>	<b>(72.8)</b>	<b>69 060</b>	<b>50 664</b>	<b>(73.4)</b>	<b>66 064</b>	<b>49 755</b>	<b>(75.3)</b>

EU/EEA countries designated as high-priority countries by WHO are presented in italics.

	2008			2009			2010			2011			2012 <sup>1</sup>		
	Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success	
		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
	817	571	(69.9)	696	445	(63.9)	691	492	(71.2)	684	477	(69.7)	647	428	(66.2)
	990	458	(46.3)	994	760	(76.5)	1086	820	(75.5)	1019	788	(77.3)	975	736	(75.5)
	3150	2618	(83.1)	2910	2453	(84.3)	2649	2231	(84.2)	2406	1991	(82.8)	2280	1916	(84.0)
	602	347	(57.6)	256	159	(62.1)	263	199	(75.7)	-	-	-	575	59	(10.3)
	50	26	(52.0)	55	12	(21.8)	61	13	(21.3)	54	34	(63.0)	69	30	(43.5)
	864	605	(70.0)	694	484	(69.7)	668	485	(72.6)	600	422	(70.3)	598	444	(74.2)
	380	302	(79.5)	334	251	(75.1)	366	271	(74.0)	381	275	(72.2)	389	248	(63.8)
	444	268	(60.4)	411	250	(60.8)	333	197	(59.2)	339	189	(55.8)	288	167	(58.0)
	341	138	(40.5)	413	171	(41.4)	317	149	(47.0)	324	131	(40.4)	276	122	(44.2)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	4521	3445	(76.2)	4444	3266	(73.5)	4390	2801	(63.8)	4307	2755	(64.0)	4217	3073	(72.9)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	1619	991	(61.2)	1407	931	(66.2)	1741	1254	(72.0)	1445	1059	(73.3)	1223	847	(69.3)
	6	5	(83.3)	9	7	(77.8)	22	20	(90.9)	9	8	(88.9)	11	9	(81.8)
	468	338	(72.2)	479	307	(64.1)	420	304	(72.4)	413	250	(60.5)	359	214	(59.6)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	1070	793	(74.1)	977	707	(72.4)	935	711	(76.0)	885	655	(74.0)	993	765	(77.0)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	2250	1589	(70.6)	2081	1405	(67.5)	1938	1282	(66.2)	1904	1326	(69.6)	1781	1192	(66.9)
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	53	39	(73.6)	44	33	(75.0)	32	19	(59.4)	33	23	(69.7)	42	10	(23.8)
	1015	848	(83.5)	1158	966	(83.4)	1068	891	(83.4)	1004	856	(85.3)	957	786	(82.1)
	313	262	(83.7)	358	303	(84.6)	336	289	(86.0)	354	308	(87.0)	374	291	(77.8)
	8080	5986	(74.1)	8236	5567	(67.6)	7509	4976	(66.3)	8478	5191	(61.2)	7542	4501	(59.7)
	3002	2599	(86.6)	2871	2343	(81.6)	2715	2054	(75.7)	2611	2017	(77.3)	2605	2004	(76.9)
	24680	19250	(78.0)	23164	18482	(79.8)	21059	16257	(77.2)	19202	15240	(79.4)	18190	14405	(79.2)
	633	566	(89.4)	506	433	(85.6)	439	384	(87.5)	399	366	(91.7)	345	303	(87.8)
	213	165	(77.5)	188	158	(84.0)	172	139	(80.8)	192	157	(81.8)	138	112	(81.2)
	-	-	-	-	-	-	7239	4861	(67.2)	6798	4760	(70.0)	6070	4286	(70.6)
	546	487	(89.2)	617	536	(86.9)	667	580	(87.0)	580	494	(85.2)	623	504	(80.9)
	8495	6428	(75.7)	8878	6918	(77.9)	8398	6600	(78.6)	8923	6892	(77.2)	8729	6866	(78.7)
	<b>64602</b>	<b>49124</b>	<b>(76.0)</b>	<b>62180</b>	<b>47347</b>	<b>(76.1)</b>	<b>65543</b>	<b>48279</b>	<b>(73.7)</b>	<b>63370</b>	<b>46664</b>	<b>(73.6)</b>	<b>60296</b>	<b>44318</b>	<b>(73.5)</b>

**Table XI. Treatment success after 12 months of previously treated TB cases (excluding relapses), European Region, 2003–2012**

Country	2003			2004			2005			2006			2007		
	Cases reported	Success N (%)		Cases reported	Success N (%)		Cases reported	Success N (%)		Cases reported	Success N (%)		Cases reported	Success N (%)	
<b>EU/EEA</b>															
Austria	25	21 (84.0)		21	17 (81.0)		32	24 (75.0)		22	20 (90.9)		21	8 (38.1)	
Belgium	97	39 (40.2)		90	30 (33.3)		65	18 (27.7)		83	26 (31.3)		77	28 (36.4)	
Bulgaria	117	80 (68.4)		-	-		-	-		-	-		71	14 (19.7)	
Croatia	0	0 (0.0)		0	0 (0.0)		0	0 (0.0)		0	0 (0.0)		0	0 (0.0)	
Cyprus	0	0		0	0		1	1 (100.0)		1	1 (100.0)		1	0 (0.0)	
Czech Republic	52	44 (84.6)		30	21 (70.0)		94	69 (73.4)		74	52 (70.3)		73	58 (79.5)	
Denmark	25	19 (76.0)		30	21 (70.0)		-	-		36	19 (52.8)		36	17 (47.2)	
Estonia	41	8 (19.5)		33	5 (15.2)		17	3 (17.6)		21	6 (28.6)		23	5 (21.7)	
Finland	-	-		-	-		-	-		-	-		5	2 (40.0)	
France	-	-		-	-		-	-		-	-		-	-	
Germany	254	159 (62.6)		211	123 (58.3)		207	122 (58.9)		147	100 (68.0)		124	92 (74.2)	
Greece	-	-		-	-		-	-		-	-		-	-	
Hungary	50	18 (36.0)		39	11 (28.2)		41	12 (29.3)		34	13 (38.2)		46	16 (34.8)	
Iceland	0	0		0	0		1	1 (100.0)		0	0		2	1 (50.0)	
Ireland	40	24 (60.0)		36	21 (58.3)		42	27 (64.3)		43	22 (51.2)		53	36 (67.9)	
Italy	-	-		-	-		-	-		-	-		-	-	
Latvia	40	16 (40.0)		31	14 (45.2)		34	22 (64.7)		38	19 (50.0)		24	16 (66.7)	
Liechtenstein	-	-		-	-		-	-		-	-		0	0	
Lithuania	224	53 (23.7)		478	153 (32.0)		197	46 (23.4)		192	57 (29.7)		171	25 (14.6)	
Luxembourg	-	-		-	-		-	-		-	-		-	-	
Malta	1	1 (100.0)		0	0		1	1 (100.0)		0	0		0	0	
Netherlands	28	15 (53.6)		14	11 (78.6)		47	35 (74.5)		32	21 (65.6)		40	33 (82.5)	
Norway	40	32 (80.0)		38	32 (84.2)		34	27 (79.4)		31	20 (64.5)		44	36 (81.8)	
Poland	1223	845 (69.1)		532	254 (47.7)		414	186 (44.9)		393	197 (50.1)		359	204 (56.8)	
Portugal	187	124 (66.3)		193	122 (63.2)		-	-		149	105 (70.5)		106	69 (65.1)	
Romania	2150	675 (31.4)		2422	744 (30.7)		2563	897 (35.0)		1992	698 (35.0)		1919	518 (27.0)	
Slovakia	17	17 (100.0)		6	6 (100.0)		14	9 (64.3)		12	9 (75.0)		6	5 (83.3)	
Slovenia	10	7 (70.0)		7	5 (71.4)		6	5 (83.3)		2	1 (50.0)		1	1 (100.0)	
Spain	-	-		-	-		-	-		-	-		-	-	
Sweden	21	17 (81.0)		-	-		28	21 (75.0)		-	-		36	27 (75.0)	
United Kingdom	468	305 (65.2)		492	304 (61.8)		500	306 (61.2)		468	313 (66.9)		454	300 (66.1)	
<b>Subtotal EU/EEA</b>	<b>5110</b>	<b>2519 (49.3)</b>		<b>4703</b>	<b>1894 (40.3)</b>		<b>4338</b>	<b>1832 (42.2)</b>		<b>3770</b>	<b>1699 (45.1)</b>		<b>3692</b>	<b>1511 (40.9)</b>	
<b>Non-EU/EEA</b>															
Albania	7	7 (100.0)		37	32 (86.5)		30	22 (73.3)		29	25 (86.2)		25	21 (84.0)	
Andorra	0	0 (0.0)		0	0 (0.0)		0	0 (0.0)		3	2 (66.7)		1	1 (100.0)	
Armenia	356	169 (47.5)		143	69 (48.3)		327	133 (40.7)		502	218 (43.4)		590	274 (46.4)	
Azerbaijan	802	410 (51.1)		2188	900 (41.1)		1314	489 (37.2)		1272	590 (46.4)		1081	479 (44.3)	
Belarus	-	-		-	-		-	-		898	574 (63.9)		862	537 (62.3)	
Bosnia and Herzegovina	98	92 (93.9)		97	89 (91.8)		106	98 (92.5)		93	88 (94.6)		156	144 (92.3)	
former Yugoslav Republic of Macedonia, the	102	72 (70.6)		70	61 (87.1)		97	55 (56.7)		72	43 (59.7)		71	46 (64.8)	
Georgia	1172	486 (41.5)		2034	1006 (49.5)		2037	1111 (54.5)		1873	1057 (56.4)		1847	1031 (55.8)	
Israel	15	13 (86.7)		13	11 (84.6)		7	6 (85.7)		5	4 (80.0)		8	8 (100.0)	
Kazakhstan	7952	4034 (50.7)		4294	2097 (48.8)		4085	1911 (46.8)		21242	7816 (36.8)		18722	9922 (53.0)	
Kyrgyzstan	849	630 (74.2)		885	651 (73.6)		845	600 (71.0)		933	662 (71.0)		1035	696 (67.2)	
Moldova	1940	716 (36.9)		1486	566 (38.1)		1713	710 (41.4)		1715	734 (42.8)		2167	781 (36.0)	
Monaco	-	-		-	-		-	-		-	-		-	-	
Montenegro	0	0 (0.0)		0	0 (0.0)		10	2 (20.0)		19	6 (31.6)		23	13 (56.5)	
Russia	1892	848 (44.8)		3011	1172 (38.9)		10855	4003 (36.9)		28419	13417 (47.2)		18527	6619 (35.7)	
San Marino	2	2 (100.0)		-	-		-	-		-	-		-	-	
Serbia	-	-		-	-		284	207 (72.9)		322	238 (73.9)		355	260 (73.2)	
Serbia excluding UN Administered Province of Kosovo <sup>b</sup>	-	-		-	-		284	207 (72.9)		322	238 (73.9)		355	260 (73.2)	
UN Administered Province of Kosovo <sup>b</sup>	-	-		-	-		-	-		-	-		-	-	
Switzerland	-	-		-	-		-	-		-	-		-	-	
Tajikistan	114	76 (66.7)		648	479 (73.9)		1762	1343 (76.2)		1715	1248 (72.8)		1995	1495 (74.9)	
Turkey	101	66 (65.3)		-	-		1593	1118 (70.2)		1951	1474 (75.6)		1885	1435 (76.1)	
Turkmenistan	558	347 (62.2)		-	-		142	97 (68.3)		240	176 (73.3)		116	48 (41.4)	
Ukraine	-	-		-	-		-	-		9380	4055 (43.2)		5240	2866 (54.7)	
Uzbekistan	1610	1100 (68.3)		6195	5012 (80.9)		3999	2758 (69.0)		5248	4066 (77.5)		4617	3468 (75.1)	
<b>Subtotal non-EU/EEA</b>	<b>17570</b>	<b>9068 (51.6)</b>		<b>21101</b>	<b>12145 (57.6)</b>		<b>29206</b>	<b>14663 (50.2)</b>		<b>75931</b>	<b>36493 (48.1)</b>		<b>59323</b>	<b>30144 (50.8)</b>	
<b>Total European Region</b>	<b>22680</b>	<b>11587 (51.1)</b>		<b>25804</b>	<b>14039 (54.4)</b>		<b>33544</b>	<b>16495 (49.2)</b>		<b>79701</b>	<b>38192 (47.9)</b>		<b>63015</b>	<b>31655 (50.2)</b>	
<b>Subtotal 18 HPC</b>	<b>19918</b>	<b>9714 (48.8)</b>		<b>23848</b>	<b>12868 (54.0)</b>		<b>31483</b>	<b>15241 (48.4)</b>		<b>77631</b>	<b>36867 (47.5)</b>		<b>60892</b>	<b>30229 (49.6)</b>	

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>b</sup> MDR TB cases reported by non-EU/EEA countries excluded for 2012.

<sup>c</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).



	2008			2009			2010			2011			2012 <sup>a</sup>		
	Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success	
		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
3	3	(100.0)	25	9	(36.0)	29	22	(75.9)	8	3	(37.5)	18	4	(22.2)	
78	23	(29.5)	76	51	(67.1)	85	54	(63.5)	56	34	(60.7)	77	51	(66.2)	
82	54	(65.9)	94	46	(48.9)	98	36	(36.7)	93	41	(44.1)	68	24	(35.3)	
0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	36	8	(22.2)	
2	2	(100.0)	3	1	(33.3)	0	0	.	2	2	(100.0)	3	2	(66.7)	
55	39	(70.9)	60	42	(70.0)	47	36	(76.6)	32	24	(75.0)	39	29	(74.4)	
40	36	(90.0)	35	31	(88.6)	34	22	(64.7)	22	15	(68.2)	44	34	(77.3)	
30	7	(23.3)	34	9	(26.5)	28	7	(25.0)	22	2	(9.1)	19	2	(10.5)	
6	1	(16.7)	9	2	(22.2)	12	6	(50.0)	6	0	(0.0)	11	6	(54.5)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
113	79	(69.9)	120	80	(66.7)	171	109	(63.7)	120	54	(45.0)	121	68	(56.2)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
36	12	(33.3)	26	7	(26.9)	101	54	(53.5)	68	32	(47.1)	41	21	(51.2)	
0	0	.	0	0	.	0	0	.	0	0	.	0	0	.	
39	27	(69.2)	52	32	(61.5)	33	18	(54.5)	25	14	(56.0)	25	14	(56.0)	
-	-	-	-	-	-	-	-	-	-	-	-	46	0	(0.0)	
19	13	(68.4)	24	11	(45.8)	18	12	(66.7)	14	9	(64.3)	22	7	(31.8)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
152	31	(20.4)	183	30	(16.4)	183	33	(18.0)	153	29	(19.0)	141	29	(20.6)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	2	(100.0)	1	0	(0.0)	3	2	(66.7)	1	1	(100.0)	1	0	(0.0)	
37	27	(73.0)	16	12	(75.0)	26	23	(88.5)	19	14	(73.7)	20	14	(70.0)	
38	28	(73.7)	28	24	(85.7)	39	30	(76.9)	31	27	(87.1)	33	24	(72.7)	
399	223	(55.9)	376	203	(54.0)	280	141	(50.4)	303	133	(43.9)	257	113	(44.0)	
97	65	(67.0)	103	62	(60.2)	-	-	-	58	33	(56.9)	48	34	(70.8)	
1998	556	(27.8)	1822	632	(34.7)	1752	530	(30.3)	1513	512	(33.8)	1413	494	(35.0)	
14	11	(78.6)	13	9	(69.2)	7	6	(85.7)	2	2	(100.0)	1	1	(100.0)	
4	2	(50.0)	1	1	(100.0)	1	1	(100.0)	2	2	(100.0)	0	0	.	
-	-	-	-	-	-	351	197	(56.1)	388	219	(56.4)	332	199	(59.9)	
36	28	(77.8)	43	32	(74.4)	52	42	(80.8)	38	31	(81.6)	31	22	(71.0)	
451	309	(68.5)	732	547	(74.7)	531	379	(71.4)	526	392	(74.5)	519	364	(70.1)	
<b>3731</b>	<b>1578</b>	<b>(42.3)</b>	<b>3876</b>	<b>1873</b>	<b>(48.3)</b>	<b>3881</b>	<b>1760</b>	<b>(45.3)</b>	<b>3502</b>	<b>1625</b>	<b>(46.4)</b>	<b>3366</b>	<b>1564</b>	<b>(46.5)</b>	
28	21	(75.0)	21	16	(76.2)	30	27	(90.0)	18	15	(83.3)	6	4	(66.7)	
0	0	(0.0)	2	2	(100.0)	0	0	(0.0)	1	0	(0.0)	0	0	(0.0)	
534	272	(50.9)	542	344	(63.5)	451	302	(67.0)	382	260	(68.1)	15	7	(46.7)	
3084	1557	(50.5)	1687	897	(53.2)	4194	2626	(62.6)	4005	2857	(71.3)	2879	2120	(73.6)	
815	477	(58.5)	616	258	(41.9)	792	379	(47.9)	1020	293	(28.7)	188	129	(68.6)	
77	58	(75.3)	116	97	(83.6)	101	96	(95.0)	104	65	(62.5)	119	92	(77.3)	
56	40	(71.4)	56	44	(78.6)	52	34	(65.4)	55	43	(78.2)	9	7	(77.8)	
1542	765	(49.6)	1521	908	(59.7)	1421	879	(61.9)	1321	811	(61.4)	886	654	(73.8)	
4	3	(75.0)	9	6	(66.7)	5	4	(80.0)	10	5	(50.0)	-	-	-	
8662	3616	(41.7)	9392	4549	(48.4)	8734	4119	(47.2)	5026	1815	(36.1)	3171	2488	(78.5)	
897	631	(70.3)	924	655	(70.9)	0	0	.	523	291	(55.6)	-	-	-	
1865	643	(34.5)	1663	569	(34.2)	1702	545	(32.0)	1500	572	(38.1)	455	177	(38.9)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
10	8	(80.0)	11	8	(72.7)	14	12	(85.7)	12	10	(83.3)	0	0	(0.0)	
18070	6562	(36.3)	16726	5663	(33.9)	14609	4984	(34.1)	26062	10818	(41.5)	7961	2966	(37.3)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
309	234	(75.7)	244	180	(73.8)	203	155	(76.4)	164	128	(78.0)	37	27	(73.0)	
309	234	(75.7)	244	180	(73.8)	203	155	(76.4)	164	128	(78.0)	15	8	(53.3)	
-	-	-	-	-	-	-	-	-	-	-	-	22	19	(86.4)	
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
1881	1422	(75.6)	1618	1165	(72.0)	1732	1243	(71.8)	1674	1183	(70.7)	1118	837	(74.9)	
1692	1262	(74.6)	1459	1069	(73.3)	1368	940	(68.7)	1262	860	(68.1)	1156	768	(66.4)	
737	596	(80.9)	-	-	-	349	186	(53.3)	387	207	(53.5)	618	389	(62.9)	
7152	2960	(41.4)	10424	4909	(47.1)	9812	4540	(46.3)	6413	2206	(34.4)	5586	2868	(51.3)	
5046	3608	(71.5)	2451	1689	(68.9)	4527	3284	(72.5)	1074	770	(71.7)	2633	1894	(71.9)	
<b>52461</b>	<b>24735</b>	<b>(47.1)</b>	<b>49482</b>	<b>23028</b>	<b>(46.5)</b>	<b>50096</b>	<b>24355</b>	<b>(48.6)</b>	<b>51013</b>	<b>23209</b>	<b>(45.5)</b>	<b>26837</b>	<b>15427</b>	<b>(57.5)</b>	
<b>56192</b>	<b>26313</b>	<b>(46.8)</b>	<b>53358</b>	<b>24901</b>	<b>(46.7)</b>	<b>53977</b>	<b>26115</b>	<b>(48.4)</b>	<b>54515</b>	<b>24834</b>	<b>(45.6)</b>	<b>30203</b>	<b>16991</b>	<b>(56.3)</b>	
<b>54258</b>	<b>25032</b>	<b>(46.1)</b>	<b>51180</b>	<b>23403</b>	<b>(45.7)</b>	<b>51770</b>	<b>24645</b>	<b>(47.6)</b>	<b>52444</b>	<b>23536</b>	<b>(44.9)</b>	<b>28329</b>	<b>15853</b>	<b>(56.0)</b>	

**Table XII.** Treatment success after 24 months of all laboratory confirmed MDR TB cases, European Region, 2005–2011

Country	2005			2006			2007			2008			2009		
	Cases reported	Success N	(%)	Cases reported	Success N	(%)	Cases reported	Success N	(%)	Cases reported	Success N	(%)	Cases reported	Success N	(%)
<b>EU/EEA</b>															
Austria	-	-	-	-	-	-	-	-	-	15	4	(26.7)	23	10	(43.5)
Belgium	11	7	(63.6)	18	10	(55.6)	14	5	(35.7)	21	14	(66.7)	10	4	(40.0)
Bulgaria	-	-	-	-	-	-	76	19	(25.0)	31	7	(22.6)	43	8	(18.6)
Croatia	-	-	-	-	-	-	-	-	-	-	-	-	2	1	(50.0)
Cyprus	-	-	-	-	-	-	-	-	-	-	-	-	4	0	(0.0)
Czech Republic	13	3	(23.1)	12	3	(25.0)	8	3	(37.5)	11	6	(54.5)	8	0	(0.0)
Denmark	5	4	(80.0)	3	2	(66.7)	2	0	(0.0)	-	-	-	2	1	(50.0)
Estonia	78	34	(43.6)	55	24	(43.6)	82	40	(48.8)	73	35	(47.9)	85	35	(41.2)
Finland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
France	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Germany	-	-	-	82	42	(51.2)	66	43	(65.2)	49	28	(57.1)	62	38	(61.3)
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hungary	17	10	(58.8)	14	7	(50.0)	12	6	(50.0)	13	4	(30.8)	18	3	(16.7)
Iceland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ireland	3	3	(100.0)	4	3	(75.0)	7	7	(100.0)	2	0	(0.0)	1	0	(0.0)
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Latvia	161	106	(65.8)	142	87	(61.3)	99	60	(60.6)	128	79	(61.7)	131	77	(58.8)
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lithuania	-	-	-	-	-	-	-	-	-	276	72	(26.1)	322	97	(30.1)
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Malta	-	-	-	-	-	-	1	1	(100.0)	0	0	-	0	0	-
Netherlands	8	5	(62.5)	6	5	(83.3)	6	6	(100.0)	15	14	(93.3)	20	12	(60.0)
Norway	-	-	-	-	-	-	3	2	(66.7)	4	2	(50.0)	8	5	(62.5)
Poland	-	-	-	-	-	-	22	13	(59.1)	19	9	(47.4)	21	12	(57.1)
Portugal	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Romania	849	153	(18.0)	673	127	(18.9)	673	125	(18.6)	792	129	(16.3)	624	102	(16.3)
Slovakia	8	1	(12.5)	7	3	(42.9)	7	2	(28.6)	4	1	(25.0)	1	0	(0.0)
Slovenia	-	-	-	-	-	-	-	-	-	2	1	(50.0)	1	0	(0.0)
Spain	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sweden	-	-	-	3	3	(100.0)	15	12	(80.0)	11	10	(90.9)	13	11	(84.6)
United Kingdom	43	25	(58.1)	58	27	(46.6)	62	22	(35.5)	55	28	(50.9)	61	25	(41.0)
<b>Subtotal EU/EEA</b>	<b>1196</b>	<b>351</b>	<b>(29.3)</b>	<b>1077</b>	<b>343</b>	<b>(31.8)</b>	<b>1155</b>	<b>366</b>	<b>(31.7)</b>	<b>1521</b>	<b>443</b>	<b>(29.1)</b>	<b>1460</b>	<b>441</b>	<b>(30.2)</b>
<b>Non-EU/EEA</b>															
Albania	-	-	-	1	0	(0.0)	0	0	-	-	-	-	0	0	(0.0)
Andorra	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)	0	0	(0.0)
Armenia	-	-	-	27	11	(40.7)	57	30	(52.6)	77	42	(54.5)	134	69	(51.5)
Azerbaijan	-	-	-	-	-	-	-	-	-	23	13	(56.5)	100	74	(74.0)
Belarus	-	-	-	-	-	-	-	-	-	-	-	-	1422	572	(40.2)
Bosnia and Herzegovina	-	-	-	-	-	-	-	-	-	-	-	-	1	1	(100.0)
former Yugoslav Republic of Macedonia, the	-	-	-	6	2	(33.3)	9	2	(22.2)	2	0	(0.0)	1	0	(0.0)
Georgia	-	-	-	-	-	-	61	23	(37.7)	417	235	(56.4)	503	270	(53.7)
Israel	16	14	(87.5)	20	18	(90.0)	14	12	(85.7)	11	10	(90.9)	6	5	(83.3)
Kazakhstan	-	-	-	930	752	(80.9)	1609	1237	(76.9)	2268	1680	(74.1)	3897	2851	(73.2)
Kyrgyzstan	-	-	-	66	32	(48.5)	132	66	(50.0)	262	130	(49.6)	545	193	(35.4)
Moldova	-	-	-	-	-	-	254	133	(52.4)	522	253	(48.5)	-	-	-
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Montenegro	-	-	-	3	2	(66.7)	3	0	(0.0)	0	0	(0.0)	1	1	(100.0)
Russia	-	-	-	-	-	-	0	0	-	1537	783	(50.9)	-	-	-
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Serbia	-	-	-	-	-	-	-	-	-	-	-	-	10	6	(60.0)
Serbia excluding UN Administered Province of Kosovo <sup>a</sup>	-	-	-	-	-	-	-	-	-	-	-	-	10	6	(60.0)
UN Administered Province of Kosovo <sup>a</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Switzerland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tajikistan	-	-	-	-	-	-	-	-	-	-	-	-	52	37	(71.2)
Turkey	-	-	-	249	177	(71.1)	240	155	(64.6)	263	180	(68.4)	222	147	(66.2)
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ukraine	-	-	-	-	-	-	-	-	-	-	-	-	3299	906	(27.5)
Uzbekistan	-	-	-	-	-	-	330	180	(54.5)	294	193	(65.6)	464	285	(61.4)
<b>Subtotal non-EU/EEA</b>	<b>16</b>	<b>14</b>	<b>(87.5)</b>	<b>1302</b>	<b>994</b>	<b>(76.3)</b>	<b>2709</b>	<b>1838</b>	<b>(67.8)</b>	<b>5676</b>	<b>3519</b>	<b>(62.0)</b>	<b>10657</b>	<b>5417</b>	<b>(50.8)</b>
<b>Total European Region</b>	<b>1212</b>	<b>365</b>	<b>(30.1)</b>	<b>2379</b>	<b>1337</b>	<b>(56.2)</b>	<b>3864</b>	<b>2204</b>	<b>(57.0)</b>	<b>7197</b>	<b>3962</b>	<b>(55.1)</b>	<b>12117</b>	<b>5858</b>	<b>(48.3)</b>
<b>Subtotal 18 HPC</b>	<b>1088</b>	<b>293</b>	<b>(26.9)</b>	<b>2142</b>	<b>1210</b>	<b>(56.5)</b>	<b>3613</b>	<b>2068</b>	<b>(57.2)</b>	<b>6963</b>	<b>3831</b>	<b>(55.0)</b>	<b>11843</b>	<b>5723</b>	<b>(48.3)</b>

<sup>a</sup> "European Region" comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

	2010			2011		
	Cases reported	Success		Cases reported	Success	
		N	(%)		N	(%)
	16	9	(56.3)	20	13	(65.0)
	19	11	(57.9)	15	11	(73.3)
	56	9	(16.1)	55	30	(54.5)
	-	-	-	-	-	-
	-	-	-	-	-	-
	9	4	(44.4)	7	2	(28.6)
	2	1	(50.0)	3	0	(0.0)
	64	30	(46.9)	78	39	(50.0)
	-	-	-	-	-	-
	-	-	-	-	-	-
	51	21	(41.2)	56	30	(53.6)
	-	-	-	-	-	-
	19	8	(42.1)	7	3	(42.9)
	-	-	-	-	-	-
	2	2	(100.0)	3	1	(33.3)
	-	-	-	-	-	-
	-	-	-	-	-	-
	88	58	(65.9)	95	51	(53.7)
	-	-	-	-	-	-
	310	91	(29.4)	296	104	(35.1)
	-	-	-	-	-	-
	1	0	(0.0)	0	0	-
	11	7	(63.6)	17	11	(64.7)
	8	4	(50.0)	4	3	(75.0)
	30	15	(50.0)	41	14	(34.1)
	28	9	(32.1)	36	19	(52.8)
	574	117	(20.4)	547	140	(25.6)
	1	0	(0.0)	3	1	(33.3)
	0	0	-	0	0	-
	-	-	-	-	-	-
	18	17	(94.4)	17	12	(70.6)
	67	30	(44.8)	86	40	(46.5)
	<b>1374</b>	<b>443</b>	<b>(32.2)</b>	<b>1386</b>	<b>524</b>	<b>(37.8)</b>
	0	0	(0.0)	-	-	-
	0	0	(0.0)	0	0	(0.0)
	132	59	(44.7)	121	61	(50.4)
	286	156	(54.5)	565	339	(60.0)
	1442	452	(31.3)	1600	807	(50.4)
	7	4	(57.1)	5	1	(20.0)
	7	1	(14.3)	1	1	(100.0)
	504	271	(53.8)	611	305	(49.9)
	12	4	(33.3)	11	7	(63.6)
	5777	4197	(72.7)	5261	3910	(74.3)
	556	236	(42.4)	492	280	(56.9)
	791	390	(49.3)	761	413	(54.3)
	-	-	-	-	-	-
	0	0	(0.0)	1	0	(0.0)
	4 681	2 035	(43.5)	15 896	5 895	(37.1)
	-	-	-	-	-	-
	10	8	(80.0)	14	9	(64.3)
	10	8	(80.0)	14	9	(64.3)
	-	-	-	-	-	-
	-	-	-	-	-	-
	245	151	(61.6)	380	242	(63.7)
	250	168	(67.2)	275	181	(65.8)
	-	-	-	-	-	-
	3 902	1 144	(29.3)	3 810	1 298	(34.1)
	628	366	(58.3)	855	455	(53.2)
	<b>19 230</b>	<b>9 642</b>	<b>(50.1)</b>	<b>30 659</b>	<b>14 204</b>	<b>(46.3)</b>
	<b>20 604</b>	<b>10 085</b>	<b>(48.9)</b>	<b>32 045</b>	<b>14 728</b>	<b>(46.0)</b>
	<b>20 286</b>	<b>9 930</b>	<b>(49.0)</b>	<b>31 698</b>	<b>14 550</b>	<b>(45.9)</b>

Table XIII. Treatment success after 36 months of XDR TB cases, European Region, 2005–2010

Country	2005			2006			2007			2008			2009			2010		
	Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success		Cases reported	Success	
		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)		N	(%)
<b>EU/EEA</b>																		
Austria	-	-	-	-	-	-	-	-	-	4	3 (75.0)	2	1 (50.0)	1	1 (100.0)	1	1 (100.0)	
Belgium	-	-	-	2	1 (50.0)		1	0 (0.0)		2	1 (50.0)	3	2 (66.7)	2	2 (100.0)	2	2 (100.0)	
Bulgaria	-	-	-	-	-	-	6	0 (0.0)		1	0 (0.0)	1	0 (0.0)	1	1 (100.0)	1	1 (100.0)	
Croatia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Cyprus	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Czech Republic	-	-	-	3	2 (66.7)		-	-		1	1 (100.0)	1	0 (0.0)	1	1 (100.0)	1	1 (100.0)	
Denmark	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Estonia	17	6 (35.3)		5	2 (40.0)		14	6 (42.9)		6	2 (33.3)	8	1 (12.5)	11	5 (45.5)			
Finland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
France	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Germany	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Greece	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hungary	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	0 (0.0)	
Iceland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Ireland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Italy	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Latvia	-	-	-	-	-	-	6	4 (66.7)		19	9 (47.4)	16	9 (56.3)	13	9 (69.2)			
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Lithuania	-	-	-	-	-	-	-	-	-	-	-	4	1 (25.0)	50	3 (6.0)			
Luxembourg	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Malta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Netherlands	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Norway	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Poland	-	-	-	-	-	-	-	-	-	3	2 (66.7)	1	0 (0.0)	1	1 (100.0)	1	1 (100.0)	
Portugal	-	-	-	-	-	-	-	-	-	-	-	-	-	4	3 (75.0)			
Romania	-	-	-	1	1 (100.0)		48	7 (14.6)		53	4 (7.5)	26	1 (3.8)	27	2 (7.4)			
Slovakia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Slovenia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Spain	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Sweden	-	-	-	-	-	-	1	0 (0.0)		1	1 (100.0)	-	-	-	-	-	-	
United Kingdom	-	-	-	-	-	-	-	-	-	3	0 (0.0)	2	1 (50.0)	3	2 (66.7)			
<b>Subtotal EU/EEA</b>	<b>17</b>	<b>6 (35.3)</b>		<b>11</b>	<b>6 (54.5)</b>		<b>76</b>	<b>17 (22.4)</b>		<b>93</b>	<b>23 (24.7)</b>	<b>64</b>	<b>16 (25.0)</b>	<b>116</b>	<b>30 (25.9)</b>			
<b>Non-EU/EEA</b>																		
Albania	-	-	-	-	-	-	-	-	-	-	-	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
Andorra	-	-	-	-	-	-	-	-	-	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
Armenia	-	-	-	-	-	-	-	-	-	0	0 (0.0)	0	0 (0.0)	3	1 (33.3)			
Azerbaijan	-	-	-	-	-	-	-	-	-	0	0 (0.0)	1	0 (0.0)	-	-	-	-	
Belarus	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Bosnia and Herzegovina	-	-	-	-	-	-	-	-	-	-	-	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
former Yugoslav Republic of Macedonia, the	-	-	-	-	-	-	-	-	-	0	0 (0.0)	0	0 (0.0)	1	0 (0.0)			
Georgia	-	-	-	-	-	-	-	-	-	49	16 (32.7)	46	18 (39.1)	35	8 (22.9)			
Israel	-	-	-	-	-	-	-	-	-	1	1 (100.0)	0	0 (0.0)	1	0 (0.0)			
Kazakhstan	-	-	-	-	-	-	-	-	-	0	0 (0.0)	-	-	-	-	-	-	
Kyrgyzstan	-	-	-	-	-	-	-	-	-	9	0 (0.0)	9	1 (11.1)	7	1 (14.3)			
Moldova	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Monaco	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Montenegro	-	-	-	-	-	-	-	-	-	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
Russia	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
San Marino	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Serbia	-	-	-	-	-	-	-	-	-	-	-	0	0 (0.0)	0	0 (0.0)			
Serbia excluding UN Administered Province of Kosovo <sup>a</sup>	-	-	-	-	-	-	-	-	-	-	-	0	0 (0.0)	0	0 (0.0)			
UN Administered Province of Kosovo <sup>a</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Switzerland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Tajikistan	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0 (0.0)			
Turkey	-	-	-	-	-	-	-	-	-	0	0 (0.0)	0	0 (0.0)	3	2 (66.7)			
Turkmenistan	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Ukraine	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Uzbekistan	-	-	-	-	-	-	-	-	-	8	4 (50.0)	5	1 (20.0)	16	0 (0.0)			
<b>Subtotal non-EU/EEA</b>	<b>0</b>	<b>0 (0.0)</b>		<b>0</b>	<b>0 (0.0)</b>		<b>0</b>	<b>0 (0.0)</b>		<b>67</b>	<b>21 (31.3)</b>	<b>61</b>	<b>20 (32.8)</b>	<b>66</b>	<b>12 (18.2)</b>			
<b>Total European Region</b>	<b>17</b>	<b>6 (35.3)</b>		<b>11</b>	<b>6 (54.5)</b>		<b>76</b>	<b>17 (22.4)</b>		<b>160</b>	<b>44 (27.5)</b>	<b>125</b>	<b>36 (28.8)</b>	<b>182</b>	<b>42 (23.1)</b>			
<b>Subtotal 18 HPC</b>	<b>17</b>	<b>6 (35.3)</b>		<b>6</b>	<b>3 (50.0)</b>		<b>74</b>	<b>17 (23.0)</b>		<b>145</b>	<b>35 (24.1)</b>	<b>116</b>	<b>32 (27.6)</b>	<b>166</b>	<b>32 (19.3)</b>			

<sup>a</sup> 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries presented in italics.

<sup>a</sup> In accordance with the UN Security Council Resolution No. 1244 (1999).

## 8. Country profiles





AD	Andorra	GE	Georgia	PL	Poland
AL	Albania	HR	Croatia	PT	Portugal
AM	Armenia	HU	Hungary	RO	Romania
AT	Austria	IE	Ireland	RS	Serbia
AZ	Azerbaijan	IL	Israel	RU	Russia
BA	Bosnia and Herzegovina	IS	Iceland	SE	Sweden
BE	Belgium	IT	Italy	SI	Slovenia
BG	Bulgaria	KG	Kyrgyzstan	SK	Slovakia
BY	Belarus	KZ	Kazakhstan	TJ	Tajikistan
CH	Switzerland	LT	Lithuania	TM	Turkmenistan
CY	Cyprus	LU	Luxembourg	TR	Turkey
CZ	Czech Republic	LV	Latvia	UA	Ukraine
DE	Germany	MD	Moldova	UK	United Kingdom
DK	Denmark	ME	Montenegro	UZ	Uzbekistan
EE	Estonia	MK	former Yugoslav Republic of Macedonia, the		
EL	Greece	MT	Malta		
ES	Spain	NL	Netherlands		
FI	Finland	NO	Norway		
FR	France				





# Albania

Population estimate 2013 by UN Statistical Database: 3 173 272

## Tuberculosis case notifications, 2013

Total number of cases	474
Notification rate per 100 000	14.9
New* & relapses	474
New* & relapses notification rate per 100 000	14.9
Pulmonary	333 (70.3%)
of which smear-positive	212 (63.7%)
of which laboratory confirmed	145 (43.5%)
Laboratory-confirmed TB cases	161 (34.0%)
Mean age of new native TB cases	43.4 years
Mean age of new foreign TB cases	30.0 years
Foreign origin of all TB cases	1 (0.2%)
New (not previously treated)	455 (96.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	31 (21.4%)
Estimated MDR N, (best-low-high)	2-0-10
Pulmonary MDR cases	1 (0.7%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	109 (23.0%)
HIV-positive TB cases	2 (1.8%)
of these on antiretroviral therapy	2 (100.0%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	407	0
Success	373 (91.6%)	0 -
Died	11 (2.7%)	0 -
Failed	1 (0.2%)	0 -
Lost to follow up	12 (2.9%)	0 -
Not evaluated	10 (2.5%)	0 -

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.

# Andorra

Population estimate 2013 by UN Statistical Database: 79 221

## Tuberculosis case notifications, 2013

Total number of cases	5
Notification rate per 100 000	6.3
New* & relapses	5
New* & relapses notification rate per 100 000	6.3
Pulmonary	-
of which smear-positive	-
of which laboratory confirmed	-
Laboratory-confirmed TB cases	-
Mean age of new native TB cases	48.0 years
Mean age of new foreign TB cases	- years
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	5 (100.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	4 (80.0%)
Estimated MDR N, (best-low-high)	0-0-3
Pulmonary MDR cases	0 (0.0%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	1 (20.0%)
HIV-positive TB cases	1 (100.0%)
of these on antiretroviral therapy	1 (100.0%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	9	0
Success	9 (100.0%)	0 -
Died	0 (0.0%)	0 -
Failed	0 (0.0%)	0 -
Lost to follow up	0 (0.0%)	0 -
Not evaluated	0 (0.0%)	0 -

\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*



\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## MDR TB cases by previous treatment history, 2004–2013

No MDR cases reported

## TB-HIV co-infection, 2006–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.

# Armenia

Population estimate 2013 by UN Statistical Database: 2 976 567

## Tuberculosis case notifications, 2013

Total number of cases	1 417
Notification rate per 100 000	47.6
New* & relapses	1 397
New* & relapses notification rate per 100 000	46.9
Pulmonary	1 069 (75.4%)
of which smear-positive	349 (32.6%)
of which laboratory confirmed	439 (41.1%)
Laboratory-confirmed TB cases	492 (34.7%)
Mean age of new native TB cases	44.3 years
Mean age of new foreign TB cases	18.8 years
Foreign origin of all TB cases	6 (0.4%)
New (not previously treated)	1 053 (74.3%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	438 (99.8%)
Estimated MDR N, (best-low-high)	75-56-100
Pulmonary MDR cases	66 (15.0%)
of which XDR cases	7 (10.6%)
TB cases tested for HIV	1 417 (100.0%)
HIV-positive TB cases	67 (4.7%)
of these on antiretroviral therapy	48 (71.6%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	1 350	121
Success	1 093 (81.0%)	61 (50.4%)
Died	81 (6.0%)	6 (5.0%)
Failed	11 (0.8%)	1 (0.8%)
Lost to follow up	142 (10.5%)	32 (26.4%)
Not evaluated	23 (1.7%)	21 (17.4%)

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.

# Austria

Total population at 1 January 2013 by EUROSTAT: 8 451 860

## Tuberculosis case notifications, 2013

Total number of cases	649
Notification rate per 100 000	7.7
New* & relapses	624
New* & relapses notification rate per 100 000	7.4
Pulmonary	523 (80.6%)
of which smear-positive	221 (42.3%)
of which laboratory confirmed	385 (73.6%)
Laboratory-confirmed TB cases	467 (72.0%)
Mean age of new native TB cases	57.5 years
Mean age of new foreign TB cases	35.4 years
Foreign origin of all TB cases	332 (51.2%)
New (not previously treated)	485 (74.7%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	446 (95.5%)
Estimated MDR N, (best-low-high)	26-14-37
Pulmonary MDR cases	16 (4.3%)
of which XDR cases	3 (18.8%)
All MDR cases	16 (3.6%)
of which XDR cases	3 (18.8%)
TB cases tested for HIV	-
HIV-positive TB cases	-
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	219	20
Success	150 (68.5%)	13 (65.0%)
Died	13 (5.9%)	1 (5.0%)
Failed	0 (0.0%)	0 (0.0%)
Lost to follow up	19 (8.7%)	5 (25.0%)
Still on treatment	37 (16.9%)	1 (5.0%)
Not evaluated	0 (0.0%)	0 (0.0%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Azerbaijan

Population estimate 2013 by UN Statistical Database: 9 413 422

## Tuberculosis case notifications, 2013

Total number of cases	8 597
Notification rate per 100 000	91.3
New* & relapses	5 860
New* & relapses notification rate per 100 000	62.3
Pulmonary	-
of which smear-positive	-
of which laboratory confirmed	3 325
Laboratory-confirmed TB cases	-
Mean age of new native TB cases	- years
Mean age of new foreign TB cases	- years
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	4 528 (52.7%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	2 824 (84.9%)
Estimated MDR N, (best-low-high)	480-380-590
Pulmonary MDR cases	965 (29.0%)
of which XDR cases	-
TB cases tested for HIV	8 329 (96.9%)
HIV-positive TB cases	131 (1.6%)
of these on antiretroviral therapy	78 (59.5%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	4 616	565
Success	3 831 (83.0%)	339 (60.0%)
Died	138 (3.0%)	98 (17.3%)
Failed	185 (4.0%)	94 (16.6%)
Lost to follow up	370 (8.0%)	34 (6.0%)
Not evaluated	92 (2.0%)	0 (0.0%)

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.

# Belarus

Population estimate 2013 by UN Statistical Database: 9 356 679

## Tuberculosis case notifications, 2013

Total number of cases	4 859
Notification rate per 100 000	51.9
New* & relapses	4 470
New* & relapses notification rate per 100 000	47.8
Pulmonary	4 311 (88.7%)
of which smear-positive	1 671 (38.8%)
of which laboratory confirmed	3 408 (79.1%)
Laboratory-confirmed TB cases	3 470 (71.4%)
Mean age of new native TB cases	45.6 years
Mean age of new foreign TB cases	- years
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	3 577 (73.6%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	3 242 (95.1%)
Estimated MDR N, (best-low-high)	1 100-1 100-1 200
Pulmonary MDR cases	1 353 (39.7%)
of which XDR cases	80 (5.9%)
TB cases tested for HIV	4 859 (100.0%)
HIV-positive TB cases	250 (5.1%)
of these on antiretroviral therapy	189 (75.6%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	3 425	1 600
Success	2 902 (84.7%)	807 (50.4%)
Died	221 (6.5%)	174 (10.9%)
Failed	194 (5.7%)	376 (23.5%)
Lost to follow up	54 (1.6%)	152 (9.5%)
Not evaluated	54 (1.6%)	91 (5.7%)

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.

# Belgium

Total population at 1 January 2013 by EUROSTAT: 11 161 642

## Tuberculosis case notifications, 2013

Total number of cases	981
Notification rate per 100 000	8.8
New* & relapses	906
New* & relapses notification rate per 100 000	8.1
Pulmonary	682 (69.5%)
of which smear-positive	303 (44.4%)
of which laboratory confirmed	582 (85.3%)
Laboratory-confirmed TB cases	770 (78.5%)
Mean age of new native TB cases	46.1 years
Mean age of new foreign TB cases	33.8 years
Foreign origin of all TB cases	512 (52.2%)
New (not previously treated)	697 (71.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	729 (94.7%)
Estimated MDR N, (best-low-high)	0-0-0
Pulmonary MDR cases	10 (1.8%)
of which XDR cases	0 (0.0%)
All MDR cases	13 (1.8%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	492 (50.2%)
HIV-positive TB cases	36 (7.3%)
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
Outcome cohort	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Case-linked data reporting	Yes	
Cases notified	392	15
Success	293 (74.7%)	11 (73.3%)
Died	30 (7.7%)	0 (0.0%)
Failed	1 (0.3%)	0 (0.0%)
Lost to follow up	44 (11.2%)	1 (6.7%)
Still on treatment	15 (3.8%)	2 (13.3%)
Not evaluated	9 (2.3%)	1 (6.7%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Bosnia and Herzegovina

Population estimate 2013 by UN Statistical Database: 3 829 309

## Tuberculosis case notifications, 2013

Total number of cases	1261
Notification rate per 100 000	32.9
New* & relapses	1261
New* & relapses notification rate per 100 000	32.9
Pulmonary	1094 (86.8%)
of which smear-positive	537 (49.1%)
of which laboratory confirmed	706 (64.5%)
Laboratory-confirmed TB cases	708 (56.1%)
Mean age of new native TB cases	53.6 years
Mean age of new foreign TB cases	- years
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	1158 (91.8%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	706 (100.0%)
Estimated MDR N, (best-low-high)	0-0-6
Pulmonary MDR cases	1 (0.1%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	74 (5.9%)
HIV-positive TB cases	0 (0.0%)
of these on antiretroviral therapy	0 -

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National			
Outcome cohort	New and relapsed TB cases notified in 2012*		All MDR TB cases notified in 2011**	
Case-linked data reporting	Yes			
Cases notified	1301		5	
Success	1096 (84.2%)	1	1	(20.0%)
Died	101 (7.8%)	2	2	(40.0%)
Failed	6 (0.5%)	2	2	(40.0%)
Lost to follow up	8 (0.6%)	0	0	(0.0%)
Not evaluated	90 (6.9%)	0	0	(0.0%)

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.



# Bulgaria

Total population at 1 January 2013 by EUROSTAT: 7 284 552

## Tuberculosis case notifications, 2013

Total number of cases	1932
Notification rate per 100 000	26.5
New* & relapses	1930
New* & relapses notification rate per 100 000	26.5
Pulmonary	1425 (73.8%)
of which smear-positive	815 (57.2%)
of which laboratory confirmed	924 (64.8%)
Laboratory-confirmed TB cases	951 (49.2%)
Mean age of new native TB cases	45.2 years
Mean age of new foreign TB cases	36.2 years
Foreign origin of all TB cases	10 (0.5%)
New (not previously treated)	1 680 (87.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	734 (77.2%)
Estimated MDR N, (best-low-high)	78-58-99
Pulmonary MDR cases	26 (3.6%)
of which XDR cases	4 (15.4%)
All MDR cases	27 (3.7%)
of which XDR cases	4 (14.8%)
TB cases tested for HIV	1 874 (97.0%)
HIV-positive TB cases	4 (0.2%)
of these on antiretroviral therapy	3 (75.0%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	896	55
Success	775 (86.5%)	30 (54.5%)
Died	59 (6.6%)	10 (18.2%)
Failed	7 (0.8%)	1 (1.8%)
Lost to follow up	40 (4.5%)	12 (21.8%)
Still on treatment	12 (1.3%)	2 (3.6%)
Not evaluated	3 (0.3%)	0 (0.0%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Croatia

Population estimate 2013 by UN Statistical Database: 4 195 881

## Tuberculosis case notifications, 2013

Total number of cases	517
Notification rate per 100 000	12.3
New* & relapses	511
New* & relapses notification rate per 100 000	12.2
Pulmonary	420 (81.2%)
of which smear-positive	251 (59.8%)
of which laboratory confirmed	328 (78.1%)
Laboratory-confirmed TB cases	346 (66.9%)
Mean age of new native TB cases	53.4 years
Mean age of new foreign TB cases	60.3 years
Foreign origin of all TB cases	63 (12.2%)
New (not previously treated)	429 (83.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	315 (91.0%)
Estimated MDR N, (best-low-high)	0-0-0
Pulmonary MDR cases	0 (0.0%)
of which XDR cases	0 -
All MDR cases	0 (0.0%)
of which XDR cases	0 -
TB cases tested for HIV	- -
HIV-positive TB cases	- -
of these on antiretroviral therapy	- -

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	245	2
Success	18 (7.3%)	- -
Died	27 (11.0%)	- -
Failed	1 (0.4%)	- -
Lost to follow up	3 (1.2%)	- -
Still on treatment	2 (0.8%)	- -
Not evaluated	194 (79.2%)	- -


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012



# Cyprus

Total population at 1 January 2013 by EUROSTAT: 865 771

## Tuberculosis case notifications, 2013

Total number of cases	41
Notification rate per 100 000	4.7
New* & relapses	41
New* & relapses notification rate per 100 000	4.7
Pulmonary	29 (70.7%)
of which smear-positive	17 (58.6%)
of which laboratory confirmed	25 (86.2%)
Laboratory-confirmed TB cases	30 (73.2%)
Mean age of new native TB cases	43.7 years
Mean age of new foreign TB cases	40.2 years
Foreign origin of all TB cases	35 (85.4%)
New (not previously treated)	38 (92.7%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	30 (100.0%)
Estimated MDR N, (best-low-high)	0-0-0
Pulmonary MDR cases	1 (4.0%)
of which XDR cases	1 (100.0%)
All MDR cases	1 (3.3%)
of which XDR cases	1 (100.0%)
TB cases tested for HIV	-
HIV-positive TB cases	-
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
Outcome cohort	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Case-linked data reporting	Yes	
Cases notified	36	-
Success	18 (50.0%)	-
Died	1 (2.8%)	-
Failed	0 (0.0%)	-
Lost to follow up	3 (8.3%)	-
Still on treatment	4 (11.1%)	-
Not evaluated	10 (27.8%)	-


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Czech Republic

Total population at 1 January 2013 by EUROSTAT: 10 515 394

## Tuberculosis case notifications, 2013

Total number of cases	501
Notification rate per 100 000	4.8
New* & relapses	471
New* & relapses notification rate per 100 000	4.5
Pulmonary	441 (88.0%)
of which smear-positive	173 (39.2%)
of which laboratory confirmed	320 (72.6%)
Laboratory-confirmed TB cases	349 (69.7%)
Mean age of new native TB cases	56.3 years
Mean age of new foreign TB cases	40.6 years
Foreign origin of all TB cases	79 (15.8%)
New (not previously treated)	471 (94.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	321 (92.0%)
Estimated MDR N, (best-low-high)	0-0-0
Pulmonary MDR cases	0 (0.0%)
of which XDR cases	0 -
All MDR cases	0 (0.0%)
of which XDR cases	0 -
TB cases tested for HIV	125 (25.0%)
HIV-positive TB cases	0 (0.0%)
of these on antiretroviral therapy	- -

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	355	7
Success	263 (74.1%)	2 (28.6%)
Died	60 (16.9%)	0 (0.0%)
Failed	1 (0.3%)	0 (0.0%)
Lost to follow up	19 (5.4%)	4 (57.1%)
Still on treatment	9 (2.5%)	0 (0.0%)
Not evaluated	3 (0.8%)	1 (14.3%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Denmark

Total population at 1 January 2013 by EUROSTAT: 5 602 628

## Tuberculosis case notifications, 2013

Total number of cases	356
Notification rate per 100 000	6.4
New* & relapses	330
New* & relapses notification rate per 100 000	5.9
Pulmonary	226 (63.5%)
of which smear-positive	123 (54.4%)
of which laboratory confirmed	219 (96.9%)
Laboratory-confirmed TB cases	278 (78.1%)
Mean age of new native TB cases	42.7 years
Mean age of new foreign TB cases	38.6 years
Foreign origin of all TB cases	215 (60.4%)
New (not previously treated)	330 (92.7%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	275 (98.9%)
Estimated MDR N, (best-low-high)	0-0-0
Pulmonary MDR cases	2 (0.9%)
of which XDR cases	1 (50.0%)
All MDR cases	2 (0.7%)
of which XDR cases	1 (50.0%)
TB cases tested for HIV	8 (2.2%)
HIV-positive TB cases	8 -
of these on antiretroviral therapy	- -

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	207	3
Success	127 (61.4%)	0 (0.0%)
Died	11 (5.3%)	0 (0.0%)
Failed	8 (3.9%)	1 (33.3%)
Lost to follow up	0 (0.0%)	0 (0.0%)
Still on treatment	7 (3.4%)	0 (0.0%)
Not evaluated	54 (26.1%)	2 (66.7%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Estonia

Total population at 1 January 2008 by EUROSTAT: 1 320 174

## Tuberculosis case notifications, 2013

Total number of cases	286
Notification rate per 100 000	21.7
New* & relapses	263
New* & relapses notification rate per 100 000	19.9
Pulmonary	268 (93.7%)
of which smear-positive	130 (48.5%)
of which laboratory confirmed	215 (80.2%)
Laboratory-confirmed TB cases	223 (78.0%)
Mean age of new native TB cases	46.1 years
Mean age of new foreign TB cases	61.5 years
Foreign origin of all TB cases	43 (15.0%)
New (not previously treated)	225 (78.7%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	220 (98.7%)
Estimated MDR N, (best-low-high)	64-49-78
Pulmonary MDR cases	50 (23.6%)
of which XDR cases	8 (16.0%)
All MDR cases	50 (22.7%)
of which XDR cases	8 (16.0%)
TB cases tested for HIV	276 (96.5%)
HIV-positive TB cases	36 (13.0%)
of these on antiretroviral therapy	24 (66.7%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National			
Outcome cohort	New culture positive pulmonary TB cases notified in 2012*		All MDR TB cases notified in 2011**	
Case-linked data reporting	Yes			
Cases notified	185	78		
Success	112 (60.5%)	39 (50.0%)		
Died	30 (16.2%)	15 (19.2%)		
Failed	1 (0.5%)	5 (6.4%)		
Lost to follow up	13 (7.0%)	11 (14.1%)		
Still on treatment	29 (15.7%)	8 (10.3%)		
Not evaluated	0 (0.0%)	0 (0.0%)		


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Finland

Total population at 1 January 2013 by EUROSTAT: 5 426 674

## Tuberculosis case notifications, 2013

Total number of cases	271
Notification rate per 100 000	5.0
New* & relapses	266
New* & relapses notification rate per 100 000	4.9
Pulmonary	217 (80.1%)
of which smear-positive	93 (42.9%)
of which laboratory confirmed	173 (79.7%)
Laboratory-confirmed TB cases	205 (75.6%)
Mean age of new native TB cases	68.7 years
Mean age of new foreign TB cases	32.7 years
Foreign origin of all TB cases	85 (31.4%)
New (not previously treated)	253 (93.4%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	203 (99.0%)
Estimated MDR N, (best-low-high)	1-0-4
Pulmonary MDR cases	2 (1.2%)
of which XDR cases	0 (0.0%)
All MDR cases	2 (1.0%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	-
HIV-positive TB cases	-
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	147	5
Success	111 (75.5%)	-
Died	21 (14.3%)	-
Failed	0 (0.0%)	-
Lost to follow up	0 (0.0%)	-
Still on treatment	4 (2.7%)	-
Not evaluated	11 (7.5%)	-


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# former Yugoslav Republic of Macedonia, the

Population estimate 2013 by UN Statistical Database: 2 107 158

## Tuberculosis case notifications, 2013

Total number of cases	323
Notification rate per 100 000	15.3
New* & relapses	318
New* & relapses notification rate per 100 000	15.1
Pulmonary	249 (77.1%)
of which smear-positive	172 (69.1%)
of which laboratory confirmed	183 (73.5%)
Laboratory-confirmed TB cases	211 (65.3%)
Mean age of new native TB cases	45.6 years
Mean age of new foreign TB cases	53.3 years
Foreign origin of all TB cases	15 (4.6%)
New (not previously treated)	290 (89.8%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	179 (97.8%)
Estimated MDR N, (best-low-high)	0-0-5
Pulmonary MDR cases	1 (0.5%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	206 (63.8%)
HIV-positive TB cases	0 (0.0%)
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%


\*\* More than 50% of TB cases tested for HIV.

## Treatment outcome monitoring

Geographical coverage	National			
Outcome cohort	New and relapsed TB cases notified in 2012*		All MDR TB cases notified in 2011**	
Case-linked data reporting	Yes			
Cases notified	346		1	
Success	298 (86.1%)	1 (100.0%)		
Died	28 (8.1%)	0 (0.0%)		
Failed	3 (0.9%)	0 (0.0%)		
Lost to follow up	16 (4.6%)	0 (0.0%)		
Still on treatment	1 (0.3%)	0 (0.0%)		
Not evaluated	-	-	-	-


\* Treatment outcome as presented is treatment outcome after 12 months.  
\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.



# France

Total population at 1 January 2013 by EUROSTAT: 65 558 428

## Tuberculosis case notifications, 2013

Total number of cases	4 939
Notification rate per 100 000	7.5
New* & relapses	4 708
New* & relapses notification rate per 100 000	7.2
Pulmonary	3 573 (72.3%)
of which smear-positive	1 788 (50.0%)
of which laboratory confirmed	1 821 (51.0%)
Laboratory-confirmed TB cases	2 335 (47.3%)
Mean age of new native TB cases	47.3 years
Mean age of new foreign TB cases	39.4 years
Foreign origin of all TB cases	2 553 (51.7%)
New (not previously treated)	4 708 (95.3%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	-
Case-linked data reporting	No
Cases with DST results	4 258 -
Estimated MDR N, (best-low-high)	0-0-0
Pulmonary MDR cases	- -
of which XDR cases	- -
All MDR cases	83 (1.9%)
of which XDR cases	21 (25.3%)
TB cases tested for HIV	- -
HIV-positive TB cases	- -
of these on antiretroviral therapy	- -


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Data not available


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013



## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012

Data not available

# Georgia

Population estimate 2013 by UN Statistical Database: 4 340 897

## Tuberculosis case notifications, 2013

Total number of cases	4 319
Notification rate per 100 000	99.5
New* & relapses	3 434
New* & relapses notification rate per 100 000	79.1
Pulmonary	3 014 (69.8%)
of which smear-positive	1 804 (59.9%)
of which laboratory confirmed	2173 (72.1%)
Laboratory-confirmed TB cases	2 680 (62.1%)
Mean age of new native TB cases	40.2 years
Mean age of new foreign TB cases	- years
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	3 133 (72.5%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	2 156 (99.2%)
Estimated MDR N, (best-low-high)	270-230-310
Pulmonary MDR cases	384 (17.7%)
of which XDR cases	71 (18.5%)
TB cases tested for HIV	2 698 (62.5%)
HIV-positive TB cases	56 (2.1%)
of these on antiretroviral therapy	50 (89.3%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.

## Treatment outcome monitoring

Geographical coverage	National	
Outcome cohort	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Case-linked data reporting	Yes	
Cases notified	3 638	611
Success	3 103 (85.3%)	305 (49.9%)
Died	73 (2.0%)	31 (5.1%)
Failed	99 (2.7%)	18 (2.9%)
Lost to follow up	224 (6.2%)	221 (36.2%)
Not evaluated	139 (3.8%)	36 (5.9%)


\* Treatment outcome as presented is treatment outcome after 12 months.  
\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.

# Germany

Total population at 1 January 2013 by EUROSTAT: 81 835 450

## Tuberculosis case notifications, 2013

Total number of cases	4 318
Notification rate per 100 000	5.3
New* & relapses	4 193
New* & relapses notification rate per 100 000	5.1
Pulmonary	3 298 (76.4%)
of which smear-positive	1 181 (35.8%)
of which laboratory confirmed	2 573 (78.0%)
Laboratory-confirmed TB cases	3 150 (73.0%)
Mean age of new native TB cases	54.6 years
Mean age of new foreign TB cases	41.5 years
Foreign origin of all TB cases	2 309 (53.5%)
New (not previously treated)	4 058 (94.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	2 901 (92.1%)
Estimated MDR N, (best-low-high)	120-95-150
Pulmonary MDR cases	85 (3.6%)
of which XDR cases	2 (2.4%)
All MDR cases	100 (3.4%)
of which XDR cases	2 (2.0%)
TB cases tested for HIV	-
HIV-positive TB cases	-
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	807	56
Success	604 (74.8%)	30 (53.6%)
Died	100 (12.4%)	4 (7.1%)
Failed	1 (0.1%)	0 (0.0%)
Lost to follow up	17 (2.1%)	2 (3.6%)
Still on treatment	28 (3.5%)	3 (5.4%)
Not evaluated	57 (7.1%)	17 (30.4%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Greece

Total population at 1 January 2013 by EUROSTAT: 11 062 508

## Tuberculosis case notifications, 2013

Total number of cases	540
Notification rate per 100 000	4.9
New* & relapses	494
New* & relapses notification rate per 100 000	4.5
Pulmonary	456 (84.4%)
of which smear-positive	294 (64.5%)
of which laboratory confirmed	298 (65.4%)
Laboratory-confirmed TB cases	339 (62.8%)
Mean age of new native TB cases	57.7 years
Mean age of new foreign TB cases	31.3 years
Foreign origin of all TB cases	229 (42.4%)
New (not previously treated)	494 (91.5%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	233 (68.7%)
Estimated MDR N, (best-low-high)	10-0-25
Pulmonary MDR cases	10 (4.8%)
of which XDR cases	0 (0.0%)
All MDR cases	10 (4.3%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	363 (67.2%)
HIV-positive TB cases	35 (9.6%)
of these on antiretroviral therapy	26 (74.3%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Data not available


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013



## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012

Data not available

# Hungary

Total population at 1 January 2013 by EUROSTAT: 9 860 935

## Tuberculosis case notifications, 2013

Total number of cases	1 045
Notification rate per 100 000	10.6
New* & relapses	1 040
New* & relapses notification rate per 100 000	10.5
Pulmonary	996 (95.3%)
of which smear-positive	203 (20.4%)
of which laboratory confirmed	439 (44.1%)
Laboratory-confirmed TB cases	448 (42.9%)
Mean age of new native TB cases	54.0 years
Mean age of new foreign TB cases	35.0 years
Foreign origin of all TB cases	34 (3.3%)
New (not previously treated)	975 (93.3%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	360 (80.4%)
Estimated MDR N, (best-low-high)	0-0-0
Pulmonary MDR cases	10 (2.8%)
of which XDR cases	1 (10.0%)
All MDR cases	10 (2.8%)
of which XDR cases	1 (10.0%)
TB cases tested for HIV	-
HIV-positive TB cases	-
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	496	7
Success	313 (63.1%)	3 (42.9%)
Died	65 (13.1%)	1 (14.3%)
Failed	0 (0.0%)	0 (0.0%)
Lost to follow up	40 (8.1%)	1 (14.3%)
Still on treatment	48 (9.7%)	2 (28.6%)
Not evaluated	30 (6.0%)	0 (0.0%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Iceland

Total population at 1 January 2013 by EUROSTAT: 321 857

## Tuberculosis case notifications, 2013

Total number of cases	11
Notification rate per 100 000	3.4
New* & relapses	11
New* & relapses notification rate per 100 000	3.4
Pulmonary	4 (36.4%)
of which smear-positive	2 (50.0%)
of which laboratory confirmed	3 (75.0%)
Laboratory-confirmed TB cases	7 (63.6%)
Mean age of new native TB cases	64.3 years
Mean age of new foreign TB cases	31.0 years
Foreign origin of all TB cases	5 (45.5%)
New (not previously treated)	11 (100.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	7 (100.0%)
Estimated MDR N, (best-low-high)	0-0-3
Pulmonary MDR cases	0 (0.0%)
of which XDR cases	0 -
All MDR cases	0 (0.0%)
of which XDR cases	0 -
TB cases tested for HIV	8 (72.7%)
HIV-positive TB cases	0 (0.0%)
of these on antiretroviral therapy	- -

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	4	0
Success	4 (100.0%)	0 -
Died	0 (0.0%)	0 -
Failed	0 (0.0%)	0 -
Lost to follow up	0 (0.0%)	0 -
Still on treatment	0 (0.0%)	0 -
Not evaluated	0 (0.0%)	0 -


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Ireland

Total population at 1 January 2013 by EUROSTAT: 4 591 087

## Tuberculosis case notifications, 2013

Total number of cases	384
Notification rate per 100 000	8.4
New* & relapses	356
New* & relapses notification rate per 100 000	7.8
Pulmonary	253 (65.9%)
of which smear-positive	129 (51.0%)
of which laboratory confirmed	206 (81.4%)
Laboratory-confirmed TB cases	282 (73.4%)
Mean age of new native TB cases	43.3 years
Mean age of new foreign TB cases	36.4 years
Foreign origin of all TB cases	171 (44.5%)
New (not previously treated)	356 (92.7%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	270 (95.7%)
Estimated MDR N, (best-low-high)	4-0-8
Pulmonary MDR cases	4 (2.0%)
of which XDR cases	1 (25.0%)
All MDR cases	4 (1.5%)
of which XDR cases	1 (25.0%)
TB cases tested for HIV	103 (26.8%)
HIV-positive TB cases	8 (7.8%)
of these on antiretroviral therapy	4 (50.0%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	158	3
Success	107 (67.7%)	1 (33.3%)
Died	4 (2.5%)	0 (0.0%)
Failed	0 (0.0%)	0 (0.0%)
Lost to follow up	2 (1.3%)	0 (0.0%)
Still on treatment	12 (7.6%)	0 (0.0%)
Not evaluated	33 (20.9%)	2 (66.7%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Israel

Population estimate 2013 by UN Statistical Database: 7 733 142

## Tuberculosis case notifications, 2013

Total number of cases	308
Notification rate per 100 000	4.0
New* & relapses	308
New* & relapses notification rate per 100 000	4.0
Pulmonary	226 (73.4%)
of which smear-positive	94 (41.6%)
of which laboratory confirmed	157 (69.5%)
Laboratory-confirmed TB cases	217 (70.5%)
Mean age of new native TB cases	33.5 years
Mean age of new foreign TB cases	38.4 years
Foreign origin of all TB cases	254 (82.5%)
New (not previously treated)	304 (98.7%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	157 (100.0%)
Estimated MDR N, (best-low-high)	9-3-18
Pulmonary MDR cases	7 (4.5%)
of which XDR cases	1 (14.3%)
TB cases tested for HIV	292 (94.8%)
HIV-positive TB cases	15 (5.1%)
of these on antiretroviral therapy	0 (0.0%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
Outcome cohort	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Case-linked data reporting	Yes	
Cases notified	509	11
Success	412 (80.9%)	7 (63.6%)
Died	30 (5.9%)	0 (0.0%)
Failed	0 (0.0%)	0 (0.0%)
Lost to follow up	14 (2.8%)	0 (0.0%)
Not evaluated	53 (10.4%)	4 (36.4%)

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.



# Italy

Total population at 1 January 2013 by EUROSTAT: 59 685 227

## Tuberculosis case notifications, 2013

Total number of cases	3 153
Notification rate per 100 000	5.3
New* & relapses	3 019
New* & relapses notification rate per 100 000	5.1
Pulmonary	2 448 (77.6%)
of which smear-positive	782 (31.9%)
of which laboratory confirmed	594 (24.3%)
Laboratory-confirmed TB cases	2 381 (75.5%)
Mean age of new native TB cases	56.1 years
Mean age of new foreign TB cases	36.3 years
Foreign origin of all TB cases	1 973 (62.6%)
New (not previously treated)	3 019 (95.8%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	No
Cases with DST results	2 350 (98.7%)
Estimated MDR N, (best-low-high)	73-38-110
Pulmonary MDR cases	-
of which XDR cases	-
All MDR cases	78 (3.3%)
of which XDR cases	7 (9.0%)
TB cases tested for HIV	-
HIV-positive TB cases	-
of these on antiretroviral therapy	-


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Data not available


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013



## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012

Data not available

# Kazakhstan

Population estimate 2013 by UN Statistical Database: 16 440 587

## Tuberculosis case notifications, 2013

Total number of cases	19 857
Notification rate per 100 000	120.8
New* & relapses	18 958
New* & relapses notification rate per 100 000	115.3
Pulmonary	17 843 (89.9%)
of which smear-positive	8 252 (46.2%)
of which laboratory confirmed	14 760 (82.7%)
Laboratory-confirmed TB cases	15 874 (79.9%)
Mean age of new native TB cases	38.2 years
Mean age of new foreign TB cases	35.8 years
Foreign origin of all TB cases	43 (0.2%)
New (not previously treated)	12 510 (63.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	14 573 (98.7%)
Estimated MDR N, (best-low-high)	2 700-2 600-2 900
Pulmonary MDR cases	6 032 (40.9%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	18 104 (91.2%)
HIV-positive TB cases	466 (2.6%)
of these on antiretroviral therapy	271 (58.2%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	16 275	5 261
Success	14 068 (86.4%)	3 910 (74.3%)
Died	923 (5.7%)	417 (7.9%)
Failed	612 (3.8%)	373 (7.1%)
Lost to follow up	439 (2.7%)	411 (7.8%)
Not evaluated	233 (1.4%)	150 (2.9%)

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.

# Kyrgyzstan

Population estimate 2013 by UN Statistical Database: 5 547 549

## Tuberculosis case notifications, 2013

Total number of cases	7 209
Notification rate per 100 000	130
New* & relapses	7 075
New* & relapses notification rate per 100 000	128
Pulmonary	5 383 (74.7%)
of which smear-positive	2 216 (41.2%)
of which laboratory confirmed	2 280 (42.4%)
Laboratory-confirmed TB cases	2 298 (31.9%)
Mean age of new native TB cases	34 years
Mean age of new foreign TB cases	- years
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	5 859 (81.3%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	3 150 (138.2%)
Estimated MDR N, (best-low-high)	1 100-950-1 300
Pulmonary MDR cases	1 160 (50.9%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	-
HIV-positive TB cases	203
of these on antiretroviral therapy	110 (54.2%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	-	492
Success	-	280 (56.9%)
Died	-	69 (14.0%)
Failed	-	35 (7.1%)
Lost to follow up	-	106 (21.5%)
Not evaluated	-	2 (0.4%)

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.

# Latvia

Total population at 1 January 2013 by EUROSTAT: 2 023 657

## Tuberculosis case notifications, 2013

Total number of cases	904
Notification rate per 100 000	44.7
New* & relapses	872
New* & relapses notification rate per 100 000	43.1
Pulmonary	808 (89.4%)
of which smear-positive	317 (39.2%)
of which laboratory confirmed	671 (83.0%)
Laboratory-confirmed TB cases	702 (77.7%)
Mean age of new native TB cases	41.7 years
Mean age of new foreign TB cases	57.8 years
Foreign origin of all TB cases	40 (4.4%)
New (not previously treated)	776 (85.8%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	681 (97.0%)
Estimated MDR N, (best-low-high)	91-72-110
Pulmonary MDR cases	75 (11.5%)
of which XDR cases	15 (20.0%)
All MDR cases	79 (11.6%)
of which XDR cases	15 (19.0%)
TB cases tested for HIV	420 (46.5%)
HIV-positive TB cases	95 (22.6%)
of these on antiretroviral therapy	47 (49.5%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	647	95
Success	506 (78.2%)	51 (53.7%)
Died	43 (6.6%)	15 (15.8%)
Failed	1 (0.2%)	7 (7.4%)
Lost to follow up	28 (4.3%)	11 (11.6%)
Still on treatment	64 (9.9%)	10 (10.5%)
Not evaluated	5 (0.8%)	1 (1.1%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Lithuania

Total population at 1 January 2013 by EUROSTAT: 2 971 511

## Tuberculosis case notifications, 2013

Total number of cases	1705
Notification rate per 100 000	57.4
New* & relapses	1573
New* & relapses notification rate per 100 000	52.9
Pulmonary	1565 (91.8%)
of which smear-positive	958 (61.2%)
of which laboratory confirmed	1315 (84.0%)
Laboratory-confirmed TB cases	1354 (79.4%)
Mean age of new native TB cases	46.9 years
Mean age of new foreign TB cases	55.7 years
Foreign origin of all TB cases	40 (2.3%)
New (not previously treated)	1393 (81.7%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	1354 (100.0%)
Estimated MDR N, (best-low-high)	0-0-0
Pulmonary MDR cases	253 (19.2%)
of which XDR cases	46 (18.2%)
All MDR cases	256 (18.9%)
of which XDR cases	47 (18.4%)
TB cases tested for HIV	1144 (67.1%)
HIV-positive TB cases	39 (3.4%)
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	983	296
Success	690 (70.2%)	104 (35.1%)
Died	97 (9.9%)	63 (21.3%)
Failed	7 (0.7%)	20 (6.8%)
Lost to follow up	88 (9.0%)	87 (29.4%)
Still on treatment	97 (9.9%)	20 (6.8%)
Not evaluated	4 (0.4%)	2 (0.7%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Luxembourg

Total population at 1 January 2013 by EUROSTAT: 537 039

## Tuberculosis case notifications, 2013

Total number of cases	38
Notification rate per 100 000	7.1
New* & relapses	38
New* & relapses notification rate per 100 000	7
Pulmonary	32 (84.2%)
of which smear-positive	17 (53.1%)
of which laboratory confirmed	28 (87.5%)
Laboratory-confirmed TB cases	33 (86.8%)
Mean age of new native TB cases	62.5 years
Mean age of new foreign TB cases	35.7 years
Foreign origin of all TB cases	36 (94.7%)
New (not previously treated)	38 (100.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	32 (97.0%)
Estimated MDR N, (best-low-high)	0-0-0
Pulmonary MDR cases	0 (0.0%)
of which XDR cases	0 -
All MDR cases	0 (0.0%)
of which XDR cases	0 -
TB cases tested for HIV	36 (94.7%)
HIV-positive TB cases	1 (2.8%)
of these on antiretroviral therapy	- -


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Data not available


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013



## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013\*



\* No data available for 2006–2009

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012

Data not available

# Malta

Total population at 1 January 2013 by EUROSTAT: 421 364

## Tuberculosis case notifications, 2013

Total number of cases	50
Notification rate per 100 000	11.9
New* & relapses	50
New* & relapses notification rate per 100 000	11.9
Pulmonary	38 (76.0%)
of which smear-positive	15 (39.5%)
of which laboratory confirmed	20 (52.6%)
Laboratory-confirmed TB cases	27 (54.0%)
Mean age of new native TB cases	83.0 years
Mean age of new foreign TB cases	26.2 years
Foreign origin of all TB cases	44 (88.0%)
New (not previously treated)	50 (100.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	27 (100.0%)
Estimated MDR N, (best-low-high)	0-0-9
Pulmonary MDR cases	1 (5.0%)
of which XDR cases	1 (100.0%)
All MDR cases	1 (3.7%)
of which XDR cases	1 (100.0%)
TB cases tested for HIV	44 (88.0%)
HIV-positive TB cases	0 (0.0%)
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
Outcome cohort	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Case-linked data reporting	Yes	
Cases notified	10	0
Success	10 (100.0%)	0 -
Died	0 (0.0%)	0 -
Failed	0 (0.0%)	0 -
Lost to follow up	0 (0.0%)	0 -
Still on treatment	0 (0.0%)	0 -
Not evaluated	0 (0.0%)	0 -


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




\* By nationality for 2000–2006


## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Moldova

Population estimate 2013 by UN Statistical Database: 3 487 203

## Tuberculosis case notifications, 2013

Total number of cases	5 051
Notification rate per 100 000	144.8
New* & relapses	4 485
New* & relapses notification rate per 100 000	128.6
Pulmonary	4 673 (92.5%)
of which smear-positive	1 864 (39.9%)
of which laboratory confirmed	2 542 (54.4%)
Laboratory-confirmed TB cases	2 878 (57.0%)
Mean age of new native TB cases	41.5 years
Mean age of new foreign TB cases	46.4 years
Foreign origin of all TB cases	39 (0.8%)
New (not previously treated)	3 604 (71.4%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	2 317 (91.1%)
Estimated MDR N, (best-low-high)	770-700-850
Pulmonary MDR cases	912 (35.9%)
of which XDR cases	35 (3.8%)
TB cases tested for HIV	4 085 (80.9%)
HIV-positive TB cases	250 (6.1%)
of these on antiretroviral therapy	165 (66.0%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.

## Treatment outcome monitoring

Geographical coverage	National	
Outcome cohort	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Case-linked data reporting	Yes	
Cases notified	4 203	761
Success	3 205 (76.3%)	413 (54.3%)
Died	418 (9.9%)	100 (13.1%)
Failed	125 (3.0%)	72 (9.5%)
Lost to follow up	331 (7.9%)	176 (23.1%)
Not evaluated	124 (3.0%)	0 (0.0%)

\* Treatment outcome as presented is treatment outcome after 12 months.  
\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.



# Montenegro

Population estimate 2013 by UN Statistical Database: 621 381

## Tuberculosis case notifications, 2013

Total number of cases	120
Notification rate per 100 000	19.3
New* & relapses	119
New* & relapses notification rate per 100 000	19.2
Pulmonary	112 (93.3%)
of which smear-positive	46 (41.1%)
of which laboratory confirmed	73 (65.2%)
Laboratory-confirmed TB cases	73 (60.8%)
Mean age of new native TB cases	47.5 years
Mean age of new foreign TB cases	40.0 years
Foreign origin of all TB cases	2 (1.7%)
New (not previously treated)	111 (92.5%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	72 (98.6%)
Estimated MDR N, (best-low-high)	0-0-6
Pulmonary MDR cases	0 (0.0%)
of which XDR cases	0 -
TB cases tested for HIV	98 (81.7%)
HIV-positive TB cases	2 (2.0%)
of these on antiretroviral therapy	2 (100.0%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
Outcome cohort	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Case-linked data reporting	Yes	
Cases notified	107	1
Success	90 (84.1%)	0 (0.0%)
Died	9 (8.4%)	0 (0.0%)
Failed	0 (0.0%)	0 (0.0%)
Lost to follow up	4 (3.7%)	0 (0.0%)
Not evaluated	4 (3.7%)	1 (100.0%)

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.

# Netherlands

Total population at 1 January 2013 by EUROSTAT: 16 779 575

## Tuberculosis case notifications, 2013

Total number of cases	848
Notification rate per 100 000	5.1
New* & relapses	832
New* & relapses notification rate per 100 000	5.0
Pulmonary	454 (53.5%)
of which smear-positive	141 (31.1%)
of which laboratory confirmed	372 (81.9%)
Laboratory-confirmed TB cases	609 (71.8%)
Mean age of new native TB cases	45.8 years
Mean age of new foreign TB cases	39.8 years
Foreign origin of all TB cases	627 (73.9%)
New (not previously treated)	807 (95.2%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	607 (99.7%)
Estimated MDR N, (best-low-high)	20-11-29
Pulmonary MDR cases	14 (3.8%)
of which XDR cases	0 (0.0%)
All MDR cases	17 (2.8%)
of which XDR cases	-
TB cases tested for HIV	432 (50.9%)
HIV-positive TB cases	17 (3.9%)
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
Outcome cohort	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Case-linked data reporting	Yes	
Cases notified	379	17
Success	311 (82.1%)	11 (64.7%)
Died	15 (4.0%)	0 (0.0%)
Failed	0 (0.0%)	0 (0.0%)
Lost to follow up	8 (2.1%)	3 (17.6%)
Still on treatment	10 (2.6%)	2 (11.8%)
Not evaluated	35 (9.2%)	1 (5.9%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Norway

Total population at 1 January 2013 by EUROSTAT: 5 051 275

## Tuberculosis case notifications, 2013

Total number of cases	401
Notification rate per 100 000	7.9
New* & relapses	362
New* & relapses notification rate per 100 000	7.2
Pulmonary	250 (62.3%)
of which smear-positive	67 (26.8%)
of which laboratory confirmed	209 (83.6%)
Laboratory-confirmed TB cases	319 (79.6%)
Mean age of new native TB cases	43.5 years
Mean age of new foreign TB cases	31.6 years
Foreign origin of all TB cases	345 (86.0%)
New (not previously treated)	362 (90.3%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	318 (99.7%)
Estimated MDR N, (best-low-high)	7-1-14
Pulmonary MDR cases	5 (2.4%)
of which XDR cases	1 (20.0%)
All MDR cases	6 (1.9%)
of which XDR cases	1 (16.7%)
TB cases tested for HIV	8 (2.0%)
HIV-positive TB cases	8 -
of these on antiretroviral therapy	- -

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	170	4
Success	134 (78.8%)	3 (75.0%)
Died	8 (4.7%)	0 (0.0%)
Failed	2 (1.2%)	1 (25.0%)
Lost to follow up	0 (0.0%)	0 (0.0%)
Still on treatment	5 (2.9%)	0 (0.0%)
Not evaluated	21 (12.4%)	0 (0.0%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Poland

Total population at 1 January 2013 by EUROSTAT: 38 529 513

## Tuberculosis case notifications, 2013

Total number of cases	7 250
Notification rate per 100 000	18.8
New* & relapses	7 043
New* & relapses notification rate per 100 000	18.3
Pulmonary	6 835 (94.3%)
of which smear-positive	2 879 (42.1%)
of which laboratory confirmed	4 663 (68.2%)
Laboratory-confirmed TB cases	4 825 (66.6%)
Mean age of new native TB cases	53.5 years
Mean age of new foreign TB cases	37.4 years
Foreign origin of all TB cases	52 (0.7%)
New (not previously treated)	6 403 (88.3%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	4 470 (92.6%)
Estimated MDR N, (best-low-high)	66-45-86
Pulmonary MDR cases	40 (0.9%)
of which XDR cases	1 (2.5%)
All MDR cases	40 (0.9%)
of which XDR cases	1 (2.5%)
TB cases tested for HIV	-
HIV-positive TB cases	-
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	4 282	41
Success	2 567 (59.9%)	14 (34.1%)
Died	351 (8.2%)	10 (24.4%)
Failed	5 (0.1%)	0 (0.0%)
Lost to follow up	285 (6.7%)	7 (17.1%)
Still on treatment	14 (0.3%)	1 (2.4%)
Not evaluated	1 060 (24.8%)	9 (22.0%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Portugal

Total population at 1 January 2013 by EUROSTAT: 10 484 679

## Tuberculosis case notifications, 2013

Total number of cases	2 393
Notification rate per 100 000	22.8
New* & relapses	2 338
New* & relapses notification rate per 100 000	22.3
Pulmonary	1 686 (70.5%)
of which smear-positive	1 066 (63.2%)
of which laboratory confirmed	1 261 (74.8%)
Laboratory-confirmed TB cases	1 453 (60.7%)
Mean age of new native TB cases	49.5 years
Mean age of new foreign TB cases	40.2 years
Foreign origin of all TB cases	389 (16.3%)
New (not previously treated)	2 209 (92.3%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	1 033 (71.1%)
Estimated MDR N, (best-low-high)	23-12-34
Pulmonary MDR cases	14 (1.5%)
of which XDR cases	4 (28.6%)
All MDR cases	15 (1.5%)
of which XDR cases	4 (26.7%)
TB cases tested for HIV	1 710 (71.5%)
HIV-positive TB cases	248 (14.5%)
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	1 448	38
Success	1 142 (78.9%)	19 (52.8%)
Died	92 (6.4%)	3 (8.3%)
Failed	0 (0.0%)	0 (0.0%)
Lost to follow up	30 (2.1%)	4 (11.1%)
Still on treatment	139 (9.6%)	5 (13.9%)
Not evaluated	45 (3.1%)	5 (13.9%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Romania

Total population at 1 January 2013 by EUROSTAT: 20 019 041

## Tuberculosis case notifications, 2013

Total number of cases	16 711
Notification rate per 100 000	83.5
New* & relapses	15 523
New* & relapses notification rate per 100 000	77.5
Pulmonary	14 276 (85.4%)
of which smear-positive	8 984 (62.9%)
of which laboratory confirmed	10 630 (74.5%)
Laboratory-confirmed TB cases	10 890 (65.2%)
Mean age of new native TB cases	42.7 years
Mean age of new foreign TB cases	30.0 years
Foreign origin of all TB cases	48 (0.3%)
New (not previously treated)	12 860 (77.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	7 141 (65.6%)
Estimated MDR N, (best-low-high)	710-540-870
Pulmonary MDR cases	547 (7.8%)
of which XDR cases	44 (8.0%)
All MDR cases	555 (7.8%)
of which XDR cases	44 (7.9%)
TB cases tested for HIV	10 196 (61.0%)
HIV-positive TB cases	267 (2.6%)
of these on antiretroviral therapy	244 (91.4%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	8 475	547
Success	7 244 (85.5%)	140 (25.6%)
Died	467 (5.5%)	106 (19.4%)
Failed	257 (3.0%)	191 (34.9%)
Lost to follow up	405 (4.8%)	90 (16.5%)
Still on treatment	102 (1.2%)	20 (3.7%)
Not evaluated	0 (0.0%)	0 (0.0%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Russia

Population estimate 2013 by UN Statistical Database: 142 833 687

## Tuberculosis case notifications, 2013

Total number of cases	142 533
Notification rate per 100 000	99.8
New* & relapses	106 053
New* & relapses notification rate per 100 000	74.2
Pulmonary	121 327 (85.1%)
of which smear-positive	42 065 (34.7%)
of which laboratory confirmed	40 409 (33.3%)
Laboratory-confirmed TB cases	57 751 (40.5%)
Mean age of new native TB cases	39.3 years
Mean age of new foreign TB cases	33.8 years
Foreign origin of all TB cases	2 432 (1.7%)
New (not previously treated)	90 427 (63.4%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	43 743 (108.3%)
Estimated MDR N, (best-low-high)	16000-11000-20000
Pulmonary MDR cases	13 521 (33.5%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	69 724 (48.9%)
HIV-positive TB cases	4 990 (7.2%)
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	89 666	15 896
Success	61 765 (68.9%)	5 895 (37.1%)
Died	7 215 (8.0%)	3 037 (19.1%)
Failed	8 004 (8.9%)	2 916 (18.3%)
Lost to follow up	6 398 (7.1%)	2 344 (14.7%)
Not evaluated	6 284 (7.0%)	1 704 (10.7%)

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.

# Serbia

Population estimate 2013 by UN Statistical Database: 9 510 504

## Tuberculosis case notifications, 2013

Total number of cases	2 103
Notification rate per 100 000	22.1
New* & relapses	2 083
New* & relapses notification rate per 100 000	21.9
Pulmonary	1 030 (49.0%)
of which smear-positive	604 (58.6%)
of which laboratory confirmed	824 (80.0%)
Laboratory-confirmed TB cases	890 (42.3%)
Mean age of new native TB cases	51.8 years
Mean age of new foreign TB cases	55.7 years
Foreign origin of all TB cases	7 (0.3%)
New (not previously treated)	1 968 (93.6%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	792 (96.1%)
Estimated MDR N, (best-low-high)	14-5-29
Pulmonary MDR cases	10 (1.2%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	106 (5.0%)
HIV-positive TB cases	19 (17.9%)
of these on antiretroviral therapy	19 (100.0%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
 \*\* More than 50% of TB cases tested for HIV.

## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	1 851	14
Success	1 546 (83.5%)	9 (64.3%)
Died	123 (6.6%)	3 (21.4%)
Failed	7 (0.4%)	0 (0.0%)
Lost to follow up	132 (7.1%)	2 (14.3%)
Not evaluated	43 (2.3%)	0 (0.0%)


\* Treatment outcome as presented is treatment outcome after 12 months.  
 \*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.



# Slovakia

Total population at 1 January 2013 by EUROSTAT: 5 410 836

## Tuberculosis case notifications, 2013

Total number of cases	401
Notification rate per 100 000	7.4
New* & relapses	398
New* & relapses notification rate per 100 000	7.4
Pulmonary	344 (85.8%)
of which smear-positive	140 (40.7%)
of which laboratory confirmed	194 (56.4%)
Laboratory-confirmed TB cases	212 (52.9%)
Mean age of new native TB cases	49.1 years
Mean age of new foreign TB cases	43.7 years
Foreign origin of all TB cases	6 (1.5%)
New (not previously treated)	341 (85.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	212 (100.0%)
Estimated MDR N, (best-low-high)	2-0-6
Pulmonary MDR cases	3 (1.5%)
of which XDR cases	0 (0.0%)
All MDR cases	3 (1.4%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	368 (91.8%)
HIV-positive TB cases	0 (0.0%)
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National			
Outcome cohort	New culture positive pulmonary TB cases notified in 2012*		All MDR TB cases notified in 2011**	
Case-linked data reporting	Yes			
Cases notified	139		3	
Success	123	(88.5%)	1	(33.3%)
Died	13	(9.4%)	2	(66.7%)
Failed	0	(0.0%)	0	(0.0%)
Lost to follow up	0	(0.0%)	0	(0.0%)
Still on treatment	0	(0.0%)	0	(0.0%)
Not evaluated	3	(2.2%)	0	(0.0%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Slovenia

Total population at 1 January 2013 by EUROSTAT: 2 058 597

## Tuberculosis case notifications, 2013

Total number of cases	140
Notification rate per 100 000	6.8
New* & relapses	139
New* & relapses notification rate per 100 000	6.8
Pulmonary	109 (77.9%)
of which smear-positive	42 (38.5%)
of which laboratory confirmed	106 (97.2%)
Laboratory-confirmed TB cases	132 (94.3%)
Mean age of new native TB cases	63.2 years
Mean age of new foreign TB cases	48.4 years
Foreign origin of all TB cases	46 (32.9%)
New (not previously treated)	133 (95.0%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	132 (100.0%)
Estimated MDR N, (best-low-high)	0-0-0
Pulmonary MDR cases	0 (0.0%)
of which XDR cases	0 -
All MDR cases	0 (0.0%)
of which XDR cases	0 -
TB cases tested for HIV	105 (75.0%)
HIV-positive TB cases	1 (1.0%)
of these on antiretroviral therapy	- -

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
Outcome cohort	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Case-linked data reporting	Yes	
Cases notified	103	0
Success	86 (83.5%)	0 -
Died	16 (15.5%)	0 -
Failed	0 (0.0%)	0 -
Lost to follow up	1 (1.0%)	0 -
Still on treatment	0 (0.0%)	0 -
Not evaluated	0 (0.0%)	0 -


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Spain

Total population at 1 January 2013 by EUROSTAT: 46 727 890

## Tuberculosis case notifications, 2013

Total number of cases	5 539
Notification rate per 100 000	11.9
New* & relapses	5 244
New* & relapses notification rate per 100 000	11.2
Pulmonary	3 998 (72.2%)
of which smear-positive	2 047 (51.2%)
of which laboratory confirmed	2 976 (74.4%)
Laboratory-confirmed TB cases	3 631 (65.6%)
Mean age of new native TB cases	48.0 years
Mean age of new foreign TB cases	34.9 years
Foreign origin of all TB cases	1 755 (31.7%)
New (not previously treated)	5 244 (94.7%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	No
Cases with DST results	1 561 (43.0%)
Estimated MDR N, (best-low-high)	29-12-47
Pulmonary MDR cases	34 (1.1%)
of which XDR cases	2 (5.9%)
All MDR cases	-
of which XDR cases	-
TB cases tested for HIV	4 069 (73.5%)
HIV-positive TB cases	273 (6.7%)
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
Outcome cohort	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Case-linked data reporting	Yes	
Cases notified	2 975	41
Success	2 169 (72.9%)	-
Died	198 (6.7%)	-
Failed	4 (0.1%)	-
Lost to follow up	39 (1.3%)	-
Still on treatment	31 (1.0%)	-
Not evaluated	534 (17.9%)	-


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013




## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Sweden

Total population at 1 January 2013 by EUROSTAT: 9 555 893

## Tuberculosis case notifications, 2013

Total number of cases	648
Notification rate per 100 000	6.8
New* & relapses	610
New* & relapses notification rate per 100 000	6.4
Pulmonary	368 (56.8%)
of which smear-positive	100 (27.2%)
of which laboratory confirmed	321 (87.2%)
Laboratory-confirmed TB cases	523 (80.7%)
Mean age of new native TB cases	47.2 years
Mean age of new foreign TB cases	34.3 years
Foreign origin of all TB cases	575 (88.7%)
New (not previously treated)	605 (93.4%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	523 (100.0%)
Estimated MDR N, (best-low-high)	11-3-20
Pulmonary MDR cases	7 (2.2%)
of which XDR cases	2 (28.6%)
All MDR cases	8 (1.5%)
of which XDR cases	2 (25.0%)
TB cases tested for HIV	-
HIV-positive TB cases	-
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
Outcome cohort	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Case-linked data reporting	Yes	
Cases notified	288	17
Success	234 (81.3%)	12 (70.6%)
Died	17 (5.9%)	1 (5.9%)
Failed	1 (0.3%)	1 (5.9%)
Lost to follow up	3 (1.0%)	0 (0.0%)
Still on treatment	8 (2.8%)	0 (0.0%)
Not evaluated	25 (8.7%)	3 (17.6%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Switzerland

Population estimate 2013 by UN Statistical Database: 8 077 835

## Tuberculosis case notifications, 2013

Total number of cases	526
Notification rate per 100 000	6.5
New* & relapses	466
New* & relapses notification rate per 100 000	5.8
Pulmonary	320 (60.8%)
of which smear-positive	101 (31.6%)
of which laboratory confirmed	311 (97.2%)
Laboratory-confirmed TB cases	432 (82.1%)
Mean age of new native TB cases	56.1 years
Mean age of new foreign TB cases	36.7 years
Foreign origin of all TB cases	396 (75.3%)
New (not previously treated)	466 (88.6%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	304 (97.7%)
Estimated MDR N, (best-low-high)	5-1-14
Pulmonary MDR cases	12 (3.9%)
of which XDR cases	1 (8.3%)
TB cases tested for HIV	-
HIV-positive TB cases	-
of these on antiretroviral therapy	-


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.

## Treatment outcome monitoring


Data not available

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*



\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013



## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012

Data not available

# Tajikistan

Population estimate 2013 by UN Statistical Database: 8 207 832

## Tuberculosis case notifications, 2013

Total number of cases	6 495
Notification rate per 100 000	79.1
New* & relapses	5 576
New* & relapses notification rate per 100 000	67.9
Pulmonary	4 313 (66.4%)
of which smear-positive	2 641 (61.2%)
of which laboratory confirmed	2 641 (61.2%)
Laboratory-confirmed TB cases	2 842 (43.8%)
Mean age of new native TB cases	34 years
Mean age of new foreign TB cases	- years
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	5 306 (81.7%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	460 (17.4%)
Estimated MDR N, (best-low-high)	480-380-600
Pulmonary MDR cases	159 (6.0%)
of which XDR cases	28 (17.6%)
TB cases tested for HIV	5 200 (80.1%)
HIV-positive TB cases	165 (3.2%)
of these on antiretroviral therapy	162 (98.2%)


\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%  
\*\* More than 50% of TB cases tested for HIV.

## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	5 811	380
Success	4 845 (83.4%)	242 (63.7%)
Died	276 (4.7%)	57 (15.0%)
Failed	422 (7.3%)	37 (9.7%)
Lost to follow up	208 (3.6%)	35 (9.2%)
Not evaluated	60 (1.0%)	9 (2.4%)


\* Treatment outcome as presented is treatment outcome after 12 months.  
\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.

# Turkey

Population estimate 2013 by UN Statistical Database: 74 932 644

## Tuberculosis case notifications, 2013

Total number of cases	13 409
Notification rate per 100 000	17.9
New* & relapses	13 170
New* & relapses notification rate per 100 000	17.6
Pulmonary	8 655 (64.5%)
of which smear-positive	4 944 (57.1%)
of which laboratory confirmed	5 837 (67.4%)
Laboratory-confirmed TB cases	7 024 (52.4%)
Mean age of new native TB cases	42.7 years
Mean age of new foreign TB cases	33.6 years
Foreign origin of all TB cases	491 (3.7%)
New (not previously treated)	12 352 (92.1%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	5 530 (94.7%)
Estimated MDR N, (best-low-high)	190-160-230
Pulmonary MDR cases	228 (3.9%)
of which XDR cases	3 (1.3%)
TB cases tested for HIV	8 787 (65.5%)
HIV-positive TB cases	32 (0.4%)
of these on antiretroviral therapy	20 (62.5%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
Outcome cohort	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Case-linked data reporting	Yes	
Cases notified	13 535	275
Success	11 946 (88.3%)	181 (65.8%)
Died	556 (4.1%)	25 (9.1%)
Failed	62 (0.5%)	8 (2.9%)
Lost to follow up	331 (2.4%)	23 (8.4%)
Not evaluated	640 (4.7%)	38 (13.8%)

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012



# Turkmenistan

Population estimate 2013 by UN Statistical Database: 5 240 073

## Tuberculosis case notifications, 2013

Total number of cases	3 675
Notification rate per 100 000	70.1
New* & relapses	3 046
New* & relapses notification rate per 100 000	58.1
Pulmonary	3 094 (84.2%)
of which smear-positive	1 773 (57.3%)
of which laboratory confirmed	-
Laboratory-confirmed TB cases	1 773 (48.2%)
Mean age of new native TB cases	- years
Mean age of new foreign TB cases	- years
Foreign origin of all TB cases	-
New (not previously treated)	2 774 (75.5%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	No
Case-linked data reporting	Yes
Cases with DST results	-
Estimated MDR N, (best-low-high)	85-25-210
Pulmonary MDR cases	-
of which XDR cases	-
TB cases tested for HIV	-
HIV-positive TB cases	-
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	2 804	-
Success	2 369 (84.5%)	-
Died	84 (3.0%)	-
Failed	238 (8.5%)	-
Lost to follow up	94 (3.4%)	-
Not evaluated	19 (0.7%)	-

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.



# Ukraine

Population estimate 2013 by UN Statistical Database: 45 238 805

## Tuberculosis case notifications, 2013

Total number of cases	48 134
Notification rate per 100 000	106.4
New* & relapses	36 510
New* & relapses notification rate per 100 000	80.7
Pulmonary	44 257 (91.9%)
of which smear-positive	26 786 (60.5%)
of which laboratory confirmed	26 786 (60.5%)
Laboratory-confirmed TB cases	26 786 (55.6%)
Mean age of new native TB cases	- years
Mean age of new foreign TB cases	- years
Foreign origin of all TB cases	0 (0.0%)
New (not previously treated)	31 399 (65.2%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	21 170 (79.0%)
Estimated MDR N, (best-low-high)	4 100-3 900-4 300
Pulmonary MDR cases	5 844 (21.8%)
of which XDR cases	0 (0.0%)
TB cases tested for HIV	42 213 (87.7%)
HIV-positive TB cases	8 290 (19.6%)
of these on antiretroviral therapy	3 949 (47.6%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	30 928	3 810
Success	21 922 (70.9%)	1 298 (34.1%)
Died	3 282 (10.6%)	1 127 (29.6%)
Failed	2 034 (6.6%)	462 (12.1%)
Lost to follow up	3 350 (10.8%)	681 (17.9%)
Not evaluated	340 (1.1%)	242 (6.4%)

\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.

# United Kingdom

Total population at 1 January 2013 by EUROSTAT: 63 896 071

## Tuberculosis case notifications, 2013

Total number of cases	7 892
Notification rate per 100 000	12.4
New* & relapses	7 384
New* & relapses notification rate per 100 000	11.6
Pulmonary	4 096 (51.9%)
of which smear-positive	1 318 (32.2%)
of which laboratory confirmed	2 924 (71.4%)
Laboratory-confirmed TB cases	4 684 (59.4%)
Mean age of new native TB cases	43.0 years
Mean age of new foreign TB cases	39.4 years
Foreign origin of all TB cases	5 529 (70.1%)
New (not previously treated)	7 384 (93.6%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	Yes
Completeness of HIV data**	-
Case-linked data reporting	Yes
Cases with DST results	4 606 (98.3%)
Estimated MDR N, (best-low-high)	69-54-85
Pulmonary MDR cases	46 (1.6%)
of which XDR cases	2 (4.3%)
All MDR cases	74 (1.6%)
of which XDR cases	3 (4.1%)
TB cases tested for HIV	-
HIV-positive TB cases	-
of these on antiretroviral therapy	-

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New culture positive pulmonary TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	2 842	86
Success	2 201 (77.4%)	40 (46.5%)
Died	159 (5.6%)	4 (4.7%)
Failed	0 (0.0%)	0 (0.0%)
Lost to follow up	139 (4.9%)	19 (22.1%)
Still on treatment	290 (10.2%)	22 (25.6%)
Not evaluated	53 (1.9%)	1 (1.2%)


\* Treatment outcome as presented is treatment outcome after 12 months.

\*\* Treatment outcome as presented is treatment outcome after 24 months.


## Tuberculosis notification rates by treatment history, 2004–2013



## New TB cases and relapses - notification rates by age group, 2004–2013




## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013

Data not available

## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new pulmonary culture-positive cases, 2003–2012



# Uzbekistan

Population estimate 2013 by UN Statistical Database: 28 934 100

## Tuberculosis case notifications, 2013

Total number of cases	25 168
Notification rate per 100 000	87.0
New* & relapses	20 812
New* & relapses notification rate per 100 000	71.9
Pulmonary	16 403 (65.2%)
of which smear-positive	6 128 (37.4%)
of which laboratory confirmed	7 828 (47.7%)
Laboratory-confirmed TB cases	9 765 (38.8%)
Mean age of new native TB cases	41.0 years
Mean age of new foreign TB cases	44.5 years
Foreign origin of all TB cases	29 (0.1%)
New (not previously treated)	16 555 (65.8%)

\* Cases with unknown previous treatment included as new cases.

## Drug resistance surveillance & TB-HIV co-infection, 2013

Completeness of DRS data*	No
Completeness of HIV data**	Yes
Case-linked data reporting	Yes
Cases with DST results	6 898 (88.1%)
Estimated MDR N, (best-low-high)	2 800-2 200-3 600
Pulmonary MDR cases	3 030 (38.7%)
of which XDR cases	167 (5.5%)
TB cases tested for HIV	24 670 (98.0%)
HIV-positive TB cases	1 097 (4.4%)
of these on antiretroviral therapy	762 (69.5%)

\* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%

\*\* More than 50% of TB cases tested for HIV.


## Treatment outcome monitoring

Geographical coverage	National	
	New and relapsed TB cases notified in 2012*	All MDR TB cases notified in 2011**
Outcome cohort		
Case-linked data reporting	Yes	
Cases notified	14 132	855
Success	11 905 (84.2%)	455 (53.2%)
Died	653 (4.6%)	112 (13.1%)
Failed	310 (2.2%)	81 (9.5%)
Lost to follow up	687 (4.9%)	190 (22.2%)
Not evaluated	577 (4.1%)	17 (2.0%)

\* Treatment outcome as presented is treatment outcome after 12 months.


\*\* Treatment outcome as presented is treatment outcome after 24 months.

## Tuberculosis notification rates by treatment history, 2004–2013\*




\* In 2013 cases with unknown history are included in new & relapses

## New TB cases - notification rates by age group, 2004–2013\*




\* 2013 data includes new and relapses.


## Tuberculosis cases by geographical origin, 2004–2013




## TB-HIV co-infection, 2006–2013



## MDR TB cases by previous treatment history, 2004–2013



## Treatment outcome, new TB cases, 2003–2012\*



\* 2012 cohort includes new and relapse cases.







## **HOW TO OBTAIN EU PUBLICATIONS**

### **Free publications:**

- via EU Bookshop (<http://bookshop.europa.eu>);
- at the European Commission's representations or delegations. You can obtain their contact details on the Internet (<http://ec.europa.eu>) or by sending a fax to +352 2929-42758.

### **Priced publications:**

- via EU Bookshop (<http://bookshop.europa.eu>).

### **Priced subscriptions (e.g. annual series of the Official Journal of the European Union and reports of cases before the Court of Justice of the European Union):**

- via one of the sales agents of the Publications Office of the European Union ([http://publications.europa.eu/others/agents/index\\_en.htm](http://publications.europa.eu/others/agents/index_en.htm)).

**European Centre for Disease  
Prevention and Control (ECDC)**

Postal address:  
Granits väg 8, SE-171 65 Solna, SWEDEN

Visiting address:  
Tomtebodavägen 11A, SE-171 65 Solna, SWEDEN

Tel. +46 858601000  
Fax +46 858601001  
<http://www.ecdc.europa.eu>

An agency of the European Union  
<http://www.europa.eu>

